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Abstract 
 
Prolonged activation of spinal NMDA receptors, after peripheral inflammation or 
nerve damage, can activate intracellular signalling cascades leading to plastic 
changes in synaptic transmission.  This results in central sensitization of dorsal horn 
sensory neurones and manifests in patients as increased sensitivity to painful stimuli 
(hyperalgesia), and pain resulting from normally non-painful tactile stimuli (allodynia).  
Therefore, targeting NMDA-mediated intracellular signalling pathways could be a 
successful analgesic strategy, potentially devoid of side-effects associated with 
receptor blockade.  NMDA receptors bind to the intracellular scaffold protein PSD-95, 
which couples the receptor to cytoplasmic effector pathways.  The role of this 
coupling in spinal sensory transmission and nociceptive plasticity was investigated 
using biochemical, electrophysiological and behavioural methods.  Disruption of 
binding between PSD-95 and NR2B subunits of NMDA receptors was achieved 
through the use of a decoy mimetic peptide, Tat-NR2B9c.  I show that Tat-NR2B9c 
selectively reduces wind-up of dorsal horn wide dynamic range neurones and 
prevents both neuronal and behavioural measures of formalin-induced central 
sensitization.  In the spinal nerve ligation model of chronic pain, Tat-NR2B9c reduced 
neuronal responses to mechanical and thermal stimulation and was able to reverse 
behavioural mechanical and cold hypersensitivity, clinical signs of neuropathic pain.  
In addition, the roles of two kinases, atypical PKCζ/PKMζ and PI3K, known to be 
involved in hippocampal LTP, were investigated using biochemical, 
immunohistochemical, electrophysiological and behavioural measures.  I found that 
activation of spinal PKCζ/PKMζ is dependent on coupling between NR2B-subtype 
receptors and PSD-95, and contributes to central sensitization of dorsal horn 
neurones.  PI3K was also found to be active in the NMDA-dependent formalin model 
and regulates various intracellular mechanisms in central sensitization.  Finally, I 
investigated the role of DDAH-1, an enzyme which is involved in the regulation of 
nNOS, in spinal nociceptive plasticity.  DDAH-1 inhibition reduced neuronal wind-up 
and both neuronal and behavioural measures of formalin-induced central 
sensitization.  These findings further our understanding of NMDA-dependent spinal 
nociceptive plasticity.  Disrupting the interaction between NR2B-containing NMDA 
receptors and PSD-95 or inhibition of downstream intracellular signalling pathways 
may be successful analgesic strategies for the treatment of chronic pain. 
 
 
 
 4 
Acknowledgements 
 
I would like to express my utmost gratitude to my supervisor, Tony Dickenson.  
Thank you for believing in my ideas and allowing me the freedom to pursue them.  It 
has been an honour to have worked in your group for the last four years.  To all the 
members of the Dickenson lab, past and present, with whom I have had the good 
fortune of working alongside: Rie, Liz, Wahida, Shaima, Jean-Laurent, Lucy, Rich, 
Curtis, Skip, Vic, Sital, Amy, Kirsty, Matt, Liam and Leonor.  I am proud to call you all 
friends (even those of you not on Facebook!).  I will especially remember strike days, 
weddings, dinners and those crazy nights out with Rich and Curtis at Tiger Tiger...or 
was it On Anon...no, wait it was Movida...   
 
To Mac and all the members of his lab:  thank you for welcoming me and adopting 
me as one of your own.  Special mentions for Sophie Pezet and Fabien Marchand, 
who deserve infinite praise for their great influence on me as a scientist.  I learnt so 
much from you both in my first few weeks as a postgraduate and have continued to 
do so during the rest of my PhD.  Your enthusiastic and fearless approach to science 
will always stay with me.  It has been a pleasure working so closely with you both, 
and I hope that we will continue to do so for many years to come.  I would like to 
thank the London Pain Consortium for starting me off in my research career.  I am 
proud to have been associated with such a prestigious and fun group of people.  I 
hope that in the future I will work with many of you again. 
 
To Carlos, Conti, Mana, Jay, Suff and all my friends outside of science, who have 
kept me sane during the last four years.  Thanks for the all the jokes and fun times 
weʼve had and also for your encouragement and appreciation of my efforts. 
 
Finally, my thanks, love and blessings to my family.  To my sister, Shivani, I smile at 
your courage and hope that you make your dreams come true.  To Mum and Dad, 
thank you for never putting pressure on me, for always encouraging me and 
supporting me in whatever I have wanted to do.  You have always inspired me to 
strive for greatness, and God-willing, one day I will achieve it.  I hope that I will 
always make you proud of me. 
 
 
 
 
 5 
Declaration of published work 
 
 
Some of the work presented in this thesis has been published previously: 
 
Rahman W, D'Mello R, Dickenson AH (2008) Peripheral Nerve Injury-Induced 
Changes in Spinal alpha(2)-Adrenoceptor-Mediated Modulation of 
Mechanically Evoked Dorsal Horn Neuronal Responses. J Pain 9:350-359 
D'Mello R, Dickenson AH (2008) Spinal cord mechanisms of pain. Br J Anaesth 
101:8-16. 
Pezet S, Marchand F, D'Mello R, Grist J, Clark AK, Malcangio M, Dickenson AH, 
Williams RJ, McMahon SB (2008) Phosphatidylinositol 3-kinase is a key 
mediator of central sensitization in painful inflammatory conditions. J Neurosci 
28:4261-4270. 
 
 
 
 
 6 
Abbreviations 
 
5-HT Serotonin/5-hydroxytryptamine 
7-NI 7-nitroindazole 
ADMA Asymmetric dimethylarginine  
AEA Anandamide 
Akt Protein kinase B 
AMPA α-amino-3-hydroxy-5-methyl-4-isoxazoleproprionic acid  
ANOVA Analysis of variance 
AP Action potential 
ASIC Acid-sensing ion channel 
ATP Adenosine triphosphate 
BCA Bicinchoninic acid 
BDNF Brain-derived neurotrophic factor 
BH4 Tetrahydrobiopterin  
BK Bradykinin receptor 
CaMKII Ca2+/Calmodulin-dependent kinase II 
cAMP Cyclic adenosine monophosphate 
CB Cannabinoid receptor 
CCI Chronic constriction injury 
CCK Cholecystokinin 
CFA Complete Freund's adjuvant 
cGMP Cyclic guanosine monophosphate 
CGRP Calcitonin gene-related peptide 
 
 
 
 7 
CK2 Casein kinase 2 
CLB Complete lysis buffer 
CLR Calcitonin-like receptor  
CNS Central nervous system 
CONTRA Contralateral 
CP Central pain 
CPP 3-[2-carboxypi-perazin4-yl]-propyl-I-phosphonic acid 
CREB cAMP response element binding protein  
CSF Cerebrospinal fluid 
CVLM Caudal ventrolateral medulla 
DAG Diacylglycerol 
DDAH Dimethylarginine dimethylaminohydrolase 
DFNS German Research Network on Neuropathic Pain  
DMA Dynamic mechanical allodynia 
DMSO Dimethyl sulfoxide  
DOR Delta (δ) opioid receptor 
DRG Doral root ganglion 
EFNS European Federation of Neurological Societies 
eNOS Endothelial nitric oxide synthase 
EPSP Excitatory post-synaptic potential 
ERK Extracellular signal-regulated kinase 
FITC Fluorescein isothiocyanate  
GABA γ-amino butyric acid  
GCH1 GTP cyclohydrolase 1 
 
 
 
 8 
GDNF Glial cell line-derived neurotrophic factor 
GFAP Glial fibrillary acidic protein 
GluR AMPA receptor subunit 
GPCR G-protein coupled receptor 
GSK Glycogen synthase kinase  
GTP Guanosine triphosphate 
HFS High frequency stimulation 
HIV Human immunodeficiency virus 
HRP Horse radish peroxidase 
IASP International Association for the Study of Pain 
IB4 Isolectin B4 
Iba1 Ionized calcium binding adaptor molecule 1 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
IP Immunoprecipitation 
IP3 Inositol 1,4,5-trisphosphate  
IPSI Ipsilateral 
KOR Kappa (κ) opioid receptor 
L-291 NG-[2-methoxyethyl] arginine methyl ester 
L-NAME N omega-nitro-L-arginine methyl ester  
L-NMMA L-NG-monomethylarginine  
L(n) Lumbar segment (n) 
LC Locus coeruleus  
LFS Low frequency stimulation 
 
 
 
 9 
LTD Long-term depression 
LTP Long-term potentiation 
MAGUK Membrane-associated guanylate kinase  
MAPK Mitogen-activated protein kinase 
mGluR Metabotropic glutamate receptor 
MOR Mu (μ) opioid receptor 
mPFC Medial prefrontal cortex  
mRNA Messenger ribonucleic acid 
mTOR Mammalian target of rapamycin 
NA Noradrenaline 
Nav Voltage-gated Na+ channel subtype 
NeuN Neuronal nuclei 
NeuPSIG Neuropathic Pain Special Interest Group 
NF200 Neurofilament 200 
NGF Nerve growth factor 
NK Neurokinin receptor 
NMDA N-methyl-D-aspartate 
nNOS Neuronal nitric oxide synthase 
NO Nitric oxide 
NOP1 Nociceptin 1 receptor 
NOS Nitric oxide synthase 
NR NMDA receptor subunit 
NS Nociceptive-specific 
OCT Optimal cutting temperature compound 
 
 
 
 10 
OFQ/N Orphanin FQ/nociceptin 
OX-42 CD11b 
P2 Purinergic receptor 
PAG Periaqueductal grey 
PB Parabrachial area 
PBS Phosphate buffered saline 
PBS-T PBS+Triton X-100 
PBS-T+Az PBS-T+Azide 
PD Post-discharge 
PDK-1 3ʼ-PI-dependent protein kinase  
PDN Painful diabetic neuropathy  
PDZ Postsynaptic density 95, discs large, and zonula occludens-1 
PFA Paraformaldehyde  
PH Pleckstrin-homology domain 
PHN Post-herpetic neuralgia 
PI Phophoinositide 
PI3K Phosphatidylinositol 3-kinase 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PIP3 Phosphatidylinositol 3,4,5-triphosphate 
PKA Protein kinase A 
PKC Protein kinase C 
PKCγ PKC gamma 
PKCε PKC epsilon 
PKCζ/PKMζ Atypical PKC zeta 
 
 
 
 11 
PKG Protein kinase G 
PLC Phospholipase C 
PP1 Protein phosphatase 1 
PPN Peripheral polyneuropathy  
PSD-93 Post-synaptic density protein-93 
PSD-95 Post-synaptic density protein-95 
PSNL Partial sciatic nerve ligation 
PSTH Post-stimulus histogram 
PVDF Polyvinylidene difluoride  
PWT Paw withdrawal threshold 
QST Quantitative sensory testing 
RAMP-1 Receptor activity-modifying protein 1  
RCP Receptor component protein  
RIPA Radioimmunoprecipitation assay 
RM Repeated measures 
RSK2 p90 Ribosomal S6 protein kinase 2 
RVM Rostroventromedial medulla 
S(n) Sacral segment (n) 
SAP Saporin 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis  
Ser Serine 
SH Src-homology domain 
SLP3 Stomatin-like protein 3  
SMA Static mechanical allodynia 
 
 
 
 12 
SNL Spinal nerve ligation 
SNP Sodium nitroprusside  
SP Substance P 
SSNRI Selective serotonin and noradrenaline reuptake inhibitor 
SynGAP Synaptic GTPase-activating protein  
TBS-T Tris-buffered saline+Tween-20 
TCA Tricyclic antidepressant 
Thr Threonine 
TNF Tumour necrosis factor 
TREK1 Two-pore domain potassium channel 
Trk Tyrosine receptor kinase 
TRP Transient receptor potential 
TRPA1 TRP ankyrin receptor-1 
TRPM8 TRP melastatin receptor-8  
TRPV1 TRP vanniloid receptor-1  
TTX-R Tetrodotoxin-resistant 
TTX-S Tetrodotoxin-sensitive 
Tyr Tyrosine 
WDR Wide dynamic range 
y+CAT y+ system cationic amino acid transporter 
 
 
 
 
 13 
List of Contents 
 
1  Introduction ..........................................................................................................27 
1.1  Acute Pain .......................................................................................................28 
1.2  Chronic Pain....................................................................................................28 
1.3  The Pain Pathway ...........................................................................................30 
1.3.1  Peripheral sensory afferent fibres ............................................................30 
1.3.1.1  Development of two classes of C-fibre nociceptors...........................31 
1.3.1.2  Peripheral terminals of sensory fibres ...............................................32 
1.3.1.3  Peripheral sensitization .....................................................................35 
1.3.1.4  Plasticity of sensory fibre Na+ channels in pain.................................38 
1.3.1.5  Na+ channels in human genetic pain syndromes ..............................40 
1.3.1.6  Central terminals of sensory fibres....................................................41 
1.3.2  Anatomical arrangement of the dorsal horn of the spinal cord.................42 
1.3.2.1  Lamina I.............................................................................................44 
1.3.2.2  Lamina II............................................................................................44 
1.3.2.3  Laminae III – IV .................................................................................45 
1.3.2.4  Lamina V ...........................................................................................45 
1.3.2.5  Electrophysiological response properties of intrinsic dorsal horn    
             sensory neurones..............................................................................46 
1.3.2.6  Contribution of non-neuronal glial cells to dorsal horn nociceptive    
             processing .........................................................................................47 
1.3.3  Anatomy of ascending projections from the dorsal horn to the brain .......48 
1.3.4  Anatomy of descending projections from the brain to the dorsal horn .....49 
1.4  Neurotransmitters and neuromodulators acting in the dorsal horn .................52 
1.4.1  Glutamate.................................................................................................52 
1.4.2  Substance P .............................................................................................53 
1.4.3  Calcitonin gene-related peptide (CGRP) ..................................................54 
1.4.4  Brain-derived neurotrophic factor (BDNF)................................................54 
1.4.5  Nitric oxide (NO).......................................................................................55 
1.4.6  GABA & Glycine .......................................................................................56 
1.4.7  Endogenous opioids.................................................................................56 
1.4.8  Cannabinoids ...........................................................................................57 
1.4.9  Serotonin (5-HT).......................................................................................58 
 
 
 
 14 
1.4.10  Noradrenaline (NA) ................................................................................59 
1.5  Spinal dorsal horn nociceptive plasticity..........................................................61 
1.5.1  Spinal wind-up & temporal summation of pain .........................................62 
1.5.2  Spinal long-term potentiation....................................................................66 
1.5.3  Central sensitization of dorsal horn neurones ..........................................69 
1.5.3.1  Intracellular mechanisms of central sensitization of dorsal horn     
             sensory neurones..............................................................................70 
1.5.3.2  Loss of spinal inhibition contributes to mechanical hypersensitivity  
             and allodynia .....................................................................................73 
1.5.3.3  Plasticity of descending modulation in chronic pain states ...............76 
1.5.3.4  Human surrogate models of central sensitization .............................81 
1.6  The NMDA receptor as a therapeutic target for chronic pain ..........................82 
1.6.1  Structure of NMDA receptors ...................................................................82 
1.6.2  Traditional NMDA receptor antagonists and efficacy in chronic pain .......84 
1.7  Alternative and novel strategies to target spinal NMDA receptors in pain ......86 
1.7.1  Specific targeting of NR2B-containing NMDA receptors ..........................86 
1.7.2  Targeting NMDA receptor protein interactions and intracellular  
          signalling ..................................................................................................86 
1.8  Thesis Aims.....................................................................................................88 
 
2  Materials and Methods ........................................................................................89 
2.1  In vivo Electrophysiology.................................................................................89 
2.1.1  Set-up.......................................................................................................89 
2.1.2  Recording system.....................................................................................90 
2.1.3  Electrical stimulation of hindpaw receptive field to induce wind-up ..........93 
2.2  Formalin Model of Central Sensitization..........................................................95 
2.2.1  In vivo Electrophysiology – Formalin Test................................................95 
2.2.2  Behavioural Formalin Test .......................................................................97 
2.3  Spinal Nerve Ligation (SNL) Model of Neuropathic Pain.................................98 
2.3.1  Surgery.....................................................................................................98 
2.3.2  Behavioural confirmation of mechanical and cold hypersensitivity prior to  
          electrophysiology....................................................................................100 
2.3.2.1  Paw Withdrawal Frequency.............................................................100 
2.3.2.2  Acetone Drop Test ..........................................................................101 
 
 
 
 15 
2.3.3  In vivo Electrophysiology – Spinal Nerve Ligation Model .......................103 
2.3.4  Behavioural assessment of mechanical and cold hypersensitivity to  
          observe effects of pharmacological interventions ..................................105 
2.3.4.1  Paw Withdrawal Threshold (PWT) ..................................................105 
2.3.4.2  Acetone Drop Test ..........................................................................105 
2.4  Assessment of locomotor function – Rotarod................................................106 
2.5  Drug administration – In vivo Electrophysiology............................................107 
2.6  Intrathecal drug administration for behaviour – Lumbar Puncture Method ...107 
2.7  Immunohistochemistry ..................................................................................108 
2.7.1  Perfusion ................................................................................................108 
2.7.2  Processing of tissue and staining...........................................................108 
2.8  Western Immunoblotting ...............................................................................109 
2.8.1  Dissection and tissue homogenization ...................................................109 
2.8.2  Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis ............109 
2.8.3  Detection and revelation.........................................................................110 
2.9  Immunoprecipitation Protocol........................................................................112 
2.9.1  Washing/preparation of Dynabeads® Protein G ....................................112 
2.9.2  Antibody coupling to Dynabeads® Protein G .........................................112 
2.9.3  Target antigen capture ...........................................................................112 
2.9.4  Denaturing elution of target protein ........................................................113 
2.10  Statistical Analyses .....................................................................................117 
 
3  Interactions between spinal NR2B-containing NMDA receptors and PSD-95  
    contribute to spinal nociceptive plasticity ......................................................118 
3.1  Introduction....................................................................................................118 
3.1.1  Expression of NR2B-containing NMDA receptors in the dorsal horn .....118 
3.1.2  Involvement of NR2B-containing NMDA receptors in spinal wind-up  
          and inflammatory pain ............................................................................119 
3.1.3  Structure of Post-synaptic density protein-95 (PSD-95).........................121 
3.1.4  Expression of PSD-95 in the dorsal horn of the spinal cord ...................123 
3.1.5  Involvement of PSD-95 in acute and inflammatory pain models ............123 
3.1.6  Coupling between NMDA receptors and PSD-95 and the  
          source-specificity hypothesis..................................................................124 
3.1.7  Disrupting protein-protein interactions specifically between NMDA  
 
 
 
 16 
          receptors and PSD-95 through the use of Tat-NR2B9c as a potential  
          treatment strategy ..................................................................................127 
3.2  Materials and Methods ..................................................................................130 
3.2.1  Animals...................................................................................................130 
3.2.2  Synthesis of Tat-NR2B9c and Tat-NR2BAA peptides............................130 
3.2.3  Immunoprecipitation of NR2B subunits and Western Immunoblotting ...131 
3.2.4  In vivo Electrophysiology........................................................................132 
3.2.4.1  Electrical stimulation of the hindpaw ...............................................132 
3.2.4.2  Neuronal Formalin Test ...................................................................132 
3.2.5  Behavioural Formalin Test .....................................................................133 
3.2.6  Statistical Analysis..................................................................................133 
3.3  Results ..........................................................................................................134 
3.3.1  A protein complex between NR2B subunits, PSD-95 and nNOS exists  
          in intrinsic spinal dorsal horn neurones ..................................................134 
3.3.2  Spinal application of Tat-NR2B9c does not alter afferent-evoked  
          responses but inhibits post-discharge of deep dorsal horn WDR  
          neurones ................................................................................................136 
3.3.3  Wind-up of deep dorsal horn WDR neurones is reduced by spinal 
          Tat-NR2B9c............................................................................................139 
3.3.4  Formalin-induced central sensitization of deep dorsal horn WDR  
          neurones is reduced by spinal pre-treatment with Tat-NR2B9c.............141 
3.3.5  Spinal Tat-NR2B9c inhibits pain-related behaviours due to  
          formalin-induced central sensitization ....................................................144 
3.3.6  Spinal Tat-NR2B9c reduces formalin-induced active pain-related  
          licking and biting behaviours ..................................................................146 
3.4  Discussion.....................................................................................................149 
 
4  Interactions between spinal NR2B-containing NMDA receptors and PSD-95  
    contribute to maintenance of nerve injury-induced pain...............................155 
4.1  Introduction....................................................................................................155 
4.1.1  Neuropathic Pain....................................................................................155 
4.1.2  Clinical presentation, epidemiology & treatment of neuropathic pain.....155 
4.1.3  Rodent models of nerve injury-induced neuropathic pain ......................159 
4.1.4  Contribution of NR2B-containing NMDA receptors to neuropathic pain.161 
 
 
 
 17 
4.1.5  Involvement of PSD-95 in neuropathic pain ...........................................163 
4.2  Materials and Methods ..................................................................................165 
4.2.1  Spinal Nerve Ligation (SNL) Model ........................................................165 
4.2.2  In vivo Electrophysiology........................................................................165 
4.2.2.1  Electrical and natural stimulation of the hindpaw ............................165 
4.2.3  Behavioural assessment of effects of Tat-NR2B9c on maintenance of  
          mechanical and cold hypersensitivity induced by spinal nerve ligation..166 
4.2.4  Assessment of effects of Tat-NR2B9c on locomotor function ................166 
4.2.5  Statistical Analysis..................................................................................167 
4.3  Results ..........................................................................................................168 
4.3.1  SNL induces behavioural mechanical and cold hypersensitivity of the  
          injured paw indicating establishment of a neuropathic pain state ..........168 
4.3.2  Spinal Tat-NR2B9c does not alter afferent-evoked responses but  
          inhibits post-discharge of deep dorsal horn WDR neurones in SNL  
          and sham-operated rats .........................................................................170 
4.3.3  Wind-up of deep dorsal horn WDR neurones is reduced by spinal 
          Tat-NR2B9c in both SNL and sham-operated rats.................................173 
4.3.4  Responses of deep dorsal horn WDR neurones evoked by natural  
          stimuli are reduced by spinal application of Tat-NR2B9c in SNL and   
          sham-operated rats ................................................................................175 
4.3.5  Spinal Tat-NR2B9c reverses behavioural mechanical and cold  
          hypersensitivity in SNL rats ....................................................................181 
4.3.6  Spinal Tat-NR2B9c does not alter locomotor performance in the  
          rotarod test .............................................................................................185 
4.4  Discussion.....................................................................................................187 
 
5  Involvement of atypical protein kinase C zeta (PKCζ /PKMζ) in  
    NMDA-dependent  spinal central sensitization...............................................192 
5.1  Introduction....................................................................................................192 
5.1.1  The Protein Kinase C family...................................................................192 
5.1.2  PKC in primary afferent fibres ................................................................192 
5.1.3  PKC in the spinal cord............................................................................194 
5.1.4  Atypical PKCζ/PKMζ and role in hippocampal LTP ...............................195 
5.1.5  Atypical PKCζ/PKMζ in pain ..................................................................197 
 
 
 
 18 
5.2  Materials and Methods ..................................................................................198 
5.2.1  Animals...................................................................................................198 
5.2.2  PKCζ/PKMζ inhibitor ..............................................................................198 
5.2.3  Behavioural Formalin Test .....................................................................199 
5.2.4  In vivo Electrophysiology........................................................................200 
5.2.4.1  Neuronal Formalin Test ...................................................................200 
5.2.5  Statistical Analysis for Formalin Test .....................................................200 
5.2.6  Immunohistochemistry for phospho-PKCζ and c-Fos ............................201 
5.2.7  Statistical Analysis for Immunohistochemistry .......................................202 
5.2.8  Immunoprecipitation of NR2B subunits and downstream Western  
          Immunoblotting.......................................................................................203 
5.3  Results ..........................................................................................................204 
5.3.1  Spinal pre-treatment with an inhibitor of PKCζ/PKMζ reduces  
          pain-related behaviours due to formalin-induced central sensitization...204 
5.3.2  Formalin-induced central sensitization of deep dorsal horn WDR  
          neurones is reduced by spinal inhibition of PKCζ/PKMζ........................206 
5.3.3  PKCζ/PKMζ is involved in the upregulation of c-Fos after formalin  
          injection ..................................................................................................209 
5.3.4  Phosphorylation of dorsal horn PKCζ/PKMζ is induced by intraplantar  
          formalin and is prevented by spinal administration of Tat-NR2B9c........211 
5.3.5  Formalin-induced upregulation of p-PKCζ is within intrinsic dorsal  
          horn neurones ........................................................................................213 
5.3.6  Co-immunoprecipitation of NMDA receptor NR2B subunits and PSD-95  
          reveals a novel interaction with PKCζ in spinal dorsal horn neurones...214 
5.4  Discussion.....................................................................................................216 
 
6  The role of phosphatidylinositol 3-kinase (PI3K) in NMDA-dependent  
    spinal nociceptive plasticity .............................................................................221 
6.1  Introduction....................................................................................................221 
6.1.2  Structure & function of Phosphatidylinositol-3-kinase ............................221 
6.1.3  Protein kinase mediators of PI3K signalling ...........................................223 
6.1.4  PI3K in brain LTP ...................................................................................224 
6.1.5  PI3K in pain pathways............................................................................225 
6.2  Materials and Methods ..................................................................................227 
 
 
 
 19 
6.2.1  In vivo Electrophysiology........................................................................227 
6.2.1.1  Electrical stimulation of the hindpaw ...............................................227 
6.2.1.2  Statistical Analysis...........................................................................227 
6.2.2  Behavioural Formalin Test .....................................................................228 
6.2.2.1  Statistical Analysis...........................................................................228 
6.2.3  Preparation of tissues for Immunohistochemistry and Western  
          Immunoblotting.......................................................................................229 
6.2.3.1  For phospho-Akt, phospho-ERK & phospho-CAMKII  
             Immunohistochemistry ....................................................................229 
6.2.3.2  For Western Immunoblotting of NMDA & AMPA receptor  
             subunits ...........................................................................................229 
6.2.4  Immunohistochemistry for phospho-Akt, phospho-ERK &  
          phospho-CaMKII ....................................................................................230 
6.2.5  Western Immunoblotting of phospho-NR2A & phospho-NR2B..............231 
6.2.6  Translocation of AMPA receptor subunit GluR1.....................................232 
6.3  Results ..........................................................................................................233 
6.3.1  Spinal application of LY294002 selectively reduces C-fibre evoked  
          responses and post-discharge of deep dorsal WDR neurones..............233 
6.3.2  Wind-up of deep dorsal horn WDR neurones is reduced by spinal  
          LY294002 ...............................................................................................235 
6.3.3  Inhibition of PI3K reduces pain-related behaviours due to central     
          sensitization induced by intraplantar formalin ........................................237 
6.3.4  Phosphorylation of Akt in spinal neurones following intraplantar  
          formalin...................................................................................................239 
6.3.5  Spinal LY294002 reduces the increase in ERK phosphorylation in the  
          dorsal horn after formalin injection in the hindpaw .................................241 
6.3.6  Spinal LY294002 prevents the increase in CaMKII phosphorylation in  
          the dorsal horn after formalin injection in the hindpaw ...........................243 
6.3.7  Spinal LY294002 prevents phosphorylation of NMDA receptor NR2B  
          subunits in the dorsal horn after formalin injection in the hindpaw.........245 
6.3.8  PI3K regulates the trafficking of dorsal horn AMPA receptor GluR1  
          subunits after formalin injection in the hindpaw......................................247 
6.4  Discussion.....................................................................................................249 
 
 
 
 
 20 
7  Involvement of dimethylarginine dimethylaminohydrolase-1 (DDAH-1) in  
    NMDA-dependent spinal nociceptive plasticity ..............................................255 
7.1  Introduction....................................................................................................255 
7.1.1  NMDA-NO signalling in the brain ...........................................................255 
7.1.2  A role for nitric oxide and nitric oxide synthases in pain at the spinal  
          level ........................................................................................................256 
7.1.3  Endogenous regulation of NOS by ADMA and DDAH ...........................258 
7.1.4  Expression of DDAH-1 and DDAH-2......................................................260 
7.1.5  Novel targeting of DDAH isoforms in disease ........................................260 
7.1.6  DDAH in the nervous system and possible role in pain .........................261 
7.2  Materials and Methods ..................................................................................262 
7.2.1  Animals...................................................................................................262 
7.2.2  Western Immunoblotting of DDAH-1 and DDAH-2 in neuronal  
          tissues ....................................................................................................262 
7.2.3  DDAH-1 specific inhibitor, L-291 and control inactive enantiomer,  
          L-456 ......................................................................................................263 
7.2.4  In vivo Electrophysiology........................................................................264 
7.2.4.1  Electrical stimulation of the hindpaw ...............................................264 
7.2.4.2  Neuronal Formalin Test ...................................................................264 
7.2.5  Behavioural Formalin Test .....................................................................265 
7.2.6  DDAH-1+/- mice Behavioural Formalin Test............................................265 
7.2.7  Statistical Analysis..................................................................................266 
7.3  Results ..........................................................................................................267 
7.3.1  DDAH-1 and DDAH-2 protein is expressed in DRG, spinal dorsal horn  
          and hippocampus ...................................................................................267 
7.3.2  Spinal L-291 inhibits C-fibre evoked responses and post-discharge of  
          deep dorsal horn WDR neurones ...........................................................269 
7.3.3  Wind-up of deep dorsal horn WDR neurones is reduced by spinal  
          L-291 ......................................................................................................272 
7.3.4  Formalin-induced central sensitization of deep dorsal horn WDR  
          neurones is reduced by spinal pre-treatment with L-291 .......................274 
7.3.5  Spinal L-291 inhibits pain-related behaviours in rats due to  
          formalin-induced central sensitization ....................................................277 
7.3.6  Spinal L-291 reduces formalin-induced pain-related active licking  
 
 
 
 21 
          and biting and reflexive lifting and flinching behaviours .........................279 
7.3.7  No change in formalin-induced pain-related behaviours in DDAH-1+/-  
          mice........................................................................................................281 
7.4  Discussion.....................................................................................................284 
 
8  Final Discussion.................................................................................................289 
8.1  NMDA-dependent spinal nociceptive plasticity can be prevented without  
       NMDA receptor blockade but through modulation of protein interactions .....289 
8.2  Disruption of interactions between NR2B-containing NMDA receptors and  
       PSD-95 can reverse neuropathic pain ..........................................................290 
8.3  Importance of dorsal horn NR2B-containing NMDA receptors in nociceptive  
       plasticity and neuropathic pain ......................................................................290 
8.4  PKCζ/PKMζ and PI3K signalling pathways are implicated downstream  
       of NMDA receptor activation in NMDA-dependent spinal nociceptive  
       plasticity ........................................................................................................291 
8.5  DDAH-1 may be an alternative target to nNOS in the treatment of pain .......291 
8.6  Possible interplay between NMDA-dependent intracellular signalling  
       pathways in dorsal horn neurones ................................................................292 
8.7  Wind-up initiates central sensitization and is a neuronal correlate of pain  
       hypersensitivity..............................................................................................296 
8.8  The Formalin Model of Pain ..........................................................................297 
8.9  Spinal administration of drugs .......................................................................303 
8.10  Ideas for future work....................................................................................305 
8.11  Closing Remarks .........................................................................................307 
 
9  References..........................................................................................................309 
 
 
 
 
 
 22 
List of Figures 
 
Fig 1.1: LʼHomme, René Descartes (1664)................................................................27 
Fig. 1.2: The peripheral terminal of nociceptors. ........................................................34 
Fig. 1.3: Peripheral sensitization of nociceptors produces primary hyperalgesia. .....37 
Fig. 1.4: Laminar arrangement of the dorsal horn. .....................................................43 
Fig. 1.5: Anatomy of ascending and descending projections between the dorsal  
              horn and the brain. .......................................................................................51 
Fig. 1.6: Wind-up of dorsal horn neurones is a likely basis for temporal summation  
              of pain rating in humans...............................................................................65 
Fig. 1.7: Intracellular mechanisms within dorsal horn neurones contribute to spinal  
              central sensitization......................................................................................72 
Fig. 1.8: Loss of spinal GABAergic and glycinergic inhibition leads to mechanical  
              allodynia. ......................................................................................................75 
Fig. 1.9: Increased serotonergic and decreased noradrenergic drive from the  
              brainstem contributes to spinal central sensitization....................................80 
Fig. 1.10: Structure of the NMDA receptor channel. ..................................................83 
Fig. 2.1: In vivo electrophysiology setup. ...................................................................91 
Fig. 2.2: Schematic of the NeuroLog data capture system. .......................................92 
Fig. 2.3: Representative post-stimulus histogram (PSTH) of electrically evoked  
              responses of a WDR neurone to electrical stimulation of the hindpaw. .......94 
Fig. 2.4: Example of a rate recording of the characteristic biphasic response of a  
              WDR neurone to formalin injection at the hindpaw receptive field. ..............96 
Fig. 2.5: Spinal nerve ligation (SNL) surgery..............................................................99 
Fig. 2.6: Behavioural testing for neuropathic pain-related behaviour following SNL  
              surgery. ......................................................................................................102 
Fig. 2.7: Example of a rate histogram displaying action potentials evoked from a  
              WDR neurone by thermal stimulation of the hindpaw receptive field. ........104 
Fig. 2.8: An accelerating rotarod device to assess locomotor performance. ...........106 
Fig. 2.9: Example western immunoblots obtained using (a) autoradiography or  
              (b) direct fluorescence................................................................................111 
Fig. 2.10: Immunoprecipitation protocol using magnetic Dynabeads® Protein G. ....114 
Fig. 3.1: Structure of Post-synaptic density protein-95.............................................122 
Fig. 3.2: The synaptic NMDA receptor complex.......................................................126 
 
 
 
 23 
Fig. 3.3: PSD-95 is absent in DRG but present in the dorsal horn and forms a  
              ternary complex with NR2B-subtype NMDA receptors and nNOS within  
              intrinsic dorsal horn neurones. ...................................................................135 
Fig. 3.4: Spinal Tat-NR2B9c decreases hyperexcitability of WDR neurones...........138 
Fig. 3.5: Spinal Tat-NR2B9c selectively reduces wind-up of WDR neurones. .........140 
Fig. 3.6: Spinal Tat-NR2B9c reduces formalin-induced central sensitization of  
              WDR neurones...........................................................................................143 
Fig. 3.7: Intrathecal Tat-NR2B9c reduces pain-related behaviours due to  
              formalin-induced central sensitization. .......................................................145 
Fig. 3.8: Intrathecal Tat-NR2B9c selectively reduces active pain-related licking  
              and biting behaviours following intraplantar formalin. ................................147 
Fig. 4.1: SNL surgery induces robust and long-lasting behavioural mechanical and  
              cold hypersensitivity of the injured paw......................................................169 
Fig. 4.2: Spinal Tat-NR2B9c decreases hyperexcitability of WDR neurones in both  
              sham and SNL rats. ...................................................................................172 
Fig. 4.3: Spinal Tat-NR2B9c selectively reduces wind-up of WDR neurones in both  
              sham and SNL rats.. ..................................................................................174 
Fig. 4.4: Brush evoked responses of WDR neurones are not significantly altered in  
              either sham or SNL rats by spinal Tat-NR2B9c. ........................................178 
Fig. 4.5: Mechanically evoked responses of WDR neurones are reduced in both  
              sham and SNL rats by spinal Tat-NR2B9c. ...............................................179 
Fig. 4.6: Thermally evoked responses of WDR neurones are reduced in both sham  
              and SNL rats by spinal Tat-NR2B9c. .........................................................180 
Fig. 4.7: Intrathecal Tat-NR2B9c reverses nerve injury-induced behavioural  
              mechanical hypersensitivity. ......................................................................183 
Fig. 4.8: Intrathecal Tat-NR2B9c reverses nerve injury-induced behavioural cold  
              hypersensitivity...........................................................................................184 
Fig. 4.9: Intrathecal Tat-NR2B9c does not alter locomotor function.........................186 
Fig. 5.1: Activation of PKCζ/PKMζ. ..........................................................................196 
Fig. 5.2: Intrathecal PKCζ/PKMζ pseudosubstrate inhibitor reduces pain-related  
              behaviours due to formalin-induced central sensitization...........................205 
Fig. 5.3: Spinal PKCζ/PKMζ pseudosubstrate inhibitor reduces formalin-induced  
              central sensitization of WDR neurones. .....................................................208 
 
 
 
 
 24 
Fig. 5.4: Inhibition of spinal PKCζ/PKMζ reduces formalin-induced upregulation  
              of c-Fos. .....................................................................................................210 
Fig. 5.5: Intrathecal Tat-NR2B9c reduces formalin-induced phosphorylation of  
              PKCζ/PKMζ. ..............................................................................................212 
Fig. 5.6: Identification of spinal cell types expressing phospho-PKCζ following  
              intraplantar formalin. ..................................................................................213 
Fig. 5.7: Identification of a novel NR2B-associated complex with PSD-95 and  
              PKCζ in spinal dorsal horn neurones. ........................................................215 
Fig. 6.1: Structure of the PI3K p85 regulatory subunit and phosphoinositide  
              pathway......................................................................................................222 
Fig. 6.2: Spinal LY294002 decreases C-fibre evoked responses and  
              post-discharge of WDR neurones. .............................................................234 
Fig. 6.3: Spinal LY294002 selectively reduces wind-up of WDR neurones. ............236 
Fig. 6.4: Intrathecal LY294002 reduces pain-related behaviours due to  
              formalin-induced central sensitization. .......................................................238 
Fig. 6.5: Intraplantar formalin-induced phosphorylation of spinal Akt is reduced by  
              LY294002...................................................................................................240 
Fig. 6.6: LY294002 reduces formalin-induced phosphorylation of spinal ERK. .......242 
Fig. 6.7: LY294002 reduces formalin-induced phosphorylation of spinal CaMKII....244 
Fig. 6.8: LY294002 prevents formalin-induced phosphorylation of spinal NMDA  
              receptor NR2B subunits. ............................................................................246 
Fig. 6.9: LY294002 alters trafficking of AMPA receptor GluR1 subunits following  
              intraplantar formalin. ..................................................................................248 
Fig. 7.1: DDAH/ADMA regulation of NOS.  NOS converts L-arginine to NO and  
              citrulline. .....................................................................................................259 
Fig. 7.2: Chemical structure of DDAH-1 inhibitor L-291 (IC50 20 µM).......................263 
Fig. 7.3: Expression of DDAH-1 and DDAH-2 protein in neuronal tissues...............268 
Fig. 7.4: Spinal L-291 decreases C-fibre evoked responses and post-discharge of  
              WDR neurones...........................................................................................271 
Fig. 7.5: Spinal L-291 selectively reduces wind-up of WDR neurones.....................273 
Fig. 7.6: Spinal L-291 reduces formalin-induced central sensitization of WDR  
              neurones. ...................................................................................................276 
Fig. 7.7: Intrathecal L-291 reduces pain-related behaviours due to formalin-induced  
              central sensitization....................................................................................278 
 
 
 
 25 
Fig. 7.8: Intrathecal L-291 reduces both active licking and biting and reflexive lifting  
              and flinching pain-related behaviours following intraplantar formalin.........280 
Fig. 7.9: DDAH+/- mice have normal behavioural responses to intraplantar  
              formalin. .....................................................................................................282 
Fig. 8.1: NMDA-dependent intracellular signalling within dorsal horn sensory  
              neurones promotes spinal central sensitization. ........................................295 
 
 
 
 
 
 
 26 
List of Tables 
 
Table 1.1: Additional neurotransmitters acting with the spinal dorsal horn. ...............60 
Table 2.1: List of antibodies used in immunohistochemistry (IHC) experiments......115 
Table 2.2: List of antibodies used in immunoprecipitation (IP) and  
                 western blotting (WB) experiments .........................................................116 
Table 3.1: Pre-drug control responses induced by transcutaneous electrical  
                 stimulation of the hindpaw receptive field of WDR neurones in rats  
                 treated with Tat-NR2B9c or Tat-NR2BAA. ..............................................137 
Table 3.2: WDR cell characteristics from Tat-NR2B9c neuronal formalin test.........142 
Table 4.1: Some common Neuropathic Pain diseases and conditions. ...................158 
Table 4.2: Pre-drug control responses induced by transcutaneous electrical  
                 stimulation of the hindpaw receptive field of WDR neurones in sham  
                 and SNL rats. ..........................................................................................171 
Table 4.3: Pre-drug control responses induced by natural stimulation of the  
                 hindpaw receptive field of WDR neurones in sham and SNL rats...........177 
Table 5.1: WDR cell characteristics from PKCζ/PKMζ pseudosubstrate inhibitor  
                 neuronal formalin test..............................................................................207 
Table 7.1: Pre-drug control responses induced by transcutaneous electrical  
                 stimulation of the hindpaw receptive field of WDR neurones in rats  
                 treated with L-456 or L-291. ....................................................................275 
 
Chapter 1 
 
 
 27 
1  Introduction 
 
 
"Fast moving particles of fire...the disturbance passes along the  
nerve filament until it reaches the brain…" Descartes (1664) 
 
 
René Descartes envisaged that pain was transmitted directly from the periphery to 
the brain by a single, direct, dedicated pain pathway (Fig. 1.1).  Today we now 
recognise this pathway as being the nociceptive system, part of the wider 
somatosensory system.  However, the transmission of pain signals from the 
periphery, through the spinal cord and up to the cortex of the brain undergoes 
extensive processing through the nervous system at various anatomical locations.  
The dorsal horn of the spinal cord, in particular, is a key site for modulation of 
noxious information.  Thus, the relationship between detection of noxious stimuli at 
the periphery and pain perception in the brain is far from linear. 
 
 
 
 
Fig 1.1: LʼHomme, René Descartes (1664) 
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1.1  Acute Pain 
 
According to the International Association for the Study of Pain (IASP), pain is 
defined as ʻan unpleasant sensory and emotional experience associated with actual 
or potential tissue damage, or described in terms of such damageʼ.  This definition 
reminds us that pain involves both physical and psychological components which 
contribute to its perception. 
 
Acute or nociceptive pain is a defence mechanism which protects the body from 
tissue injury by potentially harmful and damaging stimuli.  Nociceptors, specialized 
sensory neurones, detect such threatening stimuli and notify the central nervous 
system so that an appropriate behavioural response can be made, for example 
withdrawal from a hot surface.  Without such a defence mechanism, injuries would be 
common and of such severity that survival may be compromised, as highlighted by 
those individuals born without nociceptors and who suffer from various frequent 
painless injuries, including burns, fractures and even biting of their own lips and 
tongues due to their congenital insensitivity to pain (Indo et al., 1996; Woolf and Ma, 
2007).  Alternatively, pain may be associated with a specific underlying disease or 
injury and can be a sign of illness that provokes appropriate measures such as rest 
or medication to be taken.  Pain due to a muscular injury, for example, will promote 
rest of the injured limb and facilitate healing.    
 
 
1.2  Chronic Pain 
 
It is when any previous underlying injury or disease has not resolved and so the 
origins of the sensory event continues beyond the acute phase, that pain no longer 
serves a purpose and loses its usefulness, becoming a primary clinical problem itself.  
In this scenario, pain is a hindrance to daily life, the quality of which is greatly 
diminished.  Here, pain is caused by dysfunction of the somatosensory system, 
brought about by inflammation or neuropathy, and should be regarded as a disease 
in its own right, particularly when it is significantly prolonged and becomes chronic.  A 
recent large-scale European study was conducted to understand the prevalence and 
impact of chronic pain (Breivik et al., 2006).  Patients were defined as having chronic 
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pain if they had suffered pain for more than six months, had experienced pain within 
the last month, experienced pain at least two times per week and rated the intensity 
of their latest pain experience to be at least 5 out of 10 on a numerical rating scale, 
where 1 represents no pain at all and 10 represents the worst pain imaginable.  With 
these criteria in place, it was found that 19% of European adults were suffering from 
chronic pain, half of whom suffered pain constantly and a third of whom had pain of 
severe intensity (Breivik et al., 2006).  While the economic cost of chronic pain is 
estimated to be €200 billion per annum in Europe (Tracey and Mantyh, 2007), 
significant emotional and social costs are also suffered by patients.  Comorbidites 
such as depression, anxiety and sleep disorders are common.  Chronic pain also 
reduces the ability of patients to socialize and maintain relationships and can have a 
significant negative impact on employment, further exacerbating the economic 
burden.  In contrast to the adequate management of acute pain, the needs of chronic 
pain patients are largely unmet, with 40% of chronic pain sufferers feeling that their 
pain is not managed well, citing a lack of good drug treatments as well as a lack of 
recognition by their doctor for their pain as being more than just a symptom for this 
dissatisfaction.  Thus, a greater appreciation for chronic pain as a disease entity, 
improved diagnostic procedures and the development of novel pharmacological 
treatments are desperately required to combat the clinical problem of chronic pain.  
Development of novel treatments will be aided by a greater understanding of the 
sensory system and the pathological mechanisms which convert acute pain to 
chronic pain. 
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1.3  The Pain Pathway 
 
 
1.3.1  Peripheral sensory afferent fibres  
 
The sensory experience begins in the periphery, where the peripheral terminals of 
primary afferent fibres respond to a myriad of stimuli and translate this information 
through electrical signals into the dorsal horn of the spinal cord, where the central 
ends of these fibres terminate.  There are three main types of sensory neurone fibres 
in the peripheral nervous system, Aβ-fibres, Aδ-fibres and C-fibres, with each 
possessing different properties allowing them to respond to and transmit different 
types of sensory information.  Aβ-fibres are large in diameter and highly myelinated, 
thus allowing them to quickly conduct action potentials from their peripheral to central 
terminals, at approximately 30-80 m/s.  These fibres have low activation thresholds 
and normally respond to light touch and joint position and are responsible for 
conveying tactile information.  Aδ-fibres are smaller in diameter and thinly 
myelinated, making them slower conducting than Aβ-fibres at 6-30 m/s, and they also 
possess higher activation thresholds.  They respond to both thermal and mechanical 
stimuli.  Aδ-fibres can be further subdivided into two main categories, based on their 
thermal sensitivity.  Type I Aδ-fibres respond to very high heat (≈ 50°C) while type II 
Aδ-fibres are activated at lower noxious heat temperatures (≈ 42°C).   C-fibres are 
the smallest type of primary afferents and are unmyelinated, thus making them the 
slowest conducting, at 0.5-2 m/s.  They have the highest thresholds for activation and 
therefore detect selectively nociceptive or ʻpainfulʼ stimuli.  There are two main 
classes of C-fibres, peptidergic and non-peptidergic (see 1.3.1.1 below).  Collectively 
both Aδ-fibres and C-fibres can be termed as nociceptors or ʻpain fibresʼ, responding 
to noxious mechanical, thermal or chemical stimuli.  It is assumed that Aδ-fibre 
nociceptors mediate ʻfastʼ pain which can be described as well-localized, acute, 
sharp pain, while C-fibre nociceptors mediate ʻsecond painʼ which is delayed, more 
diffuse and dull (Julius and Basbaum, 2001).   
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1.3.1.1  Development of two classes of C-fibre nociceptors 
 
Approximately 70-80% of all rodent dorsal root ganglion (DRG) neurones require 
nerve growth factor (NGF) for survival during embryonic life and it is widely accepted 
that these neurones are small to medium-diameter nociceptors, particularly of the 
unmyelinated C-fibre class.  These nociceptors express TrkA, the tyrosine kinase 
receptor for NGF, during development and early post-natal life.  The fundamental 
importance of NGF-TrkA signalling in development of the nociceptive system is 
highlighted by patients who suffer from congenital insensitivity to pain due to 
mutations in the TrkA gene (Indo et al., 1996).  However, three weeks into rodent 
post-natal life a large proportion of TrkA expression in the DRG is lost, such that in 
the adult animal, only 40-50% of all DRG neurones express TrkA.  Thus TrkA is 
developmentally regulated (Silos-Santiago et al., 1995; Molliver and Snider, 1997).  
These TrkA-expressing nociceptors in the adult co-express the neuropeptides 
calcitonin gene-related peptide (CGRP) and substance P (SP) (Bennett et al., 
1996a), and thus are peptidergic C-fibres.  In contrast, nociceptors which lack TrkA in 
adult life are of the non-peptidergic C-fibre class and bind the isolectin IB4 (Silos-
Santiago et al., 1995; Bennett et al., 1996b).  The downregulation of TrkA in these 
non-peptidergic C-fibres coincides with an upregulation of Ret, an alternative receptor 
tyrosine kinase, which is responsive to glial cell line-derived neurotrophic factor 
(GDNF) (Bennett et al., 1998).  The peptidergic, TrkA-expressing C-fibres represent 
roughly 40% of all DRG sensory neurones, while the non-peptidergic Ret-expressing 
C-fibres represent approximately 30% (Snider and McMahon, 1998).  Regardless of 
their peptide content, all nociceptors contain and release glutamate as their 
predominant excitatory neurotransmitter.                  
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1.3.1.2  Peripheral terminals of sensory fibres 
 
The peripheral terminals of polymodal nociceptors are where noxious stimuli are 
detected and transduced to generate currents which in turn drive action potentials 
along axons towards the spinal cord and onto higher centres for the conscious 
perception of pain (Woolf and Ma, 2007).  A number of receptors and ion channels 
on nociceptors can be selectively activated by noxious thermal, mechanical or 
chemical stimuli and thus confer the sensory specificity of the nociceptor (Fig. 1.2).  
The expression of such high threshold transduction molecules, including many 
channels of the transient receptor potential (TRP) family, is in contrast to low 
threshold transducers found on large diameter sensory neurones which respond 
exclusively to innocuous stimuli.   
 
In the case of noxious heat, it is widely believed that the TRPV1 (transient receptor 
potential vanilloid receptor-1) receptor channel, which responds to capsaicin, the 
extract of chilli peppers, is also responsible for the generation of action potentials 
following application of noxious heat at or above 42°C (Caterina et al., 1997).  Both 
IB4+ and CGRP+ C-fibre nociceptors as well as type II Aδ-fibre nociceptors respond 
to capsaicin and thus are believed to express TRPV1 (Snider and McMahon, 1998).  
The endogenous ligand for this receptor is unclear, however, although the 
cannabinoid anandamide is one potential candidate (Melck et al., 1999; Zygmunt et 
al., 1999).  More recent work has identified multiple TRP channels, including TRPV2, 
TRPV3 and TRPV4, which, along with TRPV1, mediate responsiveness of 
nociceptors in the warm to hot range (Dhaka et al., 2006).  In addition, activity of a 
heat-activated, two-pore domain potassium channel (TREK1) rises in response to 
increased heat and thus may also contribute to heat-evoked activity of nociceptors 
(Alloui et al., 2006).  Type I Aδ-fibre nociceptors respond to higher intensity noxious 
heat and this may be mediated by a capsaicin-insensitive, TRPV1-like channel with 
an activation threshold of approximately 50°C and which is expressed exclusively in 
medium to large diameter-sized sensory neurones (Caterina et al., 1999).   
 
Sensitivity to cooling and noxious cold is widely accepted to be mediated by another 
member of the TRP family, the TRPM8 (TRP melastatin 8) channel which is the 
receptor for menthol.  Genetic knockout studies have shown that TRPM8-deficient 
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sensory fibres have diminished responses to cooling stimuli and mice lacking TRPM8 
have reduced behavioural responses to both cooling and noxious cold, and 
interestingly, injury-induced cold hypersensitivity (Bautista et al., 2007; Colburn et al., 
2007; Dhaka et al., 2007).  However, some sensitivity to particularly intense noxious 
cold was retained in TRPM8-/- mice, indicating that an as yet unidentified transduction 
molecule contributes to the sensation of extreme cold pain. 
 
Specific transduction molecules on the peripheral terminals of nociceptors also exist 
for chemical sensitivity.  In addition to capsaicin, TRPV1 can also be activated by 
protons and spider toxins (Dhaka et al., 2006).  The TRPA1 (TRP ankyrin 1) channel 
is expressed by C-fibre nociceptors and is a major integrator of various noxious 
chemical stimuli, including allyl isothiocyanate (AITC) and allicin, the pungent 
ingredients in mustard and garlic extracts, respectively, as well as unsaturated 
aldehydes, such as acrolein, which mediate the irritant actions of air pollutants (Woolf 
& Ma, 2007).  Furthermore, TRPA1 has been found to be specifically activated by 
formalin and to mediate formalin-induced pain, a widely used model (McNamara et 
al., 2007).  C-fibres also express a large number of purinergic receptors that respond 
to ATP (adenosine triphosphate).  In particular, the ATP-gated P2X3 ion channel is 
almost exclusively expressed in small-sized sensory neurones and approximately 
90% of these are non-peptidergic C-fibre nociceptors (Vulchanova et al., 1997). 
 
High threshold C-fibre and Aδ-fibre nociceptors terminate in the skin as free nerve 
endings, though some low threshold Aδ-fibres terminate on down hairs in the skin for 
the detection of light touch.  In contrast, Aβ-fibres innervate Merkel cells, Pacinian 
corpuscles and hair follicles for the detection of texture, vibration and light pressure 
(Basbaum et al., 2009).  At present, it remains unclear precisely how noxious 
mechanical stimulation is detected and transduced by sensory neurones, though 
several candidate transducers have been proposed, including acid-sensing ion 
channels (ASICs).  Various mutations in different ASICs can alter mechanoreceptor 
sensitivity in vivo (Price et al., 2000; Price et al., 2001).  More recently, Wetzel and 
colleagues have shown that genetic knockout of an integral membrane protein, called 
stomatin-like protein 3 (SLP3), results in a loss of mechanosensitivity in both low 
threshold Aβ-fibres and higher threshold Aδ-fibres.  SLP3 was found to 
immunoprecipitate along with various ASICs, and these ASICs were no longer 
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functional in SLP3-/- mice.  Nerve injury-induced mechanical hypersensitivity was also 
impaired in SLP3-/- mice (Wetzel et al., 2007).  Thus, SLP3 seems to be an essential 
subunit associated with some unidentified mechanotransduction molecules in A-
fibres, possibly ASICs.  In contrast, a mechanism for mechanotransduction in high 
threshold C-fibres has yet to be elucidated.   
 
 
 
 
 
 
 
Fig. 1.2: The peripheral terminal of nociceptors.  A myriad of transduction 
molecules are expressed at the peripheral terminals of nociceptors.  These receptors 
and channels respond to different stimuli including heat (TRPV1, other TRPs & 
TREK1), cold (TRPM8), chemicals (TRPV1, TRPA1, P2X3 & ASICs) and mechanical 
stimulation (SLP3 & ASICs).    
 
Chapter 1 
 
 
 35 
1.3.1.3  Peripheral sensitization  
 
The peripheral terminals of nociceptors can be excited by a number of endogenous 
chemical mediators, especially in conditions of tissue damage or inflammation, 
produced and released from local non-neuronal cells, the afferent fibres themselves, 
the vasculature and from products triggered by activation of the bodyʼs defense 
mechanisms.  These chemical mediators, commonly referred to as an ʻinflammatory 
soupʼ consisting of NGF, ATP, protons, bradykinin, prostaglandins (PGs) such as 
PGE2, substance P, CGRP and pro-inflammatory cytokines, act on specific receptors, 
sensitizing the peripheral terminals of nociceptors so that afferent activity to a given 
stimulus is increased, heightening pain (Fig. 1.3).  This is known as primary 
hyperalgesia and is characterized by thermal and mechanical hypersensitivity within 
the territory of the injury. 
 
TRPV1 seems to be a key molecular target activated following tissue damage, 
resulting in a profound decrease in the thermal activation threshold of the channel as 
well as increased responsiveness at higher temperatures.  The contribution of NGF 
to peripheral sensitization, in addition to its known developmental effects, has been 
well demonstrated, not least by the observation that peripheral administration of NGF 
is proalgesic (Lewin et al., 1994; Petty et al., 1994; McMahon et al., 1995).  NGF 
acting at TrkA receptors on peptidergic C-fibres activates downstream intracellular 
signalling pathways including phospholipase C (PLC), mitogen-activated protein 
kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K), the consequence of which 
seems to be potentiation of TRPV1 responsiveness (Julius and Basbaum, 2001).  
NGF is also thought to promote increased expression of TRPV1 (Ji et al., 2002b).  In 
addition to NGF, bradykinin, acting via BK2 receptors, has also been shown to 
promote TRPV1 sensitization, by stimulating downstream PLC which subsequently 
leads to activation of protein kinase C (PKC).  Accordingly, intraplantar administration 
of PKC inhibitors has been shown to inhibit bradykinin-induced mechanical 
hypersensitivity (Souza et al., 2002).  PKC can phosphorylate TRPV1 and thus 
increase capsaicin-induced currents, and can also promote exocytosis and 
depolarization of TRPV1.  In particular, the PKCε isozyme in primary afferents is 
translocated to the cell membrane in response to bradykinin (Cesare et al., 1999) 
and PKCε-/- mice have reduced primary hyperalgesia in response to chemical 
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mediators (Khasar et al., 1999).  Bradykinin may also increase TRPV1 sensitivity via 
a PKC-independent mechanism, involving PLC-mediated hydrolysis of 
phosphatidylinositol 4,5-bisophosphate (PIP2), thus relieving PIP2-mediated inhibition 
of TRPV1 (Chuang et al., 2001).  Other chemical mediators, such as protons and 
lipids, act as allosteric modulators of TRPV1.  In addition to TRPV1, TRPA1 and 
ASICs may also mediate some of the sensitizing effects of peripherally released 
chemical mediators following tissue damage or inflammation (Basbaum et al., 2009).  
In relation to this thesis, TRPA1 is activated by formalin, driving central sensitization 
of dorsal horn neurones (McNamara et al., 2007).   
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Fig. 1.3: Peripheral sensitization of nociceptors produces primary 
hyperalgesia.  Tissue damage or inflammation causes the release of an 
ʻinflammatory soupʼ, including prostaglandins, NGF and bradykinin.  Such mediators 
activate their receptors and initiate intracellular signalling cascades, such as protein 
kinase A (PKA), PKC, MAPK and PI3K, which then phosphorylate and sensitize 
transduction molecules, resulting in heightened nociceptor activity in response to 
subsequent stimuli, producing mechanical and thermal hypersensitivity within the 
territory of the injury. 
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1.3.1.4  Plasticity of sensory fibre Na+ channels in pain 
 
Voltage-gated sodium (Na+) channels have a primary role in nervous system 
signalling.  Opening of channels causes influx of Na+ ions into the cell, resulting in 
membrane depolarization and action potential generation and propagation from the 
peripheral to central terminals of primary sensory neurones.  Na+ channels may also 
regulate cellular excitability to incoming signals.  To date, nine different Na+ channel 
isoforms, Nav1.1–Nav1.9, have been cloned, and these are expressed in various 
tissues throughout the body (Chahine et al., 2005).  In the adult rodent, three 
channels, Nav1.7, Nav1.8 and Nav1.9, are normally expressed in primary sensory 
neurones.  Nav1.3 is expressed in embryonic neurones but absent in the adult, 
except when upregulated following nerve injury (Dib-Hajj et al., 2010).  All Na+ 
channels can be classified on the basis of their sensitivity to blockade by tetrodotoxin 
(TTX) and thus a particular channel may be described as being either TTX-sensitive 
(TTX-S) or TTX-resistant (TTX-R).   
 
Chronic pain states involve a number of peripheral changes in nerves in terms of 
electrogenesis and activity, in which Na+ channels are causally implicated.  Damaged 
or inflamed nerves may start to generate ongoing ectopic activity due to the 
accumulation and clustering of Na+ channels around the damaged axons.  This 
aberrant activity can then start to spread rapidly to the cell bodies in the dorsal root 
ganglia.  Nerve fibres can start to cross-excite each other (ephaptic transmission) 
and the same occurs in the cell bodies.  These peripheral ectopic impulses can 
cause spontaneous pain and prime the spinal cord to exhibit enhanced evoked 
responses to stimuli, which themselves have greater effects due to increased 
sensitivity of the peripheral nerves.  Animal studies have implicated four channels, 
Nav1.3, Nav1.7, Nav1.8 and Nav1.9, in pathological neuropathic and inflammatory 
pain states.   
 
Nav1.3 is a TTX-S channel specifically associated with neuropathy, since it is not 
normally expressed in adult sensory neurones but is greatly upregulated after 
peripheral nerve injury (Wood et al., 2004).  In particular, Nav1.3 is clustered in both 
rat and human neuromas, implicating the channel in aberrant ectopic action potential 
generation (Black et al., 1999; Black et al., 2008).  However, behavioural data 
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regarding the involvement of Nav1.3 in neuropathic pain is conflicting since genetic 
knockout of Nav1.3 does not alter the pain phenotype of mice following nerve injury 
(Nassar et al., 2006).  Nav1.7 is a TTX-R channel preferentially expressed in small-
sized primary sensory neurones but also present in some large neurones.  
Conditional genetic knockout of Nav1.7 in nociceptors abolishes inflammatory pain, 
while neuropathic pain is normal (Nassar et al., 2004; Nassar et al., 2005).  
Expression of the TTX-R channel Nav1.8 is specific to small and medium-sized 
sensory neurones and thus has an exclusive role in nociception.  The role of this 
channel in pain has been extensively investigated in Nav1.8 knockout mice.  These 
mice exhibit deficits in somatic and visceral inflammatory pain (Akopian et al., 1999; 
Laird et al., 2002).  In contrast, any role for this channel in neuropathic pain is not so 
clear.  Nav1.8 knockout mice as well as double knockouts of both Nav1.7 and Nav1.8 
develop normal levels of neuropathic pain (Akopian et al., 1999; Nassar et al., 2005).  
However, damaged sensory axons in Nav1.8 knockout mice show significantly 
reduced spontaneous activity (Roza et al., 2003), suggesting that Nav1.8 may 
contribute to nerve injury-induced ectopic activity and spontaneous pain, perhaps not 
adequately measured in behavioural studies.  Indeed, Nav1.8 levels have been 
shown to increase in non-injured axons, thus possibly contributing to spontaneous 
action potential generation (Gold et al., 2003).  In addition, electrophysiological and 
behavioural studies in Nav1.8 knockout mice suggest a role for this channel in 
mechanosensation (Akopian et al., 1999; Matthews et al., 2006).  Like Nav1.8, Nav1.9 
is a TTX-R channel and is expressed exclusively in non-peptidergic C-fibres.  A role 
for Nav1.9 in contributing to nerve injury-induced pain is unclear since the channel is 
downregulated after axotomy (Dib-Hajj et al., 1998) and Nav1.9 knockout mice 
develop neuropathic pain normally.  However, inflammatory pain is clearly impaired 
in Nav1.9 knockout mice (Amaya et al., 2006).   
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1.3.1.5  Na+ channels in human genetic pain syndromes  
 
In recent years, Nav1.7 has drawn much attention since various mutations in this 
channel have been found to cause human pain disorders.  Dominant gain-of-function 
mutations in the gene encoding for Nav1.7 lead to hyperexcitability of the channel and 
have been linked to inherited erythermalgia, a chronic inflammatory human disease, 
and to paroxysmal extreme pain disorder (Estacion et al., 2008; Dib-Hajj et al., 2010).  
Symptoms of both diseases include intense burning sensations (Basbaum et al., 
2009).  In contrast, recessive loss-of-function mutations in Nav1.7 lead to congenital 
insensitivity to pain (Cox et al., 2006).  Additionally, painful human neuromas have 
been shown to have increased expression of Nav1.3 and Nav1.8 (Black et al., 2008). 
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1.3.1.6  Central terminals of sensory fibres 
 
The central terminals of primary afferent fibres enter the spinal cord via the dorsal 
root entry zones and terminate in specific regions of the dorsal horn (see section 
1.3.2), synapsing with second order dorsal horn sensory neurones.  All sensory fibres 
release glutamate (De Biasi and Rustioni, 1988; Broman et al., 1993), the 
predominant excitatory neurotransmitter in the central nervous system (CNS).  
Peptidergic C-fibres as well as some Aδ-fibres release CGRP.  In addition, 
peptidergic C-fibres may also release substance P, brain-derived neurotrophic factor 
(BDNF), somatostatin and galanin (Ju et al., 1987).  Action potentials entering the 
central terminal activate the vesicle-release machinery to induce neurotransmitter 
release, a process dependent on Ca2+ influx into the afferent terminal.  Accordingly, 
nociceptors express various N-, P/Q- and T-type voltage-gated Ca2+ channels, of 
which Cav2.2 seems to be most important (Woolf and Ma, 2007).  Ziconitide, a 
blocker of Cav2.2 channels, is analgesic, acting by inhibition of neurotransmitter 
release.  Interestingly, in addition to the main pore-forming α subunit of Ca2+ 
channels, accessory proteins, such as the α2δ subunit, are known to have 
fundamental roles in the control of neurotransmitter release during nociceptive 
signalling, particularly since C-fibres upregulate α2δ in nerve injury-induced pain (Luo 
et al., 2001).  The α2δ subunit regulates activation and inactivation kinetics and 
perhaps also membrane targeting of Ca2+ channels (Davies et al., 2007).  The 
anticonvulsant drugs gabapentin and pregabalin have analgesic efficacy, thought to 
be mediated by binding to α2δ subunits, likely reducing trafficking and thus 
modulating neurotransmitter release (Gee et al., 1996; Field et al., 2006; Hendrich et 
al., 2008; Bauer et al., 2009).  Intriguingly, despite not being exposed to the 
environment, the central terminals of primary afferent fibres closely resemble their 
peripheral terminals in that they express similar receptors and channels such as 
TRPV1, TRPA1, P2X3 and BK2 receptors (Snider and McMahon, 1998; Woolf and 
Ma, 2007).  It is believed that activation of these pre-synaptic receptors in the dorsal 
horn acts to increase neurotransmitter release, particularly glutamate, from 
nociceptors.  In contrast, inhibition mediated by opioid receptors, γ-amino butyric acid 
(GABA) receptors and CB1 receptors for cannabinoids, located on primary afferent 
terminals, acts to counter neurotransmitter release  (Woolf and Ma, 2007). 
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1.3.2  Anatomical arrangement of the dorsal horn of the spinal cord 
 
Within the grey matter of the dorsal horn, intrinsic spinal neurones can be 
anatomically divided into two main classes with regard to their terminations.  Those 
cells with axons remaining within the spinal cord are classified as interneurones, and 
these may be either excitatory, through the release of glutamate, or inhibitory, 
through the release of GABA and/or glycine.  On the other hand, projection neurones 
have axons which ascend through the white matter and terminate in the brain, and 
are mainly glutamatergic.  Furthermore, descending axons from various brain 
structures also enter the dorsal horn of the spinal cord and may exert either inhibitory 
or excitatory effects on intrinsic neurones or afferent fibres.  Thus, intrinsic dorsal 
horn excitatory and inhibitory interneurones, together with descending influences 
from the brain, can modulate the transmission of sensory information through the 
dorsal horn, regulating the final output of the spinal cord to higher centres (D'Mello 
and Dickenson, 2008). 
 
The dorsal horn of the spinal cord is organized into different, anatomically diverse 
laminae, extending from the superficial to the deep dorsal horn (Fig. 1.4).  In the early 
1950s, Rexed first divided the spinal cord grey matter of the cat into a series of 
parallel laminae, numbered I to X, providing a uniform description of the arrangement 
of the spinal cord regardless of the particular spinal segment under investigation 
(Rexed, 1952, 1954).  This scheme has since been applied to other species, 
including rodents.  Together, laminae I and II are often described as the superficial 
dorsal horn and this is the main region for terminating nociceptive primary afferents.  
The remainder of the dorsal horn comprises four further laminae (III-VI), with laminae 
V-VI often collectively referred to as the deep dorsal horn.  Laminae VII-IX form the 
ventral horn of the spinal cord, while lamina X, or substantia grisea centralis, is the 
region around the central canal. 
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Fig. 1.4: Laminar arrangement of the dorsal horn.  Sensory fibres extend from the 
periphery, via the DRG where their cell bodies are located, into the dorsal horn of the 
spinal cord, terminating in specific regions.  Nociceptive Aδ and C-fibres terminate 
mainly within the superficial laminae (I-II), synapsing with NS spinal neurones, 
though some may reach deeper laminae via their deeply penetrating processes.  In 
contrast, Aβ-fibres terminate in deep laminae III-V.  Spinal cells in laminae V-VI are 
mainly WDR neurones.  A large population of excitatory interneurones within lamina 
II connect superficial nociceptor terminals to deep WDR neurones.  Alternatively, 
some WDR neurones may have dorsally extending dendrites which synapse with 
nociceptors.  Adapted from DʼMello and Dickenson (2008).    
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1.3.2.1  Lamina I 
 
Lamina I is a thin, marginal layer covering the outermost region of the dorsal horn 
grey matter.  Many Aδ-fibre and C-fibre nociceptors terminate in this layer, though 
some penetrate deeper into the dorsal horn.  Specifically, it is the peptidergic 
CGRP/TrkA-expressing C-fibres which terminate in lamina I, with some also reaching 
the most outer part of lamina II (IIo).  Since mostly nociceptors terminate in this 
region, approximately 75% of second order spinal cord neurones located here are 
nociceptive-specific (NS) cells (Bester et al., 2000; Seagrove et al., 2004), which 
receive synaptic inputs from Aδ- and C-fibres only.  These cells fire action potentials 
when a painful stimulus is detected at the periphery, and have connectivity with other 
neurones with cell bodies within the same or deeper laminae.  In addition, many of 
the cells resident in lamina I are projection neurones, their axons decussating at the 
level of the spinal cord and travelling up through the white matter to reach 
contralateral brain structures such as the parabrachial area (PB) and thalamus 
(Todd, 2002). 
 
 
1.3.2.2  Lamina II 
 
Lamina II is also known as the substantia gelatinosa and contains mainly 
interneurones which make connections with intrinsic spinal neurones but do not 
project to higher centres.  The mid-region of lamina II is where non-peptidergic IB4+ 
C-fibres terminate, as well as some Aδ-fibres, and thus the majority of cells here are 
NS neurones.  The most ventral portion, lamina II inner (IIi), contains a small subset 
of dorsal horn neurones which express the γ isoform of PKC (PKCγ).  The vast 
majority of these interneurones (92%) do not contain GABA and thus are deemed to 
be excitatory (Polgar et al., 1999).  Mice lacking the PKCγ isozyme have normal 
acute pain sensitivity but fail to develop neuropathic pain following nerve injury 
(Malmberg et al., 1997) and evidence suggests that PKCγ-expressing interneurones 
may convey tactile inputs from terminating Aβ-fibres in laminae III-IV to superficial NS 
projection neurones, a pathway which is under inhibitory control in the normal animal 
(Martin et al., 2001; Miraucourt et al., 2007). 
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1.3.2.3  Laminae III – IV 
 
Laminae III and IV are primarily responsive to innocuous mechanical stimulation 
conveyed by terminating Aβ-fibres.  Dorsal horn cells in this region are thus tactile or 
proprioceptive.  In addition, many neurones in laminae III and IV have dorsally 
extending dendrites and project to brain structures, thus contributing to the 
spinothalamic tract (Todd, 2002; DʼMello and Dickenson, 2008).   
 
 
1.3.2.4  Lamina V  
 
Dorsal horn neurones in lamina V receive monosynaptic inputs from terminating Aβ-
fibres and some deeply penetrating Aδ-fibres.  In contrast, polysynaptic inputs from 
superficially terminating C-fibres are mediated via interneurones (Braz et al., 2005).  
Alternatively, dendrites of lamina V neurones may extend dorsally to make synaptic 
contacts with C-fibres (Woolf and King, 1987).  Therefore, second order lamina V 
sensory neurones receive inputs from all three types of sensory fibre and respond to 
the full range of stimulation, from light touch to noxious pinch, heat and chemicals.  
These cells are thus appropriately termed wide dynamic range (WDR) neurones.  
WDRs also reside in lamina VI.  Many lamina V WDR neurones are believed to 
project to higher centres and thus constitute a major output of the dorsal horn, in 
addition to lamina I projection neurones.  Lamina V is of great relevance to the 
studies presented in this thesis, since all electrophysiological recordings of WDR 
neurones were conducted in this region of the dorsal horn. 
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1.3.2.5  Electrophysiological response properties of intrinsic  
             dorsal horn sensory neurones 
 
NS cells fire action potentials only when a noxious stimulus is applied at the 
peripheral receptive field, since they are normally innervated exclusively by 
nociceptors.  For example, NS cells will not fire action potentials below the heat pain 
threshold in rats of 42°C, although there can be a paradoxical response to brush 
(Bester at al., 2000; Seagrove et al., 2004).  Transcutaneous electrical stimulation of 
the receptive field produces little, if any, post-discharge or wind-up of NS cells 
(Seagrove et al., 2004), two measures of neuronal hyperexcitability and short-term 
synaptic plasticity (see section 1.5.1).  In contrast, WDR neurones fire action 
potentials in response to both innocuous and noxious thermal and mechanical 
stimuli, conveyed by the three types of sensory fibres, in a graded fashion (Suzuki et 
al., 2002b).  Responses to heat, for example, begin at approximately 32°C and 
increase with rising temperatures.  WDR neurones also respond to noxious cold as 
well as innocuous brushing of the receptive field, which is larger than that of NS cells.  
In addition, WDRs display greater responses, including a large amount of post-
discharge and wind-up, following transcutaneous electrical stimulation of the 
receptive field (Suzuki et al., 2002b).  Finally, proprioceptive cells in laminae III-IV, 
which receive inputs exclusively from Aβ-fibres, are easily identifiable since they 
respond to light touch and brushing of the receptive field only.  This response 
subsides when stimulus intensity increases and enters the noxious range.  Thus 
these cells do not respond to pinch, for example (personal observations).  
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1.3.2.6  Contribution of non-neuronal glial cells to dorsal horn  
             nociceptive processing  
 
Traditionally, the role of non-neuronal glial cells was thought to be a supportive one, 
providing metabolic homeostasis for neurones and immune surveillance within the 
central nervous system (McMahon and Malcangio, 2009).  However, growing 
evidence from the pain field now suggests that glial cells within the spinal cord, 
namely microglia and astrocytes, are also able to influence pain transmission through 
the dorsal horn by regulating neuronal function, particularly under pathological 
conditions.  Injection of inflammatory substances into the hindpaw or peripheral nerve 
injury has been shown to coincide with induction of a pain-related enhanced 
response state of glia (McMahon and Malcangio, 2009), as evidenced by 
immunohistochemical analysis of glial markers such as ionized calcium binding 
adaptor molecule 1 (Iba1; microglia), CD11b (OX-42; microglia) and glial fibrillary 
acidic protein (GFAP; astrocytes), as well as alterations of glial cell morphology.  
Furthermore, pharmacological inhibition of glial activity is analgesic in various pain 
models (Meller et al., 1994b; Watkins et al., 1997; Coyle, 1998; Jin et al., 2003; 
Raghavendra et al., 2003; Clark et al., 2007).  Thus, although the principal focus of 
the studies presented in this thesis is on neuronal mechanisms of spinal nociceptive 
plasticity, the contribution of non-neuronal glial cells should not be underestimated.  
As this field grows, accumulating evidence suggests that targeting non-neuronal cells 
may be a potentially beneficial strategy for the treatment of chronic pain (Scholz and 
Woolf, 2007; McMahon and Malcangio, 2009). 
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1.3.3  Anatomy of ascending projections from the dorsal horn to the brain 
 
The output from the dorsal horn to higher centres in the brain is carried by spinal 
projection neurones along ascending pathways (Fig. 1.5).  A large population of 
projection neurones are found superficially in lamina I, estimated to number 400 on 
each side of a particular spinal segment.  The majority of these cells have axons 
which cross the midline and ascend in the contralateral white matter (Todd, 2002).  It 
is estimated that 80% of these cells express the neurokinin 1 (NK1) receptor for 
substance P (Todd, 2002), a neuropeptide which is released by nociceptive afferents, 
meaning that these cells respond to noxious stimulation (Mantyh et al., 1997; Mantyh 
and Hunt, 2004).  NK1+ cells in lamina I have been shown to project to areas in the 
brain such as the thalamus, the periaqueductal grey (PAG) and brainstem structures 
such as the caudal ventrolateral medulla (CVLM) and, in particular, the PB.  In fact, 
projections from lamina I to the PB far outnumber those to the thalamus, 
subsequently reaching limbic structures such as the amygdala and hypothalamus, 
thus contributing largely to the affective component of pain (Todd, 2002).  From the 
PB, signals are also transmitted to other brainstem areas such as the PAG and the 
rostroventromedial medulla (RVM), a region which has descending projections back 
to the dorsal horn.  Therefore, lamina I NK1-expressing cells can modulate spinal 
processing by activation of descending pathways from the brainstem, thus forming a 
spino-bulbo-spinal loop (Suzuki et al., 2002b).  These descending pathways can be 
influenced by limbic regions in the brain and so can be altered by mood and 
attention.  A large number of projection neurones, many of them also expressing the 
NK1 receptor, are also found deeper in the dorsal horn, scattered throughout lamina 
III to VI, and these project predominantly to the thalamus, thereby making up a 
significant proportion of the spinothalamic tract.  This ascending pathway carries 
primarily sensory information and so provides the sensory discriminative component 
of the pain experience.  Many of these deep lying projection neurones have dendrites 
which extend upwards to the superficial dorsal horn, thus allowing them to make 
synaptic contacts with terminating C-fibres and receive noxious inputs (Woolf and 
King, 1987; Todd, 2002). 
 
From the thalamus, nociceptive information is transmitted to cortical regions.  There 
does not exist a single pain centre within the cortex, but rather there are multiple 
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cortical regions which may or may not be activated during a particular painful 
experience.  These regions make up what is commonly referred to as a ʻpain matrixʼ 
and include primary and secondary somatosensory, insular, anterior cingulate and 
prefrontal cortices (Tracey and Mantyh, 2007).     
 
 
1.3.4  Anatomy of descending projections from the brain to the dorsal horn  
 
Descending pathways from supraspinal structures are able to influence nociceptive 
transmission in the dorsal horn of the spinal cord.  Such descending influences may 
be either excitatory (descending facilitation) or inhibitory (descending inhibition) in 
nature (Fig. 1.5) and may equally engage primary afferent terminals or intrinsic dorsal 
horn cells, both interneurones and projection neurones.  In this way, the brain 
influences the final output from the dorsal horn to cortical regions of the brain where 
pain is perceived.  Several key supraspinal structures have been indentified which 
can directly or indirectly modulate the dorsal horn, including the PAG in the midbrain 
and brainstem nuclei such as the PB, RVM and locus coeruleus (LC).  Such 
descending modulatory pathways access the spinal cord via the dorsolateral and 
ventrolateral funiculi.  In addition, many of the structures implicated in descending 
modulation can exert both facilitatory and inhibitory influences in the dorsal horn, 
dependent on the context of the situation.     
 
Early studies demonstrated that electrical stimulation of the PAG could produce 
analgesia in the dorsal horn (Reynolds, 1969; Basbaum and Fields, 1984).  However, 
direct projections from the PAG to the cord are few in number.  Rather, the PAG 
projects to and modulates the output of brainstem nuclei and in this indirect way 
alters nociceptive processing in the dorsal horn.  Similar connectivity exists from the 
PB to the dorsal horn and these projections predominantly suppress responses of 
superficial dorsal horn neurones to both innocuous and noxious inputs (Millan, 2002).  
Numerous transmitters may be released by PAG and PB projection neurones 
including substance P, cholecystokinin (CCK), GABA and endogenous opioids 
(Millan, 2002).  Recent work has identified a small population of dopaminergic 
neurones in the PAG which mediate antinociception (Flores et al., 2004).   
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The RVM in the brainstem receives the majority of its sensory inputs relayed through 
the PAG and PB, and in turn, sends axons directly to both superficial and deep 
dorsal horn laminae (Millan, 2002).  Initial work suggested that the descending 
influence from the RVM is inhibitory since electrical stimulation in this region 
produces analgesia via profound inhibition of noxious inputs to superficial and deep 
dorsal horn neurones (Basbaum et al., 1976; Fields et al., 1976; Fields et al., 1977).  
More recent work, however has demonstrated that descending facilitatory pathways 
also originate from the RVM, particularly in chronic pain states (Burgess et al., 2002; 
Bee and Dickenson, 2007).  This bidirectional control of spinal processing is 
mediated by two distinct populations of RVM cells.  ON cells produce a burst of firing 
in response to peripheral noxious stimulation and are inhibited by endogenous 
opioids, thus they are believed to trigger descending facilitation.  In contrast, OFF 
cells are inhibited by noxious inputs since they display a transient disruption in their 
firing immediately prior to a nociceptive reflex and they are disinhibited by 
endogenous opioids, thus they are implicated in descending inhibition (Fields et al., 
1983; Heinricher et al., 1992; Bannister et al., 2009).  Though the precise 
neurochemistry of these cells remains to be elucidated, evidence implicating 
serotonin (5-HT) release from the RVM in the dorsal horn in mediating descending 
facilitation supports the notion that ON cells may be serotonergic.  Whatever the 
neurochemical signature of ON and OFF cells, it is clear that a range of 
neurotransmitters are released by descending axons from the RVM, including 5-HT, 
GABA and endogenous opioids, acting at multiple receptor subtypes coupled to 
different intracellular signalling molecules within the dorsal horn (Millan, 2002).     
 
Noradrenaline (NA), acting predominantly at the α2-adrenoceptor subclass within the 
dorsal horn, is believed to contribute significantly to descending inhibition by 
inhibiting transmitter release from primary afferent terminals and suppressing the 
firing of projection neurones in the dorsal horn (Millan, 2002; DʼMello and Dickenson, 
2008).  Brainstem sources of NA include the A1-A7 nuclei, including the locus 
coeruleus (Kwiat and Basbaum, 1992; Bannister et al., 2009).   
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Fig. 1.5: Anatomy of ascending and descending projections between the 
dorsal horn and the brain.  Spinal projection neurones may reach thalamic nuclei 
(TN) or may engage structures such as the parabrachial area (PB) and 
periaqueductal grey (PAG).  From these sites, projections may reach limbic 
structures such as the hypothalamic (HN) and amygdala nuclei (AN).  Descending 
modulation is mainly mediated via the locus coeruleus (LC) and rostroventromedial 
medulla (RVM) in the brainstem. Adapted from Hunt and Mantyh (2001) and Tracey 
and Mantyh (2007). 
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1.4  Neurotransmitters and neuromodulators acting in the dorsal horn 
 
A myriad of neurotransmitters and neuromodulators are released within the dorsal 
horn of the spinal cord and can alter processing of sensory information.  Sources of 
such transmitters include terminating primary afferents, intrinsic dorsal horn 
neurones, descending axons from supraspinal sites or even dorsal horn microglia 
and astrocytes.  Some key excitatory and inhibitory neurotransmitters and 
neuromodulators are now described in further detail.  (Additional neurotransmitters 
and neuromodulators are provided in Table 1.1).  
 
 
1.4.1  Glutamate  
 
Glutamate is an excitatory amino acid and is the major excitatory neurotransmitter 
found throughout the whole of the nervous system.  Since it is released by primary 
afferent fibres, by dorsal horn neurones, and by neurones in the brain, glutamate is 
essential for nociceptive signalling at every anatomical level.  Descending axons from 
the brain also release glutamate  (Wiertelak et al., 1994; Millan, 2002), as may dorsal 
horn glia.  In particular, astrocytes are not only important for regulating extracellular 
glutamate concentrations but may also release glutamate (McMahon and Malcangio, 
2009).  In addition to sensory perception and nociception, glutamate is involved in 
numerous CNS functions, including movement and learning and memory.   
 
There are two classes of glutamate receptor, metabotropic and ionotropic, present in 
the dorsal horn (Furuyama et al., 1993; Tolle et al., 1993).  The metabotropic class 
(mGluRs) are G protein-coupled receptors (GPCRs) and are made up of 
combinations of eight different subunits, mGluR1-8, and several of these have been 
detected in the dorsal horn.  The subunits mGluR3-5 and mGluR7 are located mainly 
superficially in both primary afferent terminals and local dorsal horn neurones, while 
mGluR1 is found mainly in deeper dorsal horn neurones (Vidnyanszky et al., 1994; 
Ohishi et al., 1995; Jia et al., 1999; Azkue et al., 2001; Walker et al., 2001).  The 
ionotropic class comprises three separate families, kainate, α-amino-3-hydroxy-5-
methyl-4-isoxazoleproprionic acid (AMPA) and N-methyl-D-aspartate (NMDA) 
receptors.  Kainate receptors are tetrameric in structure and generally have an 
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excitatory role, being expressed both in pre-synaptic afferent terminals and on the 
post-synaptic membranes of dorsal horn neurones (Bleakman et al., 2006).  AMPA 
receptors are formed from four subunits, GluR1-4, and are also tetrameric.  They are 
found at most, if not all, glutamatergic synapses throughout the spinal grey matter, as 
well as pre-synaptically in primary afferent terminals (Lee et al., 2002; Nagy et al., 
2004b).  The third family in this class are the NMDA receptors, which again form 
tetramers from combinations of seven different subunits, NR1, NR2A-D and NR3A-B.  
In the dorsal horn, a combination of the NR1 subunit and one NR2 subunit come 
together to form functional receptors.  The NR1 subunit is present throughout the 
grey matter (Tolle et al., 1993; Nagy et al., 2004a).  Both NR2A and NR2B subunits 
can also be found in most dorsal horn laminae, though the NR2B subunit is densely 
concentrated in laminae I-II and the NR2A subunit in laminae III-IV (Nagy et al., 
2004a).  Expression of NR2B has also been detected in primary afferent terminals 
(Yung, 1998; Boyce et al., 1999) of both A-fibres and C-fibres (Ma and Hargreaves, 
2000; Marvizon et al., 2002).  Dorsal horn NMDA receptors are the main focus of this 
thesis and their role in nociceptive processing and plasticity is discussed further 
below (see sections 1.6 & 1.7). 
 
 
1.4.2  Substance P 
 
Substance P is part of the tachykinin family of neuropeptides.  It is synthesized 
predominantly in small and some medium-sized neurones in the DRG, and is 
released from both peripheral and central afferent terminals.  In the dorsal horn, 
substance P-containing afferents terminate mainly in superficial laminae (I and IIo) 
with a less dense distribution in laminae III-IV (Todd, 2002).  In addition, a limited 
pool of substance P may also be released from descending axons from the RVM or 
from superficial spinal interneurones which co-express the opioid enkephalin (Hokfelt 
et al., 2000; Ribeiro-da-Silva and Hokfelt, 2000).  Three neurokinin receptors are 
expressed in the dorsal horn, NK1, NK2 and NK3.  Substance P has the greatest 
binding affinity for the NK1 receptor, and this receptor is the most abundant of the 
three in the dorsal horn (Ohkubo and Nakanishi, 1991; Todd, 2002).  Spinal NK1 
receptors are most densely located on lamina I neurones (Liu et al., 1994), many of 
which are projection neurones, while dorsally-extended dendrites of deep projection 
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neurones found in lamina III and IV also express the NK1 receptor (Naim et al., 1997; 
Todd, 2002).  NK2 receptors are present in a population of astrocytes in the 
superficial dorsal horn, while NK3 receptors are present in interneurones in laminae I-
III (McCarson and Krause, 1994; Seybold et al., 1997; Zerari et al., 1998).  Finally, 
both NK1 and NK3 receptors may be present on terminals of peptidergic C-fibres in 
order to regulate substance P release (Malcangio and Bowery, 1999).  
 
 
1.4.3  Calcitonin gene-related peptide (CGRP) 
 
Primary afferent terminals are believed to be the major, if not exclusive, source of 
CGRP in the dorsal horn.  These terminals belong mostly to peptidergic C-fibres as 
well as a few medium-to-large-sized A-fibres.  Removal of primary afferent input, by 
dorsal rhizotomy, results in an almost complete loss of CGRP immunoreactivity in the 
dorsal horn, evident of the fact that intrinsic spinal neurones and descending axons 
do not express this neuropeptide (Chung et al., 1988).  CGRP-containing fibres 
terminate in laminae I, II and V and form synapses with spinothalamic projection 
neurones and interneurones and also have connections with pre-synaptic terminals 
of non-peptidergic C-fibres.  Thus, CGRP receptors not only exist on post-synaptic 
neurones, but also on pre-synaptic terminals, acting as auto- or hetero-receptors to 
regulate neurotransmitter release.  The densest staining for CGRP receptors is in the 
superficial dorsal horn (Ye et al., 1999).  Such CGRP receptors are trimeric 
complexes consisting of the calcitonin-like receptor (CLR) (Njuki et al., 1993), the 
receptor activity-modifying protein 1 (RAMP1) (McLatchie et al., 1998) and a 
cytoplasmic receptor component protein (RCP) (Luebke et al., 1996).  These receptor 
complexes form GPCRs which activate downstream protein kinase A (PKA).  
 
 
1.4.4  Brain-derived neurotrophic factor (BDNF) 
 
As well as functioning as a trophic factor during development, BDNF has a 
neuromodulatory role in the adult.  In the dorsal horn, BDNF is mainly released from 
peptidergic C-fibre terminals in laminae I-II (Zhou et al., 2004).  More recent studies 
have indicated that microglia may also release BDNF in the dorsal horn in response 
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to peripheral nerve injury (Coull et al., 2005).  BDNF-containing afferents terminate in 
lamina II of the dorsal horn and their terminals also express the tyrosine kinase B 
receptor (TrkB) for BDNF (Salio et al., 2005) which may function to modulate 
neurotransmitter release, while lamina II spinothalamic projection neurones also have 
TrkB (Slack et al., 2005).  Evidence suggests that BDNF may facilitate both 
glutamatergic and GABAergic transmission in the dorsal horn (Pezet et al., 2002; 
Slack and Thompson, 2002).   
 
 
1.4.5  Nitric oxide (NO) 
 
Synthesis of NO in neurones is by neuronal nitric oxide synthase (nNOS), which is 
predominantly located in the superficial dorsal horn (Valtschanoff et al., 1992; Spike 
et al., 1993; Morris et al., 1994).  Intriguingly, various studies have demonstrated that 
nNOS is almost exclusively expressed in superficial GABAergic interneurones 
(Valtschanoff et al., 1992; Spike et al., 1993; Laing et al., 1994; Bernadi et al., 1995).  
The exact role of nNOS in these GABAergic interneurones remains unknown.  
However, some of the nNOS expression in these cells is found in their dorsally-
extending dendrites where GABA is not expressed, and NO may be released from 
such sites (Bernadi et al., 1995).  Since nitric oxide (NO) is a diffusible messenger, its 
effects may not necessarily be spatially restricted and it may spread up to a radius of 
100 µm (Wood and Garthwaite, 1994), thus engaging various neurones within the 
superficial dorsal horn which may be in close synaptic contact (Ruscheweyh et al., 
2006; Schmidtko et al., 2008; Garthwaite, 2008).  Cells in the dorsal horn which 
express the NO receptor, guanylate cyclase, include projections neurones and local 
excitatory and inhibitory interneurones.  Immunohistochemical evidence has shown 
these cells to lie very close to those cells which contain nNOS, often making contact.  
Co-localization between nNOS and guanylate cyclase is infrequent, suggesting that 
NO diffuses and acts in a paracrine manner (Ding and Weinberg, 2006).  In the DRG, 
nNOS expression is low and is restricted to peptidergic C-fibres (Aimi et al., 1991; 
Zhang et al., 1993).  Recently, it has been shown that the NO receptor, guanylate 
cyclase, is not present in DRG neurones but only in intrinsic dorsal horn cells, 
including NK1-expressing projection neurones (Schmidtko et al., 2008).  This would 
suggest that the contribution of NO signalling in pre-synaptic primary afferent 
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neurones is minimal, and that NO acts predominantly on intrinsic post-synaptic spinal 
sites.  Therefore, these findings challenge the hypothesis that NO acts as a 
retrograde neurotransmitter, released from spinal sites and acting on peripheral 
nerve terminals to increase neurotransmitter release.  It is more likely that NO is 
released from afferents and spinal neurones and acts exclusively at intrinsic spinal 
sites to produce sensitization of nociceptive signalling (Schmidtko et al., 2009). 
 
 
1.4.6  GABA & Glycine 
 
Inhibitory interneurones are present throughout the grey matter of the dorsal horn. 
Many of these co-express both GABA and glycine, particularly in superficial laminae, 
while some contain only GABA and a few in deeper laminae contain only glycine 
(Todd and Sullivan, 1990).  Many of these interneurones are directly stimulated by 
low threshold mechanoreceptors (Yoshimura and Nishi, 1995), conforming to the 
Gate Control Theory of pain (Melzack and Wall, 1965), or even by descending axons 
(Kato et al., 2006).  GABAA and glycine receptors are ionotropic channels permeable 
to chloride ions (Cl-) whereas GABAB receptors are GPCRs.  Despite both GABA and 
glycine receptors being expressed in lamina I, inhibitory post-synaptic currents here 
are mainly glycinergic, suggesting that only glycine receptors are located at synapses 
while GABAA receptors may be extra-synaptic (Chery and de Koninck, 1999).  In 
lamina II, both glycine and GABA exert equal inhibitory influences (Keller et al., 
2001).  GABAA receptors on primary afferent terminals also modulate 
neurotransmitter release (Rudomin and Schmidt, 1999).   
 
 
1.4.7  Endogenous opioids 
 
Two types of endogenous opioid peptides exist in the dorsal horn, enkephalins and 
dynorphins.  Enkephalins are most abundant and are contained in spinal neurones in 
laminae I and II (Todd and Spike, 1993), as well as in descending axons from 
supraspinal sites (Song and Marvizon, 2003), but are not present in primary afferent 
terminals (Pohl et al., 1994).  Additional spinal neurones contain dynorphins and 
these are mainly located in laminae I, II and V (Cruz and Basbaum, 1985; Todd and 
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Spike, 1993).  Dynorphins may also be present in primary afferent terminals 
(Botticelli et al., 1981).  Both enkephalins and dynorphins are agonists at the three 
classical opioid receptors, µ (MOR), δ (DOR) and κ (KOR), all of which couple to 
inhibitory Gi/o proteins that subsequently inhibit cAMP (cyclic adenosine 
monophosphate) formation, open K+ channels and inactivate Ca2+ channels to 
mediate analgesia (Watkins et al., 1992; Takemori and Portoghese, 1993; Budai and 
Fields, 1998).  MORs in the dorsal horn are located on superficial neurones which 
have axons projecting ventrally to laminae III-V (Eckert et al., 2003).  KORs are 
mostly expressed by lamina II neurones whereas DORs are scattered throughout the 
dorsal horn (Morris and Herz, 1987; Minami and Satoh, 1995).  All three types of 
receptor are expressed on terminals of C-fibres and thus modulate neurotransmitter 
release (Fields et al., 1980).  Finally, pronociceptive effects of dynorphins have been 
reported, particularly in chronic pain states in which spinal dynorphin content 
increases.  Such effects of dynorphins in pathological conditions may be mediated by 
actions on spinal bradykinin BK2 receptors located on primary afferent terminals, thus 
promoting neurotransmitter release (Lai et al., 2006).  Atypical opioid receptors in the 
dorsal horn include the nociceptin 1 (NOP1) receptor, also known as the opioid 
receptor-like 1 (ORL-1) receptor due to its 50% homology to the classical receptors 
(Mogil and Pasternak, 2001).  NOP1 also couples to an inhibitory Gi/o protein and the 
endogenous ligand seems to be orphanin FQ/nociceptin (OFQ/N) rather than the 
known endogenous opioids (Meunier et al., 1995; Reinscheid et al., 1995).  At 
present, the exact effects of NOP1 activation at the spinal level are unclear and may 
be both hyperalgesic and analgesic. 
 
 
1.4.8  Cannabinoids 
 
The cannabinoid system can contribute to the processing of nociceptive transmission 
(Hohmann, 2002).  Cannabinoid receptors CB1 and CB2 are associated with sites 
involved in pain signalling and may be activated by endocannabinoids such as 
anandamide (AEA).  The CB1 receptor is known to function as an inhibitory receptor, 
via coupling to an inhibitory Gi/o protein.  In nociception, therefore, CB1 receptors 
exert an analgesic effect which may be mediated at the peripheral or central 
terminals of nociceptive afferents or on excitatory spinal dorsal horn neurones (Drew 
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et al., 2000; Kelly and Chapman, 2001; Kelly et al., 2003; Agarwal et al., 2007).  For 
example, activation of CB1 receptors on peptidergic C-fibre terminals has been 
shown to inhibit release of CGRP (Ahluwalia et al., 2003).  However, a pronociceptive 
role for CB1 receptors has recently been suggested to occur via expression on 
inhibitory spinal interneurones, thus mediating spinal disinhibition (Salio et al., 2002; 
Pernia-Andrade et al., 2009).  CB2 receptors are not present in the CNS of normal 
animals, though peripheral CB2 receptors do exist and also mediate antinociception 
(Malan et al., 2001).  However, following peripheral nerve injury, CB2 receptors are 
functionally upregulated in the spinal dorsal horn (Zhang et al., 2003) and mediate 
inhibitory effects (Sagar et al., 2005; Yamamoto et al., 2008). 
 
 
1.4.9  Serotonin (5-HT) 
 
The release of 5-HT within the dorsal horn is almost exclusively from axons 
descending from supraspinal sites, in particular the RVM in the brainstem, which 
terminate in both superficial and deep laminae (Millan, 2002).  Once released, 5-HT 
can exert both anti- and pro-nociceptive roles dependent on the receptors activated 
and the cell types expressing them.  Numerous 5-HT receptors, 5-HT1-7, have been 
detected in the dorsal horn and can influence terminating primary afferents, spinal 
projection neurones or inhibitory interneurones (Millan, 2002).  For example, 5-HT1A/B 
receptors are inhibitory GPCRs and are believed to directly inhibit dorsal horn 
neurones (el-Yassir et al., 1988).  In addition, 5-HT1B receptors on peptidergic C-
fibres can inhibit release of SP and CGRP (Arvieu et al., 1996; Ma et al., 2001).  In 
contrast, the 5-HT3 receptor is an excitatory ligand-gated cation channel and thus 
promotes neuronal excitability.  5-HT3 receptors are abundant in the superficial dorsal 
horn and a significant proportion of these receptors are found on nociceptor 
terminals, thus promoting neurotransmitter release (Saria et al., 1990; Maricq et al., 
1991; Morales et al., 1998; Zeitz et al., 2002).   
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1.4.10  Noradrenaline (NA) 
 
NA is released in the dorsal horn by descending axons from noradrenergic brainstem 
nuclei, such as the locus coeruleus and subcoeruleus (Kwiat and Basbaum, 1992; 
Millan, 2002).  Spinal adrenergic receptors include the α1 and α2 subtypes which can 
account for both inhibitory and excitatory effects of dorsal horn NA release.  Inhibitory 
effects of NA are largely mediated by spinal α2A receptors which may reduce primary 
afferent release of neurotransmitters and activity of spinal neurones (Yaksh et al., 
1995; Suzuki et al., 2002a).  Conversely, α2C receptors may be located on inhibitory 
interneurones and thus may disinhibit spinal projection neurones, producing a 
facilitatory effect (Olave and Maxwell, 2004).  Additionally, excitatory α1 receptors can 
exert either facilitatory or inhibitory effects on spinal nociception via their expression 
on projection neurones and inhibitory interneurones, respectively (Gassner et al., 
2009). 
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Transmitter 
 
Sources in 
dorsal horn 
 
Receptor 
Excitatory 
or 
Inhibitory 
Location 
Somatostatin 
C-fibres, 
Interneurones, 
Descending 
axons 
sst2A Inhibitory 
Dorsal horn 
neurones 
Adenosine 
triphosphate 
(ATP) 
 
GABAergic 
interneurones? 
 
P2X3 
 
P2X4 
 
P2X7 
 
Excitatory 
 
Excitatory 
 
Excitatory 
 
Nociceptors  
 
Microglia 
 
Microglia 
 
Cholecystokinin 
(CCK) 
 
Interneurones, 
Descending 
axons 
CCKB Excitatory Afferents 
Galanin 
 
Primary 
afferents, 
Interneurones 
 
GalR1 
 
GalR2 
Inhibitory 
 
Excitatory 
Interneurones 
 
Afferents  
Neuropeptide 
Tyrosine (NPY) 
Interneurones 
Y1 
 
Y2 
Inhibitory 
 
Inhibitory 
Afferents & 
Interneurones 
 
Afferents 
 
 
Table 1.1: Additional neurotransmitters acting with the spinal dorsal horn. 
(Liu and Hokfelt, 2002; Millan, 2002; Hokfelt et al., 2007; Tsuda et al., 2010) 
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1.5  Spinal dorsal horn nociceptive plasticity 
 
The spinal cord is an important relay site at which various incoming sensory and 
nociceptive signals undergo convergence and modulation.  Spinal neurones are 
under ongoing control by peripheral inputs, interneurones and descending controls.  
One consequence of this modulation is that the relationship between stimulus and 
response to pain is not always straightforward.  The response of output cells can be 
greatly altered following a peripheral afferent barrage, as produced by electrical 
stimulation, inflammation or nerve damage, via the interaction of various 
neurotransmitter systems in the spinal cord, all of which are subject to plasticity, 
particularly during pathological conditions.  This prolonged pre-synaptic input can 
lead to spinal nociceptive plasticity such as wind-up, long-term potentiation (LTP) and 
central sensitization of dorsal horn neurones.  Central to these events is stimulation 
of dorsal horn glutamatergic NMDA receptors which can promote activation of 
intracellular signalling pathways that contribute to such spinal plasticity.  As a 
consequence, electrophysiological characteristics of spinal neurones are altered.  NS 
cells can be activated by low threshold inputs and are effectively converted to WDR 
neurones.  Responses of neurones to afferent inputs increase, as does receptive 
field size, while spontaneous action potential firing is induced or enhanced.  
Together, these mechanisms of plasticity contribute to the establishment of chronic 
pain states which manifest clinically in patients as a heightened response to painful 
stimuli (hyperalgesia) and pain resulting from normally non-painful stimuli (allodynia), 
as well as prolonged pain once a stimulus has ended (aftersensations) and 
spontaneous, ongoing pain in the absence of an evoking stimulus.  
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1.5.1  Spinal wind-up & temporal summation of pain 
 
Glutamate is released from sensory afferents in response to acute as well as more 
persistent noxious stimuli, and it is the fast AMPA receptor activation that is 
responsible for setting the initial baseline response of spinal dorsal horn neurones to 
both noxious and tactile stimuli.  However, if a repetitive and high frequency 
stimulation of nociceptive C-fibres occurs, at constant intensity, there is then an 
amplification and prolongation of the response (post-discharge) of spinal dorsal horn 
neurones to subsequent inputs, so-called wind-up (Fig. 1.6a) (Mendell and Wall, 
1965; Mendell, 1966).  Stimulation of C-fibres is usually via a train of 16 
transcutaneous electrical stimuli at 0.5-2 Hz delivered at the receptive field of the 
neurone being recorded.  It has been shown that 16 stimuli are required to reach 
maximal discharge and any further stimuli may even lead to a decline of the neuronal 
response.  Furthermore, a neurone resets to its baseline responsiveness by 5 min 
after electrical stimulation (Schouenborg and Sjolund, 1983).  High stimulation 
frequencies, for example 10 Hz or above, do not induce wind-up, likely due to the 
failure of nociceptive C-fibres to conduct impulses at such frequencies (Raymond et 
al., 1990).  In addition, electrical stimulation of C-fibres, similar to that used to evoke 
wind-up, has been shown to produce a short-lasting increase in receptive field size 
(Cook et al., 1987; Li et al., 1999), a feature of central sensitization.  
 
The enhanced activity during wind-up results from the activation of the NMDA 
receptor (Dickenson and Sullivan, 1987b).  If there are only low level acute or low 
frequency noxious or tactile inputs to the spinal cord, then activation of the NMDA 
receptor is not possible, since under normal conditions the ion channel of this 
receptor is blocked by normal physiological levels of magnesium ions (Mg2+) found in 
neuronal tissues, including the spinal cord (Mayer et al., 1984; Mayer and 
Westbrook, 1987).  This unique Mg2+ plug of the channel requires a sustained 
depolarization of the membrane in order to be removed and allow the NMDA receptor 
channel to be activated and opened.  It is likely that the co-release of peptidergic 
transmitters, such as substance P and CGRP, that are found in C-fibres along with 
glutamate, is responsible for a prolonged slow depolarization of the neurone and 
subsequent removal of the NMDA block, thus permitting wind-up to occur (Budai and 
Larson, 1996; Khasabov et al., 2002; Suzuki et al., 2003).  AMPA receptor 
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antagonists have little effect on wind-up (Stanfa and Dickenson, 1999), and the brief 
depolarization produced by this receptor would not be expected to produce any 
prolonged removal of the NMDA block, unlike the long-lasting, slow (several 
seconds) activations caused by peptides.  The absence of peptides in large Aβ-fibres 
explains the lack of wind-up after low threshold stimuli.  Once NMDA receptors are 
activated, Ca2+ influx takes place and wind-up occurs.  In addition, NMDA receptors 
may contribute to activation of L-type Ca2+ channels which further contribute to the 
rise in intracellular Ca2+, leading to wind-up (Morisset and Nagy, 2000; Fossat et al., 
2007).  Blockade of NMDA receptors selectively reduces wind-up without altering the 
pre-synaptic input to the dorsal horn, indicated by the initial response to electrical 
stimulation (Davies and Lodge, 1987; Dickenson and Sullivan, 1987b).     
 
Since wind-up occurs only in WDR neurones but not in NS neurones (Schouenborg 
and Sjolund, 1983), and given that many WDR neurones project to the brain from 
lamina V, this plasticity is most likely to potentiate the sensory discriminative aspect 
of pain conveyed by the spinothalamic tract from lamina V, as opposed to the more 
affective component of pain which largely originates from lamina I NS projection 
neurones.  Furthermore, wind-up is unaffected by spinal administration of 
ondansetron, a 5-HT3 receptor antagonist, which blocks 5-HT-mediated descending 
facilitation from the RVM, thus suggesting that wind-up is predominantly an intrinsic 
spinally generated event (Suzuki et al., 2002b). 
 
A perceptual correlate of wind-up has been demonstrated in humans, in both healthy 
volunteers as well as chronic pain patients, whereby repetitive noxious stimulation of 
C-fibre afferents produces temporal summation of pain ratings (Fig. 1.6b).  This 
increase in pain can be evoked by electrical stimulation of the skin (Price, 1972) or 
peripheral nerve (Lundberg et al., 1992), as well as by noxious natural stimuli such 
as pinprick (Magerl et al., 1998) or noxious heat (Price et al., 1992).  Price and 
colleagues showed that this temporal summation of pain was NMDA-dependent, 
analogous to that already demonstrated in animals (Price et al., 1994).  
Dextromethorphan, an NMDA receptor antagonist, was administered to healthy 
subjects and pain was assessed following electrical or noxious heat stimulation of the 
skin of the hand.  First pain, which was described as sharp and deemed to be 
mediated by Aδ-fibres, was unaltered by dextromethorphan.  Second pain, which 
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followed first pain by about one second and was described as burning, dull or diffuse, 
is mediated by C-fibres.  The first stimulus in each train of stimuli was also unaffected 
by dextromethorphan.  In contrast, dextromethorphan did reliably reduce temporal 
summation of both electrically and heat evoked second pain.  Ketamine, an 
alternative NMDA antagonist, was shown to inhibit temporal summation of both 
withdrawal reflexes and pain ratings by human volunteers following repetitive 
electrical stimulation without any effect on reflexes and pain ratings produced by a 
single stimulus (Arendt-Nielsen et al., 1995).  Kristensen and colleagues reported the 
case study of a neuropathic pain patient who displayed symptoms of hyperalgesia 
and allodynia, as well as post-discharge and wind-up, whereby an increase in pain 
rating was observed from minutes to hours after termination of stimulation, indicating 
aftersensations and temporal stimulation (Kristensen et al., 1992).  Spinal 
administration of a competitive NMDA receptor antagonist, CPP (3-[2-carboxypi-
perazin4-yl]-propyl-I-phosphonic acid) completely abolished aftersensations and 
temporal summation of pain, as well as increased receptive field size.  Thus, NMDA 
receptors do not contribute to acute first pain, nor do they alter the pre-synaptic input 
to second order neurones, which is indicated by second pain evoked by the first 
stimulus in a stimulus train or pain evoked by a single isolated stimulus, but rather 
contribute exclusively to wind-up and temporal summation of second pain via a post-
synaptic spinal mechanism. 
 
Quantitative sensory testing (QST) is the most important approach to characterize 
the somatosensory phenotype of chronic pain patients in order to define mechanisms 
and thus aid treatment (Rolke et al., 2006a).  A standardized protocol for QST has 
been developed by the German Research Network on Neuropathic Pain (DFNS) and 
the battery of tests includes one to assess wind-up pain (Rolke et al., 2006b).  
Patients are asked to rate the pain produced by both a single pinprick stimulus and 
also at the end of a train of ten pinprick stimuli, applied at constant intensity and 
frequency.  This procedure is repeated five times and a wind-up ratio is calculated 
(mean rating of the five series divided by the mean rating of the five single stimuli) to 
indicate the perceptual correlate of temporal pain summation. 
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Fig. 1.6: Wind-up of dorsal horn neurones is a likely basis for temporal 
summation of pain rating in humans.  (a) Peripheral electrical stimulation at 
noxious C-fibre intensity produces an amplification and prolongation of the response 
of spinal neurones, so-called wind-up, recorded in the anaesthetized rat.  Wind-up is 
not mediated by AMPA receptors but is dependent on NMDA receptor activity.  The 
Mg2+ block of NMDA receptors is relieved by membrane depolarization due to co-
release of peptides by C-fibres.  Adapted from Dickenson and Sullivan (1987).  (b) 
Repetitive noxious stimulation produces temporal summation of pain ratings in 
humans on a visual analogue scale (VAS) that is blocked by an NMDA antagonist, 
dextromethorphan.  Adapted from Price et al. (1994). 
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1.5.2  Spinal long-term potentiation 
 
LTP, first demonstrated in the hippocampus, is a ubiquitous mechanism throughout 
the central nervous system underlying a long-lasting localized increase in synaptic 
strength (Bliss and Lomo, 1973).  Hippocampal LTP is believed to be the neuronal 
substrate of learning and memory (Bliss and Collingridge, 1993) and is dependent on 
activation of NMDA receptors, since NMDA antagonism prevents LTP without effect 
on normal synaptic transmission (Collingridge et al., 1983).  Interestingly, spinal LTP-
related phenomena have also been reported in several animal pain models following 
both inflammation or nerve damage and recent studies have demonstrated that LTP 
can be induced in pain pathways (Ji et al., 2003; Sandkuhler, 2007).  As a result, it 
has become clear that similarities and probably common intracellular signalling 
pathways between central sensitization in the spinal cord and LTP in the 
hippocampus exist.  The generation of spinal LTP may be one mechanism whereby 
acute pain is converted to chronic. 
 
Randic and colleagues first showed that LTP could be induced in the superficial 
dorsal horn by high frequency (100 Hz) tetanic electrical stimulation at C-fibre 
intensity (HFS) of dorsal roots using an in vitro spinal cord slice preparation (Randic 
et al., 1993).  This LTP was sensitive to pharmacological blockade of NMDA 
receptors.  Subsequently, Liu & Sandkuhler demonstrated superficial dorsal horn LTP 
in vivo by recording superficial C-fibre evoked field potentials (Liu and Sandkuhler, 
1995).  Here, HFS was applied to the exposed sciatic nerve of anaesthetized rats 
and produced potentiation for over eight hours.  Natural stimuli, such as noxious heat 
and pinch applied to the skin, formalin injection into the hindpaw and acute physical 
injury (squeezing with serrated forceps) to peripheral nerve were able to mimic the 
LTP produced by electrical HFS, though only in spinalized rats, suggesting that in 
normal animals descending inhibition prevents LTP due to natural noxious stimuli 
(Sandkuhler and Liu, 1998).  Thus, spinal LTP was suggested to be a mechanism 
underlying afferent-induced hyperalgesia.  This LTP in the superficial dorsal horn 
induced by both electrical HFS and natural noxious stimuli was blocked by NMDA 
antagonism.  Later, it was shown that HFS of the sciatic nerve induces LTP of C-fibre 
evoked responses specifically in NK1-expressing neurones in lamina I which project 
to the parabrachial area (Ikeda et al., 2003).  However, the relevance of such studies 
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to chronic pain has been questioned on the basis that C-fibres do not fire at such 
high frequencies as 100 Hz, but rather have discharge rates of between 1 and 10 Hz 
(Puig and Sorkin, 1996).  Thus, efforts to induce LTP using more physiological low 
frequency stimulation (LFS), resembling the afferent barrage during inflammation, 
were made.  Ikeda and colleagues identified in vitro a population of lamina I neurones 
projecting to the PAG in which LTP was induced exclusively by LFS (2 Hz) at C-fibre 
intensity (Ikeda et al., 2006b).  This same protocol could not induce LTP in spino-PB 
projection neurones, though these cells did still respond positively to HFS.  LFS 
stimulation was subsequently shown to induce LTP in the superficial dorsal horn in 
vivo in anaesthetized rats with intact descending controls (Drdla and Sandkuhler, 
2008).  Again, this LFS-induced LTP required NMDA receptor activity.  The 
reproducibility of such spinal LTP in the superficial dorsal horn, particularly following 
HFS, has also been questioned, however.  Rygh and colleagues found that HFS 
stimulation of the sciatic nerve failed to induce LTP of C-fibre evoked action 
potentials in superficial neurones, including those projecting to the parabrachial area, 
though, in contrast, LTP was induced in deep dorsal horn WDR neurones (Rygh et 
al., 2006), suggesting that in the intact animal superficial dorsal horn neurones are 
under descending inhibitory control which prevents LTP.  The discrepancy between 
this and the aforementioned studies may be explained by examining the stimulus 
intensities used.  Although stimulation frequency was identical (100 Hz), Rygh and 
colleagues used a stimulation intensity of six times the threshold for activating C-fibre 
evoked responses, whereas studies from Sandkuhlerʼs lab often employed extreme 
suprathreshold intensities (e.g. ten times C-fibre threshold; verbal communication 
from Prof Jurgen Sandkuhler).  Thus it is possible that the higher intensity was 
sufficient to overcome inhibitory influences in the superficial dorsal horn. 
 
Simultaneous to the work demonstrating LTP in superficial laminae, studies also 
implicated spinal LTP in deep dorsal horn WDR neurones as a potential mechanism 
for central sensitization (Rygh et al., 2005).  Svendsen and colleagues first 
demonstrated that HFS of the sciatic nerve at C-fibre intensity produced a long-
lasting potentiation (> 6 hrs) of not only C-fibre evoked responses, but also Aβ-fibre 
evoked action potentials of deep WDR neurones, an observation not seen in 
superficial dorsal horn LTP (Svendsen et al., 1997).  The initiation of this deep dorsal 
horn LTP of WDR firing was mediated by AMPA and NMDA receptors, while 
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maintenance of potentiation was more NMDA-dependent (Svendsen et al., 1998; 
Svendsen et al., 1999b).  Like in superficial laminae, LTP of deep dorsal horn 
neurones was found to be influenced by descending inhibitory controls (Svendsen et 
al., 1999a).  Furthermore, Rygh and colleagues demonstrated that descending 
serotonergic facilitation is also able to modulate manifestation of deep dorsal horn 
LTP (Rygh et al., 2006).  HFS-induced potentiation of WDR neurones was blocked by 
chemical ablation of superficial NK1-expressing projection neurones and modulated, 
though not prevented, by ondansetron, a 5-HT3 antagonist.  It has also been shown 
that natural, acute, albeit severe noxious peripheral stimulation, achieved by 
repeated crushing of tissue and bone at the receptive field, can potentiate C-fibre 
evoked responses of deep WDR neurones (Rygh et al., 1999).   More recently, 
Haugan and colleagues demonstrated that a more physiological LFS (3 Hz) protocol 
could potentiate responses of deep dorsal horn WDR neurones also (Haugan et al., 
2008).  However, this electrical LFS-induced potentiation was shorter in duration (< 3 
hrs) than that induced by higher frequencies (30 or 100 Hz).  This suggests that 
spinal LTP in the deep dorsal horn, induced by physiological afferent firing 
frequencies, may contribute only partially to central sensitization and that other 
plastic mechanisms are required for the manifestation of chronic pain.  
 
Importantly, perceptual correlates of nociceptive LTP have been demonstrated in 
humans (Klein et al., 2004).  Electrical HFS (100 Hz) of noxious intensity was applied 
to the skin and subjects were asked to rate their pain evoked by mechanical 
stimulation of the affected area.  It was found that HFS alone produced potentiation 
of pain ratings due to electrical stimuli, while both HFS and extreme high intensity 
LFS (1 Hz) induced a long-lasting (> 3 hrs) increase in mechanical pain sensitivity at 
the site of the conditioning stimulus (homotopic hyperalgesia).  HFS also caused pain 
due to light brushing of adjacent skin  (secondary dynamic mechanical allodynia).  In 
contrast, sensitivity to thermal modalities was unaltered, as was temporal summation 
(wind-up) of pain (Lang et al., 2007).  A subsequent study showed that potentiation of 
pain sensitivity to only electrical stimulation at the site of the conditioning stimulus 
was prevented by ketamine, an NMDA channel blocker (Klein et al., 2007).   
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1.5.3  Central sensitization of dorsal horn neurones  
 
Central sensitization of dorsal horn neurones was initially demonstrated by Woolf in 
1983, providing the first evidence of a central component of nociceptive 
hypersensitivity in chronic pain (Woolf, 1983).  In his study, Woolf recorded 
responses from α-motoneurone efferents as a measure of the output of dorsal horn 
processing, while stimulating afferents both at the hindpaw and directly via the sural 
nerve.  Prior to peripheral injury, the majority of efferents exhibited minimal 
spontaneous activity and responded exclusively to noxious, high threshold 
mechanical and thermal stimulation at the hindpaw.  A thermal injury was then 
induced at the hindpaw (75°C for 60 s) which caused mild inflammation and 
produced significant changes in efferent properties.  Spontaneous activity increased 
and mechanical thresholds to von Frey hairs were markedly reduced.  The amplitude 
and duration (post-discharge) of responses evoked by both noxious pinch and 
electrical stimulation of the sural nerve, at noxious intensities, were also increased.  
Interestingly, electrical stimulation of Aβ-fibres began to elicit responses in efferents 
which had been absent prior to peripheral injury indicating that dorsal horn neurones 
in the pathway had reduced thresholds.  Furthermore, the cutaneous receptive fields 
expanded greatly and even extended to the contralateral hindpaw, providing 
definitive evidence that this sensitization could not be solely mediated by peripheral 
sensitization.  Expansion of the receptive field is brought about by the lowering of the 
activation threshold of dorsal horn neurones, since a large proportion of synaptic 
input to these cells is subthreshold and thus silent under normal conditions whereas 
following peripheral injury these inputs can evoke action potentials (Cook et al., 1987; 
Woolf and King, 1990).  These changes induced by peripheral thermal injury were 
mimicked by low frequency electrical stimulation of the sural nerve at C-fibre 
intensity.  Further evidence of a predominant central component of injury-induced 
changes in muscle efferents was provided by the observations that local anaesthetic 
block of the hindpaw did not reverse the elevated responses to sural nerve 
stimulation or receptive field expansion (Woolf, 1983).   
 
Subsequent studies demonstrated that, in addition to peripheral thermal injury and 
electrical simulation, central sensitization of dorsal horn neurones could also be 
induced by peripheral injection of chemicals such as formalin (Dickenson and 
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Sullivan, 1987a), mustard oil (Woolf and King, 1990) and capsaicin (Simone et al., 
1991).  Furthermore, it was demonstrated that central sensitization is an NMDA-
dependent phenomenon and that activity of NMDA receptors is required for both the 
induction and maintenance of central sensitization of dorsal horn neurones, raising 
the potential for the use of NMDA antagonists in pre-emptive analgesia and, perhaps 
more importantly, in the treatment of established pain states (Woolf and Thompson, 
1991).  For example, NMDA antagonists were able to inhibit both neuronal 
hyperexcitability and pain-related behaviours induced by the injection of formalin into 
the hindpaw (Haley et al., 1990; Coderre and Melzack, 1992; Yamamoto and Yaksh, 
1992b).   
 
It is important to note that plastic changes induced by peripheral injuries have been 
demonstrated in neurones at supraspinal sites, representative of the general 
phenomenon of central sensitization (Lee et al., 2008; Latremoliere and Woolf, 2009).  
In this thesis, use of the term central sensitization is restricted to the spinal cord and 
specifically to central sensitization of dorsal horn sensory neurones.  
 
A multitude of studies have now demonstrated that central sensitization within the 
dorsal horn involves numerous mechanisms which work in concert to increase the 
excitability of spinal sensory neurones in chronic pain states.  These mechanisms 
include signalling pathways which increase the intrinsic excitability of dorsal horn 
neurones, diminished spinal inhibition and increased facilitatory influences from 
supraspinal sites. 
 
 
1.5.3.1  Intracellular mechanisms of central sensitization of dorsal  
             horn sensory neurones 
 
Downstream of NMDA receptor activation, various intracellular signalling cascades 
are activated, often via Ca2+ influx through the NMDA receptor channel, which 
promote the increased excitability of dorsal horn neurones, contributing to central 
sensitization (Fig. 1.7).  Such intracellular effectors include the extracellular signal-
regulated kinase (ERK), Ca2+/calmodulin-dependent kinase II (CaMKII), PKA, PKC 
and the tyrosine kinase Src (Ji et al., 1999; Fang et al., 2002; Zou et al., 2002; 
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Kawasaki et al., 2004; Kohno et al., 2008).  These kinases can enhance activity of 
both AMPA and NMDA receptors during early-onset central sensitization by 
phosphorylating key regulatory sites, as well as increasing receptor numbers by 
promoting membrane trafficking and insertion, thus increasing synaptic strength.  For 
example, Ca2+-dependent PKC, inhibition of which prevents central sensitization (Lin 
et al., 1996), can enhance NMDA receptor activity by increasing the probability of 
channel opening and decreasing the Mg2+ block of the channel (Chen and Huang, 
1992).  Furthermore, PKC phosphorylates NR1 subunits of NMDA receptors following 
noxious stimulation and this may lead to the increased trafficking of NMDA receptors 
to the plasma membrane (Brenner et al., 2004).  NR2 subunits are also 
phosphorylated during central sensitization and this involves PKC and Src (Guo et 
al., 2002; Guo et al., 2004).  AMPA receptor subunits are also phosphorylated by 
PKA and PKC (Fang et al., 2003) while CaMKII promotes trafficking of AMPA 
receptors following noxious stimulation (Galan et al., 2004; Pezet et al., 2008), 
leading to central sensitization.  Late-onset central sensitization, like late-phase LTP, 
requires transcriptional changes driven by transcription factors such as the cAMP 
response element binding protein (CREB), which is phosphorylated during central 
sensitization (Ji and Rupp, 1997).  This phosphorylation may be regulated by ERK 
and contributes to expression of genes such as c-Fos, a marker of neuronal 
activation following noxious stimulation (Hunt et al., 1987).   
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Fig. 1.7: Intracellular mechanisms within dorsal horn neurones contribute to 
spinal central sensitization.  Activation of NMDA receptors following prolonged 
noxious stimulation leads to a large Ca2+ influx into dorsal horn sensory neurones.  
This activates various Ca2+-dependent intracellular processes that lead to central 
sensitization.  Src kinase, PKA, PKC and CaMKII contribute to early-onset central 
sensitization via phosphorylation and increased membrane insertion of NMDA and 
AMPA receptors.  Late-onset central sensitization involves ERK-mediated activation 
of CREB transcription factor and expression of genes such as c-Fos.  Adapted from 
Ji et al. (2003).   
Chapter 1 
 
 
 73 
1.5.3.2  Loss of spinal inhibition contributes to mechanical  
             hypersensitivity and allodynia 
 
It is believed that low threshold inputs from Aβ-fibres contribute to an inhibitory 
control of lamina I NS cells, decreasing spinal output of nociceptive information.  This 
is the basis of the Gate Control Theory (Melzack and Wall, 1965).  Additionally, it has 
been suggested that low threshold inputs may activate inhibitory interneurones in the 
dorsal horn which prevent Aβ-fibre polysynaptic inputs reaching lamina I NS cells 
from deeper laminae (Torsney and MacDermott, 2006).  Yaksh showed that blocking 
spinal inhibition, through the intrathecal administration of GABA receptor (bicuculline) 
or glycine receptor (strychnine) antagonists, resulted in pain evoked by light tactile 
stimulation, equivalent to mechanical allodynia observed in pain patients (Yaksh, 
1989).  Interestingly, morphine had little effect on this mechanical hypersensitivity, 
mimicking the clinical situation, whilst NMDA receptor antagonists attenuated 
strychnine-mediated hypersensitivity.  Thus it was suggested that a loss of spinal 
GABAergic and glycinergic inhibition might underlie the clinical manifestation of 
mechanical allodynia in chronic pain states.  When spinal inhibition is lost, Torsney 
and MacDermott propose that a novel, polysynaptic, NMDA-dependent input from 
Aβ-fibres in lamina III is disinhibited and can now activate lamina I NS projection 
cells, effectively converting them to WDR neurones (Torsney and MacDermott, 
2006).  In this way, low threshold stimulation may be processed and transmitted to 
higher centres as being painful, underlying mechanical allodynia.  In the clinic, two 
distinct forms of mechanical allodynia present in patients, static mechanical allodynia 
(SMA) and dynamic mechanical allodynia (DMA).  
 
Accumulating evidence from preclinical studies suggests that SMA may arise from a 
loss of GABAergic inhibition, while the loss of glycinergic inhibitory control may 
produce DMA (Fig. 1.8).  Spinal administration of strychnine alone produces 
behavioural mechanical hypersensitivity (Yaksh, 1989) as well as enhanced neuronal 
responsiveness to light mechanical stimuli (Sorkin and Puig, 1996).  This neuronal 
hypersensitivity is selectively blocked by NMDA antagonists while opioid agonists 
have no effect, similar to their behavioural effects.  Later, Miraucourt and colleagues 
showed that spinal strychnine produced mechanical hypersensitivity exclusively to 
dynamic light tactile stimuli (gentle air puffing).  It was found that strychnine 
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disinhibited a normally silent PKCγ-dependent and NMDA-dependent excitatory 
spinal circuit which gates low threshold tactile inputs from Aβ-fibres to NS neurones 
in the superficial dorsal horn (Miraucourt et al., 2007).  Furthermore, this circuit did 
not involve NK1-expressing projection neurones and the dynamic mechanical 
hypersensitivity produced was resistant to morphine, again resembling clinical DMA 
(Miraucourt et al., 2009).  In contrast to the selective neuronal effects of strychnine, 
selective blockade of GABAergic inhibition by spinal bicuculline produces a general 
enhancement of neuronal responses, including those evoked by light mechanical 
stimuli, and does not seem to involve NMDA receptors (Yaksh, 1989; Sorkin et al., 
1998).  This bicuculline-mediated hypersensitivity is not responsive to dynamic 
stimuli but only to static mechanical stimulation, as produced by von Frey hairs 
(Miraucourt et al., 2009), thus likely representing clinical SMA. 
 
A loss of inhibitory controls in the dorsal horn may arise from activation of the 
endocannabinoid system.  Noxious stimulation of primary afferents has been shown 
to lead to the production of spinal endocannabinoids which subsequently activate 
inhibitory CB1 receptors located on inhibitory interneurones, thus reducing the 
synaptic release of GABA and glycine (Pernia-Andrade et al., 2009).  The effect of 
this disinhibition was to promote excitation of normally NS neurones by non-painful 
stimuli.  In addition, it has been suggested that a loss of inhibitory interneurones via 
neuronal apoptosis may occur in neuropathic pain (Moore et al., 2002; Scholz et al., 
2005) though this has since been refuted as neuronal cell death is not required for 
nerve injury-induced pain to occur (Polgar et al., 2003; Polgar et al., 2004; Polgar and 
Todd, 2008).  Thus, it is more likely that any reduction in spinal inhibition results from 
an increased inhibitory or reduced excitatory control of inhibitory interneurones.  
Alternatively, Coull and colleagues proposed that failure of GABAergic inhibitory 
control of low threshold inputs in the superficial dorsal horn of neuropathic rats might 
arise from a loss of the Cl- transporter protein KCC2 (Coull et al., 2003; Coull et al., 
2005).  This results in accumulation of intracellular Cl- in lamina I cells which, when 
activated by GABA released from inhibitory interneurones, are now depolarized 
rather than hyperpolarized due to Cl- efflux, thus effectively making GABA excitatory.  
This mechanism would contribute to the unmasking of a normally silent polysynaptic 
Aβ-fibre input to lamina I cells, so that these cells now respond to innocuous 
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mechanical stimulation, leading to behavioural static mechanical hypersensitivity 
following nerve injury (Keller et al., 2007).  
 
 
 
 
 
 
 
Fig. 1.8: Loss of spinal GABAergic and glycinergic inhibition leads to 
mechanical allodynia.  Under normal conditions low threshold polysynaptic inputs 
from Aβ-fibres to superficial NS projection neurones are kept silent by inhibitory 
GABAergic and glycinergic interneurones.  Failure of such inhibitory control, perhaps 
via activation of inhibitory CB1 receptors on inhibitory interneurones or 
downregulation of the Cl- transporter KCC2, may unmask low-threshold inputs to 
superficial projection neurones.  Loss of GABA-mediated inhibition may gate Aβ-fibre 
inputs to NK1-expressing projection neurones and may underlie static mechanical 
allodynia.  Loss of glycine-mediated inhibition gates Aβ-fibre inputs to projection 
neurones lacking NK1 receptors, via PKCγ-expressing interneurones, leading to 
dynamic mechanical allodynia.  Both pathways involve activation of NMDA receptors. 
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1.5.3.3  Plasticity of descending modulation in chronic pain states 
 
In addition to the contributions of synaptic plastic mechanisms like wind-up and 
spinal LTP, plasticity of descending modulation from the brainstem is also involved in 
central sensitization in abnormal pain states (Fig. 1.9).  Descending facilitatory 
pathways from the RVM in the brainstem have been shown to be involved in the 
maintenance, rather than the initiation, of nerve injury-induced pain (Kovelowski et 
al., 2000; Burgess et al., 2002; Vera-Portocarrero et al., 2006).  Injection of the local 
anaesthetic lidocaine, into the RVM reverses established behavioural hypersensitivity 
in nerve-injured animals, but does not prevent the expression of this hypersensitivity 
(Burgess et al., 2002).  In an electrophysiological study, injection of lidocaine into the 
RVM reduced dorsal horn neuronal responses to noxious stimuli in normal animals.  
This effect of lidocaine was greater in nerve-injured animals, and in these animals it 
was observed that descending facilitation from the RVM now influenced neuronal 
responses to non-noxious tactile stimulation, thus suggesting a possible mechanism 
for mechanical allodynia (Bee and Dickenson, 2007).  Suzuki and colleagues showed 
that elimination of the ascending arm of the spino-bulbo-spinal loop, by chemical 
ablation of lamina I/III NK1-expressing neurones with a substance P and saporin 
neurotoxin conjugate (SP-SAP), reduces the excitability of deep dorsal horn WDRs, 
indicating that descending influences are predominantly facilitatory, acting via spinal 
5-HT3 receptors, since the effect of SP-SAP could be mimicked by spinally-
administered ondansetron, a selective 5-HT3 antagonist  (Suzuki et al., 2002b).  The 
contribution of such descending serotonergic facilitation to neuropathic pain was 
further confirmed by the fact that the efficacy of ondansetron to suppress spinal 
responses to mechanical punctuate stimuli was significantly enhanced after spinal 
nerve ligation, suggesting an increase in the descending serotonergic facilitatory 
drive to the spinal cord (Suzuki et al., 2004).  In accordance, depletion of spinal 5-HT 
attenuates signs of behavioural hypersensitivity following nerve ligation (Rahman et 
al., 2006).  Additionally, it has been shown that spinal SP-SAP treatment attenuates 
behavioural hypersensitivity and also abnormal neuronal coding exhibited after both 
nerve ligation (Suzuki et al., 2005) and intraplantar injection of capsaicin (Mantyh et 
al., 1997; Khasabov et al., 2002).  A small double-blinded, placebo-controlled, 
crossover clinical study has suggested an antinociceptive effect of ondansetron in 
humans which merits further investigation (McCleane et al., 2003), while SP-SAP, 
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although not tested in humans, has been found to be without toxic effects when 
administered in dogs (Allen et al., 2006).  Gabapentin is used as a first line treatment 
for neuropathic pain (Backonja et al., 1998; Rowbotham et al., 1998; Serpell, 2002) 
and binding studies have revealed interactions with the auxiliary α2δ subunit of 
voltage-gated Ca2+ channels (Gee et al., 1996).  Interestingly, it has been shown that 
the efficacy of gabapentin is partly dependent on upregulation of 5-HT3-mediated 
descending facilitation following nerve injury.  First, spinal SP-SAP was able to block 
the antinociceptive actions of gabapentin after nerve injury.  Second, blocking 5-HT3 
receptors prevented the actions of gabapentin after nerve injury and even more 
remarkably, their activation allowed the drug to now work in normal animals (Suzuki 
et al., 2005).  Thus, activation of 5-HT3 receptors enhances pain processing, but at 
the same time produces a state-dependent or permissive interaction that allows 
treatment (Suzuki et al., 2005).  Together, these studies demonstrate that superficial 
NK1-expressing neurones can trigger descending facilitations mediated through 
parabrachial-RVM connections and regulate the sensitivity of deeper lying neurones 
to gabapentin through activation of spinal 5-HT3 receptors.  These excitatory 
influences promote spinal central sensitisation and facilitate nociceptive reflexes, 
contributing to the pathology of neuropathic pain.  It is likely that enhancement of 
descending supraspinal facilitatory systems represents a central mechanism by 
which the loss of sensory input resulting from nerve damage is compensated.  
 
Like descending facilitation, inhibitory noradrenergic pathways from the brainstem to 
the dorsal horn may also undergo plastic changes in chronic pain states.  Several 
studies indicate an increase in descending noradrenergic inhibition following 
peripheral inflammation (Weil-Fugazza et al., 1986; Stanfa and Dickenson, 1994; 
Tsuruoka and Willis, 1996a, b; Green et al., 1998; Tsuruoka et al., 2003), coupled 
with an enhanced efficacy of spinally administered α2-adrenoceptor agonists (Hylden 
et al., 1991; Mansikka and Pertovaara, 1995; Suzuki et al., 2002a).  This increased 
inhibitory drive may be a homeostatic mechanism initiated in an attempt to counteract 
an enhanced facilitatory drive and increased spinal hyperexcitability.  It has also been 
suggested that there is increased noradrenergic innervation to the dorsal horn 
following nerve injury (Ma and Eisenach, 2003), again analogous to the enhanced 
facilitatory drive to the dorsal horn mediated by spinal 5-HT3 receptors.  Studies have 
demonstrated nerve injury-induced changes in noradrenergic pathways, including 
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upregulation of spinal α2A-adrenoceptors (Cho et al., 1997; Birder and Perl, 1999; 
Stone et al., 1999) and increased spinal NA content (Satoh and Omote, 1996).  While 
these findings may suggest an enhancement of descending noradrenergic inhibition, 
it is plausible that the increased noradrenergic receptor density and innervation of the 
dorsal horn observed after nerve injury is the result of compensatory mechanisms 
which occur to counteract the actual loss of a tonic descending noradrenergic 
inhibitory drive.  Therefore, it would be expected that α2-adrenoceptor agonists would 
increase in potency and efficacy after nerve injury.  In support of this, the efficacy of 
the selective α2-adrenoceptor antagonist atipamezole is reduced after nerve injury, 
though only in specific sensory modalities (Rahman et al., 2008), suggesting that 
there is in fact a loss of descending noradrenergic influences in neuropathic pain.  
Atipamezole enhanced evoked responses of dorsal horn neurones to low intensity 
mechanical stimulation.  This observation only occurred in control sham-operated 
animals, and was absent in nerve-injured animals, suggesting a selective control of 
descending inhibition, via spinal α2-adrenoceptors, on low-intensity mechanically 
evoked neuronal responses.  No effects of atipamezole were seen following noxious 
mechanical or both non-noxious and noxious thermal stimulation, in either sham-
operated or nerve-injured animals.  Further evidence for this differential control of 
stimulus modalities was shown with the use of a selective and potent α2-
adrenoceptor agonist S18616 (Suzuki et al., 2002a).  This compound suppressed 
dorsal horn neuronal responses to thermal and high intensity mechanical stimulation 
equally in both sham-operated and nerve-injured rats.  However, the suppression of 
low intensity mechanically evoked responses was greatly enhanced after nerve 
injury, supporting the loss of descending inhibitory controls of this sensory modality, 
but also supporting the upregulation of adrenergic receptor density and enhanced 
sensitivity to α2-adrenoceptor agonists.  Interestingly, atipamezole also enhanced 
spontaneous activity of dorsal horn neurones, again exclusively in sham-operated 
rats (Rahman et al., 2008).  Overall, these results suggest that there is a loss of tonic 
descending inhibitory controls of neuronal responses to low intensity mechanical 
stimulation and also of spontaneous neuronal activity in the dorsal horn following 
peripheral nerve injury.  Coupled with the enhancement of descending serotonergic 
facilitation, this decrease in descending noradrenergic inhibition would result in an 
overall enhancement of dorsal horn excitability, manifesting as mechanical 
hypersensitivity, allodynia and spontaneous pain, common complaints of neuropathic 
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pain patients.  Clonidine, which has been clinically successful in the alleviation of 
neuropathic pain (Eisenach et al., 1996), and which is licensed for the treatment of 
cancer pain in the USA (Eisenach et al., 1995), acts by partial agonism at spinal α2-
adrenoceptors.   
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Fig. 1.9: Increased serotonergic and decreased noradrenergic drive from the 
brainstem contributes to spinal central sensitization.  Superficial NK1+ projection 
neurones activate a spino-bulbo-spinal loop which modulates dorsal horn processing.  
Activation of the parabrachial area engages the limbic system and the periaqueductal 
grey, which in turn influence the output from the rostroventromedial medulla (RVM) 
and locus coeruleus (LC) in the brainstem to the dorsal horn.  An increased 
facilitatory serotonergic drive from the RVM, via activation of spinal 5-HT3 receptors, 
coupled with decreased activation of inhibitory α2 receptors by NA released from the 
LC, contributes to central sensitization.  Activation of 5-HT3 receptors may contribute 
to increased function of α2δ auxiliary subunits of Ca2+ channels, the binding site for 
gabapentin, leading to increased neurotransmitter release. 
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1.5.3.4  Human surrogate models of central sensitization 
 
Various models have been developed to study central sensitization in humans and 
these invariably involve activation of peripheral nociceptors in healthy volunteers to 
induce dorsal horn plasticity (Schmelz, 2009).  Peripheral stimuli which induce central 
sensitization include chemicals such as capsaicin (Simone et al., 1989; LaMotte et 
al., 1991), noxious heat (Moiniche et al., 1993; Pedersen and Kehlet, 1998) and 
electrical stimulation (Koppert et al., 2001).  A model employing the combination of 
heat and capsaicin has also been described (Petersen and Rowbotham, 1999).  
Outcome measures include neurogenic flare as well as hyperalgesia and allodynia, 
both within the territory of the injury and beyond, thus representative of both 
peripheral and central sensitization.  Similar to human surrogate models of wind-up 
and LTP, these models of central sensitization also involve NMDA receptors (Park et 
al., 1995; Andersen et al., 1996; Warncke et al., 1997; Koppert et al., 2001).  For 
example, ketamine reverses both spatial and temporal aspects of secondary 
hyperalgesia to punctate and dynamic stimuli, without alteration of thermal detection 
thresholds (Warncke et al., 1997).  While these models further our understanding of 
peripheral and central mechanisms of pain hypersensitivity in chronic pain, they are 
incomplete since they do not produce significant spontaneous pain, a highly common 
complaint of pain patients, and thus spontaneous pain at present can only be 
investigated in patients.  Understanding the mechanisms that cause spontaneous 
pain will allow this pain to be reproduced in healthy volunteers and improve current 
surrogate models of central sensitization. 
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1.6  The NMDA receptor as a therapeutic target for chronic pain 
 
 
1.6.1  Structure of NMDA receptors 
 
In the dorsal horn, functional glutamatergic NMDA receptors are heterotetramers 
consisting of a pore-forming NR1 subunit that binds glycine in combination with NR2 
subunits which contain the binding site for glutamate (Fig. 1.10).  The glycine-binding 
site may also be bound by endogenous D-serine (Wolosker, 2007).  Binding at both 
co-agonist sites is required for activation of the channel.  In addition, opening of the 
channel pore is voltage-dependent since at normal resting membrane potentials, the 
channel pore is blocked by extracellular Mg2+ (Mayer et al., 1984).  This tonic block is 
only relieved by membrane depolarization, produced by another membrane non-
NMDA receptor, thus the NMDA receptor can act as a coincidence detector (see 
section 1.5.1).  Once the channel is open, Na+ influx and K+ efflux occurs which 
mediates a slow excitatory post-synaptic potential (EPSP), though this contributes 
minimally to membrane depolarization and action potential generation, unlike the fast 
EPSP evoked by AMPA receptors.  In contrast to other glutamate receptors, 
significant Ca2+ influx occurs through NMDA receptor channels and subsequently 
activates numerous downstream intracellular signalling mechanisms (MacDermott et 
al., 1986).  NMDA receptors are also slow to inactivate in comparison to non-NMDA 
receptors.  Thus, the coincidence detection, slow kinetics and Ca2+ permeability of 
NMDA receptors renders them integral components of synaptic plasticity.  Various 
allosteric regulatory sites on the receptor, including a zinc ion (Zn2+) binding site, an 
inhibitory proton sensor and a polyamine site, can modulate activity (Kalia et al., 
2008).  Furthermore, the cytoplasmic tail of NR2 subunits can be phosphorylated to 
further regulate receptor activity and various interactions with intracellular effector 
proteins are mediated via this cytoplasmic tail (Sheng, 2001).   
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Fig. 1.10: Structure of the NMDA receptor channel.  NMDA receptors are 
tetramers consisting of glycine-binding NR1 subunits and glutamate-binding NR2 
subunits.  Binding at both co-agonist sites is required for receptor activation.  At 
resting membrane potentials, the channel pore is blocked by Mg2+.  This block is 
removed by membrane depolarization and on subsequent receptor activation and 
opening of the channel pore, Na+ and Ca2+ influx and also K+ efflux occurs.  The large 
Ca2+ influx activates various downstream NMDA-dependent intracellular processes.  
NR2 subunits also contain various modulatory sites which are bound by polyamines, 
protons and Zn2+ ions.  Adapted from Kalia et al. (2008). 
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1.6.2  Traditional NMDA receptor antagonists and efficacy in chronic pain 
 
Given their expression in the dorsal horn and their essential role in spinal nociceptive 
plasticity, demonstrated both in animals and humans, NMDA receptors are strong 
candidates for therapeutic targeting in chronic pain states.  Indeed, various drugs 
targeting NMDA receptor activity have been investigated in animal models of chronic 
pain following inflammation and nerve damage and there is also evidence from a 
number of clinical studies to support their use.  These drugs act at multiple regulatory 
sites found on the NMDA receptor and its channel (Bleakman et al., 2006; Childers 
and Baudy, 2007).  Licensed drugs such as ketamine, dextromethorphan and 
memantine are non-competitive NMDA receptor channel blockers, as is MK-801 
(dizocilpine).  Competitive antagonists such as CPP bind to the glutamate recognition 
site on NR2 subunits, while 5,7-dichlorokinurenic acid (5,7-DCK) is an example of a 
drug which competes for the glycine co-agonist binding site on the NR1 subunit.   
 
Spinal delivery of various NMDA receptor antagonists has been shown to reverse 
nerve injury-induced hypersensitivity in rodent models of neuropathic pain.  These 
effects were achieved at doses which did not alter the sensitivity of the uninjured paw 
or the paws of normal rats (Yamamoto and Yaksh, 1992a; Mao et al., 1993; Chaplan 
et al., 1997).  NMDA antagonists also reverse thermal and mechanical 
hypersensitivity in models of chronic inflammatory pain (Ren and Dubner, 1993; 
Yamamoto et al., 1993; Eisenberg et al., 1994).  Clinical studies have demonstrated 
analgesic efficacy of NMDA antagonists in various neuropathic pain states (Backonja 
et al., 1994; McQuay et al., 1994; Felsby et al., 1996; Nelson et al., 1997; Eisenberg 
et al., 1998; Pud et al., 1998; Jorum et al., 2003).  For example, high-dose 
dextromethorphan reduced pain in patients with painful diabetic neuropathy in a 
randomized, double-blind, placebo-controlled, crossover trial (Nelson et al., 1997), 
while amantadine, an alternative NMDA channel blocker, reduced spontaneous pain 
and wind-up pain in cancer patients with surgical neuropathic pain (Pud et al., 1998).  
Spontaneous pain, mechanical allodynia and also cold allodynia were reduced by 
ketamine in patients with post-traumatic neuralgia and post-herpetic neuralgia (Jorum 
et al., 2003).  Overall, these studies indicate that it is likely that aberrant peripheral 
activity is amplified and enhanced by NMDA receptor-mediated spinal mechanisms 
following tissue damage and that the receptor is critical for both the induction and the 
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maintenance of the subsequent pain state.  Thus, therapy after the initiating damage 
can still be effective, in addition to pre-emptive treatment.   
 
However, despite the clear analgesic efficacy of agents acting at the NMDA receptor 
in both pre-clinical and clinical studies, intolerable cognitive, psychomimetic, motor 
and memory side-effects are common.  This is largely due to the widespread 
distribution and functionality of NMDA receptors, meaning that the introduction of an 
antagonist will not only target the underlying pathology, but will also disrupt normal 
essential NMDA signalling.  Patient descriptions of such side-effects include feeling 
weird, funny in the head, spaced-out, dream-like and having nightmares (Backonja et 
al., 1994), and all are side-effects that are unlikely to be monitored in animal studies.  
In addition, sedation, confusion, tremor, ataxia, blurred vision and hypersensitivity to 
sound have all been reported following use of NMDA receptor antagonists (McQuay 
et al., 1994; Nelson et al., 1997; Eisenberg et al., 1998; Jorum et al., 2003).  Thus, 
the majority of patients cannot achieve complete pain control since adequate dosing 
is prevented by the narrow therapeutic window of existing drugs.  Nevertheless, the 
NMDA receptor remains an attractive therapeutic target, requiring novel and perhaps 
more subtle approaches for modulation. 
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1.7  Alternative and novel strategies to target spinal NMDA receptors in pain 
 
 
1.7.1  Specific targeting of NR2B-containing NMDA receptors 
 
Ultimately, the broad use of NMDA antagonists in the treatment of chronic pain will 
therefore depend on strategies that increase their therapeutic window over existing 
drugs.  These may include drugs with different use-dependent block of the channel, 
or more practically, the use of low dose NMDA blockers in combination with another 
agent.  Furthermore, drugs acting on specific receptor subtypes, such as antagonists 
of NR2B-containing NMDA receptors, are analgesic with a better side-effect profile 
than conventional NMDA antagonists (Taniguchi et al., 1997; Boyce et al., 1999).  
These NR2B-specific drugs, including ifenprodil, CP-101606 and Ro-256981, bind to 
a specific allosteric site on NR2B subunits.  In addition these compounds may also 
interact with NR1 subunits and enhance sensitivity to protons which leads to 
inhibition (Chizh et al., 2001a).  In the rat dorsal horn, NR2B-subtype receptors are 
highly concentrated in superficial layers (Nagy et al., 2004a) and thus are ideally 
situated to receive and modulate input from terminating nociceptive afferents.  
Western blot analysis of human post-mortem tissue has demonstrated expression of 
NR2B subunits in human spinal cord, albeit to a lesser extent than that found in the 
brain, similar to the expression observed in rodent tissue (Nilsson et al., 2007).  
Whether the NR2B subunit has a similar pattern of distribution in the human dorsal 
horn as in the rat remains to be seen. 
 
 
1.7.2  Targeting NMDA receptor protein interactions and intracellular signalling 
 
The NMDA receptor forms a large, multi-protein complex consisting of scaffolding 
proteins, enzymes and other membrane-bound receptors, thereby coupling NMDA 
receptor activation to various cytoplasmic processes.  It is recognised that spinal 
nociceptive plasticity is not brought about solely by NMDA receptor activation, but 
rather is mediated by intracellular signalling cascades activated downstream of 
NMDA receptors.  Such pathways are activated by the unique and large Ca2+ influx 
through NMDA receptors.  Furthermore, this Ca2+-dependent activation of 
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cytoplasmic effectors may be promoted by physical coupling of such effectors to 
NMDA receptors via the cytoplasmic tail of NR2 subunits (Tymianski et al., 1993).  
The cytoplasmic tails of NR2B subunits (residues 862-1481) comprise approximately 
42% of the whole subunit size and are capable of numerous binding interactions. 
 
Post-synaptic density protein-95 (PSD-95) is a scaffolding protein which binds to 
NR2 subunits of NMDA receptors via their cytoplasmic tail (Kornau et al., 1995).  In 
addition, PSD-95 can simultaneously bind to intracellular effector proteins and thus 
form protein complexes with membrane-associated NMDA receptors which promote 
downstream NMDA-mediated signalling.  For example, by binding to both nNOS and 
the NMDA receptor, PSD-95 can promote the direct Ca2+-dependent production of 
NO following NMDA receptor activation (Christopherson et al., 1999; Sattler et al., 
1999) and NO has long been known to mediate NMDA-dependent nociceptive 
hypersensitivity (Kitto et al., 1992; Sorkin, 1993).  Thus PSD-95 provides an 
important link between NMDA receptor activation following the release of glutamate 
and subsequent stimulation of intracellular signalling cascades which produce spinal 
nociceptive plasticity, such as central sensitization, contributing to chronic pain 
states.  Therefore, by disrupting such links, it may be possible to prevent pathological 
NMDA-mediated intracellular signalling, whilst maintaining normal synaptic 
transmission, thus achieving analgesic efficacy in chronic pain states without the 
side-effects commonly associated with traditional NMDA antagonists.  Furthermore, 
disruption of coupling specifically between NR2B-subtype receptors and PSD-95 may 
be an even more successful analgesic strategy. 
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1.8  Thesis Aims  
 
It is clear that NMDA receptors mediate spinal nociceptive plasticity which contributes 
to chronic pain states.  Indeed NMDA receptor antagonists are efficacious against 
chronic pain, but their clinical utility is greatly limited by the occurrence of numerous 
intolerable and unavoidable side-effects.  The targeting of NMDA-mediated 
intracellular signalling is an alternative strategy to receptor blockade and traditional 
NMDA receptor antagonists, and may improve on current analgesics while potentially 
avoiding side-effects.   
 
The aims of this thesis are to investigate novel intracellular mechanisms of NMDA 
receptor-dependent spinal nociceptive plasticity and assess their therapeutic 
potential as analgesic targets via two main strategies of modulation: 
 
1) Spinal delivery of Tat-NR2B9c, a mimetic peptide believed to perturb binding 
between PSD-95 and NR2B-containing NMDA receptors, thus disrupting 
downstream intracellular signalling (Chapters 3, 4 & 5) 
 
2) Direct targeting of specific intracellular signalling effector proteins, to reveal 
potential roles in NMDA-dependent spinal nociceptive plasticity, including:  
 
• Atypical protein kinase C ζ (PKCζ/PKMζ), known to be important in the late 
phase of hippocampal LTP (Chapter 5)  
 
• Phosphatidylinositol 3-kinase (PI3K), also known to be involved in 
hippocampal LTP and pain pathways (Chapter 6)  
 
• Dimethylarginine dimethylaminohydrolase (DDAH), which contributes to 
endogenous regulation of NOS isoforms implicated in plasticity (Chapter 7)  
 
 
I will employ various techniques such as in vivo electrophysiology, behavioural tests, 
surgery, immunohistochemistry and molecular biology to explore the potential 
therapeutic benefit of such strategies in pain. 
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2  Materials and Methods 
 
 
2.1  In vivo Electrophysiology 
 
 
 2.1.1  Set-up 
 
Electrophysiological experiments were conducted using a well-established protocol 
as previously described (Fig. 2.1) (Urch and Dickenson, 2003b).  Anaesthesia of rats 
was induced using 4-5% isoflurane (66% N2O & 33% O2).  Once areflexic, a 
tracheotomy was performed whereby the trachea was exposed and a polyethylene 
cannula was inserted and fastened with 3-0 silk thread.  Isoflurane was now 
delivered in a closed system through this cannula for the remainder of the 
experiment.  Rats were placed in a stereotaxic frame and secured with ear bars.  
Core body temperature was maintained at 37°C using a feedback heating blanket 
connected to a thermal rectal probe.  Anaesthesia was reduced to 2.5% isoflurane 
and a laminectomy was performed.  An incision was made into the skin along the 
length of the vertebra, exposing the underlying muscle.  Two incisions were made 
either side of the vertebral column above the level of the laminectomy and a clamp 
inserted to stabilize the cord.  Muscle and vertebrae were removed at the L1-L3 
vertebral level to expose the L4-L5 segments of the spinal cord which receive 
afferent input from the hindpaw, creating a well for drug administration.  Two further 
incisions were made either side of the vertebral column just below the level of the 
laminectomy and a clamp inserted to further stabilize and straighten the spinal cord.  
The dura was carefully removed using a pair of fine watchmaker forceps in order to 
aid drug penetration.  For the remainder of the experiment anaesthesia was 
maintained at 1.75% isoflurane, whereby animals were deeply anaesthetized and 
fully areflexic.  At the end of each experiment, rats were overdosed on 5% isoflurane 
and death was ensured by cervical dislocation of the neck. 
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 2.1.2  Recording system 
 
Extracellular recordings from single convergent deep dorsal horn (depth > 600 µm) 
wide dynamic range neurones (WDRs) were obtained using an AC recording system 
(NeuroLog system, Digitimer, UK; Fig. 2.2).  A parylene coated tungsten electrode 
(125 µm diameter, 2 MΩ; A-M Systems Inc., Washington USA) was inserted into a 
head stage attached to a 3-axis manipulator and was manually lowered into the 
exposed spinal cord (L4-L5 segments).  Grounding was achieved via one lead 
connected to the stereotaxic frame.  A second lead was attached to the body of the 
animal and the signal from the rat was subtracted from the input from the electrode 
using the NeuroLog differential recording mode to reduce interference.  Neuronal 
activity was amplified, filtered and visualized on an oscilloscope, as well as being 
heard via a speaker system.  Individual neurones were indentified by tapping at the 
hindpaw receptive field (plantar surface and toes) and looking for series of action 
potentials of common shape and amplitude with a good signal to noise ratio, such 
that the isolated neurone could be easily differentiated and counted.  WDR neurones 
respond to both innocuous and noxious stimulation in a graded manner, and can 
respond to various stimulus modalities including mechanical, thermal, electrical and 
chemical.  Data was captured and analyzed by a CED 1401 interface coupled to a 
Pentium computer with Spike 2 software (Cambridge Electronic Design, UK; PSTH 
and rate functions).  
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Fig. 2.1: In vivo electrophysiology setup.  Rats are anaesthetized and fixed to a 
stereotaxic frame.  A laminectomy is performed to expose the lumbar spinal cord and 
an electrode is driven into the dorsal horn.  In all experiments, recordings were 
conducted from deep (lamina V) dorsal horn WDR neurones.  Action potentials were 
evoked by stimulation at the hindpaw receptive field. 
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Fig. 2.2: Schematic of the NeuroLog data capture system.  A recording electrode 
(A) is inserted into the spinal cord.  The system is grounded via a lead connected to 
the stereotaxic frame and a second lead connected to the rat (B) allowing differential 
recording.  The signal is then fed into the NeuroLog data capture system, 
differentiated as A-B, amplified, filtered and then fed to an audio speaker and 
oscilloscope.  Action potentials (APs) above set amplitudes are discriminated and fed 
into the computer system via the CED 1401 interface.  Electrical stimuli are 
administered via stimulating electrodes inserted in the receptive field.  Frequency of 
stimulation, duration, amplitude of the current and number of pulses are set using the 
period generator, digital width, pulse buffer and latch counter.  The number of APs 
evoked during a set time frame (90-800 ms) is displayed on the latch counter and the 
computer.  Natural stimuli are also applied to the receptive field and evoked APs are 
displayed visually as a rate histogram and quantified per 10 s.  Adapted from Urch 
and Dickenson (2003). 
Chapter 2 
 
 
 93 
 2.1.3  Electrical stimulation of hindpaw receptive field to induce  
           wind-up 
 
Two stimulating needles were inserted under the skin of the hindpaw through which 
electrical pulses could be delivered to the receptive field of the neurone being 
recorded.  The threshold for C-fibre activation was first determined by giving single, 
incremental, electrical pulses until evoked action potentials in the C-fibre latency 
range (90-300 ms) were observed.  Each test then consisted of a train of 16 
transcutaneous electrical stimuli (2 ms wide pulses, 0.5 Hz) applied at three times the 
threshold current for C-fibres via the stimulating needles.  A post-stimulus histogram 
(Fig. 2.3) was constructed and Aβ- (0-20 ms), Aδ- (20-90 ms) and C-fibre (90-300 
ms) evoked responses were separated and quantified on a basis of latency.  
Responses occurring after the C-fibre latency band were taken to be the post-
discharge (PD) of the cell (300-800 ms).  Input (non-potentiated response) was 
quantified as the response after the first stimulus × 16, based on the initial response 
of the neurone being maintained without further enhancement during the 16 stimuli.  
Wind-up was calculated as: (total number of action potentials [APs] after 16 stimuli) – 
(number of APs after the first stimulus × 16 [i.e. input]) so that the additional 
responses produced by wind-up could be quantified.  Stable control responses (no 
more than 10% variation in the C-fibre response) to electrical stimuli were 
established by tests at 10 min intervals prior to drug administration.  Control values 
were obtained by averaging responses from the last three tests.  Following 
application of the drug, tests were continued at 10 min intervals for the remainder of 
the experiment. 
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Fig. 2.3: Representative post-stimulus histogram (PSTH) of electrically evoked 
responses of a WDR neurone to electrical stimulation of the hindpaw.  A train of 
16 transcutaneous electrical stimuli (2 ms wide pulses, 0.5 Hz, 3 x C-fibre threshold) 
is applied to the receptive field via two stimulating needles inserted under the skin of 
the hindpaw.  Aβ- (0-20 ms), Aδ- (20-90 ms) and C-fibre (90-300 ms) evoked 
responses are separated and quantified on a basis of latency.  Responses occurring 
after the C-fibre latency band are taken to be the post-discharge (PD) of the cell 
(300-800 ms), an indicator of neuronal hyperexcitability.  For the first few stimuli, prior 
to wind-up, neurones fire in the above defined latency bands.  Once wind-up is 
induced neurones continue to fire at latencies beyond the C-fibre range as a 
consequence of their increased responsivity to afferent input.     
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2.2  Formalin Model of Central Sensitization 
 
 
 2.2.1  In vivo Electrophysiology – Formalin Test 
 
Electrophysiological recordings of deep dorsal horn WDRs  (depth > 600 µm) were 
carried out as described above (see section 2.1).  Cells were characterized as being 
WDR prior to formalin administration.  Transcutaneous stimulating needles were 
used to electrically stimulate the receptive field and induce wind-up (as 2.1.3) and 
responses were monitored to thermal stimulation using a constant jet of water onto 
the centre of the receptive field to indicate a strong C-fibre innervation of the WDR 
neurone, which is required for the response to subcutaneous formalin (Dickenson 
and Sullivan, 1987a).  
 
Following cell characterization, rats were pre-treated with drug prior to the injection of 
formalin (for details of individual drug treatments refer to specific results chapter).  
Formalin (5%, 50 µl) was prepared from a 37% formaldehyde solution and then 
injected subcutaneously into the hindpaw receptive field.  The firing response of the 
WDR neurone was recorded (Fig. 2.4) for the subsequent 70 min after formalin 
injection.  Activity was displayed as a rate recording and quantified in 10 min time 
bins.  
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Fig. 2.4: Example of a rate recording of the characteristic biphasic response of 
a WDR neurone to formalin injection at the hindpaw receptive field.  Recordings 
are conducted for 70 min following formalin injection in continuous 1 s time bins and 
quantified in 10 min time bins.  An initial first phase response to the injection lasts for 
up to 10 min, followed by a quiescent interphase lasting a further 10-15 min.  A 
prolonged second phase begins at approximately 20-25 min after formalin injection 
and lasts for the remainder of the recording period.     
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 2.2.2  Behavioural Formalin Test 
 
Rats were placed in a clear Perspex box and were allowed to acclimatize for 30 min.  
For drug pre-treatment, rats were lightly anaesthetized with isoflurane and then 
injected intrathecally (lumbar puncture method, see 2.6 below) with drug (for details 
of individual drug treatments refer to specific results chapter).  The experimenter was 
blind to treatment for the whole experiment.  Twenty minutes following drug 
administration, rats received a subcutaneous injection of 50 µl of formalin (5%) into 
the plantar surface of the right hindpaw.  Lifting, flinching, licking and biting of the 
injected paw were monitored by measuring the total duration of the response in 
seconds during the 60 min period following formalin administration.  Data was 
captured in 5 min time bins.  At the end of the experiment rats were either culled and 
disposed of or sacrificed for immunohistochemistry (see 2.7 below). 
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2.3  Spinal Nerve Ligation (SNL) Model of Neuropathic Pain 
 
 
 2.3.1  Surgery 
 
Male Sprague-Dawley rats (130-150 g, Central Biological Services, University 
College London, UK) underwent surgery for ligation of L5 and L6 spinal nerves, or 
sham operation (Kim and Chung, 1992).  Under isoflurane anaesthesia (1:1 O2:N2O, 
5% isoflurane for induction, 2% for maintenance), rats were placed in a prone 
position and the left paraspinal muscles were separated from the spinal processes at 
the L4-S2 vertebral level.  Part of the L6 transverse process was carefully removed 
and the left L4-L6 spinal nerves were identified.  The L5 and L6 spinal nerves were 
isolated and tightly ligated with 6-0 silk thread (i.e. thread was looped around the 
nerve and pulled as tightly as possible), distal to the dorsal root ganglion (DRG) and 
proximal to the formation of the sciatic nerve (Fig. 2.5).  The procedure for sham 
operation was identical, except for the ligation of spinal nerves which was omitted.  
Animals were allowed to recover in a warm chamber and were checked for signs of 
motor impairment, such as dragging or non-weight bearing of the affected hindpaw. 
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Fig. 2.5: Spinal nerve ligation (SNL) surgery.  The L5 and L6 spinal nerves are 
exposed and tightly ligated with 6-0 silk thread (red).  Ligation is made distal to the 
DRG and proximal to formation of the sciatic nerve. 
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2.3.2  Behavioural confirmation of mechanical and cold hypersensitivity prior 
to electrophysiology 
 
Behavioural testing of SNL and sham-operated rats was carried out for up to 14 days 
post-operatively to assess sensitivity to mechanical and cooling stimuli.  Initially rats 
were allowed to acclimatize to the behavioural testing room for 15 min in their own 
cages.  Rats were then placed in transparent Perspex cubicles with a wire mesh 
floor, and were allowed to acclimatize to the testing apparatus for a further 15 min.  
Once rats had settled on all four paws and were fully awake, testing began.   
 
 
2.3.2.1  Paw Withdrawal Frequency 
 
Mechanical sensitivity of the ipsilateral and contralateral hindpaws in both SNL and 
sham animals was assessed by recording the frequency of foot withdrawal to 
normally innocuous mechanical punctuate stimuli.  Calibrated von Frey filaments 
(Touch-TestTM, North Coast Medical Inc., San Jose, USA) of 1, 6 and 8 g (giving 
bending forces of 9.8, 58.9 and 78.5 mN respectively) were applied 10 times for 2-3 
seconds per stimulus to the plantar surface of each hindpaw from below (Fig. 2.6a).  
Filaments were applied in ascending order to the centre of the paw, to each toe and 
to the footpads (Fig. 2.6c) and a minimum of 5 min were allowed between application 
of each von Frey hair to the same paw.  A positive response was withdrawal as well 
as licking and/or biting of the stimulated hindpaw, indicative of nocifensive behaviour.  
The responses of both the ipsilateral and contralateral hindpaws were scored as a 
withdrawal frequency (out of 10) and from these results a difference score was 
calculated for each von Frey hair per animal.  The difference score is calculated as:  
 
[the number of paw withdrawals of the ipsilateral paw –  
the number of paw withdrawals of the contralateral paw]. 
 
Thus, a positive difference score would indicate hypersensitivity of the ipsilateral 
hindpaw.  
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2.3.2.2  Acetone Drop Test 
 
Sensitivity to a cooling stimulus was measured by the application of a single drop of 
acetone, 5 times, to the plantar surface of the ipsilateral and contralateral hindpaws.  
Acetone was delivered from below through a 10 cm piece of tubing connected to a 
0.5 ml syringe (Fig. 2.6b).  A positive response was the same as with the application 
of von Frey hairs except that a short delay would often be noted between application 
of the acetone drop and foot withdrawal.  This is due to the fact that the cooling 
stimulus is brought about by evaporation of the acetone drop.  A difference score (as 
above) was also calculated for the acetone drop test for each animal.  The acetone 
drop test was performed before, between and after application of von Frey hairs, with 
a minimum of 5 min between each application to the same paw.   
 
 
The testing sequence for each session was as follows: 
 
1. Acetone drop test 1, 1 application per hindpaw 
2. von Frey hair 1 g, 10 applications per hindpaw 
3. Acetone drop test 2, 1 application per hindpaw 
4. von Frey hair 6 g, 10 applications per hindpaw 
5. Acetone drop test 3, 1 application per hindpaw 
6. von Frey hair 8 g, 10 applications per hindpaw 
7. Acetone drop test 4, 1 application per hindpaw 
8. Acetone drop test 5. 1 application per hindpaw 
 
 
Rats were monitored for normal grooming behaviour and weight gain throughout the 
post-operative period and were subsequently used for in vivo electrophysiology on 
days 15-18 after surgery. 
 
Chapter 2 
 
 
 102 
 
 
 
 
 
 
Fig. 2.6: Behavioural testing for neuropathic pain-related behaviour following 
SNL surgery.  (a,b) Animals are placed in clear Perspex boxes with wire mesh floors 
to allow for stimulation of hindpaws from below.  Mechanical hypersensitivity is 
detected using (a) calibrated von Frey hairs and cold hypersensitivity is assessed by 
application of (b) acetone delivered to the hindpaw using a syringe.  (c) Von Frey 
hairs are applied 10 times to the hindpaw at various positions, including the centre of 
the paw, footpads and toes. 
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2.3.3  In vivo Electrophysiology – Spinal Nerve Ligation Model 
 
Electrophysiological recordings of WDR neurones (as section 2.1) were conducted in 
the left side of the dorsal horn, ipsilateral to the site of nerve injury, in both SNL and 
sham-operated animals on post-operative days 15-18.  Rats weighed between 250 
and 300 g at this point.  Responses to both electrical and natural stimulation of the 
hindpaw were assessed in separate experiments. 
 
A train of 16 transcutaneous electrical stimuli (2 ms wide pulses, 0.5 Hz) was applied 
at three times the threshold current for C-fibres via two stimulating needles inserted 
under the skin of the hindpaw.  A post stimulus histogram was constructed and Aβ- 
(0-20 ms), Aδ- (20-90 ms) and C-fibre (90-350 ms) evoked responses were 
separated and quantified on a basis of latency.  (The latency band for C-fibres was 
increased up to 350 ms to allow for the larger size of the animals.)  Responses 
occurring after the C-fibre latency band were taken to be the post-discharge (PD) of 
the cell (350-800 ms).  Input and wind-up were calculated as before (see 2.1.3).  
 
In a separate set of SNL and sham-operated animals, neuronal responses to natural 
stimuli were assessed.  The hindpaw peripheral receptive field was stimulated using 
natural stimuli which extended from the non-noxious to noxious range.  Mechanical 
stimulation was achieved by application of von Frey filaments 1, 8, 15 and 26 g (9.8, 
78.5, 147.1 and 255 mN respectively).  Filaments 1 and 8 g are considered 
innocuous while filaments 15 and 26 g are noxious.  Each hair was applied in 
ascending order for 10 s.  Next the receptive field was stimulated thermally with the 
following temperatures: 35, 40, 45 & 48°C.  Temperatures including 45°C and above 
are considered noxious.  Heat was applied with a constant water jet onto the centre 
of the receptive field, again in ascending order for a period of 10 s per stimulus.  
WDR neurones respond to the whole range of natural stimuli in a graded fashion, 
from innocuous through to noxious (Fig. 2.7).  Data was captured and analyzed by a 
CED 1401 interface coupled to a Pentium computer with Spike 2 software 
(Cambridge Electronic Design, UK; PSTH and rate functions). 
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Fig. 2.7: Example of a rate histogram displaying action potentials evoked from 
a WDR neurone by thermal stimulation of the hindpaw receptive field. 
Increasing temperatures are applied to the receptive field using a jet of water from a 
syringe for 10 s.  WDR neurones respond to natural stimuli in a graded fashion from 
the non-noxious to noxious range.  At noxious temperatures, WDR neurones produce 
a prolonged response beyond the duration of the stimulus (post-discharge).  Only the 
first 10 s of each response is quantified and recorded for data analysis. 
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2.3.4  Behavioural assessment of mechanical and cold hypersensitivity to 
observe effects of pharmacological interventions  
 
Four days prior to SNL surgery, paw withdrawal thresholds (PWT) and cold 
sensitivity were assessed for both hindpaws of rats.  Following SNL surgery, testing 
was repeated up to day 14/16.  Drug effects were assessed on days 14/16. 
 
 
2.3.4.1  Paw Withdrawal Threshold (PWT) 
 
As an alternative to measuring paw withdrawal frequencies to selected von Frey 
filaments, PWTs were measured to assess mechanical sensitivity.  Von Frey 
filaments were applied 10 times to both ipsilateral and contralateral hindpaws (as Fig. 
2.6c) in ascending order.  The PWT was determined by recording the first von Frey 
filament to produce 5 positive responses out of 10.  A cut-off was set at 15 g (147.1 
mN) to avoid tissue damage. 
 
 
2.3.4.2  Acetone Drop Test 
 
Cold hypersensitivity was assessed by the acetone drop test (as 2.3.2.2) and each 
rat was given a score out of 5 for the number of positive responses for each hindpaw.   
 
Four rats were assessed during each testing session as follows: 
 
1. Acetone drop test 1, 1 application per hindpaw 
2. PWT determined in each hindpaw of rat 1 
3. Acetone drop test 2, 1 application per hindpaw 
4. PWT determined in each hindpaw of rat 2 
5. Acetone drop test 3, 1 application per hindpaw 
6. PWT determined in each hindpaw of rat 3 
7. Acetone drop test 4, 1 application per hindpaw 
8. PWT determined in each hindpaw of rat 4 
9. Acetone drop test 5, 1 application per hindpaw 
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2.4  Assessment of locomotor function – Rotarod 
 
Locomotor function and motor effects of drugs were assessed using an accelerating 
rotarod device (Fig. 2.8; Rotarod 7750, Ugo Basile, Italy).  The apparatus was set to 
accelerate from 0 to 20 revolutions per minute (rpm) over 60 s and the latency to fall 
was monitored with a maximum cut-off of 90 s.  Rats underwent a training period on 
days -3 and -1 prior to testing of drug effects in order to ensure that they could 
remain on the rotarod for a minimum of 60 s. 
 
 
 
 
 
 
 
 
Fig. 2.8: An accelerating rotarod device to assess locomotor performance.  
Rats are positioned on the rotarod facing away from the experimenter (i.e. towards 
the wall).  The time spent on the device until the animal falls is recorded. 
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2.5  Drug administration – In vivo Electrophysiology 
 
In all in vivo electrophysiological experiments, drugs were applied directly to the 
surface of the spinal cord of rats, after removal of any residual cerebrospinal fluid 
(CSF), in a volume of 50 µl, using a Hamilton syringe. 
 
 
2.6  Intrathecal drug administration for behaviour – Lumbar Puncture Method 
 
For all behavioural pharmacological studies drugs were delivered by intrathecal 
injections performed by direct lumbar puncture.  Briefly, rats were lightly 
anaesthetized with isoflurane.  Their backs were shaved and the skin was cleansed 
with gauze soaked in an anti-microbial solution.  A 25-gauge needle connected to a 
syringe was then inserted into the subarachnoidal space between the spinal 
processes of the L5 and L6 lumbar vertebrae.  Drug was injected, eliciting a tail-flick.  
The syringe was held in position for a few seconds after the injection.  Drugs were 
blinded prior to use in all behavioural experiments in the following way.  Drugs were 
made up in identical unlabelled eppendorf tubes in equal volumes.  The tubes were 
then passed on to a colleague who would label the tubes A or B and note down on a 
separate piece of paper the identity of each drug.  This information was retained until 
the end of the experiment for unblinding.   
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2.7  Immunohistochemistry 
 
 
 2.7.1  Perfusion 
 
Animals were terminally anaesthetized using pentobarbitone and perfused 
transcardially with 100 ml saline followed by 400 ml of 4% paraformaldehyde (PFA) 
with 15% of a saturated solution of picric acid.  After perfusion, the lumbar spinal cord 
(levels L4-L6, identified by tracing of dorsal roots) was excised, post-fixed for 4 hrs in 
the perfusion fixative and then cryoprotected in 20% sucrose in 0.1 M phosphate 
buffer overnight at 4°C. 
 
 
 2.7.2  Processing of tissue and staining 
 
Fixed spinal cord samples were embedded in optimal cutting temperature compound 
(OCT) and frozen using liquid nitrogen.  Transverse spinal cord sections (30 µm 
thickness) were cut using a cryostat and every section was collected and placed in 
phosphate buffered saline (PBS) solution for free-floating immunohistochemistry.  
Alternatively, sections were thaw-mounted onto glass slides.  
 
Sections were washed with PBS and then blocked with normal serum (10%) for 30 
min.  Next sections were incubated with primary antibody made up in PBS+Triton X-
100+Azide (PBS-T+Az; see Table 2.1 below and individual results chapters for 
details of specific primary antibodies).  After several washes with PBS, sections were 
then incubated at room temperature with secondary antibody (in PBS-T+Az).  After 
further washing in PBS, sections were mounted onto slides (if free-floating) and 
cover-slipped with Vectashield mounting medium (Vector Laboratories, CA, USA).  
Slides were visualized under a Zeiss Axioplan 2 Microscope (Zeiss, Hertfordshire, 
UK). 
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2.8  Western Immunoblotting 
 
 
 2.8.1  Dissection and tissue homogenization 
 
Animals were anaesthetized with urethane and then sacrificed by decapitation with a 
guillotine.  Fresh tissue (spinal cord, DRG or hippocampus) was dissected and 
placed into 1.5 ml eppendorf tubes and snap frozen in liquid nitrogen.  Tissue was 
subsequently homogenized in radioimmunoprecipitation assay (RIPA) buffer (50 mM 
Tris HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% SDS + 1% DOC 
[Deoxycholic acid] + Complete protease inhibitor cocktail) using a glass 
homogenizer.  Homogenates were transferred to fresh 1.5 ml eppendorf tubes and 
incubated on ice for 2 hrs (hippocampus) or at 37°C for 30 min (spinal cord and 
DRG), and were then centrifuged at 14,000 rpm for 10 min at 4°C.  Supernatant 
containing tissue lysate was collected and an equivalent volume of RIPA buffer was 
added to bring the final concentration of DOC to 0.5%.  The pellet containing 
insoluble debris was discarded.  Spinal, DRG and hippocampal whole cell lysates 
were next titrated to determine their protein concentration using a BCA (Bicinchoninic 
acid) Protein Assay kit (Pierce, UK). 
 
  
 2.8.2  Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
 
Lamaelli loading buffer was added to protein lysates and samples were incubated at 
70°C for 30 min in order to denature proteins and break disulphide bonds and 
protein-protein interactions.  Samples were then loaded onto 8% gels and separated 
by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE).  Gels 
were initially run at 100 V for 30 min and then at 120 V for a further 60 min.  Prior to 
transfer, gels were equilibrated in transfer buffer for 30 min at 4°C.  Proteins were 
then transferred to either polyvinylidene difluoride (PVDF, pre-soaked in methanol) or 
nitrocellulose membranes at 100 V for 60 min and subsequently blocked in 5% milk 
in TBS-T (Tris-buffered saline: Tris 20 mM, pH 7.5, NaCl 500 mM + 0.1% Tween-20) 
at room temperature for 1 hr with gentle shaking.   
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 2.8.3  Detection and revelation 
 
Next, membranes were incubated overnight at 4°C with primary antibody (see Table 
2.2 below and individual results chapters for details of specific primary antibodies), 
diluted in 5% milk in TBS-T.  Membranes were then washed six times (5 min each) at 
room temperature with TBS-T.  Horseradish peroxidase (HRP)-linked secondary 
antibody was then put on for 1 hr at room temperature, and finally membranes were 
placed in enhanced chemilluminescence (ECL)-plusTM reagent, for 5 min, for 
detection of proteins by autoradiography (Fig. 2.9a).  Alternatively, following 
incubation with primary antibody and subsequent washing with TBS-T, membranes 
were incubated with IRDye-linked secondary antibody for 1 hour at room temperature 
for detection of fluorescence (Fig. 2.9b) by use of the Odyssey Detection System 
(Licor, UK).  See individual results chapters for details of primary and secondary 
antibodies used. 
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Fig. 2.9: Example western immunoblots obtained using (a) autoradiography or 
(b) direct fluorescence.  (a) Following incubation with HRP-linked secondary 
antibodies, membranes are exposed to ECL-plusTM reagent and then placed with 
photographic film for detection of bands by autoradiography.  (b) Alternatively, 
membranes are incubated with IRDye-linked secondary antibodies for direct 
detection of fluorescence using the Odyssey detection system (Licor, UK).  In both 
cases, quantification of bands is achieved by densitometric analysis.   
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2.9  Immunoprecipitation Protocol 
 
 
 2.9.1  Washing/preparation of Dynabeads® Protein G 
 
Magnetic Dynabeads® Protein G (Invitrogen Ltd, UK) were used for 
immunoprecipitation.  Beads (25 µl per sample) were transferred to a 1.5 ml 
eppendorf tube which was then placed on a magnet (Fig. 2.10a) for 1 min and the 
supernatant was removed.  The tube was removed from the magnet and the beads 
were resuspended in 100 µl of washing buffer (Citrate-phosphate buffer, pH 5.0).  
The tube was again placed on the magnet for 1 min and the supernatant was 
removed.  This washing procedure was repeated once more. 
 
 
 2.9.2  Antibody coupling to Dynabeads® Protein G 
 
Antibody (5 µg) against the target antigen was diluted in washing buffer to a final 
volume of 50 µl.  Dynabeads were removed from the magnet and were resuspended 
using the diluted antibody.  The dynabead/antibody mix was incubated at room 
temperature for 40 min with gentle shaking to achieve coupling of the antibody to 
beads (Fig. 2.10b).  After 40 min, the tube was placed on the magnet for 2 min and 
the supernatant was removed.  The beads were washed three times in washing 
buffer using the magnet.  The final wash was made with citrate-phosphate buffer + 
0.1% Tween-20 to prevent aggregation of beads prior to downstream 
immunoprecipitation. 
 
 
 2.9.3  Target antigen capture 
 
The dynabeads/antibody complex was resuspended in sample containing 500 µg of 
spinal or hippocampal lysate and the mix was incubated overnight at 4°C with gentle 
rotation (Fig. 2.10b).  Following incubation, beads were washed three times in 200 µl 
of PBS + 0.1% Tween-20.  The beads were resuspended in 100 µl of PBS and 
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transferred to a clean tube prior to elution (to avoid coelution of non-specific proteins 
which can bind to the tube wall). 
 
 
 2.9.4  Denaturing elution of target protein 
 
The tube was placed on the magnet for 1 min and the supernatant removed.  The 
dynabeads/antibody/antigen complex was then resuspended in 40 µl of Lamaelli 
loading buffer and incubated at 70°C for 30 min (Fig. 2.10b).  The tube was then 
replaced on the magnet to separate the dynabeads from the antibody-antigen 
complex and samples were loaded directly onto 8% gels for SDS-PAGE (as 2.8.2).  
An input lane was always loaded containing total lysate (no immunoprecipitation) as 
a positive control. 
 
 
 
 
 
Chapter 2 
 
 
 114 
 
 
 
 
 
Fig. 2.10: Immunoprecipitation protocol using magnetic Dynabeads® Protein G.  
(a) A magnet is used to capture dynabeads in eppendorf tubes for easy removal of 
fluid, thus removing the need for centrifugation.  (b) Dynabeads are washed in 
washing buffer.  Antibody against the target antigen is then incubated with the beads 
for coupling to dynabeads protein G.  The antibody/dynabead complex is then 
incubated with sample lysate for immunoprecipitation.  Target antigen is then eluted 
and collected for downstream western immunoblotting.     
 
 
 
 
 
 
 
 
 
 
Table 2.1: List of antibodies used in immunohistochemistry (IHC) experiments  
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Table 2.2: List of antibodies used in immunoprecipitation (IP) and western blotting (WB) experiments  
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2.10  Statistical Analyses 
 
Details of statistical tests used can be found in individual results chapters.  All 
analyses were conducted using GraphPad Prism v.4 software (GraphPad Software 
Inc., San Diego, CA, USA). 
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3  Interactions between spinal NR2B-containing NMDA receptors and PSD-95 
contribute to spinal nociceptive plasticity 
 
 
3.1  Introduction 
 
 
3.1.1  Expression of NR2B-containing NMDA receptors in the dorsal horn  
 
The NR2B subunit of the NMDA receptor is ideally located to play a role in 
modulation of pain messages from the periphery to the spinal cord, since in the 
dorsal horn, it is highly concentrated at synapses in superficial laminae where most 
nociceptive afferents terminate.  Studies by Yung and also Boyce and colleagues 
demonstrated that protein expression of NR2B subunits is highly restricted to the 
superficial dorsal horn, although some expression is also observed deeper and in the 
ventral horn also.  Initially, the superficial expression was thought to be pre-synaptic 
in primary afferent terminals (Yung, 1998; Boyce et al., 1999).  Accordingly, NR2B 
immunoreactivity has been shown to co-localize with that of IB4 and CGRP, 
respective markers of non-peptidergic and peptidergic C-fibers, in DRG neurones, as 
well as with neurofilament 200 (NF200), a marker of A-fibres (Ma and Hargreaves, 
2000; Marvizon et al., 2002).  Nagy and colleagues later provided definitive evidence 
for the presence of NR2B subunits in intrinsic spinal dorsal horn neurones using an 
antigen-unmasking technique coupled with immunohistochemistry.  Fixed spinal 
sections were briefly treated with pepsin which is believed to digest proteins and thus 
increase access for antibodies to antigens.  The improved immunostaining of NR2B 
protein showed a punctate expression throughout the dorsal horn with a few weakly 
stained puncta in the ventral horn.  The expression of NR2B subunits was mostly 
concentrated in the superficial (laminae I-II) dorsal horn (Nagy et al., 2004a).  In 
contrast, NR2A expression was found throughout the spinal cord but was greatest in 
laminae III-IV of the dorsal horn.  Therefore, targeting NR2B subunits, for example 
through the use of non-competitive NR2B subtype-specific antagonists such as 
ifenprodil, CP-101606 and Ro-256981, may selectively target nociceptive 
transmission without interfering with normal sensory function and may have a better 
side-effect profile compared to non-selective drugs such as ketamine or MK-801.  
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Both the pre-synaptic and post-synaptic distribution of NR2B subunits in the dorsal 
horn may contribute to the analgesic efficacy of such drugs. 
 
 
3.1.2  Involvement of NR2B-containing NMDA receptors in spinal wind-up and 
inflammatory pain 
 
Very few studies have used electrophysiological techniques to study the role of 
NR2B-subtype receptors at the spinal level.  The limited data has, however, 
demonstrated that NR2B-subtype receptors contribute to NMDA-dependent wind-up 
of spinal sensory neurones.  Both Boyce and colleagues and also Chizh and 
colleagues recorded from single motor units as a surrogate measure of dorsal horn 
neuronal activity, albeit in rabbits and rats respectively.  Wind-up in this model was 
attenuated by systemic administration of NR2B-subtype antagonists.  However, 
whereas Boyce and colleagues observed inhibitions of wind-up in spinalized rats, in 
which descending controls had been eliminated, thus suggesting a spinal site of 
action for NR2B-subtype antagonists (Boyce et al., 1999), Chizh and colleagues only 
saw inhibition of wind-up in sham-spinalized rats, indicating a supraspinal site of 
action (Chizh et al., 2001b).  Therefore, although it was clear that NR2B-subtype 
receptors were involved in spinal wind-up, a question had arisen regarding the 
precise location of these receptors.  Later, Kovacs and colleagues addressed this 
question by recording directly from spinal dorsal horn neurones in spinalized rats and 
found that NR2B-subtype antagonists robustly inhibited spinal wind-up (Kovacs et al., 
2004).  Minimal inhibitory effects were seen on afferent evoked activity, indicating a 
selective role for NR2B-subtype receptors in spinal hyperexcitability.  More recently, 
intrathecal administration of the NR2B-antagonist Ro-256981 was shown to reduce 
C-fibre evoked responses of dorsal horn neurones (Qu et al., 2009).  Therefore, it is 
highly likely that NR2B-containing NMDA receptors in the spinal dorsal horn do in 
fact contribute directly to nociceptive hyperexcitability of dorsal horn neurones. 
 
In addition to spinal wind-up, plasticity within the dorsal horn can be investigated 
using the formalin model of inflammatory pain (Dubuisson and Dennis, 1977).  
Peripheral intraplantar injection of formalin results in central sensitization of dorsal 
horn sensory neurones and is dependent on activity of spinal NMDA receptors (Haley 
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et al., 1990; Chaplan et al., 1997).  Awake animals injected with formalin respond 
with pain-related behaviours which characteristically show a biphasic time course, 
and this biphasic response is replicated at the single neuronal level in 
electrophysiological recordings.  The initial phase of activity is caused by the injection 
of formalin, which is a highly noxious substance.  Recent evidence indicates that 
formalin activates TRPA1 channels on nociceptive C-fibres (McNamara et al., 2007).  
This resultant prolonged primary afferent drive leads to central sensitization of dorsal 
horn neurones and this central component underlies the second phase of the 
response to formalin.  Malmberg and colleagues investigated the specific role of 
NR2B-subtype receptors in formalin-induced pain.  Conantokin peptides derived from 
cone snail venom, which are selective inhibitors of NR2B-subtype receptors, potently 
inhibited second phase behaviours induced by formalin at doses which did not affect 
the first phase response or alter motor performance (Malmberg et al., 2003).  
Similarly, genetic knockdown of NR2B protein in the dorsal horn with siRNA resulted 
in the selective reduction of the second phase of the formalin response (Tan et al., 
2005).  Together, these studies suggest a lack of involvement of spinal NR2B-
subtype receptors in acute nociception.  Instead, spinal NR2B-subtype receptors 
contribute to the activity-dependent plasticity of dorsal horn neurones which may 
underlie chronic pain states. 
 
Involvement of NR2B-containing NMDA receptors has also been demonstrated in 
more chronic models of inflammatory pain.  Taniguchi and colleagues first tested the 
efficacy of CP-101606 on pain-related behaviours following peripheral carrageenan 
injection.  Systemic administration of CP-101606 was found to inhibit mechanical 
hypersensitivity whilst having no effect on motor performance in the rotarod test 
(Taniguchi et al., 1997).  Subsequent studies replicated this effect of CP-101606 in 
the carrageenan model and also showed efficacy of systemic Ro-256981, with both 
compounds showing no alteration of the sensitivity of the non-inflamed paw or of 
motor performance (Boyce et al., 1999; Chizh et al., 2001).  In an alternative model of 
chronic inflammatory pain, induced by peripheral injection of complete Freundʼs 
adjuvant (CFA), NR2B-selective conantokin peptide inhibitors reversed both thermal 
and mechanical hypersensitivity when administered intrathecally (Malmberg et al., 
2003).  Interestingly, no reduction was seen of CFA-induced paw oedema, 
suggesting that the inhibitory effect of NR2B-subtype blockers was mediated by a 
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selective spinal action with little peripheral contribution.  In addition, CFA has been 
shown to cause tyrosine phosphorylation of NR2B, but not NR2A, subunits in the 
spinal cord, further implicating NR2B-subtype receptors in chronic inflammatory pain 
(Guo et al., 2002; Guo et al., 2004).   
 
 
3.1.3  Structure of Post-synaptic density protein-95 (PSD-95) 
 
PSD-95, also known as SAP-90, is a 95 KDa protein and a member of the 
membrane-associated guanylate kinase (MAGUK) protein family found within the 
post-synaptic density and able to bind and cluster NMDA receptors at synapses (Tao 
and Raja, 2004).  These proteins are able to bind various intracellular signalling 
proteins and therefore associate them with NMDA receptors in the membrane, thus 
orchestrating downstream NMDA-mediated signalling pathways.  PSD-95 contains 
three postsynaptic density 95-discs large-zonula occludens-1 (PDZ) domains, a Src 
homology 3 (SH3) domain and a guanylate kinase (GUK) domain by which it can 
attach to different proteins with the correct binding motif in their structure (Fig. 3.1).  
The first and second PDZ domains of PSD-95 are able to bind NR2 subunits of the 
NMDA receptor, which contain a PDZ-binding motif (TSXV) at the C-terminus 
(Kornau et al., 1995).  In addition, nNOS also contains a PDZ domain which is able to 
bind the second PDZ domain of PSD-95, thus forming a heterodimeric PDZ-PDZ 
interaction (Brenman et al., 1996).  
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Fig. 3.1: Structure of Post-synaptic density protein-95.  PSD-95 is a 95 kDa 
protein and includes various domains which mediate protein-protein interactions, 
including three postsynaptic density 95-discs large-zonula occludens-1 (PDZ) 
domains, a Src homology 3 (SH3) domain and a guanylate kinase (GUK) domain. 
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3.1.4  Expression of PSD-95 in the dorsal horn of the spinal cord 
 
Immunohistochemical studies have demonstrated that PSD-95 is located in regions 
of the spinal dorsal horn which are important for nociception.  Tao and colleagues 
first showed that expression of PSD-95 is densest in the superficial dorsal horn, 
restricted to laminae I and IIo (Tao et al., 2000), thus perfectly situated to receive 
signals from terminating nociceptive afferents, similar to the expression of NR2B 
subunits.  PSD-95 protein was absent from DRG tissue and deafferentation, 
produced by cutting spinal nerves, had no effect on PSD-95 immunoreactivity in the 
spinal cord.  Therefore, PSD-95 is exclusively expressed post-synaptically within 
intrinsic dorsal horn neurones in the spinal cord.  In addition, PSD-95 protein was 
found to bind to dorsal horn NMDA receptors.  Garry and colleagues later confirmed 
the lack of PSD-95 expression in primary afferent fibres, since they did not observe 
the presence of PSD-95 in dorsal root entry zones, DRG, dorsal roots or sciatic 
nerve.  They did see PSD-95 expression in the dorsal horn restricted to lamina II 
(Garry et al., 2003).  Later, however, Polgar and colleagues used an antigen retrieval 
technique to unmask epitopes, prior to immunohistochemistry, for better detection of 
PSD-95 protein.  Their results showed that PSD-95 has a punctate expression 
throughout the grey matter of the dorsal horn, though this was densest in superficial 
laminae I-II (Polgar et al., 2008).  Since both Tao and colleagues and also Garry and 
colleagues did not use antigen retrieval, they presumably only detected PSD-95 in 
the region where it is most densely expressed. 
 
 
3.1.5  Involvement of PSD-95 in acute and inflammatory pain models 
 
The first evidence for a role of PSD-95 in pain was provided by Tao and colleagues, 
who employed antisense to knockdown the expression of PSD-95 in the spinal cord.  
The tail flick response of rats to thermal stimulation is potentiated by intrathecal 
NMDA administration.  This effect was blocked by PSD-95 antisense (Tao et al., 
2000).  Mechanical and thermal hypersensitivity induced by intrathecal NMDA was 
also abolished in PSD-95 mutant mice, which express a shortened form of the protein 
truncated at the third PDZ domain (Garry et al., 2003).  Surprisingly, these mice did 
not display any deficits in the response to intraplantar formalin compared to wild-type 
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mice, suggesting that PSD-95 is not involved in inflammatory pain.  However, a later 
study by Tao and colleagues provided evidence that PSD-95 is in fact important for 
the manifestation of pain following peripheral inflammation caused by CFA.  A decoy 
peptide was synthesized to mimic the second PDZ domain of PSD-95 which could 
then be used to prevent protein interactions with PSD-95.  It was found that this 
peptide, Tat-PSD-95 PDZ2, blocked both the development and maintenance of CFA-
induced chronic inflammatory pain-related behaviours in mice when administered by 
either intraperitoneal or intrathecal injections (Tao et al., 2008).  No effects were seen 
in the non-inflamed contralateral paw and no changes were observed in locomotor 
function as measured by placing, righting and grasping reflexes following peptide 
treatment.  A critical role for PSD-95 has also been established in chronic 
neuropathic pain and is further investigated in Chapter 4 of this thesis. 
 
 
3.1.6  Coupling between NMDA receptors and PSD-95 and the source-
specificity hypothesis  
 
It is well documented that Ca2+ overload of neurones causes excitotoxicity and cell 
death.  This Ca2+ overload can be the result of synaptic overactivity, such as during 
ischaemia, for example.  The influx of Ca2+ may then trigger intracellular signalling 
cascades which ultimately contribute to death of the neurone.  However, the source 
of this Ca2+ is important in that Ca2+ influx through certain channels will cause more 
excitotoxicity than influx through others.  This is the basis of the ʻsource specificityʼ 
hypothesis which was first put forward by Tymianski and colleagues.  They showed 
that when cells were stimulated with either potassium ions, which cause membrane 
depolarization and subsequent Ca2+ influx through non-specific voltage-gated Ca2+ 
channels, or with glutamate, both causing an equivalent amount of Ca2+ influx, the 
level of excitotoxicity differed between the two groups.  Cell death was greater 
following glutamate stimulation and this effect was mediated via NMDA receptors 
(Tymianski et al., 1993; Sattler et al., 1998).  This indicated that Ca2+-dependent 
processes that trigger neurotoxicity are perhaps physically linked to NMDA receptors 
and are present in close proximity to the channel pore.  In this way, Ca2+ influx 
pathways and downstream intracellular signalling cascades may be 
compartmentalized within neurones (Tymianski et al., 1993).  One effector enzyme 
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which is involved in this NMDA-induced neurotoxicity is nNOS.  Garthwaite and 
colleagues had previously established that NMDA receptor activation in the brain 
resulted in the formation of NO from L-arginine, a reaction catalyzed by nNOS 
(Garthwaite et al., 1988; Garthwaite et al., 1989).  Thus, NO is produced in an 
NMDA-dependent manner.  NO then acts as a diffusible messenger, either acting 
within the same neurone where it is produced or in neighbouring cells, to stimulate 
the production of cyclic guanosine monophosphate (cGMP) by guanylate cyclase 
(Bredt and Snyder, 1989).  Together, these findings gave rise to the idea that nNOS 
was in some way physically coupled to the NMDA receptor and contributed to NMDA-
mediated neurotoxicity.  A likely candidate for mediating this coupling was PSD-95, 
which was known to bind both NR2 subunits of NMDA receptors as well as nNOS 
(Kornau et al, 1995; Brenman et al., 1996).  Subsequently, Sattler and colleagues 
showed that knockdown of PSD-95 in cultured cortical neurones, through the use of 
antisense, blocked NMDA-dependent production of NO, without any alteration of 
nNOS expression or function, and also suppressed NMDA-dependent excitotoxicity 
(Sattler et al., 1999).  This implicated PSD-95 in the coupling of NO production to 
Ca2+ influx specifically through activated NMDA receptors.  This was further 
confirmed in a study by Christopherson and colleagues who showed that a physical 
ternary complex exists between NMDA receptors, PSD-95 and nNOS within 
neurones (Christopherson et al., 1999).  PSD-95 is able to bind the cytoplasmic tail of 
NMDA receptor subunits and to nNOS simultaneously.  Thus, nNOS is physically 
coupled to NMDA receptor activation and is held next to the channel pore where it 
can be directly activated by incoming Ca2+ to generate NO.  This complex is not only 
important in terms of neuronal cell death, but also to plasticity and behaviour (Sattler 
et al., 1999).  As well as nNOS, it is possible that many other proteins may be 
physically linked to NMDA receptors via PSD-95.  Synaptic GTPase-activating 
protein (SynGAP), for example, is known to bind to PSD-95 in a complex with NMDA 
receptors and regulates ERK/MAPK signalling in synaptic plasticity, downstream of 
NMDA receptor activation (Kim et al., 1998; Komiyama et al., 2002).  Thus, an 
extensive network of protein-protein interactions within the post-synaptic density links 
NMDA receptors to specific intracellular signalling pathways (Fig. 3.2) (Sheng, 2001). 
By disrupting such links, it may be possible to inhibit pathological NMDA intracellular 
signalling, whilst maintaining normal synaptic transmission. 
 
Chapter 3 
 
 
126 
 
 
 
 
 
 
 
 
Fig. 3.2: The synaptic NMDA receptor complex.  PSD-95 binds to a C-terminal 
threonine/serine X valine (TSXV) motif in NR2 subunits of the NMDA receptor via its 
2nd PDZ domain, as well as with the PDZ domain of nNOS.  PSD-95 also binds to 
other effectors, such as SynGAP, thus coupling NMDA activity to downstream 
intracellular signalling pathways.  Furthermore, NMDA receptors may interact with 
other membrane-associated receptors such as metabotropic glutamate receptors 
(mGluRs) via the intracellular scaffold proteins GKAP (guanylate kinase-associated 
protein), Shank and Homer.  CaMKII also binds directly to the cytoplasmic tails of 
NR2 subunits and participates in NMDA-mediated signalling.  Adapted from Tao and 
Raja (2004). 
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3.1.7  Disrupting protein-protein interactions specifically between NMDA 
receptors and PSD-95 through the use of Tat-NR2B9c as a potential treatment 
strategy  
 
Targeting of the physical link between the NMDA receptor and PSD-95 has 
previously been investigated in the field of stroke therapy by a group of Canadian 
researchers (Aarts et al., 2002).  They designed a small peptide comprising the final 
nine amino acids of the NR2B cytoplasmic tail, incorporating the TSXV PSD-95 
binding motif, that was conjugated to a human immunodeficiency virus (HIV) cell 
membrane transduction domain, Tat, for intracellular delivery (see 3.2.2 below).  This 
peptide, termed Tat-NR2B9c, was able to transduce cortical neurones in culture 
within ten minutes of application.  By twenty minutes, intraneuronal accumulation of 
Tat-NR2B9c had peaked and was detected for a further five hours.  In co-
immunoprecipitation experiments, Tat-NR2B9c was shown to selectively perturb 
interactions between PSD-95 and NMDA receptor NR2B but not NR2A subunits.  
Despite both these NR2 subunits containing the TSXV binding site for PSD-95, it is 
believed that the preceding five amino acids of Tat-NR2B9c, which are specific to 
NR2B subunits, confer this selectivity of the peptide for NR2B over NR2A subunits 
(Aarts et al., 2002).  In addition, Tat-NR2B9c was found to have no effect on basal 
synaptic transmission since it did not alter NMDA receptor-mediated currents or Ca2+ 
uptake in hippocampal neurons.  However, Tat-NR2B9c did reduce NMDA-induced 
generation of cGMP, a downstream measure of NO production by nNOS in 
neurones.  Together, this data suggests that perturbing interactions between PSD-95 
and NR2B subunits, through the use of Tat-NR2B9c, does not affect the integrity of 
NMDA receptors at the cell membrane, but selectively interferes with downstream 
intracellular signalling.  This strategy may improve on the efficacy of conventional 
NMDA receptor blockers in the treatment of nervous system disorders whilst 
reducing the side-effects associated with NMDA receptor blockade.  Indeed, systemic 
delivery of Tat-NR2B9c, which can cross the blood-brain barrier, was found to be 
highly neuroprotective in rats which had experimentally been given stroke by 
occlusion of a cerebral artery, thus producing cerebral ischaemia.  Even when 
administered one hour after the onset of stroke, thus mimicking a clinical scenario, 
Tat-NR2B9c reduced cerebral brain damage and significantly improved neurological 
scores, as measured by postural reflex and forelimb placement tests (Aarts et al., 
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2002).  In a follow-up study, it was shown that when administered three hours after 
the onset of stroke, Tat-NR2B9c could permanently reduce ischaemic infarct size and 
improve neurological function, measured 62 days post-stroke (Sun et al., 2008).  As a 
result of this successful performance in animal models and the evident wide 
therapeutic window, Tat-NR2B9c has now entered into phase II clinical trials for the 
treatment of stroke (verbal communication from Prof Mike Salter, Univ. of Toronto). 
 
Since NMDA receptors have pathological roles in various nervous system disorders, 
including chronic pain, it is plausible that Tat-NR2B9c may be employed successfully 
for the treatment of many human diseases.  So far, it has been demonstrated that 
Tat-NR2B9c may be useful for the clinical management of status epilepticus and 
Huntingtonʼs disease.  Status epilepticus is a life-threatening condition where the 
brain is in a state of permanent seizure, which causes substantial neuronal damage.  
In a rat model of status epilepticus, Tat-NR2B9c significantly attenuated neuronal cell 
loss (Dykstra et al., 2009).  Huntingtonʼs disease is a neurodegenerative genetic 
disorder which causes impaired muscle coordination and cognitive function, resulting 
from NMDA-dependent cell death in the striatum.  In a mouse model of Huntingtonʼs, 
association of PSD-95 with NR2B was enhanced in striatal tissue, while Tat-NR2B9c 
rescued cells from NMDA-mediated toxicity (Fan et al., 2009).  Therefore, it would 
appear that Tat-NR2B9c has the potential to be applied to multiple clinical disorders.  
It has yet to be demonstrated whether these include abnormal or chronic pain states.  
 
As well as being implicated in excitotoxicity and neurodegenerative disease, NR2B 
interactions with PSD-95 have also been shown to contribute to the essential role of 
NMDA receptors in synaptic plasticity in the brain.  Gardoni and colleagues 
demonstrated that Tat-NR2B9c reduced the induction of LTP, but not long-term 
depression (LTD), at hippocampal synapses.  LTP was induced by high frequency 
stimulation (100 Hz) of hippocampal neurones and was associated with synaptic 
localization of NR2B-containing NMDA receptors and their association with PSD-95 
(Gardoni et al., 2009).  This data supported the established role for PSD-95 in 
synaptic plasticity (Migaud et al., 1998; Stein et al., 2003; Ehrlich and Malinow, 
2004).   
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It is known that overactivity of NMDA receptors in the spinal cord leads to central 
sensitization of dorsal horn sensory neurones and chronic pain.  It is plausible that 
disruption of NMDA-mediated intracellular signalling via PSD-95 in the spinal cord, 
through the use of Tat-NR2B9c, may be a highly successful analgesic strategy which 
lacks the side-effects associated with non-selective NMDA antagonists.  By targeting 
signalling pathways which are known to contribute to neuronal plasticity, we may be 
able to prevent, and ultimately reverse, pathological pain states.  In this chapter, the 
effects of disrupting the specific interaction between PSD-95 and NR2B-containing 
NMDA receptors, on dorsal horn sensory transmission and wind-up, as well as 
formalin-induced central sensitization, have been investigated using 
electrophysiological and behavioural measures. 
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3.2  Materials and Methods 
 
 
3.2.1  Animals 
 
Experiments were conducted in adult male Sprague-Dawley rats (220-250 g, Central 
Biological Services, University College London, or Harlan, UK), housed in standard 
laboratory conditions with free access to food and water.  Experimental procedures 
were approved by the UK Home Office and followed guidelines under the 
International Association for the Study of Pain (Zimmermann, 1983). 
 
 
3.2.2  Synthesis of Tat-NR2B9c and Tat-NR2BAA peptides 
 
Tat-NR2B9c peptide comprises the final nine amino acids of the NR2B subunit 
cytoplasmic tail (KLSSIESDV), including the PSD-95 PDZ domain-binding motif 
(ESDV).  This sequence is conjugated to a HIV-1 virus coat protein, Tat, transduction 
domain (YGRKKRRQRRR), for intracellular delivery (Schwarze et al., 1999).  The full 
peptide is 20 amino acids (YGRKKRRQRRRKLSSIESDV) in length.  A control 
peptide, Tat-NR2BAA, was synthesized with a double substitution in the PDZ 
domain-binding motif (EADA), thereby rendering it unable to bind to its target and 
being inactive (YGRKKRRQRRRKLSSIEADA).  
 
Peptides were synthesized using an ACT 396 peptide synthesizer to > 95% purity 
with high performance liquid chromatography and mass spectrometry analysis 
(Wolfson Institute for Biomedical Research, University College London).  Peptides 
were dissolved in PBS. 
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3.2.3  Immunoprecipitation of NR2B subunits and Western Immunoblotting  
 
Rats anaesthetized with urethane were sacrificed by decapitation and fresh spinal 
cord (dorsal horn only), hippocampus and DRG tissue was dissected out and 
homogenized for immunoprecipitation (IP) and/or western immunoblotting (see 
Materials and Methods chapter).  
 
Immunoprecipitation Dynabeads® Protein G (Invitrogen Ltd, UK) were washed and 
coupled with 5 µg of rabbit anti-NR2B antibody (06-600, Upstate, USA).  Next 500 µg 
of spinal dorsal horn or hippocampus lysate was added to the antibody/dynabeads 
complex and allowed to incubate overnight for capture of target antigen.  Following 
incubation, the captured protein was eluted from the dynabeads and loaded onto gels 
for downstream SDS-PAGE.  Normal spinal and hippocampal lysate samples were 
run alongside IP samples as positive controls.  Once proteins were separated they 
were transferred to nitrocellulose membranes.  For detection of proteins of interest, 
membranes were incubated with primary antibody overnight at 4°C.  Antibodies used 
were mouse anti-NR2B (1:500, 75-101, Neuromab, USA), rabbit anti-PSD-95 
(1:1000, ab18258, Abcam, UK) and rabbit anti-nNOS (1:3000, 07-571, Millipore, UK).  
Following incubation with IRDye-linked donkey anti-rabbit 800CW or goat anti-mouse 
680 secondary antibodies, proteins were revealed using the Odyssey fluorescence 
detection system (Licor, UK). 
 
Western blotting of PSD-95 was conducted in hippocampus, spinal cord and DRG 
lysate samples (40 µg) as above.  Membranes were probed with rabbit anti-PSD-95 
(1:1000, ab18258, Abcam, UK) and rabbit anti-neuronal βIII-tubulin (1:3000, 
ab18207, Abcam, UK), which served as a loading control, followed by IRDye-linked 
donkey anti-rabbit 800CW secondary antibody. 
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3.2.4  In vivo Electrophysiology 
 
Electrophysiological recordings from deep dorsal horn WDR neurones (> 600 µm) 
were conducted as previously described (see Materials and Methods chapter).   
 
 
3.2.4.1  Electrical stimulation of the hindpaw 
 
Following the establishment of stable control responses, 12.5 ng of Tat-NR2B9c in a 
volume of 50 µl was injected onto the surface of the spinal cord (after removal of any 
residual cerebrospinal fluid) using a Hamilton syringe.  Electrical tests were continued 
at 10 min intervals for 2 hrs.  A separate group of animals received 1.25 µg of the 
control peptide Tat-NR2BAA, in a volume of 50 µl, for comparison. 
 
 
3.2.4.2  Neuronal Formalin Test 
 
Following cell characterization, rats were pre-treated by topical spinal administration 
of either 12.5 ng of Tat-NR2B9c or 1.25 µg of Tat-NR2BAA, 20 min prior to the 
injection of formalin.  Both drugs were delivered in a volume of 50 µl using a Hamilton 
syringe.  A separate group of control animals received no drug.  Formalin (5%, 50 µl) 
was prepared from a 37% formaldehyde solution and then injected subcutaneously 
into the hindpaw receptive field.  The firing response of the WDR neurone was 
recorded for the subsequent 70 min after formalin injection.  Activity was displayed as 
a rate recording and quantified in 10 min time bins.  
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3.2.5  Behavioural Formalin Test 
 
Rats were lightly anaesthetized with isoflurane and then injected intrathecally (via 
lumbar puncture method) with either 10 µl of Tat-NR2B9c (12.5 ng or 125 ng) or 10 µl 
of Tat-NR2BAA (1.25 µg).  Experimenters were blind to treatment for the whole 
experiment.  Twenty minutes later, rats received a subcutaneous injection of 50 µl of 
formalin (5%) into the plantar surface of the right hindpaw.  Lifting, flinching, licking 
and biting of the injected paw were monitored by measuring the total duration of each 
response in seconds (s) during the 60 min period following formalin administration.  
Data was captured in 5 min time bins.   
 
 
3.2.6  Statistical Analysis 
 
Data are presented as mean ± s.e.m.  Effects of Tat-NR2B9c and Tat-NR2BAA 
following electrical stimulation of the hindpaw were assessed by one-way repeated 
measures analysis of variance (one-way RM ANOVA), followed by Bonferroni 
multiple comparison post-tests.  Cell characteristics from Tat-NR2B9c, Tat-NR2BAA 
and control (no drug) groups were compared by Studentʼs unpaired t-tests (wind-up 
study) or one-way ANOVA, followed by Bonferroni post-tests (formalin study.  
Formalin neuronal and behavioural response time course data was compared 
between treatment groups and analyzed by two-way RM ANOVA, followed by 
Bonferroni post-tests.  Total activity in the first and second phases was compared 
between treatment groups by quantifying the area under each curve, and analyzed 
by one-way ANOVA, followed by Bonferroni post-tests.  Statistical analyses were 
carried out using GraphPad Prism v.4 software (GraphPad Software Inc., San Diego, 
CA, USA). 
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3.3  Results 
 
 
3.3.1  A protein complex between NR2B subunits, PSD-95 and nNOS exists in 
intrinsic spinal dorsal horn neurones 
 
Protein expression of PSD-95 was confirmed by western immunoblotting in 
hippocampus and spinal cord dorsal horn tissue.  As expected, PSD-95 protein was 
not present in DRG (Fig. 3.3a).  Thus, in the spinal cord, PSD-95 is exclusively found 
in intrinsic dorsal horn sensory neurones and not in terminating primary afferent 
fibres. 
 
Immunoprecipitation was used to reveal physical coupling between spinal dorsal horn 
or hippocampal NR2B subunits and associated proteins using a specific antibody 
against this subunit.  Both PSD-95 and nNOS protein was co-immunoprecipitated by 
the anti-NR2B antibody, as expected, confirming the presence of a heterotrimeric 
complex composed of NR2B-containing NMDA receptors, PSD-95 and nNOS in 
intrinsic spinal dorsal horn neurones and hippocampus (Fig. 3.3b).  Normal spinal 
and hippocampal lysate was run alongside immunoprecipitation samples to act as 
positive controls.  Since PSD-95 is only expressed within intrinsic dorsal horn 
neurones, the presence of PSD-95 protein in the immunoprecipitated sample 
indicates that the NR2B-associated protein complex is present within the same 
dorsal horn neurones. 
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Fig. 3.3: PSD-95 is absent in DRG but present in the dorsal horn and forms a 
ternary complex with NR2B-subtype NMDA receptors and nNOS within 
intrinsic dorsal horn neurones.  (a) Western immunoblot showing expression of 
PSD-95 in hippocampus (two left lanes), DRG (two centre lanes) and spinal dorsal 
horn (two right lanes).  β-III tubulin served as a loading control.  (b) Western 
immunoblots showing immunoprecipitates (IP, right lanes) from hippocampus and 
dorsal horn obtained using an antibody against NR2B.  Left lanes show normal tissue 
lysates with no immunoprecipitation (WB), acting as positive controls. 
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3.3.2  Spinal application of Tat-NR2B9c does not alter afferent-evoked 
responses but inhibits post-discharge of deep dorsal horn WDR neurones 
 
Electrically evoked responses of deep dorsal horn WDR neurones due to primary 
afferent activity were unaltered following spinal Tat-NR2B9c (12.5 ng, n = 6).  No 
changes were seen in Aβ-fibre, Aδ-fibre or C-fibre evoked responses (Fig. 3.4).  The 
control peptide Tat-NR2BAA (1.25 µg, n = 6) also had no effect on these evoked 
responses, at a dose 100x greater than the active peptide.  WDR neurones continue 
to fire action potentials (APs) once the afferent barrage has ceased, a measure 
known as post-discharge, indicating the hyperexcitability of the cell.  Tat-NR2B9c 
produced a significant and robust reduction of post-discharge (Fig. 3.4; % of pre-drug 
baseline = 45 ± 4%, p < 0.01), while Tat-NR2BAA had no effect.  Inhibitory effects of 
Tat-NR2B9c were evident by 20 min following spinal administration, peaked at 
approximately 40 min and persisted for the duration of the experiment.  Pre-drug 
control responses did not differ between treatment groups (Table 3.1). 
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  Tat-NR2B9c (n = 6) Tat-NR2BAA (n = 6) 
C-fibre threshold          
(mA) 0.68 ± 0.29 0.82 ± 0.24 
Depth                             
(µM) 968 ± 70 997 ± 47 
Aβ-fibre evoked response     
(No. of APs) 199 ± 21 102 ± 25 
Aδ-fibre evoked response 
(No. of APs) 266 ± 39 180 ± 14 
C-fibre evoked response 
(No. of APs) 592 ± 50 593 ± 92 
Post-discharge              
(No. of APs) 666 ± 42 460 ± 23 
Input                               
(No. of APs) 444 ± 61 442 ± 98 
Wind-up                          
(No. of APs) 893 ± 98 682 ± 81 
 
 
 
Table 3.1: Pre-drug control responses induced by transcutaneous electrical 
stimulation of the hindpaw receptive field of WDR neurones in rats treated with 
Tat-NR2B9c or Tat-NR2BAA.  C-fibre threshold, cell depth, afferent-evoked 
responses, input and wind-up are expressed as mean ± s.e.m.  There were no 
differences between cells recorded in each treatment group for any measure prior to 
drug delivery; Studentʼs unpaired t-test. 
 
 
 
 
 
 
 
 
Chapter 3 
 
 
138 
 
 
 
 
 
 
Fig. 3.4: Spinal Tat-NR2B9c decreases hyperexcitability of WDR neurones.  
Afferent-evoked responses and post-discharge of WDR neurones following 
transcutaneous electrical stimulation of the hindpaw receptive field, with spinal 
application of control Tat-NR2BAA (1.25 µg) or Tat-NR2B9c (12.5 ng).  White bars 
represent pre-drug control.  All data presented as mean ± s.e.m. of pre-drug control 
responses; ∗∗ p < 0.01, ∗∗∗ p < 0.001 versus pre-drug baseline or control peptide; 
one-way RM ANOVA followed by Bonferroni post-tests on raw data; n = 6 in each 
group. 
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3.3.3  Wind-up of deep dorsal horn WDR neurones is reduced by spinal  
Tat-NR2B9c 
 
The pre-synaptic input (non-potentiated response) as well as the wind-up of WDR 
neurones were both assessed (Fig. 3.5a).  Wind-up is the NMDA-dependent 
increasing response of WDR neurones to repetitive noxious peripheral stimulation at 
constant intensity and frequency (Fig. 3.5b,c).  Pre-drug input and wind-up values 
were similar in both treatment groups (Table 3.1).  Both Tat-NR2B9c and Tat-NR2AA 
had no effect on input (Fig. 3.5a).  In contrast, Tat-NR2B9c significantly decreased 
wind-up of WDR neurones (Fig. 3.5a,c; % of pre-drug baseline = 52 ± 4%, p < 0.05), 
while Tat-NR2BAA had no effect (Fig. 3.5a,b). 
 
Therefore, Tat-NR2B9c, believed to exert its effects by disruption of binding between 
PSD-95 and NR2B subunits, selectively reduces NMDA receptor-mediated post-
discharge and wind-up of deep dorsal horn WDR neurones, while having no effect on 
afferent-evoked responses and input, indicating a post-synaptic mechanism of action. 
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Fig. 3.5: Spinal Tat-NR2B9c selectively reduces wind-up of WDR neurones.   
(a) Effect of spinal application of Tat-NR2BAA (1.25 µg) or Tat-NR2B9c (12.5 ng) on 
input and wind-up of WDR neurones.  White bars represent pre-drug control.  Data 
presented as mean ± s.e.m. of pre-drug control responses; ∗ p < 0.05, ∗∗ p < 0.01 
versus pre-drug baseline or control peptide; one-way RM ANOVA followed by 
Bonferroni post-tests on raw data; n = 6 in each group.  (b,c) Examples of the wind-
up of single WDR neurones following repetitive electrical stimulation in the presence 
of spinal (b) Tat-NR2BAA (1.25 µg) or (c) Tat-NR2B9c (12.5 ng). 
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3.3.4  Formalin-induced central sensitization of deep dorsal horn WDR 
neurones is reduced by spinal pre-treatment with Tat-NR2B9c 
 
Formalin was injected into the hindpaw receptive field and the firing response of 
single WDR neurones was recorded (Fig. 3.6c).  This stimulus produces an afferent 
drive with a delayed central NMDA component to the response.  In control 
recordings, where no drug was applied, formalin induced a characteristic biphasic 
neuronal firing response (Fig. 3.6a-c; 1st phase: 0-10 min, total APs = 9632 ± 1678; 
2nd phase: 10-70 min, total APs = 64071 ± 16220; n = 11).  Control pre-treatment with 
spinal Tat-NR2BAA (1.25 µg, n = 11), twenty minutes prior to formalin injection did 
not alter this response (Fig. 3.6a-c; 1st phase total APs = 13970 ± 2228, p > 0.05; 2nd 
phase total APs = 54483 ± 13673, p > 0.05).  Spinal pre-treatment with Tat-NR2B9c 
(12.5 ng, n = 10) did, however, significantly and selectively reduce second phase 
neuronal firing (Fig. 3.6a-c; total APs = 9695 ± 5386, p < 0.001).  This second phase 
activity is attributed to central sensitization of spinal dorsal horn neurones (Dickenson 
and Sullivan, 1987a; Coderre et al., 1990).  Only a small, non-significant reduction of 
neuronal firing during the acute first phase was observed following Tat-NR2B9c pre-
treatment, likely reflecting the selective inhibitory effects seen previously on post-
discharge and wind-up.  All cells recorded were characterized prior to injection of 
drug and formalin to ensure that cells were comparable between treatment groups 
(Table 3.2).  
 
Thus, spinal application of Tat-NR2B9c reduces NMDA-mediated components of 
formalin-induced central sensitization of deep dorsal horn WDR neurones.   
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  Control - no drug (n = 11) 
Tat-NR2BAA 
(n = 11) 
Tat-NR2B9c  
(n = 10) 
C-fibre threshold          
(mA) 0.65 ± 0.17 0.95 ± 0.24 0.93 ± 0.12 
Depth                             
(µM) 896 ± 42 886 ± 52 905 ± 37 
Aβ-fibre evoked 
response     (No. of 
APs) 
208 ± 23 217 ± 13 193 ± 26 
Aδ-fibre evoked 
response (No. of 
APs) 
234 ± 25 256 ± 14 229 ± 33 
C-fibre evoked 
response (No. of 
APs) 
577 ± 73 541 ± 56 546 ± 83 
Post-discharge              
(No. of APs) 641 ± 117 643 ± 70 654 ± 162 
Input                               
(No. of APs) 689 ± 215 477 ± 91 525 ± 167 
Wind-up                          
(No. of APs) 634 ± 112 814 ± 129 762 ± 207 
48oC                                
(No. of APs) 2037 ± 229 1901 ± 200 1834 ± 190 
 
 
 
Table 3.2: WDR cell characteristics from Tat-NR2B9c neuronal formalin test.  
Cells were characterized prior to drug administration and formalin injection.  C-fibre 
threshold, cell depth, afferent-evoked responses, input, wind-up and response to 
48°C are expressed as mean ± s.e.m.  There were no differences between cells 
recorded in each treatment group; one-way ANOVA followed by Bonferroni post-
tests. 
 
 
 
 
 
Chapter 3 
 
 
143 
 
 
 
 
 
 
Fig. 3.6: Spinal Tat-NR2B9c reduces formalin-induced central sensitization of 
WDR neurones.  (a) Time course of WDR firing response to subcutaneous formalin 
(5%, 50 µl) injection into the hindpaw receptive field with no drug (control, n = 11) or 
following spinal pre-treatment with Tat-NR2BAA (1.25 µg, n = 11) or Tat-NR2B9c 
(12.5 ng, n = 10, ∗ p < 0.05 at 50 min versus Tat-NR2BAA, two-way RM ANOVA, 
followed by Bonferroni post-tests).  (b) Total neuronal activity during the 1st phase (0-
10 min) and 2nd phase (10-70 min) of the formalin response with no drug (control), 
Tat-NR2AA or Tat-NR2B9c (2nd phase: ∗∗ p < 0.01, ∗∗∗ p < 0.001 versus Tat-
NR2BAA and no drug, respectively, one-way ANOVA, followed by Bonferroni post-
tests).  (c) Representative rate recordings of firing responses of WDR neurones to 
formalin with no drug (control) or following spinal pre-treatment with Tat-NR2BAA 
(1.25 µg) or Tat-NR2B9c (12.5 ng).  All data presented as mean ± s.e.m. 
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3.3.5  Spinal Tat-NR2B9c inhibits pain-related behaviours due to formalin-
induced central sensitization 
 
Following the inhibitory effects of Tat-NR2B9c observed on neuronal activity related 
to spinal plasticity, effects of spinal application of Tat-NR2B9c were examined in a 
behavioural assay, using formalin injected into the hindpaw of freely moving, awake 
rats.  As with neuronal activity, formalin induced a biphasic response of pain-related 
behaviours in rats pre-treated intrathecally with the control peptide, Tat-NR2BAA 
(1.25 µg, n = 11), twenty minutes prior to formalin injection (Fig. 3.7a; 1st phase: 0-10 
min, total time of pain-related behaviour = 94 ± 9 s; 2nd phase: 10-60 min, total time 
of pain-related behaviour = 360 ± 26 s).  Pre-treatment with Tat-NR2Bc, however, 
significantly decreased pain-related behaviour during the second phase of the 
response in a dose-dependent manner (Fig. 3.7a,b; 12.5 ng, n = 10, 2nd phase total 
time of pain-related behaviour = 255 ± 13 s, p < 0.01; 125 ng, n = 6, 2nd phase total 
time of pain-related behaviour = 174 ± 16 s, p < 0.001).  No difference was seen 
during the first phase between either dose of Tat-NR2B9c and the control peptide 
(Fig. 3.7a,b; 12.5 ng, 1st phase total time of pain-related behaviour = 68 ± 8 s, p > 
0.05; 125 ng, 1st phase total time of pain-related behaviour = 84 ± 8 s, p > 0.05).  
 
Thus, Tat-NR2B9c, perhaps via disruption of NR2B subunits coupling to PSD-95, 
reduces formalin-induced pain-related behaviours produced by spinal central 
sensitization.  
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Fig. 3.7: Intrathecal Tat-NR2B9c reduces pain-related behaviours due to 
formalin-induced central sensitization.  (a) Time course of pain-related behaviours 
induced by intraplantar injection of formalin (5%, 50 µl) following intrathecal pre-
treatment with Tat-NR2BAA (1.25 µg, n = 11) or Tat-NR2B9c (12.5 ng, n = 10, ∗∗ p < 
0.01 at 25 min versus Tat-NR2BAA; 125 ng, n = 6, ∗∗∗ p < 0.001 at 20, 25 min, ∗ p < 
0.05 at 30 min, ∗∗ p < 0.01 at 35 min versus Tat-NR2BAA, two-way RM ANOVA, 
followed by Bonferroni post-tests).  (b) Total pain-related behaviour during the 1st 
phase (0-10 min) and 2nd phase (10-60 min) of the response to formalin following 
intrathecal pre-treatment with Tat-NR2AA or Tat-NR2B9c (2nd phase: 12.5 ng, ∗∗ p < 
0.01, 125 ng, ∗∗∗ p < 0.001 versus Tat-NR2BAA, one-way ANOVA, followed by 
Bonferroni post-tests).  All data presented as mean ± s.e.m. 
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3.3.6  Spinal Tat-NR2B9c reduces formalin-induced active pain-related licking 
and biting behaviours  
 
Further analysis of the different pain behaviours showed that rats injected with 
formalin spent most time licking and biting the injured paw, rather than lifting and 
flinching (Fig. 3.8).  Licking and biting behaviour alone also shows a strong biphasic 
response following pre-treatment with Tat-NR2BAA (Fig. 3.8a; 1st phase: 0-10 min, 
total time of licking and biting behaviour = 83 ± 10 s; 2nd phase: 10-60 min, total time 
of licking and biting behaviour = 285 ± 23 s), which correlates exactly with the 
biphasic neuronal activity (Fig. 3.6).  Pre-treatment with Tat-NR2B9c produced a 
significant and dose-dependent reduction of this licking and biting behaviour during 
the second phase of the response (Fig. 3.8b; 12.5 ng, 2nd phase total time of licking 
and biting behaviour = 200 ± 18 s, p < 0.05; 125 ng, 2nd phase total time of licking 
and biting behaviour = 124 ± 19 s, p < 0.001).  In contrast, rats spent little time lifting 
and flinching and this behaviour did not follow such an obvious biphasic time course 
(Fig. 3.8c).  There was no difference in total lifting and flinching behaviour in either 
the first or second phase between Tat-NR2BAA and Tat-NR2B9c groups (Fig. 3.8d).   
 
Therefore, it is clear that licking and biting behaviour is the predominant pain-related 
behaviour in rats following intraplantar formalin injection.  The reduction in total pain-
related behaviour by spinal administration of Tat-NR2B9c was due to a selective 
action on the active licking and biting responses rather than the more reflexive lifting 
and flinching. 
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Fig. 3.8: Intrathecal Tat-NR2B9c selectively reduces active pain-related licking 
and biting behaviours following intraplantar formalin.  (a) Time course of 
formalin-induced (5%, 50 µl) licking and biting behaviour following intrathecal pre-
treatment with Tat-NR2BAA (1.25 µg, n = 11) or Tat-NR2B9c (12.5 ng, n = 10).  (b) 
Total licking and biting behaviour during the 1st phase (0-10 min) and 2nd phase (10-
60 min) of the formalin response following intrathecal Tat-NR2AA or Tat-NR2B9c (2nd 
phase, 12.5 ng, ∗ p < 0.05, 125 ng, ∗∗∗ p < 0.001 versus Tat-NR2BAA, one-way 
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ANOVA, followed by Bonferroni post-tests).  (c) Time course of formalin-induced 
lifting and flinching behaviour following intrathecal pre-treatment with Tat-NR2BAA or 
Tat-NR2B9c.  (d) Total licking and biting behaviour during the 1st phase and 2nd 
phase of the formalin response following intrathecal Tat-NR2AA or Tat-NR2B9c.  
Note that due to the lower incidence of lifting and flinching behaviours the vertical 
axes are scaled differently.  All data presented as mean ± s.e.m. 
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3.4  Discussion 
 
Repetitive and prolonged primary afferent stimulation by noxious stimuli, elicited by 
transcutaneous electrical stimulation and formalin-induced inflammation, leads to 
NMDA receptor-mediated plastic changes in neuronal activity, producing wind-up and 
central sensitization of dorsal horn sensory neurones, which may lead to the 
manifestation of chronic pain states.  The novel aim of his study was to specifically 
target NR2B interactions with PSD-95 in pain using both neuronal and behavioural 
measures.  A mimetic peptide, Tat-NR2B9c, which has been shown to disrupt 
coupling between NR2B subunits and PSD-95 (Aarts et al., 2002), was employed.  
The results suggest that binding of PSD-95 to spinal NMDA receptors, composed 
specifically of NR2B subunits, is important for the sensitizing effects of NMDA 
receptor activation.  Disrupting such interactions by using Tat-NR2B9c reduces 
neuronal hyperexcitability and plasticity and also abnormal pain-related behaviours. 
 
Despite being a fast-onset and short-lasting phenomenon, wind-up may contribute to 
long-term changes in the spinal cord which occur during a sustained afferent barrage 
to the dorsal horn from the periphery, thus leading to central sensitization, such as is 
produced by peripheral formalin injection (Haley et al., 1990).  Use of the disrupting 
peptide, Tat-NR2B9c, inhibited post-discharge and wind-up, two measures of 
hyperexcitability and plasticity of dorsal horn WDR neurones.  Both of these 
phenomena are reported clinically in chronic pain patients, and a wind-up ratio, 
representing the perceptual correlate of temporal pain summation, is routinely 
assessed during quantitative sensory testing (Kristensen et al., 1992; Jensen et al., 
2001; Rolke et al., 2006a).  In contrast, responses evoked by primary afferent firing 
and pre-synaptic input were unaltered by Tat-NR2B9c.  These electrophysiological 
results are similar to those obtained by blocking NR2B-subtype receptors (Boyce et 
al, 1999; Chizh et al., 2001; Kovacs et al., 2004).  Studies by Boyce and colleagues 
and also Chizh and colleagues recorded wind-up in muscle units, rather than in 
spinal neurones, to show an antinociceptive effect of systemic NR2B antagonists.  
However, conclusions in these studies differed with regard to the site of action of 
these drugs, with Chizh and colleagues concluding that the NR2B antagonist 
ifenprodil has a supraspinal site of action with respect to its antinociceptive efficacy.  
Later, however, Kovacs and colleagues recorded directly from spinal WDR neurones, 
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as in the present study, in spinalized rats, thus eliminating supraspinal influences of 
descending controls.  It was shown that both non-selective NMDA antagonism and 
selective NR2B antagonism reduced neuronal wind-up while A-fibre and C-fibre 
evoked responses were unaltered.  These results clearly established a role for spinal 
cord NR2B receptors in hyperexcitability of dorsal horn sensory neurones, and are in 
accordance with results of the present study.  
 
The importance of NR2B-subtype receptors in pain following peripheral inflammation 
was first established by Taniguchi and colleagues and later confirmed by Boyce and 
colleagues in demonstrating anti-hyperalgesic efficacy of NR2B antagonism in rats 
with carrageenan-induced inflammation of the hindpaw  (Taniguchi et al., 1997; 
Boyce et al., 1999).  The formalin model of pain (Dubuisson and Dennis, 1977) 
produces a biphasic response, both electrophysiologically in single neurones, as well 
as behaviourally in awake animals.  Tat-NR2B9c selectively reduced the second 
phase of the formalin response, thought to represent central sensitization (Dickenson 
and Sullivan, 1987a; Coderre et al., 1990) in both neuronal and behavioural tests.  
The electrophysiological data provides a neuronal substrate for the behavioural 
effects of disrupting interactions between NMDA receptors and PSD-95.  The 
selective effects of Tat-NR2B9c on formalin-induced central sensitization are 
mimicked by NR2B-subtype receptor antagonism and genetic knockdown.  Malmberg 
and colleagues used conantokins derived from cone snail venom, which selectively 
inhibit NR2B-subtype receptors, and found that these could selectively block pain-
related behaviours during the second phase of the response to formalin.  
Interestingly, this effect was only observed when conantokins were delivered 
intrathecally, whilst systemic administration had no effect, at doses which did not 
affect motor performance (Malmberg et al., 2003).  Genetic knockdown of spinal 
NR2B subunits by intrathecal delivery of small interfering RNA (siRNA) was 
employed by Tan and colleagues.  This method had no effect on motor performance 
or on baseline thermal sensitivity, but markedly reduced formalin-induced second 
phase pain-related behaviours (Tan et al., 2005).  Together, these studies further 
support a role for spinal NR2B-containing NMDA receptors in central sensitization.  In 
contrast, a previous study failed to observe changes in formalin-induced pain-related 
behaviour in PSD-95 mutant mice with a truncation of PSD-95 at the third PDZ 
domain (Garry et al., 2003).  However, the truncated PSD-95 protein in these mice, 
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with the first two PDZ domains intact, may still be present at synapses since it is 
specifically these two domains of PSD-95 which are required for synaptic targeting, 
while PDZ domain three is dispensable (Craven et al., 1999).  In addition, the binding 
capacity at each individual PDZ domain independently contributes to synaptic 
clustering of the protein (Nonaka et al., 2006) so that any loss of the third PDZ 
domain of PSD-95 may not affect its binding to NMDA receptors.  Alternatively, if a 
truncated PSD-95 protein can no longer bind NR2 subunits or be clustered in 
synaptic regions, other related proteins may compensate for this loss.  For example, 
post-synaptic density protein-93 (PSD-93) has been shown to be important for 
inflammatory pain (Tao et al., 2003c).  It is also notable that Garry and colleagues 
used a different behavioural endpoint in the formalin test to that in the present study.  
They measured only lifting and flinching behaviour, which is a spinally-mediated 
reflex.  In the present study, it was found that this behaviour was infrequent and was 
unaltered by Tat-NR2B9c.  In contrast, licking and biting behaviour, which is more of 
an active pain-related behaviour requiring higher processing, predominated during 
the formalin response and was sensitive to the inhibitory effects of Tat-NR2B9c, and 
also exactly paralleled the neuronal firing.  It was not reported whether these active 
behaviours were altered or not in PSD-95 mutant mice.  Interestingly, differences 
were seen with these PSD-95 mutant mice in pain induced by intrathecal NMDA or 
nerve injury (Garry et al., 2003), suggesting that neuropathic pain may arise from 
protein interactions involving the third PDZ domain of PSD-95, while inflammatory 
pain may involve the first and second PDZ domains.  
 
A recent behavioural study using a different disrupting peptide, Tat-PSD-95 PDZ 2, 
which mimics the second PDZ domain of PSD-95, indicated the importance of protein 
interactions with PSD-95 in pain following peripheral inflammation (Tao et al., 2008).  
However, the analgesic effect of this peptide could be attributed to a disruption of 
binding of PSD-95 to, not only NMDA receptors, but also other signalling proteins, 
such as Shaker-type K+ channels (Kim et al., 1995) and nNOS (Brenman et al., 
1996), which also interact with PSD-95 via its second PDZ domain. A cyclic peptide, 
CN2097, which disrupts all PSD-95 interactions mediated via its three PDZ domains, 
has also been shown to reverse neuropathic pain and spinal LTP, though again, the 
particular binding partners of PSD-95 involved in this inhibitory effect were not 
identified (Leblanc et al., 2010).  The results presented in this chapter are expected 
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to be due to a more specific disruption of NR2B and PSD-95 interactions, since the 
Tat-NR2B9c peptide employed here not only exerted selective neuronal effects but 
also mimics the specific C-tail of NR2B subunits, so having no effect on the binding 
of PSD-95 to even NR2A subunits (Aarts et al., 2002).  It is therefore expected that 
other PSD-95 interactions would also remain unaltered.  In addition, Tat-NR2B9c was 
also shown not to alter NMDA-induced currents or Ca2+ influx but to reduce the 
NMDA-induced formation of cGMP, suggesting a lack of effect of Tat-NR2B9c on the 
receptor and trafficking but supporting an action on signalling downstream of NR2B-
subtype receptors via coupling to PSD-95 (Aarts et al., 2002).  Furthermore, an 
alternative peptide, Tat-2ASCV, which disrupts interactions specifically between 5-
HT2A receptors and PSD-95, does not alter interactions between NMDA receptors 
and PSD-95 (Pichon et al., 2010).  Thus, through the use of Tat-NR2B9c, it may be 
concluded that the specific interaction between PSD-95 and NR2B subunits is 
important for dorsal horn neuronal hyperexcitability and central sensitization. 
 
This study further supports the key role of NR2B-containing NMDA receptors in 
spinal cord nociceptive plasticity.  The NR2B subunit has a concentrated distribution 
in the superficial laminae (I-II) of the dorsal horn (Nagy et al., 2004a), where it is 
ideally placed to receive nociceptive inputs from terminating C-fibres.  It is likely that 
the deep dorsal horn neurones recorded in electrophysiological experiments receive 
nociceptive inputs via interneurones and/or their dorsally extending dendrites (Woolf 
and King, 1987; Martin et al., 2001; Braz et al., 2005; Kato et al., 2009) and this 
would account for the effects of Tat-NR2B9c on activity of deep WDR neurones.  
Physical coupling of PSD-95 and NR2B subunits was demonstrated in spinal 
neurones by co-immunoprecipitation, in accordance with previous work (Tao et al., 
2000).  Since PSD-95 was not found to be present in DRG, but only in spinal cord 
tissue, it can be concluded that a complex between PSD-95 and NR2B-subtype 
receptors exists in intrinsic spinal neurones and not in primary afferent fibres, and so 
the target of Tat-NR2B9c is exclusively post-synaptic in the dorsal horn of the spinal 
cord.  This would concur with the electrophysiological results which indicate a lack of 
effect of Tat-NR2B9c on primary afferent input to WDR neurones. 
 
Further evidence for a role of spinal NR2B in neuronal nociceptive plasticity was 
provided by studies into spinal LTP.  High-frequency stimulation of the rat sciatic 
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nerve induces a long-lasting potentiation of C-fibre evoked responses of dorsal horn 
WDR neurones which is sensitive to blockade of spinal NMDA receptors (Svendsen 
et al., 1998) and is also significantly inhibited by spinal application of the NR2B 
antagonist Ro-256981 (Pedersen and Gjerstad, 2007; Qu et al., 2009).  More 
recently, LeBlanc and colleagues established that PSD-95 interactions are required 
for spinal LTP.  The potentiation of C-fibre evoked responses of dorsal horn WDR 
neurones following high frequency stimulation of the sciatic nerve was blocked by a 
peptide which interferes with interactions via the three PDZ domains of PSD-95 
(LeBlanc et al., 2010).  However, which specific interactions with PSD-95 involved in 
this spinal LTP were again not identified.  It is likely that the interaction between 
NR2B subunits and PSD-95 would be involved and this could be established in future 
studies by assessing the effects of Tat-NR2B9c in spinal LTP.  It has, however, been 
established that coupling between NR2B subunits and PSD-95 is important in 
hippocampal LTP.  Gardoni and colleagues employed Tat-NR2B9c and showed that 
disruption of binding between PSD-95 and NR2B-subtype receptors reduced 
induction of LTP but not LTD.  This effect was associated with a reduction of NR2B-
subtype but not NR2A-subtype receptors at hippocampal synapses (Gardoni et al., 
2009).  This again demonstrates selectivity of Tat-NR2B9c for NR2B rather than 
NR2A NMDA receptor subunits.  The importance of NR2B subunits in hippocampal 
LTP has also been shown by studies in both mice and rats which were genetically 
engineered to overexpress NR2B in their forebrains.  These rodents have enhanced 
LTP, but not LTD, underlying enhanced learning and memory which is maintained in 
aged animals (Tang et al., 1999; Tang et al., 2001; Cao et al., 2007; Wang et al., 
2009).  A recent study highlighted the importance of the C-tail of NR2B subunits in 
LTP.  Firstly, NR2B antagonism by Ro-256981 and NR2B siRNA blocked induction of 
LTP, whereas NR2A siRNA did not.  This effect was reversed by overexpression of 
NR2B but not NR2A.  Most interesting was the finding that a chimera of the NR2A 
subunit fused with the C-tail of the NR2B subunit was able to rescue LTP induction, 
while the converse chimera could not (Foster et al., 2010).  This implicates 
interactions with the C-tail of the NR2B subunit as being essential for LTP induction, 
with PSD-95 likely to be involved.  CaMKII is known to bind to NR2B subunits via the 
C-tail and this interaction is essential for LTP (Barria and Malinow, 2005).  In a model 
of neuropathic pain, it was shown that association between CaMKII and NMDA 
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receptors increases after neuropathy, and this mechanism requires PSD-95 (Garry et 
al., 2003). 
 
At present, the downstream mechanisms involved in the inhibition by Tat-NR2B9c 
remain to be elucidated.  However, we may speculate as to which effector pathways 
and intracellular signalling molecules may be involved based on previous studies 
employing Tat-NR2B9c.  This peptide was neuroprotective in a rat model of cerebral 
ischaemia (Aarts et al., 2002) and reduced the production of NO following NMDA 
receptor stimulation.  Another study showed that Tat-NR2B9c reduced the 
phosphorylation of ERK, which occurred after co-stimulation of NMDA and mGluR5 
receptors (Yang et al., 2004b).  In both studies, the mechanism of action of Tat-
NR2B9c was a disruption of coupling between NR2B subunits and PSD-95.  As 
mentioned previously, PSD-95 mutant mice fail to exhibit an increase in CaMKII 
activity following peripheral nerve injury unlike wild-type mice, suggesting that PSD-
95 can bind CaMKII for direct activation by Ca2+ influx via NMDA receptors (Garry et 
al., 2003).  Both ERK and CaMKII have previously been implicated in central 
sensitization (Ji et al., 1999; Fang et al., 2002; Pezet et al., 2008).  It is also known 
that binding of PSD-95 to NMDA subunits stabilizes the receptor in the cell 
membrane (Roche et al., 2001).  Thus Tat-NR2B9c may decrease neuronal 
hyperexcitability by interfering with membrane localization of NMDA receptors.  
However, the fact that Tat-NR2B9c has no effects on NMDA-mediated excitatory 
post-synaptic currents (EPSCs) and Ca2+ influx in the hippocampus may suggest 
otherwise (Aarts et al., 2002). 
 
These results demonstrate that NMDA receptor-dependent phenomena, such as 
wind-up, can be prevented without the requirement for receptor blockade, a likely 
cause of the numerous neurological side-effects associated with NMDA antagonists.  
Tat-NR2B9c is suitable for systemic administration since it has been shown to cross 
the blood-brain barrier (Aarts et al., 2002), raising the potential for its use as a 
treatment for chronic pain.  The next chapter will explore this exciting therapeutic 
potential in a model of neuropathic pain. 
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4  Interactions between spinal NR2B-containing NMDA receptors and PSD-95 
contribute to maintenance of nerve injury-induced pain 
 
 
4.1  Introduction 
 
 
4.1.1  Neuropathic Pain 
 
Neuropathic pain is currently defined by IASP as ʻpain initiated or caused by a 
primary lesion or dysfunction in the nervous systemʼ (Merskey and Boduk, 1994).  
Recently, however, a group of leading pain clinicians and scientists have come 
together and put forward their suggestions for improvement of this definition (Treede 
et al., 2008).  One of the issues raised is regarding use of the word ʻdysfunctionʼ 
within the nervous system since it is difficult to distinguish from normal physiological 
or indeed pathological neuroplasticity that does not involve nerve damage.  Therefore 
ʻdysfunctionʼ should be replaced by the word ʻdiseaseʼ which specifies identifiable 
disease processes such as diabetes, autoimmune conditions or channelopathies.  In 
addition, the current definition does not distinguish between neuropathic pain and 
pain which may arise from other neurological disorders, for example, musculoskeletal 
pain which can be associated with spasticity mediated by nociceptive muscle 
afferents.  Therefore, ʻnervous systemʼ is replaced in the definition by the more 
restrictive term ʻsomatosensory systemʼ.  Thus, a new definition for neuropathic pain 
would read as ʻpain arising as a direct consequence of a lesion or disease of the 
somatosensory systemʼ (Treede et al., 2008). 
 
 
4.1.2  Clinical presentation, epidemiology & treatment of neuropathic pain 
 
Neuropathic pain constitutes a heterogeneous group of diseases and lesions that 
produce a common syndrome characterized by pain (Jensen et al., 2001).  Such 
conditions include nerve compression due to cancers, neuropathies in metabolic 
diseases such as diabetes and CNS disorders such as stroke and multiple sclerosis 
(Table 4.1 provides an incomplete list of some of these disorders).  A subset of 
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patients suffering from such conditions may develop pain as a direct consequence.  
These pains also differ by anatomical location, associated with territories which have 
lost their normal afferent input to the CNS (Jensen et al., 2009).  In the clinic 
neuropathic pain is characterized by the presence of specific symptoms: 1) Pain in a 
neuroanatomical area with partial or complete sensory loss; 2) The presence of 
stimulus-independent (spontaneous) ongoing pains; 3) The presence of stimulus-
dependent evoked pains (hyperalgesia, allodynia, movement-induced pain); 4) 
Aftersensations (pain outlasting the stimulus); 5) Abnormal summation of pain 
(increased pain following repetitive stimulation) i.e. wind-up (Jensen et al., 2009).  
Thus there are both negative and positive signs and symptoms. 
 
In 2006, Hall and colleagues conducted a large UK study to gain an insight into the 
incidence of neuropathic pain.  In their epidemiological analysis of 6.8 million 
patients, 39,731 were found to suffer from one of four neuropathic pain conditions, of 
which 25,200 cases were incident during the period of observation.  Post-herpetic 
neuralgia (PHN) accounted for 12,386 (31%) of these cases, trigeminal neuralgia 
represented 8,268 (21%) cases, incidence of phantom limb pain was 451 (5%) cases 
and painful diabetic neuropathy (PDN) accounted for 4,719 (12%) of cases.  In terms 
of the general population, these incidences per 100,000 person years correspond to 
40.2 for PHN, 26.8 for trigeminal neuralgia, 1.5 for phantom limb pain and 15.3 for 
PDN (Hall et al., 2006). 
 
Current management of neuropathic pain is unsatisfactory and often patients 
continue to suffer pain of moderate severity despite taking prescribed medications.  
Results from randomized control trials typically report less than half of patients 
obtaining satisfactory pain relief and side-effects are common (O'Connor and 
Dworkin, 2009).  Pharmacological control of neuropathic pain often involves a trial 
and error process to find a satisfactory therapy and patients are regularly given 
combinations of medicines which have not necessarily been validated in clinical trials 
(Jensen et al., 2009).  Numerous agents are prescribed clinically for the treatment of 
neuropathic pain including anticonvulsants, antidepressants, opioids, topical 
lidocaine and capsaicin, and NMDA antagonists (Jensen et al., 2009).  
Recommended first-line treatments, agreed upon by both the IASP Neuropathic Pain 
Special Interest Group (NeuPSIG) (OʼConnor and Dworkin, 2009) and the European 
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Federation of Neurological Societies (EFNS) (Attal et al., 2006), are the tricyclic 
antidepressants (TCAs), such as amitriptyline, and the anticonvulsants, gabapentin 
and pregabalin, for PHN, peripheral polyneuropathy (PPN) and central pain (CP).  
Selective serotonin and noradrenaline reuptake inhibitors (SSNRIs), such as 
venlafaxine and duloxetine, are considered first-second line treatments for PPN.  
Topical lidocaine is used as a first-line treatment for localized peripheral neuropathic 
pain.  Opioid analgesics and tramadol are generally considered second-third line 
treatments for PHN, PPN and CP, though can be used as first-line treatments for 
acute and severe neuropathic pain as well as cancer pain.  Topical capsaicin and 
drugs such as mexiletine and the NMDA antagonists, dextromethorphan and 
memantine, have shown inconsistent results in randomized clinical trials and may be 
used as third-line treatments based on individual circumstances (Attal et al., 2006; 
OʼConnor and Dworkin, 2009). 
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Peripheral 
 
Spinal 
 
Brain 
 
Neuropathies (Diabetic, 
HIV-induced etc) 
 
Post-herpetic Neuralgia 
 
Trigeminal Neuralgia 
 
Nerve Injuries 
 
Amputations 
 
Cancer 
 
Plexopathies 
 
Radiculopathies 
 
Avulsions 
 
 
Multiple Sclerosis 
 
 
Spinal Cord Injury 
 
Arachnoiditis 
 
Cancer 
 
Syringomyelia 
 
Spinal stroke 
(Ischaemia) 
 
Stroke 
 
 
Multiple Sclerosis 
 
Cancer 
 
Syringomyelia 
 
 
 
Table 4.1: Some common Neuropathic Pain diseases and conditions. 
(adapted from Jensen et al., 2001) 
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4.1.3  Rodent models of nerve injury-induced neuropathic pain 
 
During the past 25 years or so, animal models of various neuropathies have been 
used to try to understand the mechanisms contributing to neuropathic pain.  The 
majority of research in this area has utilized rodent models involving some kind of 
physical trauma of a peripheral nerve, usually the sciatic nerve, to mimic peripheral 
nerve injury (Zimmermann, 2001).  To date, the three most commonly used 
peripheral nerve injury models are the Chronic Constriction Injury model (CCI), the 
Partial Sciatic Nerve Ligation model (PSNL) and the Spinal Nerve Ligation model 
(SNL). 
 
The CCI model is induced by exposing the sciatic nerve at the mid-thigh level and 
placing four loosely-tied ligatures around the nerve, with 1 mm spacing between each 
(Bennett and Xie, 1988).  The PSNL model involves exposure of the sciatic nerve at 
the high-thigh level and placing a ligature through the nerve, so that one-third to a 
half of the nerve thickness is trapped within the ligature (Seltzer et al., 1990).  The 
last of these models to be developed was the SNL model which is induced by 
exposing and then tightly ligating the L5 and L6 spinal nerves, between the DRG and 
formation of the full sciatic nerve (Kim and Chung, 1992).  This SNL model is 
sometimes modified to ligation of the L5 spinal nerve only.   
 
A later study by Kim and colleagues compared the three models and showed that 
rats with all three types of nerve injury developed signs of mechanical and cold 
hypersensitivity, as well as ongoing (spontaneous) pain (Kim et al., 1997).  The time 
course for evoked pain-related behaviours was similar in all models, developing by 
day 1 and lasting for a number of weeks.  The magnitude of responses to mechanical 
stimulation was, however, varied between models.  The greatest degree of 
mechanical hypersensitivity was seen in the SNL model and least in the CCI model.  
Inter-animal variability was greatest in the CCI model and least in the SNL model, 
suggesting better reproducibility in the SNL model.  The contralateral paw was mainly 
unresponsive in each model.  Responses to acetone of the injured paw were similar 
between models.  Ongoing pain was found to be greatest in the CCI model, though 
with the most variability between animals, while the SNL model displayed the least 
spontaneous pain.  However, frequency of spontaneous behaviours in preclinical 
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research is rarely monitored due to the difficulty in measurement and interpretation 
(Mao, 2009).  This is arguably a major limitation of these models since spontaneous 
pain is one of the most common clinical signs observed in neuropathic pain patients. 
 
With these comparisons in mind, our lab routinely uses the SNL model both in vivo 
electrophysiological and behavioural experiments, since this model produces the 
greatest magnitude of hypersensitivity and is the most reproducible in terms of inter-
animal variability.  This high reproducibility could be due to the tight ligatures placed 
around whole spinal nerves rather than loose ones used in CCI and only partial 
ligation in the PSNL model which is not always consistent in terms of the thickness of 
the nerve that is ligated.  Studies from our lab have validated the use of this model in 
both electrophysiological and behavioural experiments.  Neuronal plasticity has been 
demonstrated in this model, in particular, an increase in spontaneous neuronal 
activity in SNL rats (Chapman et al., 1998a).  In addition, drugs used in the clinical 
management of neuropathic pain and which show plasticity in terms of their efficacy 
following nerve injury, such as gabapentin and morphine, as well as NMDA 
antagonists such as ketamine and memantine, have been validated in this model 
using both electrophysiological and behavioural measures (Yaksh et al., 1995; 
Chaplan et al., 1997; Hunter et al., 1997; Chapman et al., 1998b; Suzuki et al., 1999; 
Suzuki et al., 2001; Matthews and Dickenson, 2002). 
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4.1.4  Contribution of NR2B-containing NMDA receptors to neuropathic pain  
 
Numerous studies have shown that activity of NMDA receptors is crucial to the 
establishment of various chronic pain states, including pain induced by nerve injury.  
Blockade of NMDA receptors, with antagonists such as MK-801 and ketamine, can 
inhibit mechanical and thermal hypersensitivity in animal models of neuropathic pain.  
Accordingly, human studies of various NMDA antagonists have shown analgesic 
efficacy in various neuropathic pain states, though intolerable cognitive and memory 
side-effects were common (see Chapter 1).   
 
Targeting the NR2B subunit has been shown to be an improvement on non-selective 
NMDA antagonists by combining good analgesic efficacy in models of pain with 
fewer side-effects (Chizh et al., 2001a; Gogas, 2006; Wu and Zhuo, 2009).  As 
already highlighted in Chapter 3, the NR2B subunit is ideally located to play a role in 
pain processing from the periphery to the spinal cord.  This subunit is found in both A 
and C-fibres (Boyce et al., 1999; Ma and Hargreaves, 2001; Marvizon et al., 2002) 
and its expression in the spinal cord seems to be highly concentrated in the 
superficial dorsal horn where nociceptive afferent fibres terminate.  In contrast, the 
NR2A subunit has been found throughout the spinal cord (Nagy et al., 2004a).  
Therefore, targeting NR2B subunits, for example through the use of non-competitive 
NR2B subtype-specific antagonists such as ifenprodil, CP-101606 and Ro-256981, 
may selectively target pain whilst leaving normal sensory function intact.  Indeed 
several studies have shown great efficacy of NR2B-selective antagonists in 
neuropathic pain states.  Boyce and colleagues first demonstrated that systemic 
administration of ifenprodil, CP-101606 and Ro-256981 could reverse signs of 
neuropathic pain whilst having no effect on motor performance, as measured by the 
rotarod, at antinociceptive doses.  This was in contrast to the non-selective NMDA 
antagonist MK-801 and also gabapentin which affected both hypersensitivity and 
motor performance at the same doses (Boyce et al., 1999).  Later, Abe and 
colleagues showed that CP-101606 reversed mechanical hypersensitivity produced 
by L5 spinal nerve transection in mice, while not producing motor dysfunction or 
affecting the non-injured paw.  Tyrosine phosphorylation of the NR2B subunit (at 
Tyr1472) in the spinal dorsal horn correlated with signs of neuropathic pain and was 
also reversed by CP-101606.  Interestingly, both NR2A and NR2D knockout mice 
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developed neuropathic pain normally in this model, again implicating NR2B as the 
major player in chronic pain (Abe et al., 2005).   
 
It has been suggested that not spinal but in fact brain NR2B-subtype receptors are 
responsible for the antinociceptive effects of NR2B-selective antagonists in models of 
chronic pain (Chizh et al., 2001b; Nakazato et al., 2005).  However, more recent 
studies using spinal administration of these antagonists have clearly demonstrated a 
role for spinal NR2B-containing NMDA receptors in neuropathic pain.  Malmberg and 
colleagues showed than cone snail venom-derived conantokins, which block NR2B-
subtype receptors, were able to suppress both mechanical and thermal 
hypersensitivity when delivered via intrathecal lumbar puncture at doses which did 
not impair motor function (Malmberg et al., 2003).  Qu and colleagues administered 
ifenprodil and Ro-256981 directly to the spinal cord via intrathecal injections and 
were able to inhibit mechanical hypersensitivity, without altering motor function, when 
given both before L5 SNL surgery and following establishment of the neuropathic 
pain state (Qu et al., 2009).  In addition, intrathecal administration of NR2B-selective 
antagonists blocked spinal LTP, suggesting that NR2B-subtype receptors contribute 
to spinal synaptic plasticity in establishing a chronic pain state.  Nerve injury is also 
associated with increased expression of NR2B protein in the spinal dorsal horn, 
particularly during the maintenance phase of neuropathic pain (Wilson et al., 2005; 
Geng et al., 2010).  Bone cancer pain, a different type of chronic pain state, has 
recently been shown to involve spinal NR2B-subtype receptors (Gu et al., 2009).  
The role of NR2B subunit-containing NMDA receptors in the brain cannot be ruled 
out from being involved in chronic pain.  Mice overexpressing the NR2B subunit in 
the forebrain have enhanced pain following tissue injury (Wei et al., 2001) and 
peripheral inflammation increases expression of NR2B in the anterior cingulate cortex 
(Wu et al., 2005).  Regardless of the site of action, it is clear that NR2B-subtype 
selective antagonists demonstrate good analgesic performance in animal models of 
chronic pain, particularly after nerve injury, without the incidence of psychotomimetic 
and motor side-effects associated with non-specific NMDA antagonists.  Clinical data 
on the effects of NR2B-subtype antagonists in chronic pain is limited at present.  One 
compound, CP-101606 (traxoprodil) has progressed to phase II clinical trials, and 
preliminary findings show effective pain relief in patients suffering from central pain, 
such as following spinal cord injury, without typical psychotomimetic side-effects 
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(Gogas, 2006; Childers and Baudy, 2007).  Aside from their analgesic potential, 
clinical tolerability of these compounds has been demonstrated with a lack of 
psychotomimetic side-effects, cognitive disruption and euphoria (Patat et al., 1994; 
Marquis et al., 1998; Merchant et al., 1999; Chizh et al., 2001a).  Therefore, the 
NR2B-subtype receptor is a viable molecular target for analgesia which should be 
investigated further in chronic pain states, particularly nerve injury-induced pain. 
 
 
4.1.5  Involvement of PSD-95 in neuropathic pain 
 
Four previous studies have demonstrated a role for PSD-95 in neuropathic pain.  
Using antisense oligodeoxynucleotides to specifically knockdown spinal expression 
of PSD-95, Tao and colleagues investigated the role of PSD-95 in both the 
development and maintenance of neuropathic pain (Tao et al., 2001; Tao et al., 
2003a).  The model employed was unilateral ligation and transection of the L5 spinal 
nerve which resulted in mechanical and thermal hypersensitivity from day 3 onwards.  
In the first study, rats were treated for four continuous days with antisense against 
PSD-95 mRNA (messenger ribonucleic acid), beginning on the day before surgery, 
via an intrathecal catheter.  It was found that knockdown of PSD-95 delayed the 
development of both mechanical and thermal hypersensitivity until day 7 post-
surgery, and by day 9 antisense-treated animals showed similar hypersensitivity as 
control rats treated with saline.  Perhaps the effects of the antisense treatment would 
have diminished by day 9 and expression of PSD-95 may have returned to untreated 
control levels.  These results established that PSD-95 has a role in the development 
of central sensitization in neuropathic pain.  A second study by the same group 
showed that PSD-95 is involved in the maintenance of nerve injury-induced pain.  
This time rats were treated with antisense against PSD-95, via an intrathecal 
catheter, on days 7-10 post-surgery.  This resulted in a cessation of both mechanical 
and thermal hypersensitivity on day 11.  On day 13 responses had retuned to pre-
antisense levels.  Importantly, antisense treatment in normal animals had no effect 
on baseline mechanical and thermal sensitivity, or on locomotor function, suggesting 
that PSD-95 is involved specifically in the maintenance of sensory hypersensitivity.  
Together, both theses studies established PSD-95 as a relevant target for treatment 
of neuropathic pain.  A third study by Garry and colleagues utilized PSD-95 mutant 
Chapter 4 
 
 
164 
mice to show the involvement of PSD-95 in neuropathic pain (Garry et al., 2003).  
These mice express a short form of PSD-95 which is truncated at the third PDZ 
domain.  Both PSD-95 mutant mice and wild-type mice underwent CCI surgery to 
induce neuropathic pain.  Wild-type mice showed clear thermal, mechanical and cold 
hypersensitivity but this was either absent in PSD-95 mutant mice, or at least 
markedly reduced, as in the case of cold hypersensitivity.  In addition, it was deduced 
that PSD-95 contributes to neuropathic sensitization via a mechanism involving 
phosphorylation of NMDA receptors by CaMKII.  These results in PSD-95 mutant 
mice, therefore, reinforced those obtained from studies using antisense knockdown in 
demonstrating a role for PSD-95 in neuropathic pain.  Finally, LeBlanc and 
colleagues recently showed that PSD-95 mediated protein-protein interactions are 
essential for nerve injury-induced pain (LeBlanc et al., 2010).  A cyclic peptide which 
binds to the three PDZ domains of PSD-95, thus preventing binding to other proteins 
via these domains, was found to reduce mechanically evoked neuronal responses in 
CCI rats as well thermal hypersensitivity in behavioural experiments. 
 
Clearly, both NMDA receptors, particularly those of the NR2B-subtype, and PSD-95 
have separately been shown to be important components of central sensitization in 
neuropathic pain states.  The experiments in this chapter now aim to investigate the 
role of the specific interaction between spinal NR2B-containing NMDA receptors and 
PSD-95 in contributing to nerve injury-induced pain by employing the mimetic peptide 
Tat-NR2B9c, believed to disrupt binding between NR2B subunits and PSD-95. 
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4.2  Materials and Methods 
 
 
4.2.1  Spinal Nerve Ligation (SNL) Model 
 
SNL surgery was conducted in rats to induce a neuropathic pain state (as described 
in Materials and Methods chapter).  Sham surgery rats were used as controls in 
electrophysiological experiments.  
 
Establishment of behavioural hypersensitivity to low intensity mechanical (von Frey 
filaments 1, 6 and 8 g) and cooling stimuli (acetone) was assessed on post-operative 
days 2, 4, 7, 9, 11 and 14.  Responses of both ipsilateral (IPSI) and contralateral 
(CONTRA) paws were recorded and difference scores were then calculated (see 
Material and Methods for protocol).  Rats were then used for in vivo 
electrophysiological studies on days 15-18.  Both behavioural testing and 
electrophysiological experiments were conducted blind so that it was not known 
whether each animal had undergone SNL or sham operation. 
 
 
4.2.2  In vivo Electrophysiology 
 
Electrophysiological recordings from deep dorsal horn WDR neurones (> 600 µm) 
were conducted in both SNL and sham-operated rats, as previously described (see 
Materials and Methods chapter).  
 
 
4.2.2.1  Electrical and natural stimulation of the hindpaw 
 
Electrical and natural tests were conduced in separate animals to avoid 
overstimulation and sensitization of the sensory system.  Following the establishment 
of stable control responses, 12.5 ng of Tat-NR2B9c in a volume of 50 µl was injected 
topically onto the surface of the spinal cord (after removal of any residual 
cerebrospinal fluid) using a Hamilton syringe.  Electrical tests were continued at 10 
min intervals for 1 hr.  Natural tests (brush followed by von Frey filaments 1, 8, 15 
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and 26 g, followed by temperatures 35, 40, 45 and 48°C) were conducted at 20 min 
intervals for 1 hr. 
 
 
4.2.3  Behavioural assessment of effects of Tat-NR2B9c on maintenance of 
mechanical and cold hypersensitivity induced by spinal nerve ligation 
 
Baseline mechanical PWTs and responses to a cooling stimulus (acetone) were 
detected 4 days prior to SNL surgery (see Materials and Methods for protocol).  
Testing was then repeated in the post-operative period on days 2, 7, 10 and 14/16 to 
observe the development of mechanical and cold hypersensitivity in the ipsilateral 
injured paw versus the contralateral paw.  On day 14/16, following initial sensory 
testing, animals were treated with either Tat-NR2B9c or Tat-NR2BAA (both 125 ng in 
a volume of 10 µl, n = 8 in each group) via intrathecal lumbar puncture.  Following 
drug treatment, sensory testing recommenced and PWTs and responses to acetone 
were assessed at 30 min, 60 min, 90 min, 2 hr, 3hr, 4 hr and 5 hr after intrathecal 
injection.  Experimenters were blind to treatment. 
 
 
4.2.4  Assessment of effects of Tat-NR2B9c on locomotor function 
 
Rats were trained to remain on the rotarod for a minimum of 60 s (see Materials and 
Methods chapter).  Locomotor function was assessed following intrathecal 
administration of Tat-NR2B9c (125 ng, n = 4) via lumbar puncture.  Tests were 
carried out before injection (baseline) and at 20, 40, 60 and 120 min post-injection. 
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4.2.5  Statistical Analysis 
 
Data are presented as mean ± s.e.m.  Difference scores were compared between 
SNL and sham-operated rats by the Mann-Whitney rank sum test.  The effects of 
Tat-NR2B9c following electrical stimulation of the hindpaw were assessed by one-
way RM ANOVA, followed by Bonferroni multiple comparison post-tests.  Cell 
characteristics from SNL and sham-operated rats were compared by Studentʼs 
unpaired t-tests, except for responses to graded mechanical and thermal stimulation 
which were compared by two-way RM ANOVA with Bonferroni post-tests.  Effects of 
Tat-NR2B9c following natural stimulation (von Frey and heat) of the hindpaw were 
assessed by two-way RM ANOVA, followed by Bonferroni post-tests.  Brush-evoked 
responses were compared using one-way RM ANOVA followed by Bonferroni post-
tests.  Two-way RM ANOVA followed by Bonferroni post-tests was used to compare 
PWTs and responses to acetone between ipsilateral and contralateral paws in SNL 
rats as well as effects of Tat-NR2B9c and Tat-NR2BAA.  One-way RM ANOVA, 
followed by Dunnettʼs post-test, was used to assess effects of Tat-NR2B9c in the 
rotarod motor function test.  Statistical analyses were carried out using GraphPad 
Prism v.4 software (GraphPad Software Inc., San Diego, CA, USA). 
Chapter 4 
 
 
168 
4.3  Results 
 
 
4.3.1  SNL induces behavioural mechanical and cold hypersensitivity of the 
injured paw indicating establishment of a neuropathic pain state 
 
Difference scores were calculated for SNL (n = 10) and sham-operated (n = 8) rats to 
assess behavioural sensitivity to mechanical and cold stimuli (Fig. 4.1).  Von Frey 
filaments 1, 6 and 8 g each produced a greater number of paw withdrawal responses 
when applied to the injured ipsilateral paw compared to the non-injured contralateral 
paw in SNL rats, as indicated by positive difference scores.  This mechanical 
hypersensitivity began on day 2 post-surgery and was maintained throughout the 
testing period until day 14 (Fig. 4.1a-c).  Significantly higher difference scores were 
seen with von Frey 1 g on post-surgical day 2 (SNL difference score: 2.7 ± 0.8, sham 
difference score: 0.5 ± 0.6, p < 0.05), day 4 (SNL: 2.1 ± 0.6, sham: -1.1 ± 0.5, p < 
0.001) and day 9 (SNL: 3.3 ± 0.9, sham: -1.0 ± 0.5, p < 0.05), with von Frey 6 on 
post-surgical day 2 (SNL: 4.8 ± 0.6, sham: -0.4 ± 1.2, p < 0.001), day 4 (SNL: 3.7 ± 
0.7, sham: -0.3 ± 0.5, p < 0.01), day 7 (SNL: 3.3 ± 0.8, sham: 0.0 ± 0.8, p < 0.05) and 
day 14 (SNL: 3.8 ± 0.9, sham: -1.3 ± 0.6, p < 0.05) and with von Frey 8 on post-
surgical day 2 (SNL: 4.3 ± 0.8, sham: 0.0 ± 0.7, p < 0.01), day 4 (SNL: 4.1 ± 0.9, 
sham: -0.4 ± 0.8, p < 0.01), day 9 (SNL: 2.8 ± 1.4, sham: -0.5 ± 0.8, p < 0.05) and 
day 11 (SNL: 2.4 ± 1.3, sham: -2.0 ± 0.6, p < 0.05) in SNL rats compared to sham 
rats.  Acetone induced greater paw withdrawals of the ipsilateral paw compared to 
the contralateral paw in SNL rats rather than sham rats.  Again this cold 
hypersensitivity began on day 2 post-surgery and persisted until day 14 (Fig. 4.1d).  
Significantly higher difference scores in SNL rats compared to sham rats were seen 
on post-surgical day 2 (SNL: 2.1 ± 0.5, sham: -0.1 ± 0.2, p < 0.001), day 4 (SNL: 2.4 
± 0.5, sham: -0.6 ± 0.5, p < 0.001), day 7 (SNL: 2.2 ± 0.3, sham: -0.7 ± 0.7, p < 0.01) 
and day 11 (SNL: 2.2 ± 0.4, sham: -0.7 ± 0.7, p < 0.05).   
 
Therefore, it is clear that spinal nerve ligation (but not sham) surgery in rats results in 
mechanical and cold hypersensitivity of the injured ipsilateral hindpaw, beginning on 
day 2 after surgery and persisting for at least 2 weeks.  
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Fig. 4.1: SNL surgery induces robust and long-lasting behavioural mechanical 
and cold hypersensitivity of the injured paw.  Difference scores (the number of 
paw withdrawals of the ipsilateral paw – the number of paw withdrawals of the 
contralateral paw) were calculated for responses to von Frey hairs 1, 6 and 8 g and 
acetone in both sham (n = 8) and SNL (n = 10) rats.  Assessment of difference 
scores was conducted on days 2, 4, 7, 9, 11 and 14 post-surgery to confirm 
development of nerve injury-induced pain-related behaviour.  Data presented as 
mean ± s.e.m., ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001 between surgical groups, 
Mann-Whitney rank sum test. 
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4.3.2  Spinal Tat-NR2B9c does not alter afferent-evoked responses but inhibits 
post-discharge of deep dorsal horn WDR neurones in SNL and sham-operated 
rats 
 
The effects of spinal Tat-NR2B9c on electrically evoked responses of deep dorsal 
horn WDR neurones were compared in SNL and sham-operated rats (n = 8 in each 
group).  Responses of WDR neurones due to primary afferent activity were unaltered 
in both groups following spinal Tat-NR2B9c (12.5 ng).  No changes were seen in Aβ-
fibre, Aδ-fibre or C-fibre evoked responses (Fig. 4.2).   Post-discharge, however, was 
reduced in both SNL and sham rats to a similar extent (Fig. 4.2; SNL: % of pre-drug 
baseline = 60 ± 11%, p < 0.01; Sham: % of pre-drug baseline = 52 ± 13.0%, p < 
0.01).  This inhibitory effect of Tat-NR2B9c on the post-discharge of WDR neurones 
was similar to that seen in naïve rats (Chapter 3, Fig. 3.4).  Pre-drug control 
responses did not differ between surgical groups (Table 4.2). 
 
 
Chapter 4 
 
 
171 
 
  Sham (n = 8) SNL (n = 8) 
C-fibre threshold          
(mA) 0.67 ± 0.18 0.88 ± 0.14 
Depth                             
(µM) 965 ± 42 935 ± 60 
Aβ-fibre evoked response     
(No. of APs) 111 ± 12 130 ± 21 
Aδ-fibre evoked response 
(No. of APs) 223 ± 29 236 ± 35 
C-fibre evoked response 
(No. of APs) 715 ± 113 726 ± 89 
Post-discharge              
(No. of APs) 603 ± 178 475 ± 85 
Input                               
(No. of APs) 373 ± 50 417 ± 47 
Wind-up                          
(No. of APs) 1044 ± 272 864 ± 143 
 
 
 
Table 4.2: Pre-drug control responses induced by transcutaneous electrical 
stimulation of the hindpaw receptive field of WDR neurones in sham and SNL 
rats.  C-fibre threshold, cell depth, afferent-evoked responses, input and wind-up are 
expressed as mean ± s.e.m.  There were no differences between cells recorded in 
each surgical group for any measure prior to treatment; Studentʼs unpaired t-test. 
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Fig. 4.2: Spinal Tat-NR2B9c decreases hyperexcitability of WDR neurones in 
both sham and SNL rats.  Afferent-evoked responses and post-discharge of WDR 
neurones induced by transcutaneous electrical stimulation of the hindpaw receptive 
field in sham and SNL rats and following spinal application of Tat-NR2B9c (12.5 ng).  
White bars represent pre-drug control.  All data presented as mean ± s.e.m. of pre-
drug control responses; ∗∗ p < 0.01 versus pre-drug baseline; one-way RM ANOVA 
followed by Bonferroni post-tests on raw data; n = 8 in each group. 
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4.3.3  Wind-up of deep dorsal horn WDR neurones is reduced by spinal  
Tat-NR2B9c in both SNL and sham-operated rats 
 
As in naïve rats, no effect was seen with Tat-NR2B9c on input (non-potentiated 
response) in either SNL or sham-operated rats (Fig. 4.3a).  In contrast, Tat-NR2B9c 
produced a significant inhibition of wind-up in both surgery groups (Fig. 4.3a-c; SNL: 
12.5 ng, % of pre-drug baseline = 56 ± 10%, p < 0.01, n = 8; Sham: 12.5 ng, % of 
pre-drug baseline = 54 ± 12%, p < 0.01, n = 8).  Inhibition of wind-up was comparable 
between groups and to that observed in naïve rats (Chapter 3, Fig. 3.5).  Pre-drug 
input and wind-up values were similar in SNL and sham rats (Table 4.2). 
 
Therefore, Tat-NR2B9c selectively reduces NMDA receptor-mediated post-discharge 
and wind-up of deep dorsal horn WDR neurones, while having no effect on afferent-
evoked responses and input, in both SNL and sham-operated rats.  The inhibitory 
effect of Tat-NR2B9c on post-discharge and wind-up is not altered in neuropathy.   
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Fig. 4.3: Spinal Tat-NR2B9c selectively reduces wind-up of WDR neurones in 
both sham and SNL rats.  (a) Effect of spinal application of Tat-NR2B9c (12.5 ng) 
on input and wind-up of WDR neurones in sham and SNL rats.  White bars represent 
pre-drug control.  All data presented as mean ± s.e.m. of pre-drug control responses; 
∗∗ p < 0.01 versus pre-drug baseline; one-way RM ANOVA followed by Bonferroni 
post-tests on raw data; n = 8 in each group.  (b,c) Examples of the wind-up of single 
WDR neurones following repetitive electrical stimulation in the presence of spinal Tat-
NR2B9c (12.5 ng) in (b) sham and (c) SNL rats. 
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4.3.4  Responses of deep dorsal horn WDR neurones evoked by natural stimuli 
are reduced by spinal application of Tat-NR2B9c in SNL and sham-operated 
rats 
 
Next, the responses of deep dorsal horn WDR neurones to natural stimuli applied to 
the hindpaw receptive field were assessed.  The pre-drug brush evoked response 
was higher in sham rats compared to SNL rats, though this difference was not 
statistically significant (Table 4.3; Sham: mean number of action potentials = 473 ± 
92, n = 6, SNL: mean number of action potentials = 367 ± 73, n = 6; p > 0.05).  Spinal 
application of Tat-NR2B9c minimally reduced the response to brush in both surgical 
groups to a similar level, but this effect did not reach statistical significance (Fig. 4.4; 
12.5 ng, n = 6 in each group, Sham: APs = 298 ± 88, p > 0.05; SNL: APs = 270 ± 
137; p > 0.05).   
 
Mechanical punctate stimulation of the hindpaw was delivered by different von Frey 
filaments which produced graded responses of WDR neurones that did not differ 
significantly between SNL and sham-operated rats (Table 4.3; n = 6 in each group; 1 
g, Sham: mean number of APs = 0.7 ± 0.5, SNL: APs = 0.3 ± 0.3; 8 g, Sham: APs = 
225 ± 68, SNL: APs = 227 ± 132; 15 g, Sham: APs = 606 ± 165, SNL: APs = 539 ± 
140; 26 g, Sham: APs = 821 ± 140, SNL: APs = 1017 ± 207).  Spinal application of 
Tat-NR2B9c (12.5 ng, n = 6 in each group) reduced graded responses to mechanical 
stimulation in both SNL and sham rats (Fig. 4.5; 1 g, Sham: APs = 0.0 ± 0.0, p > 
0.05, SNL: APs = 0.2 ± 0.2, p > 0.05; 8 g, Sham: APs = 32 ± 13, p > 0.05, SNL: APs 
= 28 ± 12, p > 0.05; 15 g, Sham: APs = 214 ± 147, p < 0.001, SNL: APs = 161 ± 52, 
p < 0.01; 26 g, Sham: APs = 413 ± 127, p < 0.001, SNL: APs = 693 ± 224, p < 0.01).  
The effects of Tat-NR2B9c were similar in both surgical groups. 
 
Graded responses of WDR neurones to thermal stimulation, via a water jet of 
different temperatures, were similar in SNL and sham-operated rats (Table 4.3; n = 6 
in each group; 35°C, Sham: APs = 284 ± 97, SNL: APs = 73 ± 30; 40°C, Sham: APs 
= 346 ± 98, SNL: APs = 138 ± 60; 45°C, Sham: APs = 672 ± 106, SNL: APs = 631 ± 
205; 48°C, Sham: APs = 1282 ± 102, SNL: APs = 1254 ± 131).  Responses in both 
surgical groups were reduced by spinal application of Tat-NR2B9c (12.5 ng, n = 6 in 
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each group) to a similar degree (Fig. 4.6; 35°C, Sham: APs = 89 ± 32, p > 0.05, SNL: 
APs = 67 ± 22, p > 0.05; 40°C, Sham: APs = 74 ± 27, p > 0.05, SNL: APs = 31 ± 11, 
p > 0.05; 45°C, Sham: APs = 161 ± 93, p < 0.05, SNL: APs = 99 ± 43, p < 0.001; 
48°C, Sham: APs = 1119 ± 340, p > 0.05, SNL: APs = 857 ± 274, p < 0.01).  
Inhibitory effects of Tat-NR2B9c were evident by 20 min following spinal 
administration, peaked at approximately 40 min and persisted for the duration of the 
experiment. 
 
Therefore, spinal administration of Tat-NR2B9c reduces graded responses of deep 
dorsal horn WDR neurones to mechanical and thermal stimulation in both SNL and 
sham-operated rats.  Brush evoked responses are minimally reduced.  It would 
appear that the effects of Tat-NR2B9c on all evoked responses are unaltered after 
neuropathy.  
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  Sham (n = 6) SNL (n = 6) 
Brush response 
(No. of APs) 473 ± 92 367 ± 73 
Von Frey 1 g 
(No. of APs) 0.7 ± 0.5 0.3 ± 0.3 
Von Frey 8 g 
(No. of APs) 225 ± 68 227 ± 132 
Von Frey 15 g 
(No. of APs) 606 ± 165 539 ± 140 
Von Frey 26 g 
(No. of APs) 821 ± 140 1017 ± 207 
35°C  
(No. of APs) 284 ± 97 73 ± 30 
40°C  
(No. of APs) 346 ± 98 138 ± 60 
45°C  
(No. of APs) 672 ± 106 631 ± 206 
48°C  
(No. of APs) 1282 ± 102 1254 ± 131 
 
 
 
Table 4.3: Pre-drug control responses induced by natural stimulation of the 
hindpaw receptive field of WDR neurones in sham and SNL rats.  Responses 
evoked by brush, mechanical and thermal stimulation are expressed as mean ± 
s.e.m.  There were no differences between cells recorded in each surgical group for 
any measure prior to drug treatment; Studentʼs unpaired t-test (brush) or two-way RM 
ANOVA followed by Bonferroni post-tests (Von Frey and heat). 
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Fig. 4.4: Brush evoked responses of WDR neurones are not significantly 
altered in either sham or SNL rats by spinal Tat-NR2B9c.  (a,b) Responses of 
WDR neurones to brush stimulation of the hindpaw receptive field in (a) sham (n = 6) 
and (b) SNL (n = 6) rats and following spinal application of Tat-NR2B9c (12.5 ng).  All 
data presented as mean ± s.e.m., one-way RM ANOVA followed by Bonferroni post-
tests. 
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Fig. 4.5: Mechanically evoked responses of WDR neurones are reduced in both 
sham and SNL rats by spinal Tat-NR2B9c.  (a,b) Responses of WDR neurones to 
mechanical stimulation of the hindpaw receptive field with von Frey hairs (1, 8, 15 
and 26 g) in (a) sham (n = 6) and (b) SNL (n = 6) rats and following spinal application 
of Tat-NR2B9c (12.5 ng).  All data presented as mean ± s.e.m., ∗∗ p < 0.01, ∗∗∗ p < 
0.001, two-way RM ANOVA followed by Bonferroni post-tests. 
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Fig. 4.6: Thermally evoked responses of WDR neurones are reduced in both 
sham and SNL rats by spinal Tat-NR2B9c.  (a,b) Responses of WDR neurones to 
thermal stimulation of the hindpaw receptive field with different temperatures of water 
(35, 40, 45 and 48°C) in (a) sham (n = 6) and (b) SNL (n = 6) rats and following 
spinal application of Tat-NR2B9c (12.5 ng).  All data presented as mean ± s.e.m., ∗ p 
< 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, two-way RM ANOVA followed by Bonferroni post-
tests. 
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4.3.5  Spinal Tat-NR2B9c reverses behavioural mechanical and cold 
hypersensitivity in SNL rats 
 
As reported above, spinal nerve ligation induces mechanical and cold 
hypersensitivity of the injured paw (Fig. 4.1).  In a separate behavioural study, paw 
withdrawal thresholds (PWTs), a more sensitive measure of mechanical 
hypersensitivity, and number of responses to acetone of both hindpaws were 
measured in rats, 4 days prior to SNL surgery.  Rats were assigned to Tat-NR2B9c 
(n = 8) or Tat-NR2BAA (n = 8) treatment groups in a randomized and blinded 
fashion.  Baseline thresholds of ipsilateral and contralateral paws of rats in each 
group were identical (Fig. 4.7; Tat-NR2BAA group: IPSI PWT = 10.9 ± 1.3, CONTRA 
PWT = 10.6 ± 1.4; Tat-NR2B9c group: IPSI PWT = 10.6 ± 1.4, CONTRA PWT = 10.0 
± 1.2).  Number of responses to acetone (out of 5) was also comparable between 
hindpaws of rats in each group (Fig. 4.8; Tat-NR2BAA group: IPSI Acetone 
responses = 0.8 ± 0.3, CONTRA Acetone responses = 0.4 ± 0.3; Tat-NR2B9c group: 
IPSI Acetone responses = 0.3 ± 0.2, CONTRA Acetone responses = 0.5 ± 0.3).   
 
Assessment of PWTs and responses to acetone continued throughout the post-
operative period.  On day 2, PWTs of the ipsilateral paw of rats in each treatment 
group had significantly decreased indicating mechanical hypersensitivity, while PWTs 
of the contralateral paws remained at baseline levels (Fig. 4.7; Tat-NR2BAA group: 
IPSI PWT = 1.5 ± 0.4, CONTRA PWT = 9.8 ± 1.3, p < 0.001; Tat-NR2B9c group: IPSI 
PWT = 2.0 ± 0.9, CONTRA PWT = 10.6 ± 1.5, p < 0.001).  Similarly, rats had 
developed cold hypersensitivity of the ipsilateral paw by day 2 as indicated by a 
greater number of responses to acetone compared to the contralateral paw (Fig. 4.8; 
Tat-NR2BAA group: IPSI Acetone responses = 3.1 ± 0.5, CONTRA Acetone 
responses = 0.4 ± 0.3, p < 0.001; Tat-NR2B9c group: IPSI Acetone responses = 3.8 
± 0.5, CONTRA Acetone responses = 0.8 ± 0.3, p < 0.001).  These differences in 
PWTs and responses to acetone between ipsilateral and contralateral paws were 
maintained throughout the post-operative period, measured up to day 14 or 16, in 
both treatment groups (Fig. 4.7 and Fig. 4.8).   
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Following measurement of PWTs and acetone responses on day 14 or 16, either Tat-
NR2BAA (125 ng) or Tat-NR2B9c (125 ng) was delivered spinally to rats via 
intrathecal lumbar puncture.  PWTs and responses to acetone were then re-
measured at various time points after treatment (Fig. 4.7 and Fig. 4.8).  In the Tat-
NR2BAA treatment group there were no changes in PWT or responses to acetone 
such that mechanical and cold hypersensitivity persisted throughout the testing 
period.  In contrast, treatment with Tat-NR2B9c produced a reversal in both 
mechanical PWTs and responses to acetone of the ipsilateral hindpaw towards pre-
surgery baseline levels and those of the contralateral paw.  The ipsilateral PWTs of 
rats treated with Tat-NR2B9c were higher than those of rats treated with Tat-
NR2BAA throughout the 5 hr testing period, though statistically significant differences 
were only seen from 60 min until 2 hrs after treatment (Fig. 4.7; 60 min: Tat-NR2B9c 
group IPSI PWT = 8.1 ± 1.5, Tat-NR2BAA group IPSI PWT = 1.6 ± 0.2, p < 0.01; 90 
min: Tat-NR2B9c group IPSI PWT = 6.6 ± 1.5, Tat-NR2BAA group IPSI PWT = 1.1 ± 
0.2, p < 0.05; 2 hrs: Tat-NR2B9c group IPSI PWT = 8.7 ± 1.7, Tat-NR2BAA group 
IPSI PWT = 1.9 ± 0.9, p < 0.01).  Acetone responses of the ipsilateral hindpaw were 
lower in the Tat-NR2B9c group than the Tat-NR2BAA following treatment throughout 
the 5 hr testing period, with statistically significant differences at 30 min, 90 min, 3 
hrs, 4 hrs and 5 hrs after treatment (Fig. 4.8; 30 min: Tat-NR2B9c group IPSI acetone 
response = 2.3 ± 0.3, Tat-NR2BAA group IPSI acetone response = 4.1 ± 0.2, p < 
0.05; 90 min: Tat-NR2B9c group IPSI acetone response = 2.6 ± 0.6, Tat-NR2BAA 
group IPSI acetone response = 4.4 ± 0.4, p < 0.05; 3 hrs: Tat-NR2B9c group IPSI 
acetone response = 2.3 ± 0.4, Tat-NR2BAA group IPSI acetone response = 4.5 ± 
0.3, p < 0.01; 4 hrs: Tat-NR2B9c group IPSI acetone response = 2.3 ± 0.5, Tat-
NR2BAA group IPSI acetone response = 4.3 ± 0.4, p < 0.01; 5 hrs: Tat-NR2B9c 
group IPSI acetone response = 2.6 ± 0.6, Tat-NR2BAA group IPSI acetone response 
= 4.6 ± 0.2, p < 0.01). 
  
Thus, Tat-NR2B9c, believed to disrupt coupling between spinal NR2B subunits and 
PSD-95, reverses SNL-induced mechanical and cold behavioural hypersensitivity.  
This suggests that the interaction between NR2B-containing NMDA receptors and 
PSD-95 is involved in the maintenance of nerve injury-induced neuropathic pain. 
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Fig. 4.7: Intrathecal Tat-NR2B9c reverses nerve injury-induced behavioural 
mechanical hypersensitivity.  Mechanical paw withdrawal thresholds (PWTs) of 
SNL rats at both the ipsilateral (IPSI) and contralateral (CONTRA) hindpaws 
measured 4 days prior to SNL surgery and on post-surgical days 2, 7, 10 and 14 or 
16.  Rats received intrathecal Tat-NR2B9c (125 ng, n = 8) or Tat-NR2BAA (125 ng, n 
= 8) on day 14 or 16 and PWTs were re-assessed at 30 min, 60 min, 90 min, 2hrs, 
3hrs, 4hrs and 5 hrs following drug administration.  Data are presented as mean ± 
s.e.m., ∗ p < 0.05, ∗∗ p < 0.01 versus IPSI Tat-NR2BAA group, two-way RM ANOVA 
followed by Bonferroni post-tests. 
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Fig. 4.8: Intrathecal Tat-NR2B9c reverses nerve injury-induced behavioural 
cold hypersensitivity.  Responses to acetone stimulation of SNL rats at both the 
ipsilateral (IPSI) and contralateral (CONTRA) hindpaws measured 4 days prior to 
SNL surgery and on post-surgical days 2, 7, 10 and 14 or 16.  Rats received 
intrathecal Tat-NR2B9c (125 ng, n = 8) or Tat-NR2BAA (125 ng, n = 8) on day 14 or 
16 and responses to acetone were re-assessed at 30 min, 60 min, 90 min, 2hrs, 
3hrs, 4hrs and 5 hrs following drug administration.  Data are presented as mean ± 
s.e.m., ∗ p < 0.05, ∗∗ p < 0.01 versus IPSI Tat-NR2BAA group, two-way RM ANOVA 
followed by Bonferroni post-tests. 
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4.3.6  Spinal Tat-NR2B9c does not alter locomotor performance in the rotarod 
test 
 
Performance on the rotarod was used to assess any effects of spinal administration 
of Tat-NR2B9c on locomotor function of rats (Fig. 4.9).  Rats were initially trained to 
remain on the rotarod for a minimum of 60 s and up to 90 s.  Prior to administration of 
drug, rats spent an average of 85.3 ± 2.1 s on the rotarod.  Intrathecal lumbar 
puncture treatment with Tat-NR2B9c (125 ng, n = 4) had no effect on rotarod 
performance during the 2 hr testing period following treatment (mean time spent on 
rotarod: 20 min = 87.5 ± 2.5 s, 40 min = 86.3 ± 3.8, 60 min = 90.0 ± 0.0, 2 hrs = 88.0 
± 2.0). 
 
Therefore, spinal delivery of Tat-NR2B9c does not affect locomotor performance in 
rats at a dose which reversed mechanical and behavioural hypersensitivity following 
spinal nerve ligation and also pain-related behaviours due to formalin-induced central 
sensitization (Chapter 3).  The effects of Tat-NR2B9c can thus be attributed to 
alterations specifically in sensory processing. 
Chapter 4 
 
 
186 
 
Baseline 20 40 60 120
0
25
50
75
100
Time Post-injection (min)
 
 
 
Fig. 4.9: Intrathecal Tat-NR2B9c does not alter locomotor function.  Time spent 
on the accelerating rotarod (i.e. latency to fall) before (baseline, white bar) and after 
intrathecal injection of Tat-NR2B9c (125 ng, n = 4, black bars).  A cut-off time of 90 s 
was used.  Data presented as mean ± s.e.m., one-way RM ANOVA followed by 
Dunnettʼs post-tests. 
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4.4  Discussion 
 
The findings reported in this chapter suggest that the physical interaction between 
spinal NR2B-containing NMDA receptors and PSD-95 is crucial to the maintenance 
of nerve injury-induced neuropathic pain.  The mimetic peptide Tat-NR2B9c, believed 
to disrupt this physical interaction, reversed mechanical and cold behavioural 
hypersensitivity in SNL rats, whilst having no effects on locomotor function.  
Electrophysiological recordings showed inhibition of post-discharge and wind-up as 
well as of mechanically and thermally-evoked responses of deep dorsal horn WDR 
neurones following spinal administration of Tat-NR2B9c, suggesting that NMDA-
dependent neuronal plasticity contributes to behavioural hypersensitivity in this nerve 
injury model. 
 
In the previous chapter, it was reported that Tat-NR2B9c produced significant 
inhibitions of post-discharge and wind-up of WDR neurones in naïve rats.  This effect 
was selective since no changes were seen in primary afferent-evoked responses of 
WDR neurones or input, suggesting a post-synaptic mechanism of action.  This 
experiment was repeated in animals which had undergone SNL or sham surgery.  It 
was found that Tat-NR2B9c produced identical effects in both surgical groups to 
those seen in naïve animals.  Post-discharge and wind-up were equally reduced in 
both groups and no effect was seen on afferent-evoked responses or input.  This 
would indicate that NR2B-subtype receptors and PSD-95 do not exert effects on 
primary afferent activity in nerve-injured rats, but rather specifically regulate the 
excitability of intrinsic spinal dorsal horn neurones.  Naturally evoked responses of 
WDR neurones, by mechanical and thermal stimulation of the hindpaw, were also 
inhibited by Tat-NR2B9c to the same extent in both SNL and sham-operated rats.  
These results are in accordance with previous studies which have assessed effects 
of NMDA antagonists on spinal neuronal responses.  MK-801 inhibited post-
discharge and wind-up and also mechanically and thermally evoked responses of 
WDR neurones and these effects were comparable between SNL and sham groups 
(Suzuki et al., 2001).  A recent study showed that the NR2B-subtype specific 
antagonist, Ro-256981, reduced C-fibre-evoked responses and blocked spinal LTP 
equally in normal and SNL rats (Qu et al., 2009).  Although trends towards inhibition 
were seen of brush-evoked responses in both surgical groups in this study, these did 
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not reach statistical significance, suggesting that coupling between NR2B subunits 
and PSD-95 may contribute more to static rather than dynamic mechanical allodynia.   
 
Since the neuronal effects of Tat-NR2B9c do not change following neuropathy, it may 
seem that the role of the interaction between NR2B subunits and PSD-95 is not 
altered under pathological conditions.  However, it is important to remember that 
major changes in connectivity between primary afferents and spinal neurones have 
occurred following neuropathy.  Two thirds of the input from the sciatic nerve has 
effectively been eliminated in this SNL model.  Within the L4 spinal segment, 
although afferent inputs are maintained, these are reduced since the ligated L5 and 
L6 spinal nerves cross-innervate this segment (Pinto et al., 2008; Shehab et al., 
2008).  Despite this, baseline responses of WDR neurones evoked by electrical, 
mechanical and thermal stimulation of the hindpaw and conduction through the 
sciatic nerve were similar in SNL and sham-operated rats.  This would suggest that 
some form of compensation in spinal excitability has occurred in nerve-injured rats to 
account for the loss of peripheral input and this may involve activity of spinal NMDA 
receptors.  Therefore, it is difficult to conclude as to whether the interaction between 
NR2B subunits and PSD-95 has changed in this model using pharmacology in 
electrophysiological experiments alone. 
 
Prior to electrophysiological testing and assessment of the effects of Tat-NR2B9c on 
pain-related behaviours, neuropathic pain was allowed to develop for two weeks after 
surgery.  Two different ways of behaviourally measuring mechanical hypersensitivity 
were used in this study.  Difference scores were calculated by measurement of 
withdrawal frequency to specific von Frey hairs.  This method is quick and reliably 
shows the development of mechanical hypersensitivity in SNL rats only over sham 
rats.  However, this method has limitations, since in some rats von Frey filaments 6 
and 8 g can induce withdrawal of non-injured paws, giving large withdrawal 
frequencies, meaning that difference scores, which specifically indicate 
hypersensitivity of the injured paw, may be lower than expected.  For this reason, it 
was decided that measurement of paw withdrawal thresholds (PWTs) would be a 
more sensitive approach to assess mechanical hypersensitivity when testing the 
effects of Tat-NR2B9c on neuropathic pain behaviour.  This method allows for the 
PWT of both paws to be assessed, giving individual values for each paw, as opposed 
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to a difference score which incorporates measurements at both paws.  Importantly, 
this allows for detection of drug effects of the non-injured paw as well as the injured 
paw, whereas a difference score does not.  Cold hypersensitivity was always 
assessed by frequency of withdrawal to a single drop of acetone.  Behavioural 
analysis confirmed that unilateral mechanical and cold hypersensitivity developed by 
day 2 following surgery in SNL rats only and was maintained for the two weeks of 
testing.  Mechanical hypersensitivity has been reported to last for up to 10 weeks 
post-surgery (Kim and Chung, 1992).  This hypersensitivity is confined to the 
ipsilateral paw, while sensitivity of the contralateral paw of SNL rats remains at pre-
surgery baseline levels.  Spinal administration of Tat-NR2B9c two weeks after 
surgery via a single intrathecal injection reversed both mechanical and cold 
hypersensitivity of the ipsilateral paw, while the control peptide, Tat-NR2BAA, had no 
effect at all.  PWTs were increased and responses to acetone were reduced towards 
baseline levels and those of the contralateral paw.  These effects began 30 min after 
drug administration and lasted for the full 5 hr testing period.  NMDA antagonists, 
dextromethorphan and ketamine, also reduce pain-related behaviours in rats 
following neuropathy (Mao et al., 1993; Christoph et al., 2006).  More interestingly, 
spinal inhibition of NR2B-subtype receptors reverses mechanical and thermal 
hypersensitivity, with this effect also beginning approximately 30 min after 
administration of an NR2B-selective inhibitor (Malmberg et al., 2003; Qu et al., 2009).  
Together, all of these results confirm that spinal NR2B-subtype receptors do indeed 
have a role in chronic pain.  In the present study, no effects of Tat-NR2B9c were 
seen in the contralateral paw.  However, because a cut-off of 15 g was applied in 
mechanical testing (to avoid tissue damage), it can be argued that it was not possible 
to assess whether or not PWTs were raised above this cut-off following Tat-NR2B9c 
administration.  Nevertheless, it is clear that signs of neuropathic pain can be 
reversed by Tat-NR2B9c in nerve-injured rats. 
 
The behavioural effects of Tat-NR2B9c were achieved at a dose which was 10 times 
higher than that used in electrophysiological experiments.  This is to account for the 
fact that a smaller volume is injected intrathecally meaning that the drug may cover a 
smaller area of spinal cord.  Additionally, administration of drug during 
electrophysiology is into a static system, i.e. a laminectomy exposing the surface of 
the cord where minimal movement of fluid occurs for the whole duration of the 
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recording and thus minimal removal of drug, whereas following intrathecal injections, 
rats quickly awake from brief anaesthesia and move around, limiting the time for the 
drug to access the target area of cord.  Even at this higher dose, though, no effects 
were seen in the performance of rats on the rotarod, indicating no off-target 
locomotor effects.  
 
This work has confirmed the findings of previous studies which have demonstrated 
involvement of spinal PSD-95 in neuropathic pain.  Knockdown of PSD-95 in the 
spinal cord by intrathecal antisense treatment can delay the development of 
hypersensitivity when administered at the time of L5 spinal nerve injury (Tao et al., 
2001).  More interestingly, in terms of clinical treatment, PSD-95 antisense treatment 
was able to reverse hypersensitivity once it had already been fully established, 
without locomotor effects (Tao et al., 2003a).  This finding is in accordance with those 
of the present study.  It has also been shown that PSD-95 mutant mice fail to develop 
behavioural hypersensitivity following CCI (Garry et al., 2003) again implicating PSD-
95 in nerve injury-induced pain.  Most recently, LeBlanc and colleagues synthesized 
a peptide, termed CN2097, which binds to the three PDZ domains of PSD-95, thus 
non-selectively disrupting PSD-95 interactions with other proteins.  It was found that 
this peptide reduced mechanically evoked responses of dorsal horn WDR neurones 
as well thermal behavioural hypersensitivity (LeBlanc et al., 2010). 
 
At present, the precise mechanisms by which coupling between NR2B-containing 
NMDA receptors and PSD-95 contribute to nerve injury-induced pain are unknown.  It 
is likely that specific intracellular signalling events are activated downstream of this 
interaction which lead to central sensitization of dorsal horn neurones and which 
ultimately lead to manifestation of pain-related behaviours following peripheral nerve 
injury as well as intraplantar formalin injection (Chapter 3).  Such signalling events 
will be investigated in the remainder of this thesis. 
 
These results demonstrate that Tat-NR2B9c, a mimetic peptide believed to disrupt 
protein interactions specifically between NR2B-subtype receptors and PSD-95, can 
produce similar effects to receptor blockade in a model of neuropathic pain following 
nerve injury.  Since intolerable side-effects are particularly associated with NMDA 
antagonists, using mimetic peptides which disrupt protein interactions may be a 
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better analgesic strategy.  This is supported by the lack of effect of Tat-NR2B9c on 
locomotor function.  Another mimetic peptide, Tat-PSD-95 PDZ2, which, among other 
interactions, prevents binding of PSD-95 to NMDA receptors, has been shown to 
reverse behavioural hypersensitivity following inflammation induced by CFA (Tao et 
al., 2008).  Despite the different pain model used, these results along with those 
presented here show that binding between NMDA receptors and PSD-95 is involved 
in regulation of selective sensory modalities in chronic pain, specifically static 
mechanical hypersensitivity.  Targeting of interactions between NMDA receptors and 
the kinase Src using a peptide mimetic strategy has also shown anti-hyperalgesic 
efficacy in neuropathic and inflammatory chronic pain models (Liu et al., 2008).  
Therefore, mimetic peptides, particularly those targeting interactions within the NMDA 
receptor complex, should be considered further as novel analgesics for the treatment 
of chronic pain. 
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5  Involvement of atypical protein kinase C zeta (PKCζ /PKMζ) in  
NMDA-dependent spinal central sensitization  
 
 
5.1  Introduction 
 
 
5.1.1  The Protein Kinase C family 
 
The PKC family of enzymes comprises numerous serine/threonine kinases with 
varying dependence on Ca2+ and diacylglycerol (DAG), and which act as key 
effectors of intracellular signalling within neurones.  The conventional α, βI, βII and γ 
isozymes are both Ca2+ and DAG-dependent, while the δ, ε, η and θ isozymes are 
Ca2+-independent but DAG-dependent and are termed the novel PKCs.  A third 
group, the atypical PKCs, are independent of both Ca2+ and DAG signalling and 
include the ζ and λ/ι isozymes (Velazquez et al., 2007).  Activity of PKCs has been 
shown to be crucial at all levels of nociceptive processing, from the peripheral 
primary afferent fibres, through the spinal cord and up to the brain.  
 
 
5.1.2  PKC in primary afferent fibres 
 
Peripheral sensitization, characterized by thermal hyperalgesia and mechanical 
allodynia, can occur in response to tissue damage.  The release of an ʻinflammatory 
soupʼ containing various chemical mediators, including ATP, protons, bradykinin, 
prostaglandins, substance P, CGRP and pro-inflammatory cytokines, to name a few, 
can activate and sensitize the peripheral terminals of nociceptors, leading to 
heightened pain.  Numerous studies have provided evidence that PKCs play a key 
role in this sensitization.  Phorbol esters, which are activators of PKC, can 
themselves activate primary afferent fibres and induce nociception (Cesare and 
McNaughton, 1996; Ferreira et al., 2005), whilst the peripheral administration of PKC 
inhibitors in models of pain is anti-hyperalgesic.  For example, intraplantar 
administration of PKC inhibitors has been shown to inhibit both bradykinin-induced 
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mechanical allodynia and also pain-related behaviours during the second phase of 
the response to intraplantar formalin injection (Souza et al., 2002).   
 
In particular, the PKCε isozyme in primary afferents is thought to have a substantial 
role in nociception.  It is the only PKC isozyme translocated to the cell membrane in 
response to bradykinin (Cesare et al., 1999).  Transgenic mice lacking PKCε have 
attenuated mechanical allodynia and thermal hyperalgesia in response to chemical 
mediators, while baseline nociceptive thresholds remain intact (Khasar et al., 1999).  
Inhibition of PKCε using a selective PKCε inhibitor peptide also blocks peripheral 
sensitization and hyperalgesia (Cesare et al., 1999; Khasar et al., 1999).  It is 
believed that TRPV1 is a key molecular target for activated PKCε following tissue 
damage.  PKC can promote exocytosis and also depolarization of TRPV1, which 
means that the channel can be activated at lower temperatures (Zhou et al., 2001; 
Crandall et al., 2002; Morenilla-Palao et al., 2004).  Capsaicin, a TRPV1 agonist, 
increases immunoreactivity of PKCε in primary afferent fibres (Velazquez et al., 
2007) and PKCε is thought to phosphorylate TRPV1, enhancing capsaicin-evoked 
currents (Numazaki et al., 2002; Mandadi et al., 2006).  Thus, it may be that PKCε 
may act as a switch which allows TRPV1 to integrate heat and tissue damage to 
produce thermal hyperalgesia (Velázquez et al., 2007).  Transmission of such 
nociceptive signals from the peripheral to the central terminals of primary afferents 
may also be promoted by PKC activation by enhancement of Na+ channel currents 
(Baker, 2005).   
 
PKC also acts at the central terminals of primary afferents by enhancing the release 
of neurotransmitters such as substance P, CGRP and glutamate (Barber and Vasko, 
1996; Malcangio et al., 1998; Frayer et al., 1999) perhaps via phosphorylation of Ca2+ 
channels responsible for neurotransmitter release (Yang et al., 2005).  Activation of 
opioid and GABA receptors on the central terminals of primary afferent fibres can 
inhibit the release of neurotransmitters and thus produce analgesia.  It has been 
shown that phosphorylation of both types of receptor by PKC can block their 
inhibitory functions (Yamada and Akasu, 1996; Zhang et al., 1996).  Therefore, PKC 
can both enhance excitatory neurotransmission and reduce inhibitory tone at the 
central terminals of primary afferents, thus increasing pain. 
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5.1.3  PKC in the spinal cord 
 
PKCs in the spinal cord can contribute to the excitability of dorsal horn neurones in 
response to incoming nociceptive signals, and spinal treatment with PKC inhibitors 
results in analgesia in various inflammatory and neuropathic pain models (Lin et al., 
1996; Hua et al., 1999).  Most current evidence points to PKCγ as being the main 
isozyme involved.  PKCγ expression is within a small subset of dorsal horn neurones, 
restricted to lamina II and a few in lamina III (Malmberg et al., 1997).  These 
neurones do not contain GABA and thus are deemed to be excitatory interneurones 
(Polgar et al., 1999) which are capable of modulating lamina V neurones that belong 
to an NMDA-dependent circuit (Martin et al., 2001).  In addition, Miraucourt and 
colleagues have proposed a mechanism of dynamic mechanical allodynia in which 
blockade of spinal glycinergic inhibition gates tactile inputs to superficial nociceptive 
specific neurones via PKCγ interneurones.  Strychnine, a glycine receptor antagonist, 
produces dynamic mechanical allodynia and induces responses of superficial dorsal 
horn NS cells to Aβ-fibre inputs.  This tactile input was found to be polysynaptic and 
required activity of PKCγ interneurones.  This was demonstrated in two ways.  First, a 
brush stimulus, under glycinergic disinhibition, induced expression of c-Fos in cells of 
the superficial dorsal horn and a significant proportion of these cells were also 
immunopositive for PKCγ.  Secondly, pharmacological inhibition of PKCγ reduced 
strychnine-induced dynamic mechanical allodynia (Miraucourt et al., 2007).  Mice 
lacking the PKCγ isozyme have normal acute pain sensitivity but fail to develop 
neuropathic pain following nerve injury, thus implicating PKCγ as a mediator of 
central sensitization (Malmberg et al., 1997).   
 
It has been shown that PKC reduces the Mg2+ block of the NMDA receptor thus 
increasing the open probability of the channel and contributing to central sensitization 
(Chen and Huang, 1992).  Here, Chen and Huang injected PKC intracellularly in 
trigeminal neurones and found that this potentiated NMDA-mediated currents.  PKC 
also increased the dissociation of Mg2+ from the NMDA receptor and allowed for 
receptor activation at more hyperpolarized membrane potentials.  GPCRs, such as 
mGluRs and NK1 receptors, can activate PKC in the dorsal horn and this can lead to 
activation of spinal ERK, a marker of central sensitization (Kawasaki et al., 2004).  
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Group I mGluRs activate PKC in the dorsal horn which in turn can activate the 
tyrosine kinase Src which then phosphorylates the NR2B subunit of NMDA receptors, 
increasing channel activity (Guo et al., 2002; Guo et al., 2004).  Thus, spinal PKC 
can directly modulate the excitability of dorsal horn neurones and contribute to 
central sensitization. 
 
 
5.1.4  Atypical PKCζ /PKMζ  and role in hippocampal LTP 
 
PKCζ belongs to the atypical class of the PKC family.  This enzyme consists of four 
functional domains, including a regulatory pseudosubstrate sequence and a kinase 
domain in the C-terminus (Fig. 5.1).  The pseudosubstrate domain is a short 
sequence of amino acids which closely resembles a substrate sequence except for a 
substitution of a single amino acid (alanine for serine/threonine).  This sequence is 
therefore thought to block the substrate-binding cavity of the kinase domain, thus 
acting as an autoinhibitory mechanism.  The kinase domain of PKCζ contains an 
activation loop which is phosphorylated at Thr410 by 3ʼ-PI-dependent protein kinase 
(PDK-1) for activation.  As well as phosphorylation of the kinase domain, liberation 
from pseudosubstrate autoinhibition is required for PKCζ activation and this is 
achieved by interaction with phosphatidylinositol 3,4,5-triphosphate (PIP3) 
(Hernandez et al., 2003; Hirai and Chida, 2003).  
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Fig. 5.1: Activation of PKCζ /PKMζ .  PKCζ contains a kinase domain (KD) which at 
rest is blocked by a regulatory pseudosubstrate domain (PS).  Two steps are 
required for full activation of PKCζ.  First, interaction with PIP3 liberates the KD from 
the PS.  Second, PIP3 activates PDK-1 which phosphorylates the KD of PKCζ.  
PKMζ is a shorter form of PKCζ and has no PS domain.  However, phosphorylation 
of the KD of PKMζ is still required for full activity.  Adapted from Hirai and Chida 
(2003). 
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PKCζ has been reported to be involved in several cellular functions, from receptor 
signalling complexes (i.e. TNF-α and IL1-β receptors) to activation of NFkB 
transcription factor during immune reactions, but more importantly also in LTP in the 
hippocampus (Hirai and Chida, 2003).  Two forms of the enzyme are expressed in 
the brain.  These are the native PKCζ (75 kDa) and also a shorter protein (51 kDa), 
termed PKMζ, which consists solely of the independent catalytic domain of PKCζ, 
and is therefore persistently active.  It had been thought that PKMζ was simply a 
proteolytic fragment of PKCζ.  A recent study, however, found that PKMζ is in fact an 
independent protein and is the product of a novel mRNA which encodes a PKCζ 
catalytic domain but without an autoinhibitory domain.  This independence is shown 
by the mRNA encoding PKMζ being still expressed in a PKCζ knockout mouse 
(Hernandez et al., 2003).  LTP has been shown to increase de novo synthesis of 
PKMζ which enhances synaptic transmission by doubling the number of post-
synaptic AMPA receptors (Ling et al., 2006).  Several studies have demonstrated that 
PKMζ is the only kinase involved in the late phase of LTP as shown by inhibition of 
LTP maintenance using a myristoylated pseudosubstrate inhibitor (see 5.2.2), which 
presumably mimics the autoinhibitory domain of the full-length PKCζ isoform (Sacktor 
et al., 1993; Ling et al., 2002; Pastalkova et al., 2006).  Most interestingly, inhibition 
of PKMζ was found to erase established memories (Pastalkova et al., 2006).  
 
 
5.1.5  Atypical PKCζ /PKMζ  in pain 
 
In stark contrast to the roles of other PKCs in pain, very little is known regarding the 
involvement of PKCζ/PKMζ.  One previous study attempted to examine the role of 
PKCζ in neuropathic pain (Narita et al., 2004).  In this study, the authors observed 
increased phosphorylation of PKCζ in the ipsilateral dorsal horn after nerve injury.  
Thermal hyperalgesia and morphine-induced place preference in this neuropathic 
pain state were attenuated but through the use of a general inhibitor of PKC, thus 
limiting conclusions on the role of PKCζ in particular in pain.  Therefore, the aim of 
this study was to investigate the expression and specific involvement of atypical 
PKCζ/PKMζ in pain signalling in the spinal dorsal horn using the formalin model of 
central sensitization. 
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5.2  Materials and Methods 
 
 
5.2.1  Animals  
 
All experiments were carried out using adult male Wistar rats (220-250g, Harlan, UK 
or Central Biological Services, University College London, UK) housed in standard 
laboratory conditions with free access to food and water, and were approved by the 
UK Home Office and followed guidelines set by the International Association for the 
Study for Pain (Zimmermann, 1983).  
 
 
5.2.2  PKCζ /PKMζ  inhibitor 
 
Inhibition of PKCζ/PKMζ activity was achieved through the use of a myristoylated 
pseudosubstrate peptide inhibitor (Myr-SIYRRGARRWRKL-OH, Biosource 
International Inc., USA) which mimics the autoinhibitory domain of the full-length 
PKCζ isoform and thus prevents catalytic activity.  A control scrambled 
pseudosubstrate peptide (Myr-RLYRKRIWRSAGR-OH) was synthesized (Genscript, 
USA).  Both peptides were dissolved in 0.9% saline.  Doses for experiments were 
chosen with regard to previous in vitro studies using the inhibitor (Ling et al., 2002; 
Serrano et al., 2005; Kelly et al., 2007). 
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5.2.3  Behavioural Formalin Test 
 
Rats were lightly anaesthetized using isoflurane and then injected intrathecally 
(lumbar puncture method) with either 5 or 10 µg of the myristoylated PKCζ/PKMζ 
pseudosubstrate inhibitor, in a volume of 10 µl.  Two control groups of rats received 
either the scrambled version of the pseudosubstrate (10 µg) or vehicle (0.9% saline).  
Experimenters were blind to treatment for the whole experiment.  Thirty minutes later, 
rats received a subcutaneous injection of 50 µl of formalin (5%) into the plantar 
surface of the right hindpaw.  Lifting, flinching, licking and biting of the injected paw 
were monitored by measuring the total duration of the response in seconds (s) during 
the 60 min period following formalin administration.  Data was captured in 5 min time 
bins.  An additional group of rats were pre-treated with 125 ng of Tat-NR2B9c in 10 µl 
and subsequently received intraplantar formalin thirty minutes later (as Chapter 3).  
These rats were used to assess the effects of Tat-NR2B9c on activation of 
PKCζ/PKMζ.  At the end of the test, all animals were terminally anaesthetized and 
perfused for immunohistochemistry. 
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5.2.4  In vivo Electrophysiology 
 
Experiments were conducted in adult male Wistar rats (220-250 g, Harlan, UK or 
Central Biological Services, University College London, UK).  Electrophysiological 
recordings from deep dorsal horn WDR neurones (> 600 µm) were conducted as 
previously described (see Materials and Methods chapter). 
 
 
5.2.4.1  Neuronal Formalin Test 
 
Following cell characterization, rats were pre-treated 30 min prior to the injection of 
formalin by topical spinal administration of 10 µg of the PKCζ/PKMζ pseudosubstrate 
inhibitor, in a volume of 50 µl using a Hamilton syringe.  A separate group of control 
animals received 10 µg of the scrambled pseudosubstrate.  Formalin (5%, 50 µl) was 
prepared from a 37% formaldehyde solution and then injected subcutaneously into 
the hindpaw receptive field.  The firing response of the WDR neurone was recorded 
for the subsequent 70 min after formalin injection.  Activity was displayed as a rate 
recording and quantified in 10 min time bins.  
 
 
5.2.5  Statistical Analysis for Formalin Test 
 
Data are presented as mean ± s.e.m.  Cell characteristics from scrambled 
pseudosubstrate and PKCζ/PKMζ pseudosubstrate inhibitor groups were compared 
by Studentʼs unpaired t-tests.  Formalin neuronal and behavioural response time 
course data was compared between treatment groups and analyzed by two-way RM 
ANOVA, followed by Bonferroni post-tests.  Total activity in the first and second 
phases was compared between treatment groups by quantifying the area under each 
curve, and analyzed by one-way ANOVA, followed by Bonferroni post-tests.  
Statistical analyses were carried out using GraphPad Prism v.4 software (GraphPad 
Software Inc., San Diego, CA, USA). 
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5.2.6  Immunohistochemistry for phospho-PKCζ  and c-Fos 
 
At the end of the formalin tests, animals were terminally anaesthetized using 
pentobarbitone and perfused, after which the lumbar spinal cord was excised (see 
Material and Methods chapter for details).  Transverse sections (30 µm) were cut on 
a cryostat and thaw-mounted onto glass slides.  
 
Sections were stained for p-PKCζ immunohistochemistry as follows: after 3 washes 
in PBS, sections were incubated for 48 hrs at 4°C with a rabbit primary antibody for 
anti-phospho-atypical protein kinase C-ζ (anti-p-PKCζ, Thr410; 1:100; sc-101778, 
Santa Cruz Biotechnology, USA) followed by a secondary antibody solution for 4 hrs 
(goat anti-rabbit IgG-conjugated Alexa Fluor 488TM; 1:1000; Molecular Probes, USA), 
as previously described (Narita et al., 2004).  Slides were washed in PBS and cover-
slipped with Vectashield mounting medium (Vector Laboratories, CA, USA).  
Quantitative assessment of p-PKCζ staining was carried out by Dr Fabien Marchand, 
by determining the immunofluorescence intensity (densitometric analysis) using grey 
scale within a fixed area of the dorsal horn of the spinal cord (ipsilateral and 
contralateral to injury).  A box measuring 104 µm2 (100x100) was placed over areas 
of the medial dorsal horn and the mean intensity of each area recorded.  The 
measurement protocol was carried out on L4-L6 spinal sections from each animal (at 
least 5 sections from each animal).  The background fluorescence intensity of each 
tissue section was also determined and subtracted from recorded values.  Specificity 
of p-PKCζ staining was confirmed by omission of the primary antibody. 
 
To determine the cellular distribution of p-PKCζ, sections were counterstained with 
primary antibodies against markers for neurones [mouse anti-neuronal nuclei (anti-
NeuN); 1:500; Chemicon, Hampshire, UK], astrocytes [mouse anti-glial fibrillary 
acidic protein (anti-GFAP); 1:1000; Abcam, Cambridge, UK] and microglial cells 
[rabbit anti-ionized calcium binding adaptor molecule 1 (anti-Iba1); 1:100; Wako Pure 
Chemical Industries Ltd, Japan], followed by the appropriate secondary antibody 
solution: goat anti-mouse or goat anti-rabbit IgG-conjugated Alexa Fluor 546TM 
(1:1000; Molecular Probes, OR). 
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Sections were processed for c-Fos immunohistochemistry by Dr Fabien Marchand as 
follows: following 3 washes in PBS, sections were incubated overnight, at room 
temperature, with the primary rabbit anti-c-Fos antiserum (1:2500; AB5, Oncogene 
Science, USA).  Sections were then incubated with AlexaFluorTM 488 goat anti-rabbit 
antibody (1:1000; Molecular Probes, USA) for 4 hrs and coverslipped.  Sections were 
visualized using a Zeiss Axioplan 2 fluorescent microscope running Axiovision 3.1 
image analysis software and classified according to spinal level (L4, L5 and L6).  
From each animal 4-6 sections (L4-L6) were randomly selected for counting c-Fos 
positive cells by a blinded investigator and an average of these counts was taken.  
The contralateral dorsal horn served as an internal control for the effects of formalin 
injection.    
 
 
5.2.7  Statistical Analysis for Immunohistochemistry 
 
Immunostaining of p-PKCζ and c-Fos was analyzed by one-way and two-way 
ANOVA, respectively, followed by Bonferroni post-tests, using GraphPad Prism v.4 
software (GraphPad Software Inc., San Diego, CA, USA). 
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5.2.8  Immunoprecipitation of NR2B subunits and downstream Western 
Immunoblotting  
 
Rats anaesthetized with urethane were sacrificed by decapitation and fresh spinal 
cord tissue (dorsal horn only) was dissected out and homogenized for 
immunoprecipitation (IP) and western immunoblotting (see Materials and Methods 
chapter).  
 
Immunoprecipitation Dynabeads® Protein G (Invitrogen Ltd, UK) were washed and 
coupled with 5 µg of rabbit anti-NR2B antibody (06-600, Upstate, USA).  Next 500 µg 
of spinal cord dorsal horn lysate was added to the antibody/dynabeads complex and 
allowed to incubate overnight for capture of target antigen.  Following incubation, the 
captured protein was eluted from the dynabeads and loaded onto gels for 
downstream SDS-PAGE.  Normal spinal lysate samples were run alongside IP 
samples as positive controls.  Once proteins were separated they were transferred to 
nitrocellulose membranes.  For detection of proteins of interest, membranes were 
incubated with primary antibody overnight at 4°C.  Antibodies used were mouse anti-
NR2B (1:500, 75-101, Neuromab, USA), rabbit anti-PSD-95 (1:1000, ab18258, 
Abcam, UK), rabbit anti-PKCζ (1:500, ab59364, Abcam, UK) and rabbit anti-nNOS 
(1:3000, 07-571, Millipore, UK).  Membranes were also probed with rabbit anti-CREB 
(1:500, ab5803, Abcam, UK) and rabbit anti-P2X3 (1:500, ab10269, Abcam, UK) 
antibodies which served as negative controls.  Following incubation with IRDye-linked 
donkey anti-rabbit 800CW or goat anti-mouse 600 secondary antibodies, proteins 
were revealed using the Odyssey fluorescence detection system (Licor, UK). 
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5.3  Results 
 
 
5.3.1  Spinal pre-treatment with an inhibitor of PKCζ /PKMζ  reduces pain-
related behaviours due to formalin-induced central sensitization 
 
In control rats pre-treated intrathecally with saline (0.9%, n = 8), formalin injected into 
the hindpaw induced a biphasic response of pain-related behaviours (Fig. 5.2a,b; 1st 
phase: 0-10 min, total time of pain-related behaviour = 97 ± 8 s; 2nd phase: 10-60 
min, total time of pain-related behaviour = 328 ± 28 s).  A second group of control 
rats received a scrambled version of the PKCζ/PKMζ pseudosubstrate (10 µg, n = 6), 
via intrathecal lumbar puncture, 30 min prior to formalin.  In these rats, formalin 
induced a biphasic behavioural response which was no different to that in saline-
treated rats (Fig. 5.2a,b; 1st phase: 0-10 min, total time of pain-related behaviour = 87 
± 6 s; 2nd phase: 10-60 min, total time of pain-related behaviour = 317 ± 13 s).  In 
contrast, pre-treatment with the myristoylated PKCζ/PKMζ pseudosubstrate inhibitor 
significantly decreased pain-related behaviours during both the first and second 
phases of the response to formalin in a dose-dependent manner (Fig. 5.2a,b; 5 µg, n 
= 6, 1st phase: 0-10 min, total time of pain-related behaviour = 59 ± 9 s, p > 0.05; 2nd 
phase total time of pain-related behaviour = 207 ± 13 s, p < 0.01; 10 µg, n = 9, 1st 
phase: 0-10 min, total time of pain-related behaviour = 46 ± 8 s, p < 0.05; 2nd phase 
total time of pain-related behaviour = 145 ± 14 s, p < 0.001) compared to the 
scrambled pseudosubstrate group.  
 
Thus, inhibition of the PKCζ/PKMζ pathway reduces formalin-induced pain-related 
behaviours associated with spinal central sensitization.  
 
  
Chapter 5 
 
 
205 
 
 
 
 
 
 
 
Fig. 5.2: Intrathecal PKCζ /PKMζ  pseudosubstrate inhibitor reduces pain-
related behaviours due to formalin-induced central sensitization.  (a) Time 
course of pain-related behaviours induced by intraplantar formalin (5%, 50 µl) 
following intrathecal pre-treatment with saline (n = 8), scrambled pseudosubstrate (10 
µg, n = 6) or PKCζ/PKMζ pseudosubstrate (5 µg, n = 6, ∗∗∗ p < 0.001 at 5, 15 and 20 
min versus scrambled pseudosubstrate; 10 µg, n = 9, ∗ p < 0.05 at 25 min, ∗∗ p < 
0.01 at 40 min, ∗∗∗ p < 0.001 at 5, 15, 20 and 30 min versus scrambled 
pseudosubstrate; two-way RM ANOVA followed by Bonferroni post-tests).  (b) Total 
pain-related behaviour during the 1st (0-10 min) and 2nd (10-60 min) phases of the 
formalin response with saline, scrambled pseudosubstrate or PKCζ/PKMζ 
pseudosubstrate (1st phase: 10 µg, ∗ p < 0.05 versus scrambled pseudosubstrate; 2nd 
phase: 5 µg, ∗∗ p < 0.01, 10 µg, ∗∗∗ p < 0.001 versus scrambled pseudosubstrate; 
one-way RM ANOVA followed by Bonferroni post-tests).  All data presented as mean 
± s.e.m. 
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5.3.2  Formalin-induced central sensitization of deep dorsal horn WDR 
neurones is reduced by spinal inhibition of PKCζ /PKMζ  
 
In rats pre-treated with the control scrambled pseudosubstrate peptide (10 µg; n = 8) 
formalin injected into the hindpaw receptive field produced the characteristic biphasic 
neuronal firing response of spinal WDR neurones (Fig. 5.3a,b; 1st phase: 0-10 min, 
total APs = 8743 ± 1778; 2nd phase: 10-70 min, total APs = 83358 ± 11531).  Spinal 
pre-treatment with the myristoylated PKCζ/PKMζ pseudosubstrate inhibitor (10 µg, n 
= 8) significantly reduced the second phase neuronal firing, while the first phase was 
only minimally reduced (Fig. 5.3a,b; 1st phase: 0-10 min, total APs = 4847 ± 979, p > 
0.05; 2nd phase: 10-70 min, total APs = 29643 ± 11132, p < 0.001).  All cells recorded 
were characterized prior to injection of drug and formalin to ensure that cells were 
comparable between treatment groups (Table 5.1).  
 
Thus, inhibition of PKCζ/PKMζ reduces formalin-induced central sensitization of 
deep dorsal horn WDR neurones.   
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Scrambled 
pseudosubstrate  
(n = 8) 
PKCζ /PKMζ  
pseudosubstrate  
(n = 8) 
C-fibre threshold          
(mA) 0.41 ± 0.08 0.64 ± 0.07 
Depth                             
(µM) 1033 ± 55 1029 ± 56 
Aβ-fibre evoked response     
(No. of APs) 147 ± 9 148 ± 9 
Aδ-fibre evoked response 
(No. of APs) 165 ± 16 133 ± 17 
C-fibre evoked response 
(No. of APs) 496 ± 54 507 ± 65 
Post-discharge              
(No. of APs) 676 ± 122 569 ± 93 
Input                               
(No. of APs) 220 ± 29 266 ± 46 
Wind-up                          
(No. of APs) 1050 ± 185 897 ± 138 
48oC                                
(No. of APs) 1363 ± 171 1213 ± 129 
 
 
 
Table 5.1: WDR cell characteristics from PKCζ /PKMζ  pseudosubstrate 
inhibitor neuronal formalin test.  Cells were characterized prior to drug 
administration and formalin injection.  C-fibre threshold, cell depth, afferent-evoked 
responses, input, wind-up and response to 48°C are expressed as mean ± s.e.m.  
There were no differences between cells recorded in each treatment group; Studentʼs 
unpaired t-test. 
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Fig. 5.3: Spinal PKCζ /PKMζ  pseudosubstrate inhibitor reduces formalin-
induced central sensitization of WDR neurones.  (a) Time course of WDR firing 
response to formalin (5%, 50 µl) injected into the hindpaw receptive field following 
spinal pre-treatment with the scrambled pseudosubstrate (10 µg, n = 8) or 
PKCζ/PKMζ pseudosubstrate (10 µg, n = 8, ∗∗ p < 0.01 at 50 and 60 min versus 
scrambled pseudosubstrate; two-way RM ANOVA followed by Bonferroni post-tests).  
(b) Total neuronal activity during the 1st (0-10 min) and 2nd (10-70 min) phases of the 
formalin response with the scrambled pseudosubstrate or PKCζ/PKMζ 
pseudosubstrate (2nd phase: ∗∗∗ p < 0.001 versus scrambled pseudosubstrate; one-
way RM ANOVA followed by Bonferroni post-tests).  (c) Representative rate 
recordings of firing responses of WDR neurones to formalin following spinal pre-
treatment with scrambled pseudosubstrate or PKCζ/PKMζ pseudosubstrate.  All data 
presented as mean ± s.e.m. 
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5.3.3  PKCζ /PKMζ  is involved in the upregulation of c-Fos after formalin 
injection 
 
Noxious peripheral stimulation induces expression of the immediate early-onset gene 
c-Fos in dorsal horn neurones (Hunt et al., 1987).  The involvement of the 
PKCζ/PKMζ pathway on induction of spinal c-Fos expression following formalin 
injection in the hindpaw was assessed using immunohistochemistry.  Intraplantar 
formalin injection induced an increase of c-Fos in superficial (laminae I-II) and deep 
laminae (V-VI) of the dorsal horn in the lumbar cord (L4, L5 and L6) 60 min after 
formalin injection in rats pre-treated with the scrambled pseudosubstrate (n = 5; Fig. 
5.4a,c), as previously described (Presley et al., 1990).  Intrathecal pre-treatment with 
the myristoylated PKCζ/PKMζ pseudosubstrate inhibitor (10 µg, n = 5) resulted in a 
significant reduction of c-Fos expression in the superficial dorsal horn (L4: 45.5% ± 
5.8 reduction; L5: 51.3 % ± 5.9 reduction; L6: 59.3% ± 1.1 reduction, all p < 0.001) 
and deeper dorsal horn (L4: 53.2% ± 8.4 reduction; L5: 51.6% ± 9.2 reduction; L6: 
52.9 ± 11.4 reduction, all p < 0.001) in comparison to scrambled pseudosubstrate-
treated rats (Fig. 5.4b,c).  
 
Thus, the formalin-induced upregulation of c-Fos in spinal dorsal horn neurones 
involves activity of the PKCζ/PKMζ pathway. 
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Fig. 5.4: Inhibition of spinal PKCζ /PKMζ  reduces formalin-induced 
upregulation of c-Fos.  (a,b) Representative photomicrographs of formalin-induced 
upregulation of c-Fos expression in superficial (I-II) and deep laminae (V-VI) of the 
ipsilateral lumbar (L5) dorsal horn in rats pre-treated with intrathecal (a) scrambled 
pseudosubstrate (10 µg, n = 5) or (b) PKCζ/PKMζ pseudosubstrate (10 µg, n = 5).  
(c) Quantification of number of c-Fos-positive cells per section in superficial (I-II) and 
deep laminae (V-VI) of the lumbar (L4, L5 and L6) dorsal horn.  All data presented as 
mean ± s.e.m., ∗∗∗ p < 0.001, two-way ANOVA followed by Bonferroni post-tests.  
Scale bars = 100 µm. 
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5.3.4  Phosphorylation of dorsal horn PKCζ /PKMζ  is induced by intraplantar 
formalin and is prevented by spinal administration of Tat-NR2B9c  
 
Activation of the PKCζ pathway was assessed by immunohistochemistry using a 
phospho-specific antibody which recognizes the Thr410 phosphorylation site of both 
PKCζ and PKMζ isoforms, 60 min after intraplantar formalin (Fig. 5.5).  In control rats 
pre-treated intrathecally with saline (0.9%, n = 4) or scrambled pseudosubstrate 
peptide (10 µg, n = 5), and in rats which received the myristoylated PKCζ/PKMζ 
pseudosubstrate inhibitor (10 µg, n = 5), intraplantar formalin injection into the 
hindpaw produced a significant increase of p-PKCζ in the superficial (I-II) layers of 
the ipsilateral dorsal horn (levels L4-L5) compared to the contralateral side (saline: 
mean percentage increase = 26 ± 3 %, p < 0.05; scrambled peptide: mean 
percentage increase = 22 ± 2 %, p < 0.05; pseudosubstrate inhibitor: mean 
percentage increase = 25 ± 2 %, p < 0.05; Fig. 5.5a-c).  No difference was seen 
between saline, scrambled peptide and PKCζ/PKMζ pseudosubstrate inhibitor 
groups (Fig. 5.5e).  In sections where the primary anti-p-PKCζ antibody had been 
omitted from the staining protocol, a complete loss of immunoreactivity was 
observed, indicating specificity of the antibody for phosphorylated PKCζ (not shown).  
 
An additional group of rats were pre-treated with Tat-NR2B9c (125 ng, n = 5).  The 
formalin-induced upregulation of p-PKCζ in the ipsilateral dorsal horn was prevented 
by intrathecal pre-treatment with Tat-NR2B9c (mean percentage increase = 4 ± 2 %, 
p < 0.001; Fig. 5.5d,e).   
 
Therefore, PKCζ/PKMζ is activated in the spinal dorsal horn after peripheral injection 
of formalin into the hindpaw.  The effect of the myristoylated PKCζ/PKMζ 
pseudosubstrate inhibitor seems to be inhibition of activity of this pathway, rather 
than prevention of its activation.  Furthermore, upregulation of p-PKCζ was prevented 
by Tat-NR2B9c, suggesting that phosphorylation of PKCζ/PKMζ is mediated by 
coupling between NR2B-containing NMDA receptors and PSD-95 in spinal dorsal 
horn neurones. 
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Fig. 5.5: Intrathecal Tat-NR2B9c reduces formalin-induced phosphorylation of 
PKCζ /PKMζ .  (a-d) Representative photomicrographs of expression of p-PKCζ in 
superficial laminae of the ipsilateral (right) lumbar dorsal horn following intraplantar 
formalin in rats pre-treated with intrathecal (a) saline (0.9% n = 4), (b) scrambled 
pseudosubstrate (10 µg, n = 5), (c) PKCζ/PKMζ pseudosubstrate (10 µg, n = 5) or 
(d) Tat-NR2B9c (125 ng, n = 5).  (e) Quantification of increased expression of p-
PKCζ in the ipsilateral dorsal horn presented as a percentage of contralateral dorsal 
horn expression, mean ± s.e.m., ∗∗∗ p < 0.001, one-way ANOVA followed by 
Bonferroni post-tests.  Scale bars = 100 µm. 
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5.3.5  Formalin-induced upregulation of p-PKCζ  is within intrinsic dorsal horn 
neurones 
 
Phospho-PKCζ immunoreactivity was observed in NeuN-positive cells, marking 
neuronal nuclei (Fig. 5.6c), and seemed to be located in the membrane of neurones, 
since there was no overlap with NeuN staining.  No obvious co-localization was 
observed with GFAP-positive astrocytes or Iba1-positive microglial cells (Fig. 5.6a-b). 
Thus, phosphorylated PKCζ/PKMζ, following intraplantar formalin, seems to be 
exclusively present in neurones within the spinal dorsal horn. 
 
 
 
 
 
 
Fig. 5.6: Identification of spinal cell types expressing phospho-PKCζ  following 
intraplantar formalin.  (a-c) Double staining of p-PKCζ with (a) GFAP (astrocyte 
marker) and (b) Iba1 (microglia marker) did not show any co-expression.  However, 
p-PKCζ was co-expressed with (c) NeuN (neuronal marker).  Scale bars = 50 µm. 
Chapter 5 
 
 
214 
5.3.6  Co-immunoprecipitation of NMDA receptor NR2B subunits and PSD-95 
reveals a novel interaction with PKCζ  in spinal dorsal horn neurones 
 
Immunoprecipitation can be used to reveal physical coupling between proteins in 
vivo.  An antibody against NR2B subunits was used to immunoprecipitate NR2B 
protein from spinal dorsal horn tissue lysate.  The immunoprecipitated sample was 
then separated by SDS-PAGE and associated proteins were revealed by western 
blotting (Fig. 5.7).  As expected, PSD-95 protein, known to bind to the cytoplasmic tail 
of NR2B subunits, was co-immunoprecipitated by the anti-NR2B antibody, as was 
nNOS.  In addition, PKCζ was also detected in the immunoprecipitated sample, 
revealing a novel protein-protein interaction of this kinase with spinal NMDA 
receptors and specifically with NR2B subunits.  Normal spinal lysate was run 
alongside immunoprecipitation samples to act as positive controls.  To ensure that 
the immunoprecipitation step had worked, and that proteins were not being detected 
non-specifically, two negative control proteins, CREB and P2X3, were probed for.  
CREB is a nuclear protein which should therefore not be physically linked to 
membrane-bound NMDA receptors.  The P2X3 receptor is located on the central 
terminals of primary afferents rather than on intrinsic dorsal horn neurones, and thus 
should not be found in a complex including NR2B subunits and PSD-95.  
Accordingly, both CREB and P2X3 were detected in the normal spinal tissue lysates, 
but were not found in the immunoprecipitation samples, as expected, indicating that 
the immunoprecipitation had worked and that proteins found in this sample are 
physically coupled to NR2B subunits of NMDA receptors.  Since PSD-95 is not 
expressed pre-synaptically in the spinal dorsal horn (i.e. in primary afferent 
terminals), but only within intrinsic dorsal horn neurones, the presence of PSD-95 
protein in the immunoprecipitated sample would suggest that the NR2B-associated 
complex is present within the same intrinsic dorsal horn sensory neurones. 
 
These data confirmed the physical interaction between NR2B subunits of spinal 
NMDA receptors and PSD-95, an association which modulates receptor activity and 
couples NMDA receptor activity to downstream intracellular signalling.  Western 
blotting of PKCζ confirmed its expression in the dorsal horn of the spinal cord and co-
immunoprecipitation with NR2B subunits revealed a possible novel physical 
interaction between these proteins within intrinsic spinal dorsal horn neurones, 
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perhaps mediated via the scaffolding protein PSD-95.  Thus, these findings suggest 
that activation of NR2B-containing NMDA receptors and coupling with PSD-95 may 
lead to the direct activation of signalling via the PKCζ/PKMζ pathway, contributing to 
spinal central sensitization. 
 
 
 
 
 
 
 
 
Fig. 5.7: Identification of a novel NR2B-associated complex with PSD-95 and 
PKCζ  in spinal dorsal horn neurones.  Western immunoblot of normal lumbar 
spinal dorsal horn lysates (left two lanes) and co-immunoprecipitates from lumbar 
spinal dorsal horn lysate obtained using an antibody against NR2B (right two lanes), 
probed with antibodies against NR2B, nNOS, PSD-95, PKCζ, CREB and P2X3. 
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5.4  Discussion 
 
This study demonstrates that atypical PKCζ/PKMζ is involved in central sensitization 
of spinal dorsal horn neurones following peripheral formalin injection.  A specific 
pseudosubstrate inhibitor of PKCζ/PKMζ, injected intrathecally, reduced pain-related 
behaviours and neuronal expression of c-Fos elicited by intraplantar injection of 
formalin.  In addition, direct spinal application of this inhibitor reduced the firing 
response of WDR neurones to formalin administration into the hindpaw receptive 
field.  Pain-related behaviours were associated with increased expression of 
phospho-PKCζ in the ipsilateral dorsal horn, specifically within neurones, which was 
abolished by spinal administration of the mimetic peptide Tat-NR2B9c, believed to 
disrupt binding between NR2B-subtype receptors and PSD-95.  Immunoprecipitation 
revealed the presence of an NR2B-associated complex with PSD-95 and PKCζ 
within dorsal horn neurones, implicating atypical PKCζ/PKMζ as a novel downstream 
effector of NMDA-dependent nociceptive plasticity. 
 
Both neuronal and behavioural formalin tests showed a significant reduction in 
second phase activity with the use of the PKCζ/PKMζ inhibitor.  In contrast, a 
significant reduction of first phase activity was observed in the behavioural response 
only with the high dose (10 µg) of the inhibitor.  The lower dose (5 µg) did not affect 
the first phase yet selectively and significantly reduced second phase pain-related 
behaviours.  Neuronal firing during the first phase was reduced only slightly.  This 
discrepancy between neuronal and behavioural first phase effects of the PKCζ/PKMζ 
inhibitor could be explained by the fact that electrophysiological recordings were 
conducted exclusively from deep dorsal horn WDR neurones.  It is possible that other 
spinal sensory neurones, such as NS cells, which are mainly populated in the 
superficial dorsal horn, also contribute to the behavioural response to formalin.  
Inhibition of PKCζ/PKMζ within NS neurones or other cells in the superficial dorsal 
horn may reduce the responsiveness of these cells to incoming signals from 
nociceptive C-fibres, which is a major component of the first phase.  It must also be 
remembered that there is a fundamental difference between recording neurones and 
behavioural activity in terms of what that activity means.  In behavioural studies, a rat 
will produce a pain-related behaviour once the threshold for that response has been 
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reached.  An increase in stimulus intensity cannot increase this behaviour in any 
detectable way and rats cannot communicate heightened pain to us.  Therefore, in 
behavioural experiments we are dealing simply with thresholds: the rat will either 
respond or it will not, depending on whether the threshold for that particular 
behaviour is reached.  In contrast, neurones can give us much more information.  
They will respond to sub-threshold, threshold and supra-threshold stimulation, 
particularly WDR neurones which produce graded responses as stimulus intensity 
increases.  This gives us a quantifiable output, which correlates with heightened pain, 
that behavioural measures cannot.  Therefore, the neuronal responses to formalin 
will consist of activity induced by sub-threshold, threshold and supra-threshold 
stimulation of the hindpaw receptive field.  What is not clear, in this model, is how 
much neuronal activity is induced by each category of stimulus and therefore, we 
cannot say how much neuronal activity is required to reach the threshold of formalin-
induced pain-related behaviour.  Subsequently, we cannot say how much inhibition of 
neuronal activity is required to reduce behaviour.  It may be that a small reduction on 
neuronal firing will greatly reduce behaviour.  Additionally, it cannot be ruled out that 
PKCζ/PKMζ may function within primary afferent fibres, thus contributing to the first 
phase response.  However, the immunohistochemical and biochemical data, which 
indicates that phosphorylation of PKCζ/PKMζ is predominantly within intrinsic dorsal 
horn neurones in this formalin model, would suggest otherwise.  Lumbar rhizotomy, 
which causes a loss of primary afferent terminals within the dorsal horn, did not alter 
spinal expression of PKCζ/PKMζ (verbal communication from Dr. Fabien Marchand).  
Ultimately, the electrophysiological and behavioural data together clearly implicate 
PKCζ/PKMζ in spinal mechanisms of central sensitization.   
 
Others studies have demonstrated reduction of pain-related behaviours in 
inflammatory pain models using non-selective blockers of PKC (Coderre, 1992; 
Coderre and Yashpal, 1994; Sweitzer et al., 2004).  Interestingly, PKCγ knockout 
mice exhibit a reduction of the second phase of the formalin test (Malmberg et al., 
1997).  However, PKCγ only contributes to increased hyperexcitability of a subset of 
lamina V NMDA-dependent neurones following an inflammatory stimulus, suggesting 
only a partial contribution of this particular kinase in central sensitization (Martin et 
al., 2001).  Therefore, other PKCs must be involved, with PKCζ/ PKMζ a likely 
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contributor.  Following intraplantar injection of formalin, upregulation of c-Fos was 
observed in superficial and deep laminae of the dorsal horn, which was reduced 
following PKCζ/PKMζ inhibition, reinforcing the hypothesis of a profound effect on 
neuronal activity.  Another kinase, PKCε, also influences c-Fos expression in the 
lumbar dorsal horn following formalin, though its effects are mediated by inhibition of 
neurotransmitter release from primary afferent fibre terminals (Velazquez et al., 
2007).  Furthermore, decreased expression of c-Fos following formalin injection in 
PKCγ knockout mice only occurs in laminae I-II (Malmberg et al., 1997).      
 
The Tat-NR2B9c mimetic peptide, believed to disrupt a protein complex located 
specifically within intrinsic dorsal horn neurones, almost completely abolished 
phosphorylation of PKCζ.  This result further corroborates that the formalin-induced 
upregulation of p-PKCζ is restricted to intrinsic dorsal horn neurones rather than 
terminating primary afferent fibres.  The pseudosubstrate PKCζ/PKMζ inhibitor did 
not affect the phosphorylation of PKCζ following formalin, as previously described, at 
least for PKMζ in hippocampal slices following electrically-induced LTP (Kelly et al., 
2007).  Therefore, the antinociceptive effect of this inhibitor may be due to a 
reduction of the phosphorylating capacity of PKCζ via specific blockade of its 
enzymatic site, rather than its ability to be phosphorylated and further activated.  The 
phospho-specific antibody used in this study recognizes the Thr410 phosphorylation 
site of both PKCζ and PKMζ isoforms, so it is likely that both isoforms are activated 
following intraplantar formalin.  In addition, the pseudosubstrate inhibitor blocks both 
isoforms and therefore, the behavioural and electrophysiological results are likely due 
to blockade of activity of both PKCζ and PKMζ proteins.  
 
Phosphorylation of PKCζ/PKMζ was observed in the superficial dorsal horn where 
expression of NR2B subunits is also thought to be concentrated (Nagy et al., 2004a).  
As mentioned previously (Chapter 3), the deep dorsal horn neurones recorded here 
likely receive nociceptive inputs from the superficial dorsal horn via interneurones 
and/or their dorsally extending dendrites (Woolf and King, 1987; Braz et al., 2005).  
This would account for the effects of the PKCζ/PKMζ inhibitor on activity of deep 
WDR neurones in electrophysiological experiments.  Also, the PKCζ/PKMζ inhibitor 
was able to reduce c-Fos expression in both superficial and deep laminae of the 
Chapter 5 
 
 
219 
dorsal horn, indicating some connectivity and crosstalk between superficial neurones 
expressing PKCζ/PKMζ and deeper cells.  
 
One of the major findings of this study is that PKCζ/PKMζ is not simply activated 
downstream of the NMDA receptor, but is physically linked to the receptor in a 
complex which also involves PSD-95.  Spinal treatment with Tat-NR2B9c, believed to 
disrupt the interaction between NR2B subunits and PSD-95, not only inhibits 
nociceptive plasticity and pain-related behaviour (Chapters 3 & 4), but also prevents 
activation of PKCζ/PKMζ.  Along with the data from the co-immunoprecipitation 
experiment, this result suggests the presence of a signalling complex between 
NR2B-containing NMDA receptors, PSD-95 and PKCζ/PKMζ, with activation of 
PKCζ/PKMζ being downstream of coupling between NR2B subunits and PSD-95.  
Further evidence, such as the use of immunohistochemistry and confocal microscopy 
to assess co-localization of these proteins, is required to strengthen this hypothesis.  
Cells expressing p-PKCζ are neuronal, as suggested by association with cells 
expressing NeuN.   Specifically, p-PKCζ staining was observed around the NeuN 
staining, thus confirming that p-PKCζ is non-nuclear, perhaps located in the 
membrane of neurones, consistent with the finding that PKCζ was found to be in a 
complex with NR2B-subtype receptors and PSD-95, two membrane-associated 
proteins.  Again, confocal microscopy may be used to shed further light on the 
precise subcellular location of PKCζ.  The presence of PKCζ in such a complex may 
allow it to be specifically regulated by other kinases such as PI3K, CaMKII, ERK and 
mTOR (mammalian target of rapamycin), all of which have been shown to regulate 
PKMζ in hippocampal LTP as well as regulate spinal central sensitization (Ji et al., 
1999; Fang et al., 2002; Choi et al., 2006; Kelly et al., 2007; Pezet et al., 2008; 
Asante et al., 2009).  CaMKII is known to interact with PSD-95 in contributing to 
neuropathic pain (Garry et al., 2003), while disrupting NR2B interactions with PSD-95 
in the brain using Tat-NR2B9c has been shown to regulate ERK (Yang et al., 2004).  
The mTOR pathway has been shown to be functionally linked to NMDA receptor 
activity in neuronal protein synthesis (Gong et al., 2006; Huang et al., 2007).  PI3K 
has been shown to be activated by NMDA receptor stimulation (Sutton and Chandler, 
2002; Man et al., 2003) and can influence synaptic trafficking of PSD-95 (Yoshii and 
Constantine-Paton, 2007), while Akt (PKB), a downstream target of PI3K, is 
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complexed with NR2B subunits in the dorsal horn (Peng et al., 2009).  In fact, PI3K 
itself has been shown to bind NR2B subunits of NMDA receptors (Hisatsune et al., 
1999).  Phosphorylation of PKCζ at Thr410 of its activation loop is by PDK-1 (Chou 
et al., 1998; Le Good et al., 1998) and activation of PDK-1 requires binding to PIP3, 
which is produced by PI3K.  PIP3 is also required to relieve PKCζ from autoinhibition 
(Hirai and Chida, 2003).  Thus, PI3K is significantly involved in regulation of PKCζ.  
The role of PI3K in formalin-induced central sensitization is investigated in Chapter 6 
of this thesis. 
 
This study highlights a new spinal mechanism contributing to abnormal pain states 
with potential therapeutic applications.  PKCζ/PKMζ, a kinase expressed in spinal 
sensory neurones, is involved in central sensitization and inhibition of this pathway 
may be a novel analgesic target.  A physical interaction exists between PKCζ and 
NR2B-containing NMDA receptors in a complex also including PSD-95, thus 
implicating PKCζ/PKMζ as an effector of NMDA-dependent nociceptive plasticity in 
the dorsal horn of the spinal cord. 
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6  The role of phosphatidylinositol 3-kinase (PI3K) in  
NMDA-dependent spinal nociceptive plasticity 
 
 
6.1  Introduction 
 
 
6.1.2  Structure & function of Phosphatidylinositol-3-kinase 
 
PI3K is a heterodimer enzyme associated directly with growth factor tyrosine kinase 
receptors and adaptor proteins (Cantley, 2002).  The 85 kDa regulatory subunit (p85) 
maintains the 110 kDa catalytic subunit (p110) in a low activity state.  Upon receptor 
activation, the regulatory subunit binds to phosphotyrosine residues of receptors 
which promotes the endogenous enzymatic activity of the catalytic subunit (Kapeller 
and Cantley, 1994).  The Src-homology domains (SH2 and SH3) of the regulatory 
subunit (Fig. 6.1a) bind directly to specific phosphotyrosine motifs and proline-rich 
short amino acid sequences and thus mediate the specificity of association between 
PI3K and other proteins.  The p110 catalytic subunit binds to the p85 regulatory 
subunit via its N-terminal region (Kapeller and Cantley, 1994). 
 
PI3K is part of a larger family of phosphatidylinositol kinases (PIKs) which 
phosphorylate and synthesize phosphoinositides (PIs).  Sequential phosphorylation 
of PI to produce phosphatidylinositol 4-phosphate (PI4-P) and phosphatidylinositol 
4,5-bisphosphate (PI4,5-P2) had been known to involve PI4K and PI5K respectively.  
The resultant PI4,5-P2 acts as a substrate for PLC and is hydrolysed to inositol 1,4,5-
trisphosphate (IP3), which promotes release from intracellular Ca2+ stores, and DAG, 
which activates PKC (Kapeller and Cantley, 1994).  It was later discovered that a 
distinct PIK lead to the production of a novel PI, termed phosphatidylinositol 3-
phosphate (PI3-P).  Phosphorylation of PI3-P had occurred at the D-3 position of the 
inositol ring (Whitman et al., 1988), rather than at the D-4 position which produces 
PI4-P via PI4K.  Thus, PI3K selectively phosphorylates the D-3 position of the inositol 
ring of PIs, generating membrane-associated second messengers.  In addition to 
producing PI3-P, PI3K can phosphorylate PI4-P and PI4,5-P2 to generate PI3,4-P2 
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and PI3,4,5-P3 (from this point onwards referred to as PIP2 and PIP3) respectively 
(Fig. 6.1b).  
 
 
 
 
 
 
 
 
 
Fig. 6.1: Structure of the PI3K p85 regulatory subunit and phosphoinositide 
pathway.  (a) The p85 regulatory subunit of PI3K consists of three Src-homology 
(SH) domains and proline-rich sequences which mediate interactions with other 
proteins.  The p110 catalytic subunit of PI3K binds to the p85 subunit via its N-
terminal region.  (b) PI3K phosphorylates the D-3 position of the inositol ring of 
phosphoinositides to generate the second messengers PIP, PIP2 and PIP3.  Adapted 
from Kapeller and Cantley (1994). 
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6.1.3  Protein kinase mediators of PI3K signalling 
 
PI3K has been implicated in diverse cellular functions, including mitogenesis, 
inhibition of apoptosis, intracellular vesicle trafficking and regulation of the 
cytoskeleton (Carpenter and Cantley, 1996).  More recently, biochemical targets of 
PIs generated by PI3K have been identified, including various protein kinases, for 
example Akt, PDK-1, PKCζ and MAPKs.  PIP2 and PIP3 are not, however, involved in 
the release of Ca2+ from intracellular stores. 
 
Akt is a major downstream effector of PI3K signalling and contains a pleckstrin-
homology (PH) domain to which PIP2 binds, with greater affinity than PIP3, 
contributing to activation of the enzyme (Franke et al., 1997).  PIP2 recruits Akt to the 
plasma membrane and facilitates dimerization and partial activation of the enzyme.  
This produces a conformational change in Akt which exposes it to upstream kinases, 
such as PDK-1, which itself is regulated by PI3K-generated PIs, to be 
phosphorylated and fully activated (Toker and Cantley, 1997).  For full activation of 
Akt, phosphorylation is required at Thr308 in the activation loop by PDK-1 and at 
Ser473 in the C-terminal region by an, at present, unidentified kinase, though 
phosphorylation at Thr308 may trigger autophosphorylation at Ser473 without the 
need for an additional kinase (Toker, 2000).  Once activated, Akt leaves the plasma 
membrane to phosphorylate various intracellular targets, including the nuclear 
transcription factor CREB.  Akt also phosphorylates and suppresses Bcl-2 family pro-
apoptotic factors such as BAD.  A third target of Akt is glycogen synthase kinase 3 
(GSK3) which, when phosphorylated, can no longer inhibit the synthesis of glycogen 
(Cantley, 2002). 
 
PDK-1 also contains a PH domain allowing it to be translocated to the plasma 
membrane by PIP3, which also promotes intrinsic catalytic activity of the kinase 
(Toker and Newton, 2000).  Several kinases are phosphorylated by PDK-1 including 
conventional PKCs and atypical PKCζ, and also p70S6K, involved in cell growth, and 
p90RSK, both of which are involved in signalling in the MAPK pathway (Toker, 2000).  
PKCζ, known to be involved in LTP, is itself thought to be regulated directly by PIP3, 
despite the fact that a PIP3-binding site has not been located in its structure.  It is 
believed that PIP3 directly modulates the pseudosubstrate domain of PKCζ, thus 
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relieving autoinhibition and promoting catalytic activity (Hirai and Chida, 2002).  
Additionally, PKCζ has been shown to be activated downstream of the mTOR (Kelly 
et al., 2007) which itself is downstream of both PDK-1 and Akt in a PI3K-dependent 
pathway. 
 
All of the kinases mentioned thus far are able to contribute to PI3K-mediated 
regulation of the MAPK pathway.  Aside from its function as a lipid kinase, PI3K may 
also possess the ability to directly phosphorylate proteins.  This protein kinase 
activity was retained in a mutant of PI3K which was deficient of lipid kinase function 
but was still able to activate MAPK (Bondeva et al., 1998).  This shows that PIs are 
not always necessary for regulation of MAPK by PI3K.  Therefore, PI3K can activate 
the MAPK pathway at various points in the cascade involving activation of protein 
kinases by PIP3, as well as via its own intrinsic protein kinase function (Toker, 2000).  
 
 
6.1.4  PI3K in brain LTP  
 
Several reports have demonstrated a requirement of PI3K activity in brain synaptic 
plasticity, including LTP.  An electrophysiological study in rat hippocampal slices 
showed that PI3K activity was induced during LTP.  Conversely, established LTP 
was reduced by two widely-used inhibitors of PI3K, LY294002 and wortmannin.  
However, following drug washout, LTP recovered, suggesting a predominant role of 
PI3K in the expression of LTP (Sanna et al., 2002).  A subsequent study confirmed a 
role for PI3K in hippocampal LTP, when PI3K inhibitors, applied at the time of the 
conditioning stimulus, prevented LTP.  However, inhibition of PI3K had no effect on 
LTP once it had already been established, indicating that PI3K is more involved in 
the induction rather than maintenance or expression of LTP (Opazo et al., 2003).  
Despite the obvious discrepancies regarding the timing of activation of PI3K during 
LTP, it is clear that PI3K plays a crucial role in this form of neuronal synaptic 
plasticity.  One potential mechanism by which PI3K might contribute to synaptic 
strengthening could be by promoting the membrane insertion of AMPA receptors.  
The NMDA-dependent increase in AMPA receptor surface expression during 
hippocampal LTP requires PI3K activity (Man et al., 2003) and further studies 
showed that PI3K activity in LTP is downstream of NMDA receptor activation (van 
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der Heide et al., 2005; Peineau et al., 2007).  In addition, PI3K is involved in LTP via 
both ERK-dependent and ERK-independent mechanisms since not all forms of PI3K-
dependent LTP, such as, for example, that induced by LFS paired with post-synaptic 
depolarization, can be blocked by ERK inhibitors (Opazo et al., 2003; Tsokas et al., 
2007).  Interestingly, stress-induced alterations of LTP involve PI3K signalling, 
perhaps via upregulation of PSD-95, since stress increased dendritic expression of 
PSD-95 in hippocampal neurones (Yang et al., 2008).  Finally, mTOR has been 
shown to be an important effector of PI3K signalling in LTP (Tsokas et al., 2007).  
High frequency stimulation in the medial prefrontal cortex (mPFC) induced LTP and 
caused phosphorylation of the PI3K/Akt-mTOR pathway, both of which were 
suppressed by pharmacological inhibition of either PI3K or mTOR (Sui et al., 2008). 
 
 
6.1.5  PI3K in pain pathways  
 
A role for PI3K in nociceptive pathways was first established in terms of sensitization 
of peripheral nociceptors.  Bonnington and McNaughton used Ca2+ imaging to show 
that NGF potentiated the capsaicin-induced rise in intracellular Ca2+ in a subset of 
nociceptive sensory neurones.  This effect of NGF was abolished by application of 
the PI3K inhibitor wortmannin (Davies et al., 2000) indicating that activation of the 
NGF tyrosine kinase receptor, TrkA, leads to signalling via PI3K in nociceptors 
(Bonnington and McNaughton, 2003).  This work was expanded on by Zhuang and 
colleagues who showed that intradermal injection of capsaicin and NGF in rats 
caused activation of PI3K and ERK in C-fibres.  Inhibition of PI3K prevented both 
ERK activation and heat hyperalgesia, without effect on basal heat sensitivity 
(Zhuang et al., 2004).  Subsequently it was shown that PI3K activates Src kinase 
which phosphorylates TRPV1, inducing insertion of TRPV1 into the plasma 
membrane following NGF (Zhang et al., 2005).  An alternative mechanism for this 
potentiation of TRPV1 by PI3K was suggested by Stein and colleagues who 
demonstrated that PI3K is physically linked to TRPV1 via its p85 subunit and that 
NGF increased the number of channels in the membrane.  Thus, it was proposed 
that NGF-mediated heat hyperalgesia is brought about by a physical coupling 
between TRPV1 and PI3K which facilitates trafficking of TRPV1 to the membrane of 
primary sensory neurones (Stein et al., 2006), perhaps via activation of the MAPK 
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pathway (Zhu and Oxford, 2007).  Accordingly, phosphorylation of Akt has been 
detected in small and medium-sized nociceptive DRG neurones, following 
intradermal capsaicin, confirming activation of PI3K signalling.  Neurones expressing 
phospho-Akt (p-Akt) were also positive for TrkA and TRPV1 and were both 
peptidergic (CGRP+) and non-peptidergic (IB4+) (Pezet et al., 2005; Sun et al., 2007).  
In contrast to NGF-induced hyperalgesia, acute peripheral administration of GDNF 
induces mechanical hyperalgesia involving non-peptidergic nociceptors which can 
also be attenuated by pharmacological inhibition of PI3K (Bogen et al., 2008).   
 
Prior to publication of the work presented in this chapter (Pezet et al., 2008), little 
was known regarding involvement of PI3K in spinal cord pain transmission.  One 
study had shown increased expression of p-Akt in the dorsal horn following 
intradermal capsaicin, measured using both immunohistochemistry and western 
blotting (Sun et al., 2006), while another study had demonstrated a role for PI3K in 
neuropathic pain following L5 SNL (Xu et al., 2007).  It was found that p-Akt 
increased in both injured (L5) and non-injured (L4) DRG neurones, particularly non-
peptidergic C-fibres.  Interestingly, phosphorylation of Akt was also detected in the L5 
spinal cord.  Inhibition of PI3K signalling reduced hypersensitivity in both pain 
models.  
 
The work in this chapter explores the specific contribution of spinal dorsal horn PI3K 
to NMDA-dependent nociceptive plasticity in wind-up and the formalin model of 
central sensitization. 
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6.2  Materials and Methods 
 
 
6.2.1  In vivo Electrophysiology 
 
Experiments were conducted in adult male Sprague Dawley rats (220-250 g, Central 
Biological Services, University College London, UK).  Electrophysiological recordings 
from deep dorsal horn WDR neurones (> 600 µm) were conducted as previously 
described (see Materials and Methods chapter).  Halothane anaesthesia was used in 
this study prior to the changeover to the safer isoflurane. 
 
 
6.2.1.1  Electrical stimulation of the hindpaw 
 
Stable control responses to electrical stimuli were established at 10 min intervals 
before drug administration.  LY294002 (Tocris Biosciences, Bristol, UK), a potent 
inhibitor of PI3K, at a dose of 0.8 µg in 50 µl, was applied directly to the exposed 
surface of the spinal cord (after removal of any residual cerebrospinal fluid) using a 
Hamilton syringe.  Electrical tests were continued for 1 hr at 10 min intervals.  After 1 
hr any remaining solution was removed from the surface of the spinal cord and 
replaced by 1.6 µg of LY294002 in 50 µl and tests were continued for a further 1 hr.  
A separate group of control animals received vehicle, 10% dimethyl sulfoxide 
(DMSO). 
 
  
6.2.1.2  Statistical Analysis 
 
Data are presented as mean ± s.e.m.  The effects of vehicle or LY294002 versus 
pre-drug control values were assessed by one-way RM ANOVA, followed by 
Bonferroni post-tests, using GraphPad Prism v.4 (GraphPad Inc., San Diego, CA, 
USA).  
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6.2.2  Behavioural Formalin Test 
 
Adult male Wistar rats (Harlan, UK) were injected intrathecally (lumbar puncture 
method) with LY294002 (50 or 100 µg in a volume of 10 µl) or vehicle (10% DMSO).  
Fifteen minutes later rats received 50 µl of 5% formalin injected subcutaneously into 
the plantar surface of the right hindpaw.  Lifting, shaking, biting and licking of the 
injected paw were monitored by measuring the total duration of the response in 
seconds during 60 minutes following formalin administration.  Data are presented in 5 
min bins.  
 
 
6.2.2.1  Statistical Analysis 
 
All data is presented as mean ± s.e.m.  Formalin behavioural response time course 
data was compared between treatment groups and analyzed by two-way RM 
ANOVA, followed by Bonferroni post-tests.  Total activity in the first and second 
phases was compared between treatment groups by quantifying the area under each 
curve, and analyzed by one-way ANOVA, followed by Bonferroni post-tests.  
Statistical analyses were carried out using GraphPad Prism v.4 software (GraphPad 
Software Inc., San Diego, CA, USA). 
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6.2.3  Preparation of tissues for Immunohistochemistry and Western 
Immunoblotting 
 
 
6.2.3.1  For phospho-Akt, phospho-ERK & phospho-CAMKII  
             Immunohistochemistry 
 
Adult male Wistar rats (Harlan, UK) were first anaesthetized with urethane (1 mg/kg), 
then pre-treated intrathecally via lumbar puncture method with LY294002 (100 µg in 
10 µl) or vehicle (10 µl of 10% DMSO).  Fifteen minutes later, rats were injected with 
50 µl of 5% formalin into the plantar surface of the right hindpaw.  A further five 
minutes after formalin administration, rats were perfused transcardially with 100 ml of 
heparinized saline followed by 400 ml of 4% PFA containing 15% of a saturated 
solution of picric acid.  Rats were dissected and lumbar cord (levels L3-L6) was 
collected for immunohistochemistry.   
 
 
6.2.3.2  For Western Immunoblotting of NMDA & AMPA receptor  
             subunits 
 
Rats anaesthetized with urethane were pre-treated intrathecally via lumbar puncture 
with LY294002 (100 µg in 10 µl) or vehicle (10 µl of 10% DMSO) and then injected 
with 5% formalin into the right hindpaw fifteen minutes later.  After a further five 
minutes, rats were sacrificed by decapitation and fresh tissues were dissected out for 
western immunoblotting of NR2A and NR2B NMDA receptor subunits.  Alternatively, 
for the detection of GluR1 AMPA receptor subunits, animals were sacrificed by 
decapitation 10, 45 and 90 min after the injection of formalin into the hindpaw.  A 
group of control rats were also sacrificed without the injection of formalin (0 min) for 
comparison.  Dorsal spinal cord, both ipsi- and contralateral, from the L4 and L5 
levels, was collected and immediately frozen in liquid nitrogen. 
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6.2.4  Immunohistochemistry for phospho-Akt, phospho-ERK & phospho-
CaMKII  
 
Transverse spinal cord sections (30 µm thickness) were cut using a cryostat and 
every section was collected and placed in PBS solution for free-floating 
immunohistochemistry.  Sections were washed with PBS and then incubated with 
primary antibody, either rabbit anti-phospho-Akt1 Ser473 (1:300, New England 
Biolabs, Beverly, MA, USA), rabbit anti-phospho-ERK (1:300, New England Biolabs, 
Beverly, MA, USA) or rabbit anti-phospho-CaMKII Tyr286 (1:300, ref 5683, Abcam, 
UK) overnight at room temperature.   
 
Immunostaining against p-ERK was performed using direct fluorescence.  After 
several washes with PBS, sections were incubated for 2 hrs at room temperature 
with secondary antibody (goat anti-rabbit IgG-conjugated Alexa FluorTM 488, 1:1000, 
Molecular Probes, Oregon, USA).  Immunostaining against phospho-Akt Ser473 and 
phospho-CaMKII Tyr286 required tyramide amplification.  Sections were incubated 
with the secondary antibody, goat anti-rabbit biotin (1:300 in PBS-T, Vector 
Laboratories, CA, USA) for 1 hr at room temperature.  Following several washes, 
sections were incubated in avidin biotinylated enzyme complex (1:500 in PBS, Vector 
Laboratories, CA, USA) for 1 hr, followed by several washes in PBS.  The sections 
were then incubated in biotinyl tyramide (1:75 in amplification buffer, Perkin Elmer, 
UK) for 10 min.  After several washes in PBS, sections were finally incubated in 
extravidin fluorescein isothiocyanate (FITC, 1:500, diluted in PBS, Sigma).   
 
After staining, sections were mounted onto slides and cover-slipped with Vectashield 
mounting medium (Vector Laboratories, CA, USA).  Slides were visualized under a 
Zeiss Axioplan 2 fluorescent microscope and L4 and L5 sections were identified for 
quantification (5 sections per level per animal, chosen randomly).  For p-ERK, 
labelled spinal cord neurones were counted in laminae I-II and V-VI, for both 
ipsilateral and contralateral (control) sides by one blinded investigator.  For 
assessment of p-Akt and p-CaMKII upregulation, images of dorsal horn (ipsilateral 
and contralateral at the level of lamina II, where changes are mostly observed) from 
5 sections per animal, chosen randomly, were taken at magnification x20, using the 
same set-up of acquisition for all animals.  Densitometric analysis of medial p-Akt 
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and p-CaMKII staining (since staining was too abundant to count individual 
neurones) was carried out using Scion Image software.  Results for p-Akt and p-
CaMKII expression are given as a percentage increase in the ipsilateral versus 
contralateral (control) dorsal horn.  Statistical significance was tested by the Kruskal-
Wallis test followed by Dunnʼs multiple comparison test or the Mann-Whitney Rank 
Sum test using GraphPad Prism v.4 software (GraphPad Software Inc., San Diego, 
CA, USA).  All imaging and quantification was conducted by Dr Sophie Pezet. 
 
 
6.2.5  Western Immunoblotting of phospho-NR2A & phospho-NR2B 
 
Proteins (30 µg/sample) were separated using 8% SDS-PAGE, and transferred to 
PVDF membranes.  Membranes were then incubated with primary antibody, either 
rabbit phospho-NR2A Y1387 (1:500, ab16647, Abcam, UK) or rabbit phospho-NR2B 
Y1472 (1:1000, ab5403, Chemicon, USA), overnight at 4°C.  After several washes in 
TBST, membranes were incubated with donkey anti-rabbit HRP-linked secondary 
antibody (1:5000, Amersham, UK) for 1 hr at room temperature, and revealed using 
ECL-plusTM reagent (5 min) for detection of phosphorylation by autoradiography.  
Gels were scanned and bands were quantified by densitometric analysis using Scion 
Image software.   
 
Results are expressed as percentage phosphorylation in the ipsilateral dorsal horn 
compared to the contralateral (control) dorsal horn for each animal (both ipsilateral 
and contralateral samples were run on the same gel).  Mann-Whitney Rank Sum 
tests were carried out using GraphPad Prism v.4 software (GraphPad Software Inc., 
San Diego, CA, USA) to test the statistical significance of the results.  Reprobing of 
the membranes with Ponceau red showed a lack of significant differences between 
the protein content of samples loaded on the same gel.  Analysis of gels and 
quantification was conducted by Dr Sophie Pezet. 
 
 
In all biochemical experiments, the contralateral dorsal horn served as an internal 
control for the effects of formalin injection.  Urethane anaesthesia was used to allow 
for quick perfusion at multiple timepoints following formalin injection.  
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6.2.6  Translocation of AMPA receptor subunit GluR1  
 
Subcellular fractioning (isolation of cytoplasm and plasma membranes) was carried 
out using a protocol previously described by Galan et al. (2004).  In brief, spinal cord 
samples were homogenized in complete lysis buffer (CLB: 10 mM Tris pH 7.5, 300 
mM sucrose, 1 mM EDTA, 1 mM sodium orthovanadate and protease inhibitor 
cocktail [Complete, Roche, UK]), and then centrifuged at 7000 g for 5 min.  
Supernatant containing cytoplasm (S1) was separated from the pellet containing 
nuclei and debris (P1), which was discarded.  Supernatant (S1) was then centrifuged 
at 40,000 g for 30 min to obtain pure cytoplasmic extract in the supernatant (S2) and 
crude membrane in the pellet (P2).  This pellet (P2), which includes plasma and 
cellular organelle membranes, was resuspended in PBS with protease inhibitor 
cocktail and sodium orthovanadate.  Protein titration was conducted using a BCA 
Protein Assay Kit (Pierce, UK) to determine protein concentrations in the cytoplasmic 
and membrane samples and 7.7 µg and 6.0 µg of proteins were loaded onto gels for 
each cytoplasmic (S2) and membrane (P2) sample, respectively.  Proteins were 
separated using 8% SDS-PAGE, and transferred to PVDF membranes.  Membranes 
were incubated with rabbit anti-GluR1 primary antibody (1:1000, Chemicon, ab1504, 
Temecula, CA, USA) overnight at 4°C.  After several washes in TBS-T, membranes 
were incubated with donkey anti-rabbit HRP-linked secondary antibody (1:5000, 
Amersham, UK) for 1 hr at room temperature and revealed using ECL-plusTM reagent 
(5 min) for detection by autoradiography.  Gels were scanned and bands were 
quantified by densitometric analysis using Scion Image software.  Analysis of gels 
and quantification was conducted by Dr Sophie Pezet. 
 
Results are expressed as percentage of GluR1 expression in naïve rats (0 min, 
100%) at each time point.  Mann-Whitney Rank Sum tests were carried out using 
GraphPad Prism v.4 software (GraphPad Software Inc., San Diego, CA, USA) to test 
the statistical significance of the results. 
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6.3  Results 
 
 
6.3.1  Spinal application of LY294002 selectively reduces C-fibre evoked 
responses and post-discharge of deep dorsal WDR neurones  
 
Electrically evoked responses of deep dorsal horn WDR neurones were reduced by 
spinal application of LY294002 (0.8 µg, n = 6; 1.6 µg, n = 6) in a dose-dependent 
manner (Fig. 6.2) in comparison to vehicle (10% DMSO, n = 6).  Statistically 
significant reductions were seen of C-fibre evoked responses (0.8 µg, % of pre-drug 
control response = 78 ± 4%, p < 0.05; 1.6 µg, % of pre-drug control response = 73 ± 
4%, p < 0.01).  These effects were selective as reductions of Aδ-fibre evoked 
responses did not reach statistical significance, while no changes were seen in Aβ-
fibre evoked responses.  The post-discharge of WDR neurones was also reduced by 
LY294002 (0.8 µg, % of pre-drug control response = 61 ± 14%, p < 0.05; 1.6 µg, % of 
pre-drug control response = 49 ± 5%, p < 0.05; Fig. 2) compared to vehicle.  
Inhibitory effects of LY294002 were evident by 10 min following spinal administration 
and persisted for the duration of the experiment.  Administration of vehicle (10% 
DMSO) alone had no effect on any evoked response.   Pre-drug control responses 
did not differ between treatment groups. 
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Fig. 6.2: Spinal LY294002 decreases C-fibre evoked responses and post-
discharge of WDR neurones.  Afferent-evoked responses and post-discharge of 
WDR neurones induced by transcutaneous electrical stimulation of the hindpaw 
receptive field, following spinal application of vehicle (10% DMSO) or LY294002 (0.8 
µg or 1.6 µg).  White bars represent pre-drug control.  All data presented as mean ± 
s.e.m. of pre-drug control responses; ∗ p < 0.05, ∗∗ p < 0.01 versus vehicle; one-way 
RM ANOVA followed by Bonferroni post-tests on raw data; n = 6 in each group. 
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6.3.2  Wind-up of deep dorsal horn WDR neurones is reduced by spinal 
LY294002 
 
Inhibition of PI3K by application of LY294002 directly onto the spinal cord produced a 
significant reduction of wind-up of WDR neurones (Fig. 6.3b,c; 0.8 µg, % of pre-drug 
control response = 43 ± 8%, p < 0.01; 1.6 µg, % of pre-drug control response = 50 ± 
6%, p < 0.01) compared to vehicle (10% DMSO).  No change in wind-up was seen 
with vehicle (10% DMSO) alone (Fig. 6.3b,d).  Importantly, neither LY294002 nor 
vehicle had any effect on input (Fig. 6.3a), a measure of the non-potentiated neuronal 
response, suggesting that effects of LY294002 were more likely due to a direct effect 
on dorsal horn neuronal excitability rather than via pre-synaptic mechanisms.  Pre-
drug input and wind-up values were similar in both treatment groups. 
 
Therefore, inhibition of PI3K reduces responses of deep dorsal horn WDR neurones 
evoked by electrical stimulation of nociceptive C-fibres.  Favourably, A-fibre evoked 
responses remained unaltered.  The post-discharge and wind-up of WDR neurones 
were also reduced by inhibition of PI3K, while there was no effect on input, indicating 
a post-synaptic mechanism of action. 
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Fig. 6.3: Spinal LY294002 selectively reduces wind-up of WDR neurones.   
(a,b) Effect of spinal application of vehicle (10% DMSO) or LY294002 (0.8 µg and 1.6 
µg) on (a) input and (b) wind-up of WDR neurones.  White bars represent pre-drug 
control.  All data presented as mean ± s.e.m. of pre-drug control responses; ∗∗ p < 
0.01 versus vehicle; one-way RM ANOVA followed by Bonferroni post-tests on raw 
data; n = 6 in each group.  (c,d) Examples of the wind-up of single WDR neurones 
following repetitive electrical stimulation in the presence of spinal (c) LY294002 (0.8 
µg and 1.6 µg) or (d) vehicle (10% DMSO). 
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6.3.3  Inhibition of PI3K reduces pain-related behaviours due to central 
sensitization induced by intraplantar formalin 
 
The intraplantar injection of formalin into the hindpaw of awake and freely-moving 
rats induced the characteristic biphasic response of pain-related behaviours in those 
rats pre-treated intrathecally with vehicle, 10% DMSO (n = 8, Fig. 6.4; 1st phase: 0-10 
min, total time of pain-related behaviour = 131 ± 11 s; 2nd phase: 10-60 min, total 
time of pain-related behaviour = 368 ± 29 s).  Pre-treatment with the PI3K inhibitor 
LY294002, however, 15 min prior to the injection of formalin, via intrathecal lumbar 
puncture, significantly decreased pain-related behaviours in a dose-dependent 
manner.  Both the first phase response (Fig. 6.4; 50 µg, n = 8, 1st phase total time of 
pain-related behaviour = 96 ± 10 s; 100 µg, n = 6, 1st phase total time of pain-related 
behaviour = 82 ± 13 s, p < 0.05) and the second phase response (Fig. 6.4; 50 µg, n = 
8, 2nd phase total time of pain-related behaviour = 254 ± 47 s; 100 µg, n = 6, 2nd 
phase total time of pain-related behaviour = 193 ± 36 s, p < 0.05) were reduced by 
LY294002 in comparison to vehicle treatment. 
 
Thus, inhibition of PI3K reduces formalin-induced pain-related behaviours, 
suggesting that PI3K is involved in the transmission of nociceptive signalling within 
the spinal cord and development of spinal central sensitization. 
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Fig. 6.4: Intrathecal LY294002 reduces pain-related behaviours due to formalin-
induced central sensitization.  (a) Time course of pain-related behaviours induced 
by intraplantar formalin (5%, 50 µl) following intrathecal pre-treatment with vehicle 
(10% DMSO, n = 8) or LY294002 (50 µg, n = 8; 100 µg, n = 6).  (b) Total pain-related 
behaviour during the 1st (0-10 min) and 2nd (10-60 min) phases of the formalin 
response with vehicle (10% DMSO) or LY294002 (1st phase: 100 µg, ∗ p < 0.05 
versus vehicle; 2nd phase: 100 µg, ∗ p < 0.05 versus vehicle; one-way RM ANOVA 
followed by Bonferroni post-tests).  All data presented as mean ± s.e.m. 
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6.3.4  Phosphorylation of Akt in spinal neurones following intraplantar formalin  
 
The phosphorylation of downstream kinase Akt (Ser473) can be measured using 
immunohistochemistry to indicate activation of the PI3K pathway.  Intraplantar 
formalin injection into the hindpaw of rats produced a large increase of p-Akt in the 
medial part of the superficial layers (I-II) of the ipsilateral dorsal horn (levels L4-L5) 
compared to the contralateral side in vehicle-treated rats (10% DMSO, n = 5) within 
five minutes (mean percentage increase = 82 ± 22%, p < 0.05; Fig. 6.5).  Inhibition of 
PI3K by intrathecal injection of LY294002 (100 µg, n = 5), fifteen minutes prior to 
formalin injection, prevented the increase in Akt phosphorylation in the ipsilateral 
dorsal horn such that the level of p-Akt staining did not differ significantly from that of 
the contralateral side (mean percentage increase = 18 ± 21%, Fig. 6.5c).  
 
This result confirms that Akt, a downstream marker of the PI3K pathway, is activated 
in the spinal dorsal horn after peripheral administration of formalin in the hindpaw and 
this effect is dependent on upstream PI3K activity. 
 
Taken together, these results show that activity of the PI3K pathway is involved in 
neuronal plasticity which contributes to formalin-induced spinal central sensitization 
and the resultant pain-related behaviours.  In order to define the molecular 
mechanisms by which PI3K is involved in the development of central sensitization, 
the effect of PI3K inhibition on the activation of various intracellular signalling 
pathways and glutamate receptors, known to be involved in synaptic plasticity in the 
hippocampus and activated in the spinal cord following an inflammatory stimulus, 
was studied.  
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Fig. 6.5: Intraplantar formalin-induced phosphorylation of spinal Akt is reduced 
by LY294002.   Representative photomicrographs of medial expression of p-Akt in 
superficial laminae of the (a) ipsilateral and (b) contralateral lumbar dorsal horn 
following intraplantar formalin in rats pre-treated with vehicle (10% DMSO).  (c) 
Quantification of formalin-induced upregulation of p-Akt in the medial part of the 
ipsilateral dorsal horn following intrathecal pre-treatment with vehicle (10% DMSO, n 
= 5) or LY294002 (100 µg, n = 5).  Data presented as a percentage of contralateral 
dorsal horn expression, mean ± s.e.m., ∗ p < 0.05 versus contralateral, Kruskal-
Wallis test followed by Dunnʼs Multiple Comparison post-test.  Scale bars = 80 µm. 
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6.3.5  Spinal LY294002 reduces the increase in ERK phosphorylation in the 
dorsal horn after formalin injection in the hindpaw 
 
Using immunohistochemical methods, it was shown that p-ERK expression is 
increased in the superficial layers (I-II) of the ipsilateral dorsal horn (levels L4-L5) five 
minutes after formalin injection compared to the contralateral side (Fig. 6.6a-c; mean 
number of positively-labelled cells per section: ipsilateral = 18.3 ± 0.5, contralateral = 
2.9 ± 1.9, p < 0.001), in vehicle-treated rats (10% DMSO, n = 5).  Some p-ERK 
expression was also induced in the ipsilateral dorsal horn in deeper laminae (V-VI) 
compared to the contralateral side, though this was much less than in superficial 
laminae (mean number of positively-labelled cells per section: ipsilateral = 5.1 ± 1.0, 
contralateral = 0.1 ± 0.1, p < 0.001).  Intrathecal pre-treatment with LY294002 (100 
µg, n = 5) significantly reduced p-ERK expression in both superficial (Fig. 6.6d) and 
deep laminae of the ipsilateral dorsal horn compared to vehicle-treated rats (mean 
number of positively-labelled cells in ipsilateral dorsal horn per section: superficial = 
12.6 ± 1.2, p < 0.01; deep = 1.8 ± 0.7, p < 0.05).  However, levels of p-ERK 
expression in LY294002-treated rats were still significantly greater in the ipsilateral 
dorsal horn than the contralateral side (mean number of positively-labelled cells in 
contralateral dorsal horn per section: superficial = 2.7 ± 1.0, p < 0.001; deep = 0.1 ± 
0.1, p < 0.05).  No changes were seen in the contralateral side with LY294002 
treatment.  
 
Thus, formalin injection in the hindpaw induces phosphorylation of ERK in the spinal 
dorsal horn, indicating activation of the ERK pathway.  Inhibition of PI3K by spinal 
administration of LY294002 reduces ERK activation but does not completely reverse 
it, suggesting that activation of ERK is in part mediated by the PI3K pathway, 
contributing to spinal central sensitization. 
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Fig. 6.6: LY294002 reduces formalin-induced phosphorylation of spinal ERK.  
(a,b) Representative photomicrographs of formalin-induced p-ERK expression in the 
(a) contralateral and (b) ipsilateral lumbar dorsal horn of rats pre-treated with 
intrathecal vehicle (10% DMSO).  (c,d) High power photomicrographs of formalin-
induced ipsilateral p-ERK expression following intrathecal (c) vehicle (10% DMSO) or 
(d) LY294002 (100 µg).  (e) Quantification of the number of formalin-induced p-ERK 
positive profiles per section in both superficial (I-II) and deep (V-VI) dorsal horn 
laminae following intrathecal pre-treatment with vehicle (10% DMSO, n = 5,) or 
LY294002 (100 µg, n = 5).  Data presented as mean ± s.e.m., ∗ p < 0.05, ∗∗ p < 0.01, 
∗∗∗ p < 0.001 versus contralateral side; + p < 0.05, ++ p < 0.01 between treatment 
groups; Mann-Whitney Rank Sum tests.  Scale bar = (a,b) 125 µm, (c) 32 µm. 
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6.3.6  Spinal LY294002 prevents the increase in CaMKII phosphorylation in the 
dorsal horn after formalin injection in the hindpaw 
 
Expression of p-CaMKII was quantified in the medial part of the superficial (I-II) 
layers of the dorsal horn (levels L4-L5).  Formalin injection produced a significant 
increase in the expression of p-CaMKII in the ipsilateral dorsal horn of vehicle-treated 
rats (10% DMSO, n = 5) within five minutes, when compared to the contralateral side 
(Fig. 6.7a-c; mean density per section: ipsilateral = 108.7 ± 4.4, contralateral = 93.2 ± 
2.9, p < 0.05; Fig. 6.7e, main).  There was no difference observed in p-CaMKII 
expression in animals pre-treated via intrathecal lumbar puncture with LY294002 
(100 µg, n = 5) between the ipsilateral and contralateral sides of the dorsal horn (Fig. 
6.7e; mean density per section: ipsilateral = 96.3 ± 3.6, contralateral = 93.7 ± 4.4, p > 
0.05).  Thus, LY294002 attenuated the formalin-induced increase in p-CaMKII 
expression in the ipsilateral dorsal horn compared to vehicle-treated rats (Fig. 6.7d; 
mean % of contralateral: vehicle group = 12.9 ± 2.9%, LY294002 group = 3.9 ± 1.6%, 
p < 0.05; Fig. 6.7e, inset).  Constitutive expression of p-CaMKII was found in the 
lateral regions of the superficial dorsal horn (Fig. 6.7a,b) and this was not altered 
following intraplantar formalin or drug treatment.  
 
Thus, formalin injection in the hindpaw induces phosphorylation of CaMKII in the 
spinal dorsal horn, indicating activation of the CaMKII pathway.  Inhibition of PI3K by 
LY294002 inhibits CaMKII phosphorylation suggesting that activation of the CaMKII 
pathway is downstream of PI3K activity, contributing to spinal central sensitization. 
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Fig. 6.7: LY294002 reduces formalin-induced phosphorylation of spinal CaMKII.  
(a,b) Representative photomicrographs of formalin-induced p-CaMKII expression in 
the (a) contralateral and (b) ipsilateral lumbar dorsal horns of rats pre-treated with 
intrathecal vehicle (10% DMSO).  Box shows p-CaMKII upregulation in the medial 
part of the superficial dorsal horn.  (c,d) High power photomicrographs of formalin-
induced p-CaMKII expression in medial superficial dorsal horn following intrathecal 
(c) vehicle (10% DMSO) or (d) LY294002 (100 µg).  (e) Quantification of mean 
density (main: arbitrary units; inset: percentage of contralateral) of formalin-induced 
p-CaMKII expression in medial part of the superficial dorsal horn following intrathecal 
vehicle (10% DMSO, n = 5,) or LY294002 (100 µg, n = 5).  All data presented as 
mean ± s.e.m; ∗ p < 0.05 versus contralateral side (main) or between treatment 
groups (inset); Mann-Whitney Rank Sum tests.  Scale bar = (a,b) 130 µm, (c) 32 µm. 
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6.3.7  Spinal LY294002 prevents phosphorylation of NMDA receptor NR2B 
subunits in the dorsal horn after formalin injection in the hindpaw 
 
Western blot analysis was used to test the role of PI3K in phosphorylation of NMDA 
receptor subunits NR2A and NR2B in the dorsal horn (levels L4-L5) five minutes after 
formalin injection.  Vehicle-treated rats (10% DMSO, n = 4) showed a marked 
increase in both ipsilateral NR2A and NR2B phosphorylation after formalin in 
comparison to the contralateral dorsal horn, though this effect was only significant for 
p-NR2B (Fig. 6.8; % of contralateral side: p-NR2A = 180.5 ± 48.1%; p-NR2B = 154.4 
± 18.4%, p < 0.05).  Intrathecal LY294002 (100 µg, n = 4) attenuated both p-NR2A 
and p-NR2B upregulation in the ipsilateral dorsal horn (Fig. 6.8; % of contralateral 
side: p-NR2A = 103.0 ± 12.3%; p-NR2B = 77.0 ± 7.0%), such that levels of 
phosphorylation of both subunits no longer differed from the contralateral side.  The 
expression of p-NR2A and p-NR2B in the ipsilateral dorsal horn differed between 
vehicle and LY294002-treated groups, however this difference was only statistically 
significant for p-NR2B expression (p < 0.05). 
 
Therefore, intraplantar formalin injection in the hindpaw induces a significant 
increased phosphorylation of NR2B NMDA receptor subunits in the ipsilateral dorsal 
horn.  This phosphorylation is attenuated by spinal inhibition of PI3K indicating that 
activity of the PI3K pathway leads to heightened activity of spinal NMDA receptors, 
particularly of the NR2B-subtype, contributing to spinal central sensitization. 
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Fig. 6.8: LY294002 prevents formalin-induced phosphorylation of spinal NMDA 
receptor NR2B subunits.  (a,b) Western immunoblots showing (a) p-NR2A and (b) 
p-NR2B expression in the dorsal horn induced by intraplantar formalin in rats pre-
treated with intrathecal vehicle (10% DMSO) or LY294002 (100µg).  (c) 
Quantification of formalin-induced expression of p-NR2A and p-NR2B.  Data 
expressed as mean ± s.e.m., + p < 0.05 versus contralateral side, ∗ p < 0.05 between 
treatment groups, Mann-Whitney Rank Sum test. 
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6.3.8  PI3K regulates the trafficking of dorsal horn AMPA receptor GluR1 
subunits after formalin injection in the hindpaw 
 
Using a combination of subcellular fractioning and western blot analysis, the effect of 
inhibition of PI3K on the trafficking of AMPA receptor GluR1 subunits from the 
cytoplasm to the plasma membrane of dorsal horn neurones after intraplantar 
formalin injection was tested.  As previously demonstrated following visceral 
inflammatory stimulation (Galan et al., 2004),  intraplantar injection of formalin 
induced an initial significant reduction of the relative amount of GluR1 receptor in the 
cytoplasm in vehicle-treated rats (10% DMSO, n = 3), 10 min after formalin injection, 
in comparison to naïve rats (34% decrease, p < 0.05; Fig. 6.9a,c).  This reduction 
was prevented by spinal pre-treatment with LY294002 (100 µg, n = 3).  This was 
followed by an increase at 45 min and a significant increase at 90 min after formalin 
injection in the amount of cytoplasmic GluR1 (90 min: 111% increase, p < 0.05, Fig. 
6.9a,c) which, again, was blocked by spinal LY294002.  The changes in the 
cytoplasm following formalin were paralleled by a trend towards increased GluR1 in 
the membrane fraction at 45 and 90 min in the vehicle-treated group only (Fig. 
6.9b,d), though these increases did not reach statistical significance.  
 
Therefore, injection of formalin into the hindpaw produces changes in cytosolic and 
membrane GluR1 content, perhaps suggesting an alteration of trafficking of GluR1 
AMPA receptor subunits from the cytoplasm to the plasma membrane of spinal 
dorsal horn neurones, a mechanism contributing to synaptic plasticity.  Inhibition of 
PI3K, by administration of LY294002, blocks such changes, suggesting that the PI3K 
pathway may regulate trafficking of GluR1 in response to noxious peripheral 
stimulation, contributing to spinal central sensitization. 
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Fig. 6.9: LY294002 alters trafficking of AMPA receptor GluR1 subunits 
following intraplantar formalin.  (a,b)  Western immunoblots of GluR1 expression 
in (a) cytoplasmic and (b) membrane fractions of the ipsilateral dorsal horn at 0 
(naïve rats), 10, 45 and 90 min following intraplantar formalin (5%, 50 µl) injection in 
rats pre-treated with intrathecal vehicle (10% DMSO) or LY294002 (100 µg).  (c,d)  
Quantification of formalin-induced changes in GluR1 expression in (c) cytoplasmic 
and (d) membrane fractions of the ipsilateral dorsal horn following intrathecal vehicle 
(10% DMSO, n = 3) or LY294002 (100 µg, n = 3).  Data are presented as a 
percentage of GluR1 expression in naïve rats (0 min) mean ± s.e.m., ∗ p < 0.05 
versus naïve animals (0 min, 100%), Mann-Whitney Rank Sum test.  
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6.4  Discussion 
 
The results presented in this chapter suggest that PI3K is involved in the expression 
of spinal neuronal nociceptive plasticity following electrical stimulation of the hindpaw 
and intraplantar injection of formalin.  Spinal treatment with a PI3K inhibitor, 
LY294002, robustly inhibited C-fibre evoked responses, post-discharge and wind-up 
of spinal WDR neurones.  The selectivity of these effects indicates a post-synaptic 
site of action.  Intraplantar formalin activated Akt, a downstream marker of the PI3K 
pathway, and produced pain-related behaviours, both of which were reduced by 
intrathecal LY294002.  A reduction in formalin-induced central sensitization by 
LY294002 coincided with reduced formalin-induced phosphorylation of NMDA 
receptor subunits, ERK and CaMKII, as well as abolishment of the formalin-induced 
changes of GluR1 AMPA receptor subunit cytosolic content.  Each of these 
intracellular mechanisms is considered to have essential roles in the manifestation of 
both hippocampal LTP in learning and memory and spinal central sensitization (Ji et 
al., 2003).  
 
PI3K has been shown to have a key role in the various stages of LTP in the 
mammalian hippocampus (Sanna et al., 2002; Opazo et al., 2003), amygdala (Lin et 
al., 2001) and medial prefrontal cortex (Sui et al., 2008).  Based on the hypothesis 
that central sensitization represents a spinal form of LTP (Ji et al., 2003), the aim of 
this study was investigate whether PI3K plays a similar role in spinal plasticity of pain 
pathways to that in the brain.  Firstly, it was demonstrated that PI3K is required for 
the full expression of wind-up, as LY294002 was able to reduce wind-up by 
approximately 50%.  This form of spinal plasticity is NMDA-dependent, as is LTP, 
and seems to be the neuronal correlate of pain hypersensitivity.  Reductions were 
seen of the post-discharge of WDRs, which is considered to be a measure of 
hyperexcitability of these cells.  In addition, spinal inhibition of PI3K produced 
significant reductions of C-fibre evoked responses, as well as a small inhibitory effect 
on Aδ-evoked responses, suggesting that PI3K blockade mainly interferes with 
nociceptive signalling.  Favourably, no effect was seen on Aβ-fibre evoked 
responses.  Importantly, input was also unaltered by LY294002, indicating that the 
reductions observed in evoked neuronal responses and wind-up were most likely not 
due to an inhibition of primary afferent signalling, but rather due to a direct effect on 
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post-synaptic dorsal horn neurones themselves.  In support of this, inhibition of PI3K 
does not affect pre-synaptic afferent release of substance P following electrical 
stimulation of dorsal roots attached to isolated dorsal horn slices (Pezet et al., 2008), 
though an effect on glutamate release from primary afferent fibres cannot be ruled 
out.  Thus, it is likely that PI3K is predominantly involved at the post-synaptic level in 
the dorsal horn in contributing to the expression of neuronal wind-up.  
 
Activation of the PI3K pathway five minutes after formalin administration was 
demonstrated by an increase in phosphorylation of downstream Akt, similar to that 
observed following intradermal capsaicin (Sun et al., 2006).  This indicates an 
important involvement of PI3K signalling in early central sensitization following 
noxious peripheral stimulation.  Accordingly, a dose-dependent inhibitory effect of 
PI3K blockade on pain-related behaviours during both the first and second phase of 
the response to intraplantar formalin was observed.  The first phase of the formalin 
test is thought to be mediated mainly by direct stimulation of second order neurones 
in the superficial laminae of the dorsal horn by C-fibres.  Reduction of this acute 
phase by LY294002 could reflect the decreases in C-fibre evoked responses, as well 
as post-discharge and wind-up of WDR neurones, observed electrophysiologically 
following electrical stimulation of the hindpaw.  A peripheral effect of LY294002 on 
primary afferent terminals cannot be entirely ruled out, particularly since peripheral 
noxious stimulation has extensively been shown to activate PI3K in nociceptive 
primary afferent fibres (Zhuang et al., 2004; Pezet et al., 2005; Sun et al., 2007).  
However, the lack of effect on peripheral input with LY294002 coupled with the 
evidence from release studies following electrical stimulation would point to an effect 
on intrinsic spinal excitability.  Thus, inhibition of PI3K may reduce the 
responsiveness of spinal neurones to incoming nociceptive signals induced by 
formalin and consequently reduce pain perception and resultant behaviours during 
the first phase.  Since LY294002 significantly reduced pain-related behaviours during 
the second phase of the response to formalin, it is evident that spinal PI3K activity is 
required for the manifestation of central sensitization.  Formalin-induced expression 
of c-Fos in dorsal horn neurones is also markedly reduced by spinal administration of 
LY294002 (Pezet et al., 2008) reinforcing the hypothesis of a role of PI3K in central 
sensitization of spinal sensory neurones.   
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Formalin-induced central sensitization is dependent on activation of spinal NMDA 
receptors (Haley et al., 1990; Chaplan et al., 1997) and accordingly, increased 
phosphorylation of NR2A and NR2B subunits was observed in this study five minutes 
after intraplantar formalin injection.  PI3K inhibition significantly reduced 
phosphorylation of NR2B subunits, and to a lesser extent that of NR2A subunits, 
suggesting that increased activity and/or responsiveness of NMDA receptors is 
regulated by PI3K signalling.  NMDA receptor subunit phosphorylation, particularly of 
the NR2B subunit, has been correlated with pain hypersensitivity in various pain 
models (Guo et al., 2002; Abe et al., 2005) and inhibition of NR2B-subtype receptors 
produces a potent antinociceptive effect (Taniguchi et al., 1997; Boyce et al., 1999; 
Malmberg et al., 2003; Tan et al., 2005).  In addition, NR2B-subtype receptors play a 
key role in LTP in the hippocampus (Tang et al., 1999; Gardoni et al., 2009; Foster et 
al., 2010) as well as in the spinal cord (Pedersen and Gjerstad, 2007; Qu et al., 
2009). 
 
Inhibition of PI3K by intrathecal administration of LY294002 produced a significant 
reduction in formalin-induced p-ERK expression, implicating PI3K as an upstream 
activator of ERK in the dorsal horn.  LTP has also been shown to involve activation of 
ERK via PI3K signalling (Opazo et al., 2003) and PI3K inhibitors suppress NMDA 
receptor-mediated ERK activation in hippocampal neurones (Chandler et al., 2001; 
Perkinton et al., 2002).  Although the exact mechanisms for this role of ERK in LTP 
have not been identified, it is postulated that ERK activation facilitates synaptic 
NMDA function and may also contribute to activity-dependent membrane insertion of 
AMPA receptors (Opazo et al., 2003).  PI3K signalling may thus promote ERK to act 
through similar mechanisms in the spinal cord to produce central sensitization.  The 
phosphorylation of ERK has been previously shown in inflammatory pain models (Ji 
et al., 2002a; Obata and Noguchi, 2004).  For example, ERK activation occurs rapidly 
in dorsal horn neurones after formalin injection and ERK inhibition blocks the 
resulting pain-related behaviour (Ji et al., 1999).  Zhuang and colleagues 
demonstrated that PI3K and ERK signalling pathways were intricately associated in 
peripheral primary sensory neurones (Zhuang et al., 2004).  
 
CAMKII has a crucial role in LTP, both in the hippocampus (Malinow et al., 1988; 
Malinow et al., 1989) as well as in the spinal cord (Yang et al., 2004a; Pedersen et 
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al., 2005).  In addition, influx of Ca2+ via NMDA receptors leads to the 
phosphorylation and activation of CaMKII, and its inhibition prevents central 
sensitization in the spinal cord in inflammatory and neuropathic pain models (Fang et 
al., 2002; Dai et al., 2005; Choi et al., 2006).  The results of this study show that PI3K 
regulates activity of CaMKII in the dorsal horn, a particularly intriguing finding since a 
dependence of CaMKII on upstream PI3K has not been shown in LTP.  Intraplantar 
formalin increased expression of p-CaMKII in the ipsilateral dorsal horn, an effect 
which was significantly reduced by intrathecal LY294002.  Similarly, Fang and 
colleagues saw increased expression of p-CaMKII after a noxious stimulus, in this 
case capsaicin.  Inhibition of CaMKII during behavioural testing prevented the 
hypersensitivity associated with central sensitization (Fang et al., 2002).  More 
recently, Dai and colleagues have shown upregulation of p-CaMKII after peripheral 
nerve injury.  Again, inhibition of CaMKII activity prevented behavioural 
hypersensitivity (Dai et al., 2005).  
 
Finally, trafficking of AMPA receptor GluR1 subunits to the plasma membrane of 
dorsal horn neurones may occur after formalin injection.  Increased numbers of 
AMPA receptors on the membrane of spinal sensory neurones would increase the 
responsiveness of these cells to glutamate release from primary afferent fibres and 
thus amplify responses to and consequently perception of peripheral stimulation.  
Prior to this study, this mechanism had never been demonstrated before at the spinal 
cord level in a model of somatic inflammatory pain.  However, it had been shown that 
AMPA GluR1 subunits are recruited to the plasma membrane of spinal cord 
neurones after noxious visceral stimulation (Galan et al., 2004).  Therefore, this is a 
mechanism which could contribute to the expression of central sensitization following 
noxious inputs from varying locations and via different pathways.  In the 
hippocampus, it has been shown that exocytosis of GluR1 is PI3K-dependent, 
whereas that of GluR2 is not (Passafaro et al., 2001).  Subsequently, Man and 
colleagues showed that PI3K is required for AMPA receptor insertion during LTP 
(Man et al., 2003).  The results here suggest that PI3K may regulate GluR1 trafficking 
in the dorsal horn after intraplantar formalin.  Formalin-induced changes in both 
cytosolic and membrane AMPA receptor content were prevented by spinal 
LY294002.  An initial decrease in cytosolic GluR1 content may be due to increased 
trafficking to the plasma membrane.  This is supported by the increasing trend in 
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membrane AMPA receptor content observed up to 90 min after formalin injection, 
even after pain-related behaviour has subsided, suggesting that central sensitization 
has been persistently established.  The later increase in cytosolic GluR1 content may 
serve to replenish and increase the overall cellular content of GluR1 and contribute to 
neuronal plasticity.  Furthermore, the effect of CaMKII on pain transmission in this 
model may be due to an alteration of the trafficking and/or activation of GluR1 
subunits as previously observed following visceral inflammatory stimulation (Galan et 
al., 2004).  Phosphorylation of GluR1 and membrane insertion are also essential 
components of LTP and both involve CaMKII (Fukunaga et al., 1996; Barria et al., 
1997; Derkach et al., 1999; Hayashi et al., 2000).   
 
It is also important to consider that in these experiment rats were sacrificed five 
minutes after intraplantar formalin injection and so central sensitization may not yet 
have been fully established.  Changes in the spinal expression of p-ERK, p-CaMKII 
and p-NR2B may be components which lead to central sensitization, suggesting that 
PI3K is an initiatory upstream molecule which triggers multiple changes in spinal 
sensory neurones, resulting in central sensitization.  It therefore follows that inhibition 
of PI3K activity soon after a noxious stimulus may be a highly effective way of 
preventing central sensitization by blocking initiation of various signalling pathways.  
Further studies are required to establish whether PI3K is involved in the maintenance 
of central sensitization. 
 
Of note in these studies is the fact that doses of LY294002 used in 
electrophysiological experiments are much lower than those used in the behavioural 
formalin test.  The ability to apply the drug locally to a restricted cord zone in a static 
system during electrophysiological recordings explains the low effective doses as 
compared to the behavioural study where CSF flow and dilution, and the smaller 
volume make higher doses necessary.  It is possible that at the higher behavioural 
doses LY294002 may exert non-specific effects, inhibiting other kinases such as 
glycogen synthase kinase 3 (GSK3), casein kinase 2 (CK2) and p90 ribosomal S6 
protein kinase 2 (RSK2) (Davies et al., 2000), though this is made less likely since 
the actual effective dose should be much lower than the administration dose due to 
dilution by CSF and minimal access to the cord. 
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In conclusion, this study reinforces that similarities exist between LTP in the brain 
and central sensitization in the spinal cord.  PI3K regulates various intracellular 
mechanisms which collectively contribute to the induction of central sensitization of 
dorsal horn sensory neurones. 
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7  Involvement of dimethylarginine dimethylaminohydrolase-1 (DDAH-1) in 
NMDA-dependent spinal nociceptive plasticity 
 
 
7.1  Introduction 
 
 
7.1.1  NMDA-NO signalling in the brain 
 
Activation of nNOS and subsequent generation of NO is coupled to upstream 
stimulation of NMDA receptor activity.  This was first demonstrated by Garthwaite 
and colleagues who showed that stimulation of NMDA receptors in cerebellar cells by 
glutamate induced release of a diffusible messenger, NO, in a Ca2+-dependent 
manner, and lead to a rise in cGMP levels.  In addition, they showed that this NMDA-
mediated rise in cGMP could be blocked by L-NG-monomethylarginine (L-NMMA), an 
inhibitor of NO production from L-arginine by NOS.  This block was reversed by 
subsequent application of L-arginine (Garthwaite et al., 1988; Garthwaite et al., 
1989).  In addition, the relationship between NMDA receptors and NO was shown to 
exist in the hippocampus (East and Garthwaite, 1991).  Later it was shown that 
nNOS is in fact physically coupled to NMDA receptors via PSD-95 in a ternary 
complex (Brenman et al., 1996; Christopherson et al., 1999) such that Ca2+ influx 
through the NMDA channel pore can directly drive the production of NO in an NMDA-
dependent manner.  This complex was found to contribute to NMDA-mediated 
excitotoxicity and is believed to be involved in plasticity and behaviour (Sattler et al., 
1999).   
 
Various studies have demonstrated that NO is required for hippocampal LTP (Bohme 
et al., 1991; Haley et al., 1992b; O'Dell et al., 1994; Doyle et al., 1996; Kantor et al., 
1996; Son et al., 1996).  Together, this work suggested that both eNOS (endothelial 
nitric oxide synthase) and nNOS are required for LTP, and that loss of one enzyme 
may be compensated for by the presence of the other so that LTP may be normal.  
Hopper and Garthwaite confirmed the requirement for both eNOS and nNOS in 
hippocampal LTP and concluded that eNOS produces tonic NO while nNOS 
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generates phasic NO signals which are particularly important for late LTP (Hopper 
and Garthwaite, 2006).  Thus, NO is a key messenger in brain synaptic plasticity.   
 
 
7.1.2  A role for nitric oxide and nitric oxide synthases in pain at the spinal 
level 
 
In the dorsal horn of the spinal cord, it has clearly been established that nitric oxide 
and downstream cGMP, which is produced by the NO receptor guanylate cyclase, 
contribute to sensitization of nociceptive signalling in both inflammatory and 
neuropathic pain states, though apparently not to basal pain perception (Schmidtko 
et al., 2009).  Two very similar studies showed that the facilitation of the nociceptive 
tail-flick reflex in response to thermal stimulation that occurs after intrathecal 
administration of NMDA is abolished by spinal treatment with the non-selective NOS 
inhibitor N omega-nitro-L-arginine methyl ester (L-NAME), while L-arginine, which is 
converted to NO, and NO donors, such as sodium nitroprusside (SNP), produced 
hypersensitivity (Kitto et al., 1992; Meller et al., 1992a).  Thus it was shown that 
downstream NO signalling contributes to acute NMDA-dependent hypersensitivity.  
Sorkin subsequently demonstrated that intrathecal NMDA caused extracellular 
release of glutamate and citrulline, a metabolite of NO synthesis, in the spinal cord.  
This NMDA-induced release of glutamate was blocked by L-NAME (Sorkin, 1993), 
thus suggesting that activation of NMDA receptors and subsequent generation of NO 
leads to further release of glutamate as part of a feed-forward control of spinal 
nociceptive processing.  However, where this glutamate originates from could not be 
determined and thus could be of either pre- or post-synaptic origin.  Citrulline was 
measured rather than NO in this study since the short half-life of NO makes it 
particularly difficult to measure in the extracellular space.  In addition, Malmberg and 
Yaksh showed that L-NAME could block the second phase of the behavioural 
formalin test with no effect on baseline nociceptive thresholds (Malmberg and Yaksh, 
1993), while a similar antinociceptive effect on the neuronal response to formalin was 
shown in an electrophysiological study using L-NAME (Haley et al., 1992a).   
 
A role for NOS and NO was shown in more chronic inflammatory pain, as induced by 
hindpaw injection of carrageenan.  L-NAME produced a dose-dependent block of 
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thermal hypersensitivity in the injected paw, while there was no change in the non-
injected paw or of baseline nociceptive thresholds prior to inflammation (Meller et al., 
1994a).  In particular, it would appear that nNOS is most important in producing 
inflammatory hyperalgesia, with eNOS and iNOS (inducible nitric oxide synthase) 
having little, if any, involvement.  The selective nNOS inhibitor 7-nitroindazole (7-NI) 
reduced both early (development) and late (maintenance) phases of carrageenan-
induced thermal hypersensitivity.  Interestingly, however, nNOS knockout mice had 
reduced hypersensitivity during the late phase only.  The intact early phase 
hypersensitivity in these mice was explained by an upregulation of eNOS which 
compensated for the loss of nNOS (Tao et al., 2004).  Mice lacking iNOS had normal 
carrageenan-induced thermal hyperalgesia, though this may have been due to a 
compensatory upregulation of nNOS (Tao et al., 2003b).  Similarly, genetic knockout 
of nNOS selectively reduced late phase hypersensitivity following CFA-induced 
inflammation of the hindpaw, while pharmacological inhibition with 7-NI reduced both 
early and late phases (Chu et al., 2005).  Together these studies would suggest that 
nNOS plays differing but critical roles in the development and maintenance phases of 
chronic inflammatory hyperalgesia. 
 
It has also been demonstrated that NO signalling is required for the expression of 
nerve injury-induced pain.  Meller and colleagues found that acute administration of 
L-NAME could block thermal hypersensitivity in rats with CCI-induced neuropathic 
pain for two hours (Meller et al., 1992b).  This finding was later confirmed by Salter 
and colleagues, who additionally found that L-NAME administered 
intracerebroventricularly could reverse thermal hypersensitivity, though this effect 
was not as prolonged as that achieved by intrathecal administration of the drug 
(Salter et al., 1996).  Later, Guan and colleagues combined genetic and 
pharmacological approaches to elucidate a role specifically for nNOS in nerve injury-
induced pain.  Mice lacking nNOS failed to develop mechanical hypersensitivity 
following L5 SNL and intrathecal administration of L-NAME or 7-NI robustly inhibited 
mechanical hypersensitivity in nerve-injured wild-type mice.  No effect of either drug 
was seen on mechanical sensitivity of the contralateral paw (Guan et al., 2007).  
Most interestingly, especially in the context of this thesis, Florio and colleagues have 
recently demonstrated the importance of interactions between nNOS and PSD-95 in 
neuropathic pain.  Small molecule inhibitors which can disrupt association of nNOS 
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with PSD-95 were found to attenuate the NMDA-induced facilitation of the tail-flick 
reflex and also reverse mechanical hypersensitivity following CCI, when administered 
intrathecally at doses which did not alter baseline nociceptive thresholds or motor 
performance on the rotarod (Florio et al., 2009).  Thus, nNOS activity is implicated in 
the nociceptive sensitization that contributes to neuropathic pain states. 
 
Additional evidence of a role for NO in pain sensitization was provided by Tegeder 
and colleagues who showed that inhibition of tetrahydrobiopterin (BH4), an essential 
cofactor for NO production by NOS, could inhibit inflammatory and neuropathic pain 
in rodents.  Furthermore, in humans, a polymorphism in the gene encoding GTP 
cyclohydrolase 1 (GCH1), the rate-limiting enzyme for BH4 synthesis, was found to 
be protective against neuropathic pain and was associated with reduced 
experimental inflammatory hyperalgesia in healthy individuals (Tegeder et al., 2006).  
GCH1 was one of the first susceptibility genes identified for chronic pain.    
 
 
7.1.3  Endogenous regulation of NOS by ADMA and DDAH 
 
The majority of studies described above investigating the role of NO have utilized 
exogenously applied direct inhibitors of NOS as a means for targeting this signalling 
pathway.  However, regulation of NOS, and thus regulation of NO generation, 
involves multiple enzymes and substrates as part of a complex regulatory pathway 
which may equally be targeted.  A key endogenous inhibitor of NOS activity is 
asymmetric dimethylarginine (ADMA), which is formed as a by-product of continuous 
protein turnover in all cells of the body.  ADMA is structurally similar to L-arginine, 
which is the substrate converted to NO by NOS.  Therefore, ADMA can compete with 
L-arginine and inhibit NOS activity and in this way regulate the formation of NO.  For 
example, Vallance and colleagues showed that impaired renal function can lead to 
accumulation of ADMA in the body, which may in turn impair NO synthesis and 
cause hypertension, since NO is a vasodilator in blood vessels (Vallance et al., 
1992).  Later, Cardounel and Zweier measured the levels of ADMA in the brain and in 
neurones and found that physiological concentrations were sufficient to modulate 
nNOS function and suppress NO-mediated excitotoxic injury (Cardounel and Zweier, 
2002).  ADMA is itself actively regulated by an enzyme called dimethylarginine 
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dimethylaminohydrolase (DDAH), of which there are two isoforms, DDAH-1 and 
DDAH-2, strengthening the suggestion that ADMA is more than simply a by-product 
of protein turnover, but rather has an important physiological function (Leiper et al., 
1999).  DDAH metabolizes ADMA and converts it to citrulline and dimethylamine 
(Rossiter et al., 2005).  Inhibition of DDAH has been shown to sufficiently increase 
levels of ADMA to inhibit synthesis of NO (MacAllister et al., 1996).  Therefore, 
activity of DDAH can indirectly influence NOS activity, by relieving the inhibitory 
influence of ADMA and thus increasing the generation of NO (Fig. 7.1). 
 
 
 
 
 
 
 
 
Fig. 7.1: DDAH/ADMA regulation of NOS.  NOS converts L-arginine to NO and 
citrulline.  ADMA is produced endogenously by protein turnover and is structurally 
similar to L-arginine.  Thus, ADMA can act as an endogenous competitive inhibitor of 
NOS and decreases generation of NO.  ADMA itself is regulated and metabolized by 
DDAH.  Thus, activity of DDAH indirectly modulates NOS activity by relieving 
endogenous inhibition by ADMA and so increasing generation of NO. 
Chapter 7 
 
 
260 
7.1.4  Expression of DDAH-1 and DDAH-2  
 
The distribution of DDAH mRNA correlates well with NOS in various tissues, with 
DDAH-1 found predominantly in tissues expressing nNOS and DDAH-2 associated 
more with eNOS (Leiper et al., 1999).  DDAH-1 mRNA was strongly detected in 
brain, liver, kidney and pancreas, while the greatest expression of DDAH-2 was in 
heart, kidney, placenta, pancreas and lung.  DDAH-1 was completely absent from 
heart, placenta and lung, while DDAH-2 was barely detectable in brain (Leiper et al., 
1999).  Perhaps surprisingly, DDAH-2 mRNA is abundant in the spinal cord and this 
expression was found to be greater than that of DDAH-1 mRNA (Tran et al., 2000).   
 
 
7.1.5  Novel targeting of DDAH isoforms in disease 
 
Interest in the DDAH/ADMA pathway has increased with the accumulating evidence 
that ADMA is involved in numerous pathological processes and diseases, while a 
role for NOS in disease has been established for some time.  Therefore, recent 
attempts have been made to design novel inhibitors of DDAH isoforms in an effort to 
elucidate precise roles for DDAH in both physiological and pathophysiological 
processes.  To that end, a selective inhibitor of DDAH-1, L-291 (NG-[2-methoxyethyl] 
arginine methyl ester), has recently been synthesized.  This compound is based on 
the structure of ADMA and acts as a competitive inhibitor of DDAH-1 (IC50 20 µM), 
with no direct effect on NOS activity, but rather reduces NO signalling through 
accumulation of ADMA (Rossiter et al., 2005; Leiper et al., 2007).  L-291 is specific 
for DDAH-1 based on recombinant protein activity assays and on functional assays in 
culture (unpublished observations, verbal communication from Dr Manasi Nandi, 
UCL).  In addition, transgenic mice globally lacking DDAH-1 have been genetically 
engineered.  Although complete deletion of DDAH-1 is lethal in utero (indicating the 
importance of DDAH-1 in embryonic development), heterozygous mice (DDAH-1+/-) 
are viable.  These mice have been fully characterized biochemically and show 
reduced DDAH-1 mRNA, protein and activity, with no compensatory change in 
DDAH-2, as well as increased circulating and tissue levels of ADMA (Leiper et al., 
2007).  From a therapeutic point of view, pharmacological and genetic inhibition of 
DDAH-1 was found to be protective in a model of endotoxic shock, in which NO 
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production is known to reach excessive and pathological levels (Leiper et al., 2007).  
Thus, targeting of DDAH isoforms may be beneficial in other diseases where 
increased NO signalling is implicated, particularly in the nervous system. 
 
 
7.1.6  DDAH in the nervous system and possible role in pain 
 
As outlined above, mRNA for DDAH isoforms has been detected in various neuronal 
tissues.  To date, however, nothing is known regarding the functional role of DDAH in 
the nervous system.  A single study has demonstrated that mRNA for DDAH and 
nNOS are both upregulated in injured motoneurones following axotomy (Nakagomi et 
al., 1999), though the functional significance of this finding remains unknown.  Since 
mRNA for DDAH isoforms has been detected in the spinal cord, and that nNOS is 
known to be important for sensitization of spinal pain processing, it was hypothesized 
that DDAH may too influence spinal pain processing, perhaps via indirect regulation 
of nNOS.  Thus, the aim of this study was to first detect protein expression of DDAH 
isoforms in the nervous system, including the spinal cord, and to subsequently 
assess the functional contribution of DDAH-1 to spinal pain processing using both 
pharmacological and genetic strategies. 
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7.2  Materials and Methods 
 
 
7.2.1  Animals 
 
Experiments were conducted in adult male Sprague-Dawley rats (220-250 g, Central 
Biological Services, University College London, or Harlan, UK) and C57BL/6 DDAH+/- 
or wild-type mice (25-30 g, donated by Dr Manasi Nandi (UCL) and Dr James Leiper 
(UCL), housed in standard laboratory conditions with free access to food and water.  
Experimental procedures were approved by the UK Home Office and followed 
guidelines under the International Association for the Study of Pain (Zimmermann, 
1983). 
 
 
7.2.2  Western Immunoblotting of DDAH-1 and DDAH-2 in neuronal tissues 
 
Rat dorsal horn, DRG and hippocampus tissue was homogenized and 40 µg of each 
lysate was run on an 8% gel for SDS-PAGE (see Material and Methods).  Proteins 
were transferred to nitrocellulose membranes which were then probed overnight at 
4°C with goat anti-DDAH-1 (1:500, ab2231, Abcam) or goat anti-DDAH-2 (1:500, 
ab1383, Abcam, UK) primary antibodies.  Rabbit anti-neuronal β-III tubulin served as 
a loading control (1:3000, ab18207, Abcam, UK).  Next membranes were incubated 
with IRDye-linked donkey anti-goat 680 or donkey anti-rabbit 800CW secondary 
antibody for 1 hr at room temperature, and proteins were subsequently revealed 
using the Odyssey fluorescence detection system (Licor, UK). 
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7.2.3  DDAH-1 specific inhibitor, L-291 and control inactive enantiomer, L-456 
 
L-291 (NG-[2-methoxyethyl] arginine methyl ester; Fig. 7.2) is a selective small 
molecule inhibitor of DDAH-1 while L-456 is its mirror image inactive D-enantiomer 
and therefore serves as a control.  Both compounds were donated by Dr Manasi 
Nandi (UCL) and Dr James Leiper (UCL) and subsequently dissolved in 0.9% saline. 
 
 
 
 
 
 
 
Fig. 7.2: Chemical structure of DDAH-1 inhibitor L-291 (IC50 20 µM) 
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7.2.4  In vivo Electrophysiology 
 
Electrophysiological recordings from deep dorsal horn WDR neurones (> 600 µm) 
were conducted as previously described (see Materials and Methods chapter).   
 
 
7.2.4.1  Electrical stimulation of the hindpaw 
 
Following the establishment of stable control responses, L-291 was injected directly 
onto the surface of the spinal cord (after removal of any residual cerebrospinal fluid) 
in cumulative doses of 1.2, 12 and 120 µg in a volume of 50 µl using a Hamilton 
syringe.  Electrical tests were continued at 10 min intervals with the effect of each 
dose followed for 1 hr.  A separate group of animals received 120 µg of the control 
peptide L-456, in a volume of 50 µl, for comparison. 
 
 
7.2.4.2  Neuronal Formalin Test 
 
Following cell characterization, rats were pre-treated by topical spinal administration 
of either 12 µg of L-291 or 120 µg of L-456, 20 min prior to the injection of formalin.  
Both drugs were delivered in a volume of 50 µl using a Hamilton syringe.  Formalin 
(5%, 50 µl) was prepared from a 37% formaldehyde solution and then injected 
subcutaneously into the hindpaw receptive field.  The firing response of the WDR 
neurone was recorded for the subsequent 70 min after formalin injection.  Activity 
was displayed as a rate recording and quantified in 10 min time bins. 
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7.2.5  Behavioural Formalin Test 
 
Rats were lightly anaesthetized with isoflurane and then injected intrathecally (lumbar 
puncture method) with either 10 µl of L-291 (12 µg or 24 µg) or 10 µl of L-456 (24 
µg).  Experimenters were blind to treatment for the whole experiment.  Twenty 
minutes later, rats received a subcutaneous injection of 50 µl of formalin (5%) into the 
plantar surface of the right hindpaw.  Lifting, flinching, licking and biting of the 
injected paw were monitored by measuring the total duration of the response in 
seconds (s) during the 60 min period following formalin administration.  Data was 
captured in 5 min time bins.   
 
 
7.2.6  DDAH-1+/- mice Behavioural Formalin Test 
 
Heterologous null DDAH-1+/- and wild-type littermates received an intraplantar 
injection of formalin (2%, 20 µl).  As with rats, lifting, flinching, licking and biting of the 
injected paw were monitored by measuring the total duration of the response in 
seconds (s) during the 60 min period following formalin administration.  Data was 
captured in 5 min time bins.  No obvious phenotypic differences were observed 
between DDAH-1+/- and wild-type mice, and experimenters were blind to genotype 
throughout the testing period.  Global homologous deletion of DDAH-1 is lethal in 
utero. 
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7.2.7  Statistical Analysis 
 
All data is presented as mean ± s.e.m.  Effects of L-291 and L-456 following electrical 
stimulation of the hindpaw were assessed by one-way RM ANOVA, followed by 
Bonferroni multiple comparison post-tests.  Cell characteristics from L-291 and L-456 
groups were compared by Studentʼs unpaired t-tests.  Formalin neuronal and 
behavioural response time course data was compared between treatment groups 
and analyzed by two-way RM ANOVA, followed by Bonferroni post-tests.  Total 
activity in the first and second phases was compared between treatment groups by 
quantifying the area under each curve, and analyzed by one-way ANOVA, followed 
by Bonferroni post-tests.  Statistical analyses were carried out using GraphPad Prism 
v.4 software (GraphPad Software Inc., San Diego, CA, USA). 
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7.3  Results 
 
 
7.3.1  DDAH-1 and DDAH-2 protein is expressed in DRG, spinal dorsal horn and 
hippocampus 
 
Protein expression of DDAH-1 or DDAH-2 has never been shown previously in rat 
spinal cord dorsal horn and DRG.  Using western blotting, both DDAH-1 and DDAH-2 
protein was found to be present in the hippocampus, DRG and the dorsal horn of the 
spinal cord (Fig. 7.3).  Protein content of DDAH-1 was greatest in DRG, followed by 
similar expression in spinal dorsal horn and hippocampus.  DDAH-2 expression was 
also greatest in DRG followed by spinal dorsal horn and then by hippocampus.  
DDAH-1 expression in all three types of neuronal tissue was greater than DDAH-2.  
This would agree with previous findings which have suggested that DDAH-1 is mainly 
found in tissues which express nNOS, while DDAH-2 seems to co-localize more with 
eNOS (Leiper et al., 1999).   
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Fig. 7.3: Expression of DDAH-1 and DDAH-2 protein in neuronal tissues.  
Western immunoblots showing expression of DDAH-1 (top) and DDAH-2 (bottom) in 
hippocampus (two left lanes), DRG (two centre lanes) and spinal dorsal horn (two 
right lanes).  β-III tubulin served as a loading control. 
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7.3.2  Spinal L-291 inhibits C-fibre evoked responses and post-discharge of 
deep dorsal horn WDR neurones 
 
Having observed expression of DDAH protein in DRG and spinal cord dorsal horn, 
the function of DDAH-1 in sensory and nociceptive signalling was assessed using the 
specific DDAH-1 inhibitor L-291.  Spinal administration of L-291 produced selective 
and significant dose-dependent inhibitions of C-fibre evoked responses of WDR 
neurones (Fig. 7.4; 1.2 µg, n = 9, % of pre-drug baseline = 89 ± 8 %, p > 0.05; 12 µg, 
n = 9, % of pre-drug baseline = 78 ± 7 %, p < 0.05; 120 µg, n = 6, % of pre-drug 
baseline = 74 ± 4 %, p < 0.01) as well as of post-discharge (Fig. 7.4; 1.2 µg, n = 9, % 
of pre-drug baseline = 74 ± 13 %, p > 0.05; 12 µg, n = 9, % of pre-drug baseline = 62 
± 12 %, p < 0.05; 120 µg, n = 6, % of pre-drug baseline = 57 ± 16 %, p < 0.01).  No 
changes were seen in Aβ-fibre or Aδ-fibre evoked responses (Fig. 7.4).  Peak 
inhibitory effects of L-291 were evident by 40 min post-administration and persisted 
for the remainder of the recording period.  The control compound L-456 (120 µg, n = 
8) did not affect any evoked response or post-discharge.  Pre-drug control responses 
did not differ between treatment groups (Table 7.1). 
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  L-456 (n = 8) L-291 (n = 9) 
C-fibre threshold          
(mA) 0.68 ± 0.21 0.63 ± 0.10 
Depth                             
(µM) 934 ± 58 922 ± 45 
Aβ-fibre evoked response     
(No. of APs) 153 ± 22 142 ± 13 
Aδ-fibre evoked response 
(No. of APs) 216 ± 31 172 ± 22 
C-fibre evoked response 
(No. of APs) 512 ± 37 495 ± 48 
Post-discharge              
(No. of APs) 668 ± 81 564 ± 61 
Input                               
(No. of APs) 327 ± 46 368 ± 64 
Wind-up                          
(No. of APs) 940 ± 91 776 ± 62 
 
 
 
Table 7.1: Pre-drug control responses induced by transcutaneous electrical 
stimulation of the hindpaw receptive field of WDR neurones in rats treated with 
L-456 or L-291.  C-fibre threshold, cell depth, afferent-evoked responses, input and 
wind-up are expressed as mean ± s.e.m.  There were no differences between cells 
recorded in each treatment group for any measure prior to drug delivery; Studentʼs 
unpaired t-test. 
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Fig. 7.4: Spinal L-291 decreases C-fibre evoked responses and post-discharge 
of WDR neurones.  Afferent-evoked responses and post-discharge of WDR 
neurones induced by transcutaneous electrical stimulation of the hindpaw receptive 
field, following spinal application of L-291 (1.2 µg, n = 9; 12 µg, n = 9; 120 µg, n = 6) 
or L-456 (120 µg, n = 8).  White bars represent pre-drug control.  Data presented as 
mean ± s.e.m. of pre-drug control responses; ∗ p < 0.05, ∗∗ p < 0.01 versus pre-drug 
control, one-way RM ANOVA followed by Bonferroni post-tests. 
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7.3.3  Wind-up of deep dorsal horn WDR neurones is reduced by spinal L-291 
 
No effect was seen on input following spinal application of L-291 or L-456 (Fig. 7.5a).  
In contrast, L-291 produced a significant and dose-dependent inhibition of wind-up of 
WDR neurones (Fig. 7.5b,c; 1.2 µg, n = 9, % of pre-drug baseline = 67 ± 8 %, p < 
0.05; 12 µg, n = 9, % of pre-drug baseline = 63 ± 11 %, p < 0.01; 120 µg, n = 6, % of 
pre-drug baseline = 58 ± 13 %, p < 0.01), while L-456 had no effect (Fig. 7.5d).  Pre-
drug input and wind-up values were similar in both treatment groups (Table 7.1). 
 
Therefore, inhibition of spinal DDAH-1 by L-291 selectively reduces C-fibre evoked 
responses, post-discharge and NMDA-dependent wind-up of WDR neurones, 
indicating a role for DDAH-1 in nociceptive signalling and plasticity within the dorsal 
horn.  No changes were seen in A-fibre evoked responses and input, indicating 
minimal pre-synaptic effects. 
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Fig. 7.5: Spinal L-291 selectively reduces wind-up of WDR neurones. 
(a,b) Effect of spinal application of L-291 (1.2 µg, n = 9; 12 µg, n = 9; 120 µg, n = 6) 
or L-456 (120 µg, n = 8) on (a) input and (b) wind-up of WDR neurones.  White bars 
represent pre-drug control.  Data presented as mean ± s.e.m. of pre-drug control 
responses; ∗ p < 0.05, ∗∗ p < 0.01 versus pre-drug control; one-way RM ANOVA 
followed by Bonferroni post-tests.  (c,d) Examples of the wind-up of single WDR 
neurones following repetitive electrical stimulation in the presence of spinal (c) L-291 
(1.2 µg and 12 µg) or (d) L-456 (120 µg). 
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7.3.4  Formalin-induced central sensitization of deep dorsal horn WDR 
neurones is reduced by spinal pre-treatment with L-291 
 
In recordings where rats were pre-treated with spinal application of control L-456 
(120 µg, n = 14), formalin injection into the hindpaw induced a characteristic biphasic 
neuronal firing response (Fig. 7.6a,b; 1st phase: 0-10 min, total APs = 9524 ± 1778; 
2nd phase: 10-70 min, total APs = 37855 ± 7595).  Spinal pre-treatment with L-291 
significantly and selectively reduced second phase neuronal firing (12 µg, n = 10; 
total APs = 8258 ± 5198, p < 0.001).  No change in neuronal firing during the first 
phase was observed.  All cells recorded were characterized prior to injection of drug 
and formalin to ensure that cells were comparable between the two treatment groups 
(Table 7.2).  
 
Thus, spinal inhibition of DDAH-1 reduces NMDA-dependent central sensitization of 
deep dorsal horn WDR neurones following intraplantar formalin.   
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  L-456 (n = 14) 
L-291 
(n = 10) 
C-fibre threshold          
(mA) 0.60 ± 0.11 0.54 ± 0.09 
Depth                             
(µM) 859 ± 26 886 ± 31 
Aβ-fibre evoked response     
(No. of APs) 139 ± 9 162 ± 16 
Aδ-fibre evoked response 
(No. of APs) 168 ± 19 250 ± 33 
C-fibre evoked response 
(No. of APs) 481 ± 74 536 ± 70 
Post-discharge              
(No. of APs) 518 ± 78 488 ±75 
Input                               
(No. of APs) 489 ± 122 424 ± 75 
Wind-up                          
(No. of APs) 602 ± 69 665 ± 99 
48oC                                
(No. of APs) 1295 ± 164 1450 ± 138 
 
 
 
Table 7.2: WDR cell characteristics from L-291 neuronal formalin test.  Cells 
were characterized prior to drug administration and formalin injection.  C-fibre 
threshold, cell depth, afferent-evoked responses, input, wind-up and response to 
48°C are expressed as mean ± s.e.m.  There were no differences between cells 
recorded in each treatment group; Studentʼs unpaired t-test. 
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Fig. 7.6: Spinal L-291 reduces formalin-induced central sensitization of WDR 
neurones.  (a) Time course of WDR firing response to subcutaneous formalin (5%, 
50 µl) injection into the hindpaw receptive field following spinal pre-treatment with 
control L-456 (120 µg, n = 14) or L-291 (12 µg, n = 10; ∗∗ p < 0.01 at 50 min, ∗∗∗ p < 
0.001 at 60min, ∗∗∗ p < 0.001 at 70min versus L-456; two-way RM ANOVA followed 
by Bonferroni post-tests).  (b) Total neuronal activity during the 1st (0-10 min) and 2nd 
phases (10-70 min) of the formalin response with spinal L-456 or L-291 (2nd phase: 
∗∗∗ p < 0.001 versus L-456, one-way ANOVA followed by Bonferroni post-tests).  (c) 
Representative rate recordings of firing responses of WDR neurones to formalin 
following spinal pre-treatment with L-456 or L-291.  All data presented as mean ± 
s.e.m. 
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7.3.5  Spinal L-291 inhibits pain-related behaviours in rats due to formalin-
induced central sensitization 
 
Effects of spinal inhibition of DDAH-1 were next assessed in the formalin behavioural 
test.  In rats pre-treated intrathecally with control L-456 formalin induced a biphasic 
response of pain-related behaviours as expected (Fig. 7.7a,b; 24 µg, n = 6; 1st phase: 
0-10 min, total time of pain-related behaviour = 61 ± 5 s; 2nd phase: 10-60 min, total 
time of pain-related behaviour = 487 ± 83 s).  Pre-treatment with the DDAH-1 
inhibitor L-291 significantly and selectively decreased pain-related behaviour during 
the second phase of the response (Fig. 7.7a,b; 24 µg, n = 6, 2nd phase total time of 
pain-related behaviour = 218 ± 54 s, p < 0.01).  No difference was seen during the 
first phase between L-291 and L-456 treatment groups.  
 
Thus, inhibition of spinal DDAH-1 reduces formalin-induced pain-related behaviours 
produced by spinal central sensitization.  
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Fig. 7.7: Intrathecal L-291 reduces pain-related behaviours due to formalin-
induced central sensitization.  (a) Time course of pain-related behaviours induced 
by intraplantar injection of formalin (5%, 50 µl) following intrathecal pre-treatment with 
L-456 (24 µg) or L-291 (24 µg, ∗ p < 0.05 at 35 min versus L-456; two-way RM 
ANOVA followed by Bonferroni post-tests).  (b) Total pain-related behaviour during 
the 1st phase (0-10 min) and 2nd phase (10-60 min) of the response to formalin 
following intrathecal pre-treatment with L-456 or L-291 (2nd phase: ∗∗ p < 0.01 versus 
L-456; one-way ANOVA followed by Bonferroni post-tests).  All data presented as 
mean ± s.e.m., n = 6 in each group. 
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7.3.6  Spinal L-291 reduces formalin-induced pain-related active licking and 
biting and reflexive lifting and flinching behaviours 
 
Pain-related behaviours produced by intraplantar formalin were separated into two 
categories: the reflexive lifting and flinching behaviours and the active licking and 
biting of the injured paw.  Further analysis showed that L-291 reduced both licking 
and biting (Fig. 7.8a,b; 2nd phase total time of licking and biting behaviour = 138 ± 48 
s, p < 0.01) and lifting and flinching (Fig. 7.8c,d; 2nd phase total time of lifting and 
flinching behaviour = 81 ± 10 s, p < 0.01) during the second phase of the formalin 
response only in comparison to L-456 (Fig. 7.8a,b; 2nd phase total time of licking and 
biting behaviour = 318 ± 51 s; Fig. 7.8c,d; 2nd phase total time of lifting and flinching 
behaviour = 169 ± 37 s).  No differences were seen during the first phase in any 
behaviour between L-291 and L-456 treatment groups. 
 
Therefore, the reduction in total pain-related behaviour produced by spinal 
administration of L-291 was due to action on both the active licking and biting 
responses and also the more reflexive lifting and flinching. 
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Fig. 7.8: Intrathecal L-291 reduces both active licking and biting and reflexive 
lifting and flinching pain-related behaviours following intraplantar formalin.  (a) 
Time course of formalin-induced (5%, 50 µl) licking and biting behaviour following 
intrathecal pre-treatment with L-456 (24 µg, n = 6) or L-291 (24 µg, n = 6).  (b) Total 
licking and biting behaviour during the 1st (0-10 min) and 2nd phases (10-60 min) of 
the formalin response following intrathecal L-456 or L-291 (2nd phase, ∗ p < 0.01 
versus L-456; one-way ANOVA followed by Bonferroni post-tests).  (c) Time course 
of formalin-induced lifting and flinching behaviour following intrathecal pre-treatment 
with L-456 or L-291.  (d) Total lifting and flinching behaviour during the 1st and 2nd 
phases of the formalin response following intrathecal L-456 or L-291 (2nd phase, ∗ p < 
0.01 versus L-456; one-way ANOVA followed by Bonferroni post-tests).  Note that 
due to the lower incidence of lifting and flinching behaviours the vertical axes are 
scaled differently.  Data presented as mean ± s.e.m. 
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7.3.7  No change in formalin-induced pain-related behaviours in DDAH-1+/- mice 
 
The effect of global heterologous deletion of the DDAH-1 gene was assessed in the 
formalin behavioural test (Fig. 7.9).  DDAH+/- mice (n = 5) produced the characteristic 
biphasic behavioural response to intraplantar formalin which surprisingly did not differ 
from the response in wild-type DDAH+/+ mice (n = 7).  No differences were seen at 
any time point in either phase (Fig. 7.9a,b).  Further analysis of the different pain 
behaviours showed that mice spent most time licking and biting (Fig. 7.9c,d) the 
injected paw, rather than lifting and flinching (Fig. 7.9e,f).  Both behaviours showed a 
biphasic pattern though this was much reduced and arguably less obvious for lifting 
and flinching.  It would seem clear that active licking and biting behaviours 
predominate in mice, at least in this experiment, over the more reflexive lifting and 
flinching behaviour.  Again no differences were seen in these behaviours between 
DDAH+/- and wild-type mice (Fig. 7.9d,f). 
 
Thus, global heterologous deletion of DDAH-1 does not alter formalin-induced 
behaviours and spinal central sensitization.  
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Fig. 7.9: DDAH+/- mice have normal behavioural responses to intraplantar 
formalin.  (a) Time course of pain-related behaviours induced by intraplantar 
formalin (5%, 50 µl) injection in DDAH+/- (n = 5) and wild-type DDAH+/+ mice (n = 7).  
(b) Total pain-related behaviour during the 1st phase (0-10 min) and 2nd phase (10-60 
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min) of the response to formalin in DDAH+/- and wild-type mice.  (c) Time course of 
formalin-induced licking and biting behaviour in DDAH+/- and wild-type mice.  (d) 
Total licking and biting behaviour during the 1st and 2nd phases of the formalin 
response in DDAH+/- and wild-type mice.  (e) Time course of formalin-induced lifting 
and flinching behaviour in DDAH+/- and wild-type mice.  (f) Total licking and biting 
behaviour during the 1st and 2nd phases of the formalin response in DDAH+/- and wild-
type mice.  Note that due to the lower incidence of lifting and flinching behaviours the 
vertical axes are scaled differently.  All data presented as mean ± s.e.m. 
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7.4  Discussion 
 
The results of this study suggest that DDAH-1, an enzyme which metabolizes 
methylarginines, is involved in NMDA-dependent plasticity of spinal dorsal horn 
sensory neurones following noxious peripheral stimulation. Pharmacological 
inhibition of DDAH-1, using a novel DDAH-1 specific small molecule inhibitor, L-291, 
reduces neuronal hyperexcitability as well as pain-related behaviours produced by 
formalin-induced spinal central sensitization in rats.  Surprisingly, however, global 
heterologous deletion of DDAH-1 had no effect on formalin-induced pain-related 
behaviours in transgenic mice. 
 
Spinal administration of L-291 produced significant dose-dependent inhibitions of 
post-discharge and wind-up of WDR neurones induced by transcutaneous electrical 
stimulation of the hindpaw receptive field.  C-fibre evoked responses were also dose-
dependently reduced, although to a lesser extent than post-discharge and wind-up. 
No effect was seen on A-fibre evoked responses or on input at any dose.  These 
selective inhibitory effects of spinal DDAH-1 antagonism on NMDA-mediated 
neuronal events suggest a post-synaptic site of action and are similar to those 
produced by spinal inhibition of nNOS (Stanfa et al., 1996; Urch and Dickenson, 
2003a) as well as drugs targeting spinal NMDA receptors (Chapter 3) (Dickenson 
and Sullivan, 1987b).  Together, these data confirm the intimate relationship between 
NMDA receptor activation and downstream NO signalling.  Targeting of DDAH-1 may 
be a novel way of modulating this pathway.  The fact that effects of DDAH-1 inhibition 
were selective would also suggest that there were no vascular effects, as these 
would be expected to alter all spinal responses in a non-selective manner.  Indeed, 
no obvious changes in the central blood vessel shape or size were observed during 
electrophysiological recordings following administration of L-291. 
 
In both neuronal and behavioural formalin tests, spinal administration of L-291 
reduced central sensitization of dorsal horn neurones, as shown by a reduction of 
second phase activity.  No effects were seen in the first phase of either response, 
suggesting that L-291 does not alter normal acute pain, but rather alters potentiation 
of pain transmission.  These findings are consistent with those of several studies 
which investigated the effect of inhibition of NOS in the formalin test.  Both systemic 
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and spinal administration of NOS inhibitors has been shown to selectively reduce 
second phase pain-related behaviours induced by intraplantar formalin injection, with 
no effect on the first acute phase (Malmberg and Yaksh, 1993; Moore et al., 1993; 
Coderre and Yashpal, 1994).  Interestingly, Wiertelak and colleagues showed that 
hindpaw injection of formalin lead to a facilitation of the noxious tail-flick response, 
and this hypersensitivity was found to be mediated by the NMDA-NO signalling 
cascade at the level of the spinal cord (Wiertelak et al., 1994).  Formalin injection in 
the hindpaw has also been shown to upregulate nNOS in the dorsal horn of the 
spinal cord (Herdegen et al., 1994; Lam et al., 1996), and formalin-induced c-Fos is 
reduced by spinal inhibition of NOS, primarily in the superficial dorsal horn (Roche et 
al., 1996).  Together, these data establish a significant contribution of NO and NOS 
in central sensitization of spinal sensory neurones, and provide a context for the 
inhibitory effects of DDAH-1 antagonism, which indirectly suppresses generation of 
NO by NOS.  Interestingly, the DDAH-1 antagonist L-291 reduced both active and 
reflexive pain-related behaviours induced by formalin, in contrast to disruption of 
NR2B interactions with PSD-95 which altered only active licking and biting 
behaviours (Chapter 3, Fig. 3.8).  This suggests that activation of nNOS and 
regulation by DDAH-1 may involve alternative mechanisms in addition to upstream 
NR2B-subtype receptor activation via PSD-95.  For example, the sensitizing effects 
of substance P are also known to involve downstream nNOS (Coderre and Yashpal, 
1994).  Nevertheless, disruption of binding between PSD-95 and nNOS has recently 
been shown to inhibit NMDA-induced thermal hypersensitivity and also neuropathic 
pain (Florio et al., 2009), confirming the importance of the ternary complex between 
NMDA receptors, PSD-95 and nNOS in pain hypersensitivity. 
 
Surprisingly, DDAH-1+/- mice showed no differences in their behavioural response to 
intraplantar formalin compared to wild-type littermates.  This may be because only 
50% of DDAH-1 was absent in these mice, and the remaining DDAH-1 may have 
been sufficient for the full expression of the formalin response.  A greater loss of 
DDAH-1 may be required and this hypothesis is supported by the fact that relatively 
high doses of L-291 were required to inhibit formalin-induced pain-related behaviours 
in rats, though neuronal effects of L-291 were still selective at these doses.  The 
lowest effective dose in electrophysiological experiments was 12 µg in 50 µl (1 mM), 
which is 50 times the IC50 of the drug, whilst in behavioural studies a dose of 24 µg in 
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20 µl (5 mM), at 250 times the IC50 of L-291 was effective, suggesting that a major 
blockade of DDAH-1 is required.  Lower doses were ineffective (data not shown).  
Unfortunately, total global knockout of DDAH-1 is lethal in utero, and therefore, 
tissue-specific (conditional) knockouts of DDAH-1 are now being constructed.  
Complete loss of DDAH-1 in nociceptors and/or spinal cord may reveal a phenotype 
in the formalin test.  Additionally, DDAH-2 may also be involved in the response to 
formalin and so may functionally compensate for the loss of DDAH-1, even though 
expression levels of DDAH-2 are unaltered in DDAH-1+/- mice (Leiper et al., 2007).  
DDAH-2 knockout mice (DDAH-2-/-) have been bred successfully and may reveal a 
role for DDAH-2 in the formalin test in future studies.  Furthermore, DDAH-2-/- mice 
have been successfully crossed with heterozygous DDAH-1+/- mice and so the effects 
of complete DDAH-2 deletion on a DDAH-1 haploinsufficient background can be 
investigated (for further information visit www.ddah.org.uk).  Functional compensation 
in these mice by DDAH-2 for the loss of DDAH-1, or vice-versa, will have been 
eliminated or reduced, respectively.  Alternatively it may be argued that L-291 may 
act via another mechanism which does not involve DDAH-1 inhibition, explaining the 
lack of behavioural changes in DDAH-1+/- mice.  However, inhibition of DDAH-1 is the 
most likely mechanism of action of L-291 since this compound is based on the 
structure of ADMA and acts as a competitive inhibitor of DDAH-1 (IC50 20 µM) by 
binding directly to the active site of the enzyme, as shown by crystallography (Leiper 
et al., 2007).  Furthermore, recombinant protein activity assays and functional assays 
in culture have demonstrated the specificity of L-291 for DDAH-1 (unpublished 
observations, verbal communication from Dr Manasi Nandi, UCL).   
 
Western blot analysis confirmed protein expression of both DDAH-1 and DDAH-2 in 
neuronal tissues, specifically in DRG, spinal dorsal horn and hippocampus, which not 
only contain neurones but also vascular structures which would be expected to 
express DDAH isoforms.  Immunohistochemical studies are required to elucidate the 
exact neuronal expression patterns of DDAH isoforms, particularly in the dorsal horn 
of the spinal cord, though this would be expected to be similar to that of nNOS.  Early 
studies demonstrated that nNOS is predominantly located in the superficial dorsal 
horn (Valtschanoff et al., 1992; Spike et al., 1993; Morris et al., 1994) and formalin 
injection in the hindpaw has been shown to increase this expression (Herdegen et 
al., 1994; Lam et al., 1996).  Intriguingly, extensive evidence suggests that nNOS is 
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present almost exclusively in GABA-positive interneurones in the superficial dorsal 
horn (Valtschanoff et al., 1992; Spike et al., 1993; Laing et al., 1994; Bernardi et al., 
1995).  This finding is perhaps confusing considering the abundance of functional 
evidence implicating nNOS in NMDA-mediated excitatory events as well as the 
presence of nNOS in NMDA receptor complexes (Chapter 3, Fig. 3.3 & Chapter 5, 
Fig. 5.7).  The exact role of nNOS in these GABAergic interneurones remains 
unknown.  However, some of the nNOS expression in these interneurones is found in 
their dorsally-extending dendrites where GABA is not expressed, and NO may be 
released from such sites (Bernardi et al., 1995).  NMDA receptors on inhibitory 
interneurones may cause NO to be generated which may then counteract GABA-
mediated inhibitions, permitting NMDA-dependent spinal events such as wind-up, 
LTP and central sensitization to occur.  In addition, since NO is a diffusible 
messenger, its effects are not restricted to inhibitory interneurones and may easily 
engage many types of neurones within the superficial dorsal horn, including lamina I 
projection neurones (Ruscheweyh et al., 2006; Schmidtko et al., 2008), to increase 
excitations.  In the DRG, nNOS expression is much less abundant and is restricted to 
peptidergic C-fibres (Aimi et al., 1991; Zhang et al., 1993).  More recently, it has been 
shown that NO-sensitive guanylate cyclase is absent in DRG neurones but present in 
astrocytes (Schmidtko et al., 2008).  Together, these studies would suggest that the 
contribution of NO signalling in pre-synaptic primary afferent neurones is minimal, 
and that spinally administered drugs targeting nNOS and NO signalling act 
predominantly on intrinsic post-synaptic spinal sites.  These findings also challenge 
the hypothesis that NO may act as a retrograde transmitter, released from spinal 
sites and acting on peripheral nerve terminals to increase neurotransmitter release.  
It is more likely that NO is released from spinal sites and acts exclusively on spinal 
neurones to produce sensitization of nociceptive signalling (Schmidtko et al., 2009).  
DDAH-1 expression in DRG may also be minimal in neurones and this would fit with 
the lack of effect of L-291 on input and afferent-evoked responses in comparison to 
post-discharge and wind-up, which are neuronal events induced within intrinsic 
dorsal horn neurones. 
 
It would be interesting to assess the effects of DDAH-1 inhibition on LTP in spinal 
pain pathways.  Ikeda and colleagues demonstrated that LTP in the superficial dorsal 
horn increases NO production, as indicated by the use of an NO-sensitive dye.  The 
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amount of NO produced correlated well with the level of LTP.  In addition, inhibitors of 
NOS blocked both LTP and NO production (Ikeda et al., 2006a).   
 
A question remains regarding exactly how L-291 gains access to the intracellular 
compartment of cells to exert its effects on DDAH-1.  Since L-291 mimics L-arginine 
structurally, it is believed that the same mechanisms which transport L-arginine 
across cell membranes from the extracellular space will also transport L-291.  This is 
in fact the case for direct NOS inhibitors such as L-NMMA and L-NAME which are 
also based on the structure of L-arginine.  The y+ system cationic amino acid 
transporters (y+CATs) are thought to be the primary transmembrane proteins 
responsible for the transport of L-arginine into cells, and have been characterized in 
a variety of neuronal populations (Wiesinger, 2001).  It is possible that, in addition to 
binding to and inhibiting DDAH-1, L-291 may limit the availability of L-arginine by 
competing for transporters, thus further reducing NO signalling.  Accordingly, addition 
of L-arginine can reverse the effects of L-291 on blood vessels (Leiper et al., 2007).   
 
The results presented in this study are the first to demonstrate protein expression of 
DDAH isoforms in the nervous system as well as suggesting a functional role for 
DDAH-1 in neuronal signalling.  Similar to inhibition of nNOS, inhibition of DDAH-1 by 
L-291 modulates NMDA-dependent nociceptive plasticity in the dorsal horn of the 
spinal cord.  Thus, DDAH-1 may be a novel analgesic target in chronic pain states. 
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8  Final Discussion 
 
 
The main aims of this thesis were to investigate novel ways of modulating NMDA 
receptors and downstream intracellular signalling cascades in the dorsal horn of the 
spinal cord as a strategy for analgesia whilst avoiding side-effects associated with 
receptor blockade by traditional NMDA receptor antagonists.  I attempted to modulate 
NMDA-mediated intracellular signalling in two ways: first, through disruption of 
binding to the scaffolding protein PSD-95, and second, by directly targeting specific 
signalling pathways in models of NMDA-dependent spinal nociceptive plasticity.  The 
studies presented here demonstrate that NMDA-dependent spinal mechanisms of 
plasticity, particularly central sensitization, are important for the manifestation of 
persistent pain states.  I have used behavioural studies, in vivo electrophysiology, 
immunohistochemistry and molecular biology to draw these conclusions.  The main 
findings are now summarized. 
 
 
8.1  NMDA-dependent spinal nociceptive plasticity can be prevented without 
NMDA receptor blockade but through modulation of protein interactions 
 
Both spinal dorsal horn wind-up, produced by electrical stimulation at the peripheral 
receptive field, and formalin-induced central sensitization are robust models for 
studying spinal nociceptive plasticity.  I have confirmed that both of these 
phenomena require activity of dorsal horn NMDA receptors and interactions with the 
scaffolding protein PSD-95, which couples the NMDA receptor to downstream 
intracellular signalling pathways.  Furthermore, I have shown that, rather than 
receptor blockade, disruption of NMDA-mediated signalling, by perturbing the 
interaction with PSD-95, can prevent such spinal nociceptive plasticity without 
altering primary afferent input.  A lack of effect on acute sensory and noxious 
processing was evident by unaltered afferent-evoked responses of WDR neurones 
and 1st phase neuronal and behavioural activity following formalin injection into the 
hindpaw, which is driven by peripheral C-fibres.  This data, together with the fact that 
PSD-95 is absent from DRG neurones, suggests an exclusively post-synaptic action 
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of the disrupting peptide Tat-NR2B9c on intrinsic dorsal horn neurones, which is 
selective for neuronal and behavioural hypersensitivity. 
 
 
8.2  Disruption of interactions between NR2B-containing NMDA receptors and 
PSD-95 can reverse neuropathic pain 
 
A single acute injection of Tat-NR2B9c, delivered spinally via intrathecal lumbar 
puncture, was able to produce a significant, though not complete, reversal of 
mechanical and cold hypersensitivity in nerve-injured rats.  No effects were observed 
in the sensitivity of the non-injured paw, supporting the idea of selective roles for 
NR2B-subtype receptors and interactions with PSD-95 in aberrant pathophysiological 
signalling and not in normal acute transmission.  In addition, Tat-NR2B9c robustly 
reduced mechanically and thermally evoked responses and also wind-up of dorsal 
horn WDR neurones in nerve-injured rats as well as sham rats, though this inhibitory 
effect was translated behaviourally only when associated with nerve injury, again 
suggesting a selective action of Tat-NR2B9c on the hypersensitivity.  Here, it is likely 
that the NMDA receptor is recruited by intense suprathreshold and prolonged 
stimulation used in electrophysiological studies, whilst playing a minimal role at 
behavioural thresholds.  Spinal Tat-NR2B9c produced no adverse motor impairment 
in the rotarod test at a therapeutically effective dose, suggesting improved tolerability 
over conventional NMDA antagonists.  In these studies, efficacy of Tat-NR2B9c in 
both wind-up and formalin tests was a good predictor of efficacy in the nerve injury 
model of neuropathic pain.  Thus, wind-up and the formalin test may be used to 
predict efficacy of novel pharmacological interventions in chronic pain states, at least 
for nerve injury-induced neuropathic pain.  
 
 
8.3  Importance of dorsal horn NR2B-containing NMDA receptors in 
nociceptive plasticity and neuropathic pain 
 
Although numerous studies have implicated NR2B-subtype receptors in pain, the 
precise location of these receptors has been controversial, with some studies 
indicating the importance of supraspinal over spinal NR2B-subtype receptors, though 
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most support an intrinsic spinal role.  By employing exclusively spinal administration 
of Tat-NR2B9c, I have confirmed that spinal NR2B-subtype receptors do in fact have 
a crucial role in neuronal and behavioural hypersensitivity.  In addition, PKCζ/PKMζ 
was found to be coupled to spinal NR2B-subtypre receptors and to contribute to 
central sensitization, while intraplantar formalin also increased phosphorylation of 
spinal NR2B subunits.  Therefore, spinal NR2B-containing NMDA receptors remain 
an important drug target for the treatment of chronic pain.   
 
 
8.4  PKCζ /PKMζ  and PI3K signalling pathways are implicated downstream of 
NMDA receptor activation in NMDA-dependent spinal nociceptive plasticity 
 
Activation of PKCζ/PKMζ and PI3K signalling pathways contributes to central 
sensitization, and blockade of both kinases inhibits the resultant neuronal plasticity 
and behavioural hypersensitivity, similar to Tat-NR2B9c.  Inhibition of PI3K reduced 
NMDA-dependent wind-up of WDR neurones without affecting primary afferent input, 
again similar to disruption of binding of PSD-95 to NR2B subunits.  In addition, PI3K 
was found to be a key upstream modulator of ERK and CaMKII activity in central 
sensitization.  PKCζ/PKMζ has an intimate role in NMDA-dependent nociceptive 
plasticity.  I have demonstrated the presence of a novel physical complex between 
NR2B-containing NMDA receptors, PSD-95 and PKCζ/PKMζ in spinal dorsal horn 
neurones.  Binding between NR2B subunits and PSD-95 mediates activation of 
PKCζ/PKMζ signalling, contributing to central sensitization.  While Tat-NR2B9c itself 
had no effect on the 1st phase behavioural response to formalin, direct inhibition of 
PKCζ/PKMζ did produce a small but significant reduction of this acute phase.  This 
may suggest that not all of the PKCζ/PKMζ in the dorsal horn is bound to and 
regulated by NR2B-containing NMDA receptors and PSD-95.   
 
 
8.5  DDAH-1 may be an alternative target to nNOS in the treatment of pain 
 
I confirmed that nNOS is coupled to NR2B-containing NMDA receptors via PSD-95 in 
dorsal horn neurones, implicating the generation of NO as a key downstream 
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signalling molecule of NMDA-dependent nociceptive plasticity.  In addition, I showed 
that DDAH isoforms, which indirectly modulate NOS isoforms, are present in the 
DRG and dorsal horn of the spinal cord.  DDAH-1, which is believed to indirectly 
modulate nNOS activity, was shown to be involved in NMDA-dependent wind-up and 
central sensitization.  As with Tat-NR2B9c, inhibition of DDAH-1 was without effect 
on pre-synaptic input from primary afferents and on acute pain processing as 
observed in the 1st phase of the neuronal and behavioural responses to intraplantar 
formalin.  These results are similar to those achieved with direct nNOS inhibitors, 
thus implicating DDAH-1 as an alternative target to nNOS for the treatment of chronic 
pain. 
 
 
8.6  Possible interplay between NMDA-dependent intracellular signalling 
pathways in dorsal horn neurones 
 
The implications of these findings and their relationship to what is already known in 
the field have been discussed previously in the relevant results chapters.  I will now 
put forward some ideas and evidence which may link these findings together and are 
summarized in the subsequent schematic (Fig. 8.1). 
 
In addition to PSD-95, nNOS and PKCζ/PKMζ (Chapters 3 & 5), the PI3K signalling 
pathway has also been shown to couple directly to NR2 subunits of NMDA receptors.  
The p85 regulatory subunit of PI3K binds directly to a phosphorylated tyrosine 
(Tyr1336) within the cytoplasmic tail of NR2 subunits (Hisatsune et al., 1999).  This 
interaction between PI3K and NR2 subunits does not require PSD-95.  In addition, it 
has been shown that Akt, a downstream effector of PI3K, forms a complex with 
NR2B subunits and PSD-95 in the dorsal horn (Peng et al., 2009).  It may be that 
generation of PIP2 by PI3K causes translocation of Akt to the plasma membrane 
where it now interacts with NMDA receptors, via PSD-95, and can be phosphorylated 
and fully activated, as occurs in formalin-induced central sensitization (Chapter 6).  
Furthermore, PI3K signalling is believed to increase trafficking of PSD-95 to the 
plasma membrane (Yoshii and Constantine-Paton, 2007) and this may be a 
mechanism for maintenance and consolidation of NMDA receptor complexes.  
Together these studies demonstrate that the PI3K signalling cascade is directly 
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linked to NMDA receptor NR2 subunits and has a key regulatory role within the 
NMDA receptor complex. 
 
PI3K also phosphorylates PIP2 to generate PIP3 which acts as an intracellular second 
messenger.  PIP3 has a dual role in the activation of PKCζ/PKMζ.  First, PIP3 can 
directly modulate the pseudosubstrate domain of PKCζ, thus relieving autoinhibition 
and promoting catalytic activity.  Second, PIP3 is required for activation of PDK-1, 
which in turn phosphorylates PKCζ/PKMζ on its activation loop (Thr410).  This 
phosphorylation is upregulated in formalin-induced central sensitization (Chapter 5).  
These PIP3-regulated steps are required for complete and stable activation of 
PKCζ/PKMζ (Hirai and Chida, 2002).  PDK-1 may also phosphorylate Akt in a PI3K-
dependent manner (Toker and Cantley, 1997).  Activation of both ERK and CaMKII 
signalling is also regulated by upstream PI3K in central sensitization (Chapter 6), as 
is mTOR, which is also implicated in central sensitization (Asante et al., 2009).  All of 
these aforementioned kinases (PI3K, Akt, PDK-1, ERK, CaMKII and mTOR) have 
been shown to regulate PKCζ/PKMζ in the hippocampus during LTP (Kelly et al., 
2007) and this may also be the case in spinal central sensitization.  
 
CaMKII has also been shown to bind directly to NR2B subunits of NMDA receptors at 
residues 1290-1306 of the cytoplasmic tail (Strack et al., 2000).  This binding is 
facilitated by autophosphorylation of CaMKII at Thr286 (Strack and Colbran, 1998), 
which activates the enzyme and occurs in formalin-induced central sensitization 
(Chapter 6). 
 
Binding of nNOS to NR2B-containing NMDA receptors is mediated via PSD-95 
(Chapter 3).  DDAH-1 indirectly regulates nNOS by metabolizing ADMA, an 
endogenous inhibitor of nNOS and is involved in central sensitization (Chapter 7).  At 
present, it is not clear if DDAH-1 regulates only the nNOS which is coupled to NMDA 
receptors or only free nNOS, or both.  Therefore, it is unknown if the regulation of 
nNOS by coupling between NR2B subunits and PSD-95 overlaps with the regulation 
by DDAH-1.  Phosphorylation of nNOS is also required for regulation of activity and 
involves CaMKII.  Two sites on nNOS, Ser741 and Ser847 are phosphorylated by 
CaMKII (Hayashi et al., 1999; Song et al., 2004), perhaps mediated by PSD-95 
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(Watanabe et al., 2003), the effect of which is a decrease in activity and synthesis of 
NO.  Interestingly, phosphorylation of nNOS is bidirectionally regulated by NMDA 
receptors whereby low glutamate concentrations induce phosphorylation of Ser847 
by CaMKII but high glutamate concentrations, as occurs during heightened 
stimulation, induces dephosphorylation of Ser847 by protein phosphatase 1 (PP1) 
which increases nNOS activity (Rameau et al., 2004).  Additional NMDA-induced 
activation of nNOS is achieved by phosphorylation of Ser1412 by Akt (Rameau et al., 
2007), again implicating the PI3K pathway in NMDA-mediated signalling. 
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Fig. 8.1: NMDA-dependent intracellular signalling within dorsal horn sensory 
neurones promotes spinal central sensitization.  The cytoplasmic tails of NR2B 
subunits of NMDA receptors bind to PSD-95, a physical interaction which mediates 
NMDA-dependent downstream signalling via cytoplasmic effectors such as 
PKCζ/PKMζ and nNOS.  PKCζ/PKMζ is phosphorylated and activated by various 
kinases including PI3K, PDK-1, Akt, CaMKII, ERK and mTOR, promoting central 
sensitization and expression of genes such as c-Fos.  PI3K is a key regulator of 
central sensitization and also binds to the cytoplasmic tail of NR2 subunits.  PI3K 
promotes activation of multiple intracellular signalling pathways via generation of PIP2 
and PIP3 and phosphorylation of Akt, CaMKII and ERK, as well as phosphorylation of 
NMDA receptor NR2 subunits and increased membrane trafficking of AMPA 
receptors via CaMKII.  NMDA-dependent generation of NO by nNOS is regulated by 
ADMA which itself is metabolized by DDAH.  Activity of nNOS is further regulated by 
phosphorylation by CaMKII and dephosphorylation by PP1.      
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8.7  Wind-up initiates central sensitization and is a neuronal correlate of pain 
hypersensitivity  
 
In many of my studies I have used wind-up as a model of short-term spinal 
nociceptive plasticity.  I found that drugs which reduced wind-up also reduced central 
sensitization.  Wind-up is widely regarded as a neuronal correlate of the pain 
hypersensitivity which occurs after central sensitization.  Indeed, there are many 
similarities between these two phenomena.  Both wind-up and central sensitization 
are dependent on activation of NMDA receptors (Dickenson and Sullivan, 1987b; 
Woolf and Thompson, 1991) and both can increase responsiveness and receptive 
field size of dorsal horn neurones (Woolf, 1983; Cook et al., 1987; Li et al., 1999).  
However, it is not correct to say that wind-up is equivalent to central sensitization, 
since there are also differences between the two.  The most obvious difference 
between wind-up and central sensitization is the duration of effects.  Wind-up is 
short-lasting and its effects, both the enhanced responsiveness and expansion of 
receptive field size of dorsal horn neurones, are gone within a matter of minutes, 
while central sensitization and the resultant hypersensitivity persist for a long period 
beyond the conditioning stimulus.  Furthermore, unlike in central sensitization where 
conditioning stimulation of C-fibres can increase A-fibre evoked responses 
(heterosynaptic facilitation) of dorsal horn neurones (Woolf, 1983), this is not the 
case in wind-up since only C-fibre evoked responses are enhanced (homosynaptic 
facilitation), suggesting that wind-up may be a selective reflection of central 
sensitization to C-fibre inputs only (Li et al., 1999).  Therefore, while there are 
important similarities between wind-up and central sensitization, they are in fact 
separate phenomena.  It would seem that wind-up is in fact an initiator of central 
sensitization.  This notion is compatible with the short duration of wind-up.  Noxious 
stimuli applied immediately after the initial conditioning stimulus can prolong and 
maintain wind-up (Li et al., 1999) and might lead to long-lasting central sensitization if 
they are of sufficient intensity, frequency and duration.  It is likely that the Ca2+ influx 
which occurs following NMDA receptor activation during wind-up is a key step in 
initiating central sensitization, which is also known to involve Ca2+-depdendent 
processes.  Thus, drugs that block wind-up, such as NMDA antagonists, also block 
the initiation of central sensitization (Dickenson and Sullivan, 1987b; Haley et al., 
1990; Woolf and Thompson, 1991).  Indeed, in my studies I have shown that the 
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peptide Tat-NR2B9c, which interferes with NMDA receptors, reduces both wind-up 
and central sensitization of dorsal horn neurones.  A trend towards inhibition of the 
first phase of the neuronal response to formalin, where central sensitization is 
initiated, was observed following Tat-NR2B9c, likely reflecting the inhibitory effects of 
this peptide on spinal wind-up.  Therefore, in my opinion, wind-up is certainly a useful 
model for studying the neuronal basis of pain hypersensitivity, particularly central 
mechanisms since wind-up is a purely central phenomenon (Herrero et al., 2000).  
Recording wind-up is quick, reproducible and effects of pharmacological 
manipulations are easily observed.  Finally, as described previously (see Chapter 1), 
several studies have demonstrated that a perceptual correlate of wind-up manifests 
in healthy human volunteers as an NMDA-dependent temporal summation of pain 
following repetitive noxious stimulation of C-fibres (Price, 1972; Price et al., 1994).  
Furthermore, symptoms of wind-up, temporal summation of pain and aftersensations, 
have been observed in chronic pain patients (Kristensen et al., 1992).  Together, 
these human representations of wind-up support the clinical relevance of this model 
of nociceptive plasticity. 
 
 
8.8  The Formalin Model of Pain 
 
In this thesis, I have utilized the formalin model of pain in many studies, and so it is 
important to discuss both the merits and disadvantages of this test.  The behavioural 
formalin pain test for rodents was first described by Dubuisson and Dennis in 1977, 
whereby 50 µl of 5% formalin was injected into the hindpaw of rats, as a method for 
studying pain and assessing analgesic potential of treatments (Dubuisson and 
Dennis, 1977).  At that time, most pain studies employed acute pain tests, such as 
the tail-flick test, the hot-plate test and the pinch test.  Whilst useful, these tests had 
the disadvantages that they were testing only transient pain without any underlying 
clinically relevant pathology and would only determine pain thresholds through 
predominantly reflex responses.  Significant restraint of animals was required to 
conduct some of the tests which may affect results by exacerbating fear and anxiety 
of the animal.  In addition, assessment of pain is perhaps overly subjective to 
interpretation by the experimenter, particularly in cases of evoked pain.  Thus, the 
formalin test has significant advantages over these other tests.  Little or no restraint 
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is required to conduct the test.  The pain produced is prolonged, with pain-related 
behaviours routinely observed for a one-hour testing period.  Inflammation occurs 
following formalin injection, as indicated by redness and swelling of the injected paw, 
and drives the pain response, thus giving the test clinical relevance to inflammatory 
pain conditions.  Pain-related behaviours, such as lifting, flinching, licking and biting 
of the injected paw, as later characterized by Wheeler-Aceto and colleagues 
(Wheeler-Aceto et al., 1990), are ongoing and can be easily distinguished and 
recorded.  In the case of licking and biting behaviours, it is clear that the animal is 
addressing the injured paw and hence processing in higher centres must be involved 
in these active behaviours.  Pain-related behaviours were found to be sensitive to 
morphine and also stimulation of the PAG (Dubuisson and Dennis, 1977).  The 
formalin-induced behavioural response is highly reproducible and is similar in both 
rats and mice (Chapter 7) (Hunskaar et al., 1985).  Dubuisson and Dennis also 
described the extent of tissue damage following formalin injection.  In addition to 
significant swelling, which lasts for several weeks, a small blister develops.  
However, despite this damage, approximately two hours after formalin administration 
the injected paw is used normally again for locomotion, grooming and eating 
(Dubuisson and Dennis, 1977).  Since animals are usually observed for one hour 
following formalin injection, and not often assessed after this testing period, the 
tissue damage caused by formalin is not really a disadvantage.  Perhaps most 
significantly, Dubuisson and Dennis reported that formalin injection in humans 
produced intense, burning and throbbing pain that had a similar time-course to the 
behavioural response in rodents (Dubuisson and Dennis, 1977).   
 
The main reason why I find the formalin model particularly useful is the 
unquestionable correlation between pain-related behaviours in awake animals and 
activity of individual dorsal horn neurones recorded electrophysiologically in 
anaesthetized animals, both induced by hindpaw administration of formalin.  This 
correlation makes it easier to understand neuronal changes which bring about an 
abnormal pain state.  Neuronal changes are not often observed or particularly 
obvious in many chronic pain models and are often inferred on the basis of altered 
efficacy of drugs following a particular injury.  In nerve injury models, interpretation of 
neuronal changes is further complicated by the loss of some afferent input as a result 
of the peripheral nerve injury.  This is not the case for the formalin test where spinal 
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neuronal activity is directly driven by formalin and can be observed before, during 
and after formalin administration.  Both behavioural and neuronal responses follow 
the same biphasic time course and there is clear differentiation between peripheral 
mechanisms which mainly drive the first phase and central mechanisms which 
mainly contribute to the second phase.  For example, I have observed during 
electrophysiological recordings that fixation of the receptive field occurs following 
injection of formalin (taking some minutes so not affecting the first phase firing 
response).  Despite this, firing of dorsal horn neurones during the second phase 
persists, suggesting that this activity is mainly generated centrally following the initial 
afferent barrage.  This was evident by the fact that pinching of the injected toe (i.e. 
the receptive field) at the end of the experiment no longer evoked firing of the 
neurone, though spontaneous firing still occurred indicating that the same cell was 
still being recorded.  Most interestingly, pinching of an adjacent toe, which prior to 
formalin injection did not excite the neurone being recorded, now evoked firing, 
indicating expansion of the receptive field, a known feature of spinal central 
sensitization observed clinically in chronic pain patients (Woolf, 1983; Cook et al., 
1987; Dubner et al., 1987).  The formalin-induced second phase is a well-established 
model for spinal central sensitization and this plasticity is known to be dependent on 
NMDA receptor activation (Haley et al., 1990; Chaplan et al., 1997).  Drugs such as 
ketamine reduce this central sensitization without alteration of responses to acute 
stimuli (see Chapter 3).  In addition, gabapentin, which is used clinically in the 
treatment of chronic pain, also selectively reduces the formalin-induced second 
phase response with no effect on the tail-flick reflex, a test of acute pain (Singh et al., 
1996; Shimoyama et al., 1997; Yoon and Yaksh, 1999).  Conversely, morphine is 
known to alter acute pain and, accordingly, reduces both phases of the formalin 
response (Wheeler-Aceto and Cowan, 1991).  Thus, clinically relevant drugs are 
effective in the formalin test and clear distinctions can be made between effects on 
acute pain and on hyperalgesia.  This further increases the clinical relevance of the 
formalin model. 
 
The question of clinical relevance in the formalin model has been put to me several 
times.  One common argument made against the use of the formalin model is that 
injection of formalin does not specifically mimic any known cause of a human chronic 
pain syndrome, as is the case of injuring a nerve to mimic neuropathic pain, for 
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example.  However, as I mentioned above, formalin produces a clear inflammatory 
response which is localized to the injected paw and the late phase is sensitive to 
non-steroidal anti-inflammatory drugs (Hunskaar and Hole, 1987).  Thus it can be 
argued that the formalin test is a good model of pain induced by inflammation.  In my 
opinion, one of the best arguments for the use of the formalin model, in terms of its 
clinical relevance, is not to do with the particular injury which produces the pain, but 
rather the specific behavioural outcome of that pain, that is spontaneous pain-related 
behaviours.  Spontaneous pain is one of the most common symptoms observed in 
chronic pain patients (Jensen et al., 2001), and yet, despite this fact, many chronic 
pain models do not reflect this.  The incidence of spontaneous pain in nerve injury 
models is low or highly variable (Kim and Chung, 1997) and not routinely assessed.  
Wheeler-Aceto and colleagues compared the incidence of spontaneous pain in 
various models of peripheral inflammation, including the formalin test.  Formalin was 
confirmed to produce significant spontaneous pain-related behaviour in rats.  In 
contrast, little or no spontaneous pain occurred following hindpaw injection of 
numerous noxious agents including carrageenan, kaolin, serotonin and mustard oil 
and so these compounds were found to offer no advantage over formalin in 
assessing spontaneous, ongoing pain (Wheeler-Aceto et al., 1990).  Therefore, I 
would argue that the formalin model should not be seen plainly as a model of 
inflammatory pain, but can be thought of as a model of spontaneous pain, which is a 
clinically relevant symptom of chronic pain states.  As we try to move towards a 
mechanism-based approach for the treatment of chronic pain (Woolf et al., 1998; 
Woolf and Decosterd, 1999), we need to understand the mechanisms for different 
types of pains and so we require models which exhibit different pain characteristics.  
Studying the mechanisms which cause spontaneous pain-related behaviours in the 
formalin model may provide insights which can then be applied to more disease-
specific models and ultimately to patients.  For example, it is now known that 
stimulation of peripheral nociceptors by formalin, which in turn drives spinal central 
sensitization, is not non-specific but rather occurs through activation of TRPA1 
channels on C-fibres (McNamara et al., 2007).  This may implicate TRPA1 in 
spontaneous pain.  Interestingly, a mutation in human TRPA1 has recently been 
detected in a Colombian family who have an abnormal genetic pain syndrome 
characterized by episodic spontaneous pains (unpublished observations from the lab 
of Prof John Wood, UCL).  If a nerve injury model in a rat produces little or no 
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spontaneous pain, then should this model be described as being clinically relevant to 
human neuropathic pain?  If we consider clinical relevance to be more important with 
respect to the symptoms produced by the model rather than the cause, then the 
answer would be no.  If we believe that disease specificity is most important in terms 
of measuring clinical relevance, then the answer is yes.  The formalin model may 
thus be considered to be more clinically relevant than the nerve injury model in terms 
of symptoms, since it produces symptoms which are common to patients, but less 
clinically relevant in terms of the underlying disease.  Despite the various aetiologies 
of neuropathic pain in humans, ranging from diabetes to viral infection, trauma and 
chemotherapy, these diverse causes have no relation to symptoms, since patients 
with the same disease can present with very different symptoms.  Thus, signs and 
symptoms are arguably more important than the underlying disease.  
 
A second argument used to dispute the clinical relevance of the formalin model is 
regarding the relatively short time-course of the response.  I agree that pain-related 
behaviours produced over a period of one hour cannot be considered to be chronic.  
This argument would conclude that a nerve injury model which produces pain-related 
behaviours over a number of weeks is more clinically relevant in terms of chronic 
duration.  I do not see this is a problem or as a reason not to use the formalin test as 
I have never considered it as a model of chronic pain.  However, it is clear that the 
injection of formalin is not a simple acute pain test like the tail-flick reflex, for 
example.  Thus the formalin model sits somewhere in between acute and chronic 
models of pain and may be referred to as tonic.  I would argue that the short time 
course of the formalin test is an advantage and makes this model a good screen to 
assess analgesic potential of novel compounds and a good predictor of performance 
in chronic pain models.  Studies are relatively short and results are obtained quickly.  
We should also note that although pain-related behaviours are assessed routinely for 
only one hour, hypersensitivity of the injected paw is likely to persist for a prolonged 
period after, perhaps lasting days and even weeks.  Many of the neuronal changes 
that occur during the initial hour following formalin injection are likely to be sustained, 
thus contributing to a prolonged hypersensitivity of the injured paw.  In Chapter 6, for 
example, changes in AMPA receptor trafficking were observed at 90 minutes after 
formalin administration (Fig. 6.9).  Formalin-induced upregulation of protein kinase G 
(PKG) has been shown to occur one hour after formalin injection and persist for up to 
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96 hours (Schmidtko et al., 2003).  Finally, formalin injection can induce mechanical 
hypersensitivity of the hindpaw which lasts for days and is maximal at 48 hrs (Shi et 
al., 2005).  Despite the short duration of the observed response to formalin injection, 
it is clear (from the studies presented in this thesis) that the formalin model shares 
many spinal mechanisms with LTP, as well as chronic pain states, making the 
formalin test an excellent model for central sensitization.  Formalin-induced pain-
related behaviours during the second phase, representing central sensitization, are 
dependent on NMDA receptor activation and downstream signalling via PSD-95.  
Activation of c-Fos and ERK, common markers of neuronal activity in nociceptive 
pathways, and activation of PI3K and PKCζ/PKMζ, both of which are known to be 
important for hippocampal LTP, occur in response to formalin.  Together these 
findings confirm that the formalin test is an excellent model for studying neuronal 
plasticity in pain pathways, particularly in the spinal cord, resulting in central 
sensitization.   
 
Although the formalin test is not used as a pain model in humans, injection of another 
chemical irritant, capsaicin, is widely used to study mechanisms of hyperalgesia in 
humans as well efficacy of analgesics.  Intradermal injection of capsaicin in healthy 
individuals produces intense burning pain and peripheral inflammation, indicated by a 
flare, similar to that reported for formalin (Dubuisson and Dennis, 1977) and results in 
secondary hyperalgesia, caused by central sensitization, in the area of skin outside 
of the territory of the flare (Simone et al., 1989; LaMotte et al., 1991; Hughes et al., 
2002).  This model of central sensitization has been validated using both 
psychophysical and imaging measures (LaMotte et al., 1991; Iadarola et al., 1998; 
Baron et al., 1999; Zambreanu et al., 2005).  Interestingly, both formalin and 
capsaicin activate specific TRP channels, TRPA1 and TRPV1 respectively, located 
on nociceptive C-fibres (Caterina et al., 1997; McNamara et al., 2007).  Similar to 
formalin-induced central sensitization in rodents, this capsaicin-induced central 
sensitization in humans is also NMDA-dependent (Park et al., 1995; Andersen et al., 
1996).  Thus the injection of chemical irritants can be considered to be clinically 
relevant since the symptoms produced mimic those seen in chronic pain patients.  
Similar symptoms, such as secondary hyperalgesia and allodynia, are also produced 
in humans in a surrogate model of LTP, whereby conditioning electrical stimulation of 
cutaneous afferents of the forearm produces an NMDA-dependent potentiation of 
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pain ratings (Klein et al., 2004; Klein et al., 2007). Again, understanding the 
mechanisms producing these symptoms in both preclinical and human surrogate 
models of central sensitization should aid drug development for chronic pain.  Both 
the capsaicin test and LTP induced by electrical stimulation in humans are good 
models for testing efficacy of novel analgesics which have been identified by 
preclinical models, such as the formalin test.  Development of newer and better 
human surrogate models may further our understanding of mechanisms of central 
sensitization. 
 
In my opinion, the formalin test is an excellent pre-clinical model for central 
sensitization.  Factors such as the high incidence of spontaneous, ongoing pain and 
evidence of receptive field expansion, as well as excellent correlation between pain-
related behaviours and neuronal activity, make the formalin test a highly useful model 
for developing and assessing novel analgesics for potential use in chronic pain 
patients. 
 
 
8.9  Spinal administration of drugs 
 
In all of the studies presented in this thesis, drugs were administered spinally, either 
directly onto the surface of the spinal cord during electrophysiological experiments or 
via intrathecal lumbar puncture in behavioural studies.  The reason for this selective 
spinal administration was to allow for investigation of the importance of intrinsic 
spinal mechanisms of nociceptive plasticity in the various models used.  The spinal 
cord is a key site for modulation of nociceptive processing (D'Mello and Dickenson, 
2008).   
 
It may be argued, however, that while drugs are administered to the lumbar spinal 
cord, spread via CSF or blood flow may occur to other sites, including supraspinal 
structures, which may then contribute to drug effects.  I believe that this is unlikely or, 
at most, minimal in the studies presented in this thesis for various reasons.  In 
electrophysiological studies, drugs are administered into a ʻwellʼ on the surface of the 
lumbar spinal cord, created by a laminectomy.  The drug sits within this ʻwellʼ for the 
duration of the entire recording in a static system with no CSF flow and so it is 
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unlikely to be transported elsewhere via this route.  In all studies, drug effects on the 
responses of neurones were selective and, importantly, were regulated by afferent 
pathophysiology, indicating a lack of non-specific effects.  Low drug doses were 
effective in the majority of cases.  Effects were also seen relatively quickly following 
drug administration, sometimes within ten minutes, as in the case of wind-up studies, 
which is unlikely to be enough time to allow for significant spread of the drug to other 
sites.  In behavioural studies, drugs were administered in low volumes and effects 
were again found to be selective at relatively low doses.  Of all the compounds 
tested, only L-291 (DDAH-1 inhibitor) was administered at seemingly high doses, 
though these corresponded to the IC50 of the drug, and these doses were also found 
to be selective in both electrophysiological and behavioural studies.  In addition, a 
lack of motor impairment following intrathecal administration of the highest dose of 
Tat-NR2B9c would suggest a lack of off-target effects.  Finally, during control 
intrathecal injections where lidocaine was administered, paralysis was observed of 
the hindpaws only.  This would suggest that rostral spread of drug further along the 
surface of the spinal cord was minimal and insignificant, and that the majority of drug 
action was in the lumbar cord.  In agreement, a study testing the safety of lumbar 
intrathecal injection of a drug (SP-SAP) in dogs found that there was no effect of the 
drug in the cervical cord, with no generalized neurotoxicity as indicated by a lack of 
significant neuronal loss, astrocytic activation or behavioural side-effects (Allen et al., 
2006).  Together, all the evidence suggests that, even if spread of drug to non-spinal 
sites cannot be entirely ruled out, the effect of this spread is minimal and of little 
consequence.  I am confident that drug effects in my studies were mediated via 
spinal sites of action. 
 
A further point of interest in these studies is the fact that drug doses used in 
electrophysiological experiments were often lower than those used in behavioural 
studies.  This reflects the ability to apply the drug locally to a restricted cord zone in a 
static system during electrophysiological recordings as compared to intrathecal 
injections in behavioural studies where CSF flow and dilution, and the smaller volume 
make higher doses necessary.  Nevertheless, in all studies, drug effects were found 
to be selective in both electrophysiological and behavioural studies.  
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8.10  Ideas for future work 
 
Here I will outline some ideas for future experiments which may further the work 
presented in this thesis.  These experiments were not conducted during my PhD 
mainly due to time constraints. 
 
In my studies I have mainly focused on the activation of downstream intracellular 
signalling as being a major consequence of binding of NR2B subunits by PSD-95.  
However, it is also known that PSD-95 may contribute to trafficking and membrane 
stability of NMDA receptors (Roche et al., 2001).  Therefore, it would be interesting to 
see if Tat-NR2B9c alters membrane localization of NMDA receptors on dorsal horn 
neurones, as this would be another potential mechanism of action for altering spinal 
nociceptive plasticity. 
 
I believe I have identified two potential novel analgesic applications for disrupting 
interactions between NR2B-containing NMDA receptors and PSD-95, through the 
use of Tat-NR2B9c.  The first is in the treatment of pain in osteoarthritis.  Ramage 
and colleagues showed that in human chondrocytes, obtained from osteoarthritis 
patients, expression of NR2B-subtype receptors is upregulated.  In normal 
chondrocytes this subtype is absent.  This upregulation of NR2B-subtype receptors 
produced altered Ca2+ influx and membrane depolarization of chondrocytes, which 
were both blocked by NMDA antagonists, removal of extracellular Ca2+, inhibition of 
nNOS and also by Tat-NR2B9c (Ramage et al., 2008).  I propose that this altered 
NMDA receptor activity in chondrocytes drives the abnormal pain state in 
osteoarthritis patients.  Thus, intra-articular administration of Tat-NR2B9c into the 
knee joint may not only normalize excitability of chondrocytes, but may also reduce 
nociceptive drive to the spinal cord, producing pain relief.  In addition, peripheral 
NMDA receptors have been suggested to have a role in chronic pain states (Carlton, 
2009).  Drugs which target NMDA receptors and are restricted peripherally would 
avoid CNS-mediated intolerable side-effects.  Second, I propose that Tat-NR2B9c 
may have analgesic potential in HIV-induced neuropathic pain.  It is not entirely clear 
how HIV affects neurones, though one proposed mechanism is through the coat 
glycoprotein gp120, which has neurotoxic effects (Wallace et al., 2007).  An 
alternative mechanism for neurotoxicity is through the full-length HIV transduction 
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molecule Tat, which can potentiate glutamate-induced excitotoxicity and promote 
neuronal apoptosis (Eugenin et al., 2007).  Eugenin and colleagues demonstrated 
that the Tat receptor, the lipoprotein receptor-related protein (LRP), forms a 
macromolecular complex, via PSD-95, with the ternary NMDAR-PSD-95-nNOS 
complex, triggered by Tat (Eugenin et al., 2007).  Thus, it may be that Tat also 
triggers neuronal changes in pain pathways, for example in the spinal cord, that 
involve this complex.  Disruption of this complex with Tat-NR2B9c and/or other 
interfering peptides may inhibit or reverse HIV-induced neuropathic pain.    
 
Signalling pathways, in addition to PKCζ/PKMζ, activated downstream of NR2B-
containing NMDA receptors via PSD-95 can be identified.  It would be of interest to 
investigate the role of PDK-1 in spinal nociceptive plasticity, since this kinase is 
involved in both PI3K and PKCζ/PKMζ signalling (Hirai and Chida, 2003) and, as yet, 
has not been studied in pain. 
 
Spinal LTP is another model of nociceptive plasticity requiring activity of NMDA 
receptors (Liu and Sandkuhler, 1995; Svendsen et al., 1998) and can provide further 
insights into chronic pain mechanisms.  I would like to examine the effects of Tat-
NR2B9c and inhibition of PI3K, PKCζ/PKMζ and DDAH-1 in this model.  In addition, 
the effects of inhibition of PI3K, PKCζ/PKMζ and DDAH-1 should also be 
investigated in chronic pain models, such as the SNL model. 
 
Although I have demonstrated a role for DDAH-1 in spinal pain processing and 
plasticity, it remains unclear which types of cells in the spinal cord and DRG express 
DDAH-1.  Thus, immunohistochemical approaches should be employed to identify 
DDAH-1-expressing cells.  It would be expected that DDAH-1 would co-localize with 
nNOS.  Surprisingly, I did not observe an altered phenotype of DDAH-1+/- mice in the 
formalin test.  Conditional knockout mice are currently being generated and these 
may have altered sensitivity in the formalin test and other pain models. 
 
As discussed above, I utilized spinal administration of drugs to specifically target 
spinal cord mechanisms of pain processing.  It would be of interest to look at other 
areas of the pain pathway where these mechanisms may also act.  For example, 
brain administration can be achieved through intracerebroventricular injections or 
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through microinjection into specific brain structures.  Additionally, intraplantar 
hindpaw administration can be used to assess peripheral contributions of relevant 
targets.  Finally, systemic administration of all compounds should be investigated 
since this is the most likely route of administration to be tested clinically in patients.  
Systemic administration would also allow for greater assessment of side-effects.  
Studies have demonstrated that peptides, including Tat-NR2B9c, can cross the 
blood-brain barrier, such that systemic administration results in spinally-mediated 
effects (Aarts et al., 2002; Liu et al., 2008; Tao et al., 2008).    Although systemic 
administration of Tat-NR2B9c may raise the potential for brain-mediated side-effects, 
clinical testing of Tat-NR2B9c in stroke patients has not revealed any adverse 
psychotropic or neurological effects (verbal communication from Prof Mike Salter, 
Univ. of Toronto). 
 
 
8.11  Closing Remarks 
 
NMDA receptors are undeniably implicated in the pathophysiology of many 
neurological and psychiatric diseases.  Therefore, the NMDA receptor remains an 
important therapeutic target in such diseases, including chronic pain.  However, 
efforts to modulate NMDA receptor activity with non-selective antagonists have failed 
in the clinic due to the occurrence of intolerable side-effects and this has perhaps led 
to the NMDA receptor being ignored or disregarded as a viable drug target.  These 
side-effects inform us that we rely on NMDA receptor activity in various neuronal 
systems for everyday functions, such as memory formation or learning of new 
movements.  Clear distinctions do exist, however, between NMDA receptor-mediated 
physiological and pathological activity.  These distinctions may be made by the 
varying arrangement of NMDA receptor subunits or by coupling to different 
intracellular signalling pathways.  By identifying which receptor subtypes, such as 
NR2B-containing NMDA receptors, or which signalling cascades are important in 
each system, we can design interventions which specifically target one system and 
leave others intact.  Over one hundred different proteins have been found to exist 
within the NMDA receptor complex (Husi et al., 2000) and each one may thus be a 
potential candidate for regulation in NMDA-dependent pathophysiology, including 
pain hypersensitivity.  Additionally, we can try different routes of drug delivery, such 
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as spinal administration, to make use of spatial boundaries which exist between 
different NMDA-dependent neuronal circuits, therefore allowing for different systems 
to be targeted individually.   
 
Thus, in my opinion, successful targeting of pathological NMDA receptor activity is 
possible, not through the use of non-selective NMDA receptor antagonists, which will 
inhibit NMDA receptor function in all systems and consequently produce side-effects, 
but rather through more selective approaches which avoid receptor blockade.  As I 
have shown in this thesis, alternative modulation of NMDA receptor-mediated 
pathological activity may be achieved by disrupting interactions with intracellular 
signalling proteins, such as PSD-95, which orchestrate pathological signalling 
cascades downstream of NMDA receptor activation, or through the direct inhibition of 
such signalling cascades.  I have proved these strategies to be successful in 
reducing spinal nociceptive plasticity and therefore the potential is there for them to 
be applied to chronic pain patients.  It is my hope that the studies presented here will 
further our understanding of pain processing in the spinal cord, particularly under 
pathological conditions, and will lead to the development of new and more selective 
treatments for chronic pain. 
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